

533 Rec'd PCT/PTO 17 SEP 2001

FORM PTO-1390 (Modified)
(REV 11-2000)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

GKS-101.0 (7911/83687)

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR

09/936852

INTERNATIONAL APPLICATION NO.
PCT/EP00/02410INTERNATIONAL FILING DATE
March 17, 2000PRIORITY DATE CLAIMED
March 17, 1999

TITLE OF INVENTION

NUCLEIC ACID MOLECULE COMPRISING A NUCLEIC ACID SEQUENCE CODING FOR A HAEMOCYANIN

APPLICANT(S) FOR DO/EO/US

Jurgen MARKL, Benjamin ALTENHEIN, Bernhard LIEB and Thomas STIEFEL

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (24) indicated below.
4. ☐ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
 - a. ☒ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☐ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☐ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☒ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail
23. ☐ Other items or information:

U.S. APPLICATION NO. 09/936852		INTERNATIONAL APPLICATION NO. PCT/EP00/02410		ATTORNEY'S DOCKET NUMBER GKS-101.0 (7911/83687)	
---------------------------------------	--	--	--	---	--

24. The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :	CALCULATIONS	PTO USE ONLY																														
<input type="checkbox"/> Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO	\$1000.00																															
<input checked="" type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO	\$860.00																															
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO	\$710.00																															
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)	\$690.00																															
<input type="checkbox"/> International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)	\$100.00																															
ENTER APPROPRIATE BASIC FEE AMOUNT =	\$860.00																															
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	\$0.00																															
<table border="1" style="width:100%; border-collapse: collapse;"> <thead> <tr> <th style="width:15%;">CLAIMS</th> <th style="width:20%;">NUMBER FILED</th> <th style="width:15%;">NUMBER EXTRA</th> <th style="width:15%;">RATE</th> <th style="width:15%;"></th> <th style="width:20%;"></th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>44 - 20 =</td> <td>24</td> <td>x \$18.00</td> <td></td> <td style="text-align: right;">\$432.00</td> </tr> <tr> <td>Independent claims</td> <td>11 - 3 =</td> <td>8</td> <td>x \$80.00</td> <td></td> <td style="text-align: right;">\$640.00</td> </tr> <tr> <td colspan="5">Multiple Dependent Claims (check if applicable). <input type="checkbox"/></td> <td style="text-align: right;">\$0.00</td> </tr> <tr> <td colspan="5">TOTAL OF ABOVE CALCULATIONS =</td> <td style="text-align: right;">\$1,932.00</td> </tr> </tbody> </table>	CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE			Total claims	44 - 20 =	24	x \$18.00		\$432.00	Independent claims	11 - 3 =	8	x \$80.00		\$640.00	Multiple Dependent Claims (check if applicable). <input type="checkbox"/>					\$0.00	TOTAL OF ABOVE CALCULATIONS =					\$1,932.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																													
Total claims	44 - 20 =	24	x \$18.00		\$432.00																											
Independent claims	11 - 3 =	8	x \$80.00		\$640.00																											
Multiple Dependent Claims (check if applicable). <input type="checkbox"/>					\$0.00																											
TOTAL OF ABOVE CALCULATIONS =					\$1,932.00																											
<input type="checkbox"/> Applicant claims small entity status. (See 37 CFR 1.27). The fees indicated above are reduced by 1/2.	\$0.00																															
SUBTOTAL =	\$1,932.00																															
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492 (f)).	\$0.00																															
TOTAL NATIONAL FEE =	\$1,932.00																															
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) (check if applicable). <input type="checkbox"/>	\$0.00																															
TOTAL FEES ENCLOSED =	\$1,932.00																															
	Amount to be: refunded	\$																														
	charged	\$																														

a. ☒ A check in the amount of **\$1,932.00** to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **23-0920** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:



SIGNATURE

Shannon L. Nebolsky

NAME

41,217

REGISTRATION NUMBER

September 17, 2001

DATE

09/936852

JC12 Rec'd PCT/PTO 17 SEP 2001

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Jürgen MARKL, et al.)	
Serial No.:	Not yet assigned)	Attorney Docket:
Filing Date:	September 17, 2001)	GKS-101.0
)	7911/83687
For:	NUCLEIC ACID MOLECULE)	
	COMPRISING A NUCLEIC ACID)	
	SEQUENCE CODING FOR A)	
	HAEMOCYANIN)	
)	Group Art Unit:
Examiner:	Not yet assigned)	Not yet assigned

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231

Sir:

This paper is a Preliminary Amendment for the U.S. national phase filing of PCT/EP00/02410 filed herewith as a new patent application under 35 U.S.C. § 371. Please enter this Preliminary Amendment and amend the accompanying application as follows.

New §371 Application
Based on PCT/EP00/02410
Filed August 17, 2001
Markl, et al.

- 2 -

IN THE ABSTRACT:

Please cancel the Abstract section that was originally
filed, entitled "Abstract" and substitute the new ABSTRACT.

- -ABSTRACT

The present invention relates to a nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin. The invention furthermore relates to constructs which comprise the nucleic acid molecule and, where appropriate, a promoter suitable for expression control. In a preferred embodiment, the construct furthermore comprises a nucleic acid sequence which codes for an antigen. The invention moreover relates to host cells which contain these nucleic acid molecules and/or constructs. The invention furthermore relates to recombinant expression of the nucleic acid molecules and/or constructs in the host cells. The invention furthermore relates to haemocyanin, a haemocyanin domain, a fragment with the immunological properties of at least one domain of haemocyanin and haemocyanin fusion proteins, which are coded by the nucleic acid molecules and/or constructs. The invention furthermore relates to pharmaceutical compositions which comprise the nucleic acid molecules and/or haemocyanin, a haemocyanin domain, a fragment thereof or a fusion protein. The invention furthermore relates to liposomes which comprise the nucleic acid molecules and/or haemocyanin, a haemocyanin domain, a fragment

New §371 Application
Based on PCT/EP00/02410
Filed August 17, 2001
Markl, et al.

- 3 -

thereof or a fusion protein. The invention furthermore relates to antibodies which are obtainable by immunization of a test animal with haemocyanin, a haemocyanin domain, a fragment thereof or a fusion protein, and the use thereof in screening methods for the identification of tumours.--

IN THE CLAIMS

Please cancel Claims 1 through 44 and substitute new Claims 1 through 44.

REMARKS

Prosecution and consideration of the claimed subject matter in the accompanying patent application is respectfully requested.

I. The Amendments

The attached English translation of the claims as filed in the corresponding international patent application were amended to conform to standard U.S. practice. As a result, the originally-filed English translation of Claims 1 through 44 were cancelled and replaced with the substitute Claims 1 through 44.

A copy of the claims showing the amendments effected by this substitution of the claims is enclosed. The substitute

- 4 -

Claims 1-44 are in the case and are before the Examiner. It is thus seen that no new matter has been presented. A complete, clean copy of the claims before the Examiner is enclosed herewith.

The Abstract and the claims were amended to conform to standard U.S. practice.

A filing fee is enclosed based on the number of independent and dependent claims in the application after entry of this Preliminary Amendment. No further fee or petition is believed to be necessary. However, should any further fee be needed, please charge our Deposit Account No. 23-0920, and deem this paper to be the required petition.

Respectfully submitted,


Shannon L. Nebolsky, Reg. No. 41,217

- 5 -

CERTIFICATE OF EXPRESS MAILING

I hereby certify that this Preliminary Amendment including clean and marked-up copies of the Amendments, together with a 371 application and its papers and fee, are being deposited with the United States Postal Service as Express Mail Label No. EL706574854US, postage prepaid, in an envelope addressed to: Commissioner for Patents, Box PCT, Washington, D.C. 20231 on September 17, 2001.

Frank Jones

09/9368

1 7 SEP 2001

The haemocyanin of the Californian keyhole limpet *Megathura crenulata* is of particular immunological interest. The haemocyanin is therefore also called keyhole limpet haemocyanin (KLH). Haemocyanins are very potent antigens. Immunization of a

vertebrate leads to a non-specific activation of the immune system which to date is not very well understood. By the general activation of the immune system, it is then possible also to achieve an immune reaction to other foreign structures which have previously been tolerated. KLH is used above all as a hapten carrier in order thus to achieve the formation of antibodies against the hapten.

In addition to *Megathura crenulata*, the abalone *Haliotis tuberculata* also belongs to the Archaeogastropoda group, which is relatively old in respect of evolution. It is known that *Haliotis* also produces haemocyanin.

KLH is a mixture of two different haemocyanins, which are called KLH1 and KLH2. The subunit of KLH1 is a 390 kDa polypeptide which consists of eight globular domains called 1 a to 1 h according to their sequence in the subunit. On the other hand, KLH2 has a molecular weight of 350 kDa and according to the most recent data also contains 8 domains, called 2 a to 2 h. *In vivo* every type of subunit forms homo-oligomers, while no hetero-oligomers have been observed.

Amino-terminal, internal and carboxy-terminal domains have been obtained by limited proteolysis and crossed immunoelectrophoresis of the subunit of KLH1 and KLH2, and their amino-terminal sequences has been determined (Söhnngen et al., Eur. J. Biochem. 248 (1997), 602-614; Gebauer et al., Zoology 98(1994), 51-68). However, the resulting sequences do not allow designing of sequence-specific primers and/or probes which promise success for hybridization with genomic DNA. Although both KLH types have been known since 1991 and 1994 respectively, it has so far not been possible to clarify the primary structure.

At the DNA level, in respect of molluscs only the cDNA sequence of the haemocyanin subunit from the cephalopod *Octopus dofleini* is so far known (Miller et al., J. Mol. Biol. 278 (1998), 827-842). *Octopus dofleini* is phylogenetically very far removed from the archaeogastropods. A haemocyanin gene sequence from molluscs is so far not known at all.

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),

SEQ ID NO:10 (HtH2 domain c),
 SEQ ID NO:11 (HtH2 domain d),
 SEQ ID NO:12 (HtH2 domain e),
 SEQ ID NO:13 (HtH2 domain f),
 SEQ ID NO:14 (HtH2 domain g),
 SEQ ID NO:15 (HtH2 domain h),
 SEQ ID NO:16 (partial KLH1 domain b),
 SEQ ID NO:17 (KLH1 domain c),
 SEQ ID NO:18 (KLH1 domain d),
 SEQ ID NO:19 (partial KLH1 domain e),
 SEQ ID NO:20 (KLH2 domain b),
 SEQ ID NO:21 (KLH2 domain c),
 SEQ ID NO:22 (partial KLH2 domain d),
 SEQ ID NO:23 (KLH2 domain g),
 SEQ ID NO:24 (partial KLH2 domain h),
 SEQ ID NO:49 (HtH1 domain a' + signal peptide),
 SEQ ID NO:50 (partial HtH2 domain a),
 SEQ ID NO:51 (HtH2 domain b'),
 SEQ ID NO:52 (HtH2 domain d'),
 SEQ ID NO:53 (HtH2 domain e'),
 SEQ ID NO:54 (KLH1 domain e'),
 SEQ ID NO:55 (KLH1 domain f),
 SEQ ID NO:56 (KLH1 domain g),
 SEQ ID NO:57 (KLH2 domain b'),
 SEQ ID NO:58 (KLH2 domain c'),
 SEQ ID NO:59 (KLH2 domain d'),
 SEQ ID NO:60 (KLH1 domain e),
 SEQ ID NO:61 (KLH2 domain f),
 SEQ ID NO:62 (KLH2 domain g'),
 SEQ ID NO:80 (HtH1 domain a" + signal peptide),
 SEQ ID NO:81 (HtH1 domain b"),
 SEQ ID NO:82 (HtH1 domain c"),
 SEQ ID NO:83 (HtH1 domain d"),
 SEQ ID NO:84 (HtH1 domain e"),

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;

The "immunological properties of at least one domain of haemocyanin" means the property of a polypeptide of inducing, in the same manner as at least one domain of haemocyanin, an immunological response of the recipient immunized with the polypeptide. "Immunological response" here is understood as meaning T and/or B cell responses to haemocyanin epitopes, such as, for example, an antibody production. The immunological reaction can be observed, for example, by immunization of a mammal, such as e.g. a mouse, a rat or a rabbit, with the corresponding polypeptide and comparison of the immune response to the polypeptide used for the immunization with the immune response to natural haemocyanins.

According to the invention, the term "antigen" includes both haptens and weak and potent antigens. Haptens are characterized in that they are substances of low molecular weight (less than 4,000 Da), but without being coupled to a carrier molecule are not capable of inducing an immunological reaction. Weak antigens are substances which can themselves already induce an immunological reaction and of which the potential to be able to induce an immunological reaction can be increased further by coupling with a carrier molecule at the protein and/or DNA level.

"His tag" means a sequence of at least 6 histidine amino acids which, by corresponding cloning and fusion with an expressible sequence, leads to a fusion protein which has at least 6 His residues on the NH₂ terminus and can easily be purified by complexing with an Ni²⁺ column.

"Cloning" is intended to include all cloning methods known in the prior art which could be employed here but which are not all described in detail because they belong to the obvious hand tools of the skilled person.

"Variants" of a nucleic acid sequences include additions, deletions, insertions or inversions and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin. Variants can be synthetic or natural. Allelic variants are an example of natural variants.

"Recombinant expression in a suitable host cell" is to be understood as meaning all the expression methods known in the prior art in known expression systems which could be employed here but which are not all described in detail because they belong to the obvious hand tools of the skilled person.

The nucleic acid sequence contained in the nucleic acid molecule according to the invention can be genomic DNA, cDNA or synthetic DNA, synthetic DNA sequences also being understood as meaning those which comprise modified internucleoside bonds. The nucleic acid sequences can furthermore be RNA sequences, which may be necessary e.g. for expression by means of recombinant vector systems. The nucleic acid sequences according to (b) are obtainable, for example, by using a detectably

marked probe which corresponds to one of the sequences described under (a) or a fragment, or a counter-strand thereof for screening cDNA/genomic DNA libraries from molluscs or arthropods. The mRNA on which the cDNA library is based is preferably to be obtained from mollusc tissues which express haemocyanin to a particularly high degree, such as e.g. mantle tissue from gastropods and branchial gland tissue from cephalopods.

Positive cDNA/genomic DNA clones are identified by standard methods. Cf. Maniatis et al., *Molecular Cloning* (1989) Cold Spring Harbor Laboratory Press.

In a preferred embodiment, the hybridization described under (b) or (d) is carried out under stringent conditions. Stringent hybridization conditions are e.g. 68°C overnight in 0.5 x SSC; 1% blocking reagent (Boehringer Mannheim); 0.1% sodium lauryl sarcosinate and subsequent washing with 2 x SSC; 0.1% SDS.

In a preferred embodiment, nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a) are provided. The nucleic acid sequences are preferably at least 80% homologous to one of the nucleic acid sequences described under (a). The nucleic acid sequences are particularly preferably at least 90 % homologous to one of the nucleic acid sequences described under (a). In particular, the nucleic acid sequences are at least 95% homologous to one of the nucleic acid sequences described under (a).

According to the invention, the term "homology" means homology at the DNA level, which can be determined by known methods, e.g. computer-assisted sequence comparisons (Basic local alignment search tool, S.F. Altschul et al., *J. Mol. Biol.* 215 (1990), 403-410).

The term "homology" known to the skilled person describes the degree to which two or more nucleic acid molecules are related, this being determined by the concordance between the sequences. The percentage of "homology" is obtained from the percentage of identical regions in two or more sequences, taking into account gaps or other sequence peculiarities.

Preferred methods for the determination of homology initially produce the greatest concordance between the sequences analysed. Computer programs for determination of the homology between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux, J., et al., *Nucleic Acids Research* 12 (12): 387 (1984); Genetics Computer Group University of Wisconsin, Madison, (WI)); BLASTP, BLASTN and FASTA (Altschul, S. et al., *J. Mol. Biol.* 215:403-410 (1990)). The BLASTX program can be obtained from the National Centre for Biotechnology Information (NCBI) and from other sources (BLAST Handbook, Altschul S., et al., NCB NLM NIH Bethesda MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215:403-410 (1990)). The known Smith Waterman algorithm can also be used for determining homologies.

Algorithm:	Needleman and Wunsch, J. Mol. Biol 48:443-453 (1970)
Comparison matrix:	Concordance (matches) = + 10 Non-concordance (mismatch) = 0
Gap penalty:	50
Gap length penalty:	3

Further algorithms, gap opening penalties, gap extension penalties and comparison matrices by way of example, including those mentioned in the Program Handbook, Wisconsin Package, version 9, September 1997, can be used. The choice depends on the comparison to be made and furthermore on whether the comparison is to be made between sequence pairs, in which case GAP or Best Fit are preferred, or between a sequence and a comprehensive sequence databank, in which case FASTA or BLAST are preferred.

A concordance of 60% determined with the abovementioned algorithm is designated 60% homology in the context of this application. The same applies accordingly to higher degrees of homology.

In a preferred embodiment, the DNA sequence according to the invention is a combination of several of the DNA sequences described under (a) to (f), which can be obtained by fusion and optionally cloning, which are known to the skilled person. These combinations are of particular interest, since they are particularly immunogenic. Combinations which contain several or all of the domains in the sequence (a to h) which occurs naturally in the subunit are particularly preferred. Embodiments in which the nucleic acid sequences which code for the domains are coupled to one another directly in frame are particularly preferred.

Constructs which comprise the nucleic acid molecules according to the invention are furthermore provided. In a preferred embodiment, the construct according to the invention comprises a promoter which is suitable for expression, the nucleic acid sequence being under the control of the promoter. The choice of promoter depends on the expression system used for expression. Generally, constitutive promoters are preferred, but inducible promoters, such as e.g. the metallothionein promoter, are also possible.

In a further preferred embodiment, the construct furthermore comprises an antigen-coding nucleic acid sequence which is bonded directly to the haemocyanin nucleic acid according to the invention. The antigen-coding sequence can be located both 5' and 3' relative to the haemocyanin sequence or also on both ends. It either follows the haemocyanin sequence directly in the same reading frame, or is coupled to it by a nucleic acid linker, the reading frame being preserved. By fusion of the antigen-coding sequence with the haemocyanin sequence the formation of a fusion protein in which the antigen-coding sequence is bonded covalently to the haemocyanin sequence is intended. The antigen according to the invention is a medically relevant antigen, which is selected, for example, from: tumour antigens, virus antigens and antigens of bacterial or parasitic pathogens. Tumour antigens can be, for example, Rb and p53. The virus antigens preferably originate from immunologically relevant viruses, such as e.g. influenza virus, hepatitis virus and HIV. Pathogen antigens are, inter alia, those from

In another preferred embodiment, the construct furthermore comprises at least a part of a vector, in particular regulatory regions, the vector being selected from: bacteriophages, such as λ derivatives, adenoviruses, vaccinia viruses, baculoviruses, SV40 viruses and retroviruses, preferably MoMuLV (Moloney murine leukaemia virus).

A construct which additionally comprises a His tag-coding DNA sequence, which, when expressed, leads to the formation of a fusion protein with a His tag on the NH₂ terminus of the haemocyanin, facilitating purification of the protein on a nickel column by chelate formation, is furthermore preferred.

The invention furthermore provides host cells which contain the construct and which are suitable for expression of the construct. Numerous prokaryotic and eukaryotic expression systems are known in the prior art, the host cells being selected, for example, from prokaryotic cells, such as *E. coli* or *B. subtilis*, from eukaryotic cells, such as yeast cells, plant cells, insect cells and mammalian cells, e.g. CHO cells, COS cells or HeLa cells, and derivatives thereof. For example certain CHO production lines of which the glycosylation patterns are altered compared with CHO cells are known in the prior art. The haemocyanins obtained using glycosylation-deficient or glycosylation-reduced host cells possibly have additional epitopes which are otherwise not accessible to the immune system of the recipient in the case of complete glycosylation, so that haemocyanins with a reduced glycosylation under certain circumstances have an increased immunogenicity. From plant cells transformed with the construct according to the invention it is possible to produce transgenic plants or plant cell cultures which produce haemocyanin polypeptides, for example tobacco, potato, tomato, sugar beet, soya bean, coffee, pea, bean, rape, cotton, rice or maize plants or plant cell cultures.

The present invention also relates to a process for the preparation of a haemocyanin polypeptide. For this, the nucleic acid molecule according to the invention and/or the

construct is expressed in a suitable host cell and the protein is isolated from the host cell or the medium by means of conventional processes.

Numerous processes for expression of DNA sequences are known to the skilled person; compare Recombinant Gene Expression Protocols in Methods in Molecular Biology, volume 62, Humana Press Totowa New Jersey (1995). The expression can be both constitutive and inducible, inducers such as, for example, IPTG and Zn^{2+} being known to the skilled person. If a His tag has been fused on to the NH_2 terminus of the haemocyanin, the haemocyanin prepared can be purified by chelate formation on a nickel column. Processes for the purification of haemocyanin, in particular KLH, are to be found in Harris et al., Micron 26 (1995), 201-212. The haemocyanin is preferably purified by ion exchange chromatography and/or gel filtration chromatography. The procedure for these measures is known to the skilled person.

In another preferred embodiment, the haemocyanin prepared according to the invention is modified. The modifications include di-, oligo- and polymerization of the monomeric starting substance, for example by crosslinking, e.g. by means of dicyclohexylcarbodiimide or pegylation or association (self assembly). The di-, oligo- and polymers prepared in this way can be separated from one another by gel filtration. The formation of decamers, didecamers or multidecamers is intended in particular. Further modifications include side chain modifications, for example of ϵ -amino-lysine residues of the haemocyanin, or amino- or carboxy-terminal modifications. Modification of the haemocyanin by covalent bonding to an antigen is particularly preferred, it being possible for the antigen to be reacted stoichiometrically or non-stoichiometrically with the haemocyanin. The antigen is preferably selected from tumour antigens, virus antigens and pathogen antigens, as mentioned above. Further modifications include post-translational events, e.g. glycosylation or partial or complete deglycosylation of the protein.

In a preferred embodiment, the haemocyanin obtained by recombinant expression in prokaryotes or glycosylation-deficient eukaryotes is non-glycosylated. Haemocyanin which is glycosylated by recombinant expression in eukaryotes which are capable of glycosylation, such as yeast cells, plant cells, insect cells or mammalian cells, such as CHO cells or HeLa cells, is also possible according to the invention.

- SEQ ID NO:25 (HtH1 domain a + signal peptide),
SEQ ID NO:26 (HtH1 domain b),
SEQ ID NO:27 (HtH1 domain c),
SEQ ID NO:28 (HtH1 domain d),
SEQ ID NO:29 (HtH1 domain e),
SEQ ID NO:30 (HtH1 domain f),
SEQ ID NO:31 (HtH1 domain g),
SEQ ID NO:32 (HtH1 domain h),
SEQ ID NO:33 (partial HtH2 domain b),
SEQ ID NO:34 (HtH2 domain c),
SEQ ID NO:35 (HtH2 domain d),
SEQ ID NO:36 (HtH2 domain e),
SEQ ID NO:37 (HtH2 domain f),
SEQ ID NO:38 (HtH2 domain g),
SEQ ID NO:39 (HtH2 domain h),
SEQ ID NO:40 (partial KLH1 domain b),
SEQ ID NO:41 (KLH1 domain c),
SEQ ID NO:42 (partial KLH1 domain d),
SEQ ID NO:43 (partial KLH1 domain e),
SEQ ID NO:44 (KLH2 domain b),
SEQ ID NO:45 (KLH2 domain c),
SEQ ID NO:46 (partial KLH2 domain d),
SEQ ID NO:47 (KLH2 domain g),
SEQ ID NO:48 (partial KLH2 domain h),
SEQ ID NO:63 (HtH1 domain a' + signal peptide),
SEQ ID NO:64 (HtH1 domain h'),

The term "homology" known to the skilled person describes here the degree to which two or more polypeptide molecules are related, this being determined by the concordance between the sequences, concordance being understood as meaning both identical concordance and conservative amino acid exchange. The percentage of

"homology" is obtained from the percentage of regions in concordance in two or more sequences, taking into account gaps or other sequence peculiarities.

The expression "conservative amino acid exchange" relates to an exchange of an amino acid residue for another amino acid residue, where the exchange does not lead to a change in polarity or charge. An example of a conservative amino acid exchange is the exchange of a non-polar amino acid residue for another non-polar amino acid residue.

The homology of polypeptide molecules which are related to one another can be determined with the aid of known methods. As a rule, special computer programs with algorithms which take account of the particular requirements are employed. Preferred methods for the determination of homology initially produce the greatest concordance between the sequences analysed. Computer programs for determination of the homology between two sequences include, but are not limited to, the GCG program package, including GAP (Devereux, J., et al., *Nucleic Acids Research* 12 (12): 387 (1984); Genetics Computer Group University of Wisconsin, Madison, (WI)); BLASTP, BLASTN and FASTA (Altschul, S. et al., *J. Molec. Biol* 215:403/410 (1990)). The BLAST X program can be obtained from the National Centre for Biotechnology Information (NCBI) and from other sources (BLAST Handbook, Altschul S., et al., NCB NLM NIH Bethesda MD 20894; Altschul, S., et al., *J. Mol.* 215:403/410 (1990)). The known Smith Waterman algorithm can also be used for determining homology.

Preferred parameters for the sequence comparison include the following:

Algorithm:	Needleman and Wunsch, <i>J. Mol. Biol</i> 48:443-453 (1970)
Comparison matrix:	BLOSUM 62 of Henikoff and Henikoff, <i>Proc. Natl. Acad. Sci. USA</i> 89:10915-10919 (1992)
Gap penalty:	12
Gap length penalty:	4
Similarity threshold:	0

The GAP program is also suitable for use with the above parameters. The above parameters are the standard parameters (default parameters) for amino acid sequence comparisons where gaps at the ends do not reduce the homology value. If sequences are very short

Further algorithms, gap opening penalties, gap extension penalties and comparison matrices by way of example, including those mentioned in the Programm-Handbuch, Wisconsin-Paket [Program Handbook, Wisconsin Package], version 9, September 1997, can be used. The choice depends on the comparison to be made and furthermore on whether the comparison is to be made between sequence pairs, in which case GAP or best fit are preferred, or between a sequence and a comprehensive sequence database, in which case FASTA or BLAST are preferred.

In another embodiment, the invention provides haemocyanin polypeptides which are obtainable by the recombinant preparation method or modifications thereof.

Haemocyanin 1 from *Haliotis tuberculata*, which has an apparent molecular weight of 370 kDa in SDS-PAGE under reducing conditions, is particularly preferred.

Haemocyanin 2 from *Haliotis tuberculata*, which has an apparent molecular weight of 370 kDa in SDS-PAGE under reducing conditions, is furthermore particularly preferred.

The haemocyanins are obtainable from whole haemocyanin from *Haliotis tuberculata* by the selective dissociation process described in the examples.

In particular, the invention provides the use of a nucleic acid molecule according to the invention which is bonded to an antigen-coding DNA sequence for specific immunization against this antigen. Without being bound to this theory, the immunization here is based on non-specific stimulation of the immune system by haemocyanin polypeptide epitopes and more extensive specific immunization by recognition of antigen epitopes by the immune system.

Such an immunization is particularly valuable in respect of pathogen antigens, and especially in respect of tumour antigens. The usability of the pharmaceutical composition according to the invention for treatment of tumour diseases also results from the cross-reactivity of the haemocyanin-specific antibodies with carbohydrate residues, which occur on the surface of tumours, such as e.g. the Thomsen-Friedenreich antigen, which occurs in the majority of human tumours, such as epithelial carcinomas, ovarian carcinoma, colorectal carcinoma, mammary carcinoma, bronchial carcinoma and bladder carcinoma.

The pharmaceutical compositions according to the invention can furthermore be employed for treatment of parasitic diseases, such as schistosomiasis, and for prevention of cocaine abuse.

Pharmaceutical compositions which comprise a haemocyanin polypeptide according to the invention in combination with one or more physiologically tolerated additives are provided as a further embodiment of the present invention. As already mentioned above, such a haemocyanin polypeptide can consist of a complete haemocyanin subunit, of one or more domains and of one or more fragments of such domains, provided that these fragments still have the immunological properties of at least one domain of a haemocyanin. Such a pharmaceutical composition is suitable e.g. as an antiparasitic composition, antiviral composition or antitumour composition due to either the non-specific immunostimulation, which is to be attributed solely to the haemocyanin, or due to the specific immune reaction to antigens associated with the haemocyanin. It can thus be employed e.g. for treatment of schistosomiasis, epithelial carcinomas, ovarian carcinoma, colorectal carcinoma, mammary carcinoma, bronchial carcinoma and bladder carcinomas, but is also suitable for treatment of high blood pressure. The treatment of high blood pressure is achieved by carrying out an immunization with the aid of haemocyanin- β -adrenergic receptor peptide constructs and/or fusion proteins.

In another embodiment, the pharmaceutical compositions according to the invention are used as vaccines. They can thus make a valuable contribution to the prophylaxis of diseases caused by known pathogens. This applies in particular to pharmaceutical compositions in which a haemocyanin polypeptide is coupled to a virus, virus

constituent, killed bacteria, bacteria constituents, in particular surface proteins from virus or bacteria envelopes, DNA, DNA constituents, inorganic or organic molecules, e.g. carbohydrates, peptides and/or glycoproteins.

According to another preferred embodiment, the pharmaceutical composition according to the invention is used for prevention of cocaine abuse.

Liposomes are particularly suitable for administration both of the nucleic acid molecules according to the invention and of the haemocyanin polypeptides. The present invention accordingly relates to liposomes which comprise a nucleic acid molecule according to the invention, a construct according to the invention or a haemocyanin polypeptide according to the invention.

Various methods for the preparation of liposomes which can be used for pharmaceutical purposes are known to the skilled person. The selectivity of the liposomes comprising the nucleic acid molecules or haemocyanin polypeptides according to the invention can be increased by the additional incorporation into the liposome of cell recognition molecules, which bind selectively to target cells. Receptor ligands which bind to receptors of the target cells or, especially in the case of tumours, antibodies directed against surface antigens of the particular target cells envisaged are particularly suitable for this.

The haemocyanin polypeptides according to the invention are furthermore envisaged as carrier molecules for medicaments, such as e.g. cytostatics. The increase in the molecular weight prolongs the physiological half-life of the medicaments considerably since the loss due to ultrafiltration in the kidneys is significantly reduced.

The vaccines are formulated by methods known to the skilled person; in some embodiments the additional use of adjuvants, such as e.g. Freund's adjuvant or polysaccharides, is envisaged.

The invention furthermore provides antibodies which react specifically with the haemocyanin polypeptide according to the invention and are obtainable by immunization of a test animal with a haemocyanin polypeptide. Polyclonal antibodies can be obtained

by immunization, for example, of rabbits and subsequent isolation of antisera.

Monoclonal antibodies can be obtained by standard methods by immunization of e.g. mice, isolation and immortalization of the spleen cells and cloning of the hybridomas which produce antibodies specific for haemocyanin.

A screening method for identification of tumour-specific DNA in a cell is furthermore provided, this comprising the steps:

- a) bringing cell DNA and/or cell protein into contact with a probe comprising the nucleic acid molecule according to the invention and/or the antibody according to the invention and
- b) detecting the specific binding.

The tumour to be detected is preferably a bladder carcinoma, epithelial carcinoma, ovarian carcinoma, mammary carcinoma, bronchial carcinoma or colorectal carcinoma.

It is intended to illustrate the invention with the following figures and examples, but not to limit this in any way. Further embodiments, which are also included, are accessible to the skilled person on the basis of the description and the examples.

Fig. 1 shows the characterization and purification of *Haliothis tuberculata* haemocyanin (HtH):

- (a) Electron microscopy of negatively stained whole HtH, which has been purified by ultracentrifugation of cell-free haemolymph;
- (b) SDS polyacrylamide gel electrophoresis (7.5% polyacrylamide) of HtH1 compared with KLH (MW 370 kDa);
- (c) Native polyacrylamide gel electrophoresis (5% polyacrylamide) of the HtH subunit preparation, the anode being at the lower edge;
- (d) Crossed immunoelectrophoresis of the two HtH subunits using anti-HtH antibodies from the rabbit;
- (e) Electron microscopy of the remaining HtH1 didecamers (white arrows) after selective dissociation of HtH2 (black arrows);

- (f) Elution profile of the gel filtration chromatography (Biogel A15m) in the presence of ammonium molybdate/polyethylene glycol solution (pH 5.9) after selective dissociation of HtH2 into its subunit and subsequent concentration of HtH1 by ultracentrifugation;
- (g) Native polyacrylamide gel electrophoresis (6.5% polyacrylamide) of HtH1 and HtH2 subunits purified by gel chromatography compared with the starting material;
- (h,i) Crossed immunoelectrophoresis of chromatographically purified HtH subunits; and
- (j,m) Crossed immunoelectrophoresis of the purified HtH subunits using anti-KLH antibodies from the rabbit which are specific for KLH1 and KLH2.

Fig. 2 shows the analysis of the subunit organization of HtH1, anti-HtH1 antibodies from the rabbit having been used for the immunoelectrophoresis and the anode being on the left-hand side;

- (a) Crossed immunoelectrophoresis after limited proteolysis of HtH1 with the aid of elastase;
- (b) SDS polyacrylamide gel electrophoresis (7.5% polyacrylamide) of the elastase-cleaved HtH1 subunit;
- (c,d,g-j,l,n,p) Crossed immunoelectrophoresis of the elastase cleavage products of the HtH1 subunit;
- (e) Crossed immunoelectrophoresis after limited proteolysis of HtH1 with the aid of V8 protease;
- (f) SDS polyacrylamide gel electrophoresis (7.5% polyacrylamide) of the V8 protease-cleaved HtH1 subunit;
- (k,m,o) Crossed immunoelectrophoresis after limited proteolysis of HtH1 with the aid of the three stated proteases.

Fig. 3 shows the separation of proteolytic cleavage products of the subunit HtH1 with the aid of HPLC.

Fig. 4 shows the cDNA sequence of HtH1 in combination with the intron structure.

Fig. 5 shows the primary structure deduced for HtH1.

Fig. 6 shows the cDNA sequence of Hth2 in combination with the intron structure.

Fig. 7 shows the primary structure deduced for Hth2.

Fig. 8 shows the cDNA sequence of KLH1 in combination with the intron structure.

Fig. 9 shows the primary structure deduced for KLH1.

Fig. 10 shows the cDNA sequence of KLH2 in combination with the intron structure.

Fig. 11 shows the primary structure deduced for KLH2.

EXAMPLES

Material and methods

1. Preparation of the haemolymph and isolation of haemocyanin

Individuals of the European abalone *Haliotis tuberculata* from the French Atlantic coast region were provided by S.M.E.L (Blainville sur Mer, France) and Biosyn (Fellbach, Germany). The animals were kept in a 300 l sea-water aquarium at 17°C and fed with brown algae. For removal of the haemolymph, the abalones were placed on ice in a closed plastic bag. After one hour, large volumes of haemolymph had been secreted through their skin. It emerged that the haemocyanin obtained by this process is identical to the haemocyanin which could be collected by cutting a hollow in the foot of cooled-down sea snails using a scalpel blade. The blood cells were separated from the haemolymph by centrifugation at 800 g for 30 min at 4°C. The whole haemocyanin was then immediately sedimented by preparative ultracentrifugation at 30,000 g for 4 hours at 4°C. The supernatant was discarded and the blue haemocyanin pellet was suspended overnight in "stabilization buffer" (0.05 M Tris, 5 mM CaCl₂, 5 mM MgCl₂, 0.15 M NaCl, 1 mM PMSF, pH 7.4) and stored at 4°C.

Using the process described by Harris et al., 1995, supra, intact Hth1 was obtained from the whole Hth by selective dissociation of Hth2 in ammonium molybdate/polyethylene

glycol (1%/0.2%) solution, pH 5.9 and subsequent ultracentrifugation. The partly purified HtH1 pellet formed was dissolved and purified to homogeneity by gel filtration on a Biogel A15m device. The last step resulted in small amounts of purified HtH2. Native HtH1 and HtH2 was dissociated quantitatively into the subunits by dialysis against "dissociation buffer" (0.13 M glycine/NaOH, pH 9.6) at 4°C overnight; the presence of EDTA was not necessary. 1 mM PMSF was added at each stage of the purification to inhibit proteolysis.

2. Electron microscopy

Conventional "negative staining" was carried out by the individual drop method (Harris and Horne in Harris, J.R. (editors) *Electron microscopy in biology*, (1991), IRL Press Oxford, p. 203-228). Carbon carrier films were initially subjected to glow discharge for 20 seconds to render them hydrophilic and adsorptive for the protein. The protein samples are allowed to adsorb on to the carbon films for 60 seconds. The buffer salts are then removed by sequential washing with four successive 20 µl drops of water. Finally, the gratings are negatively stained with a 20 µl drop of 5% aqueous ammonium molybdate containing 1% trehalose (pH 7.0) and left to dry at room temperature. A Zeiss EM 900 transmission electron microscope is used for the electron microscopy analysis.

3. Polyacrylamide gel electrophoresis and immunoelectrophoresis

SDS polyacrylamide gel electrophoresis (SDS-PAGE) was carried out by the method of Laemmli (*Nature* 227 (1970), 670-685). An alkaline system according to Markl et al. (1979) *J. Comp. Physiol.* 133 B, 167-175 with a 0.33 M Tris/borate, pH 9.6 as the gel buffer and 0.065 M Tris/borate, pH 9.6 as the electrode buffer was used for the native PAGE. Crossed and "crossed-line" immunoelectrophoresis (IE) were carried out in accordance with Weeke (*Scand. J. Immunol.* 2 (1973), Suppl. 1, 47-56) or Kroll (*Scand. J. Immunol.* 2, Suppl. 1 (1973), 79-81). Rabbit antibodies against dissociated whole HtH and purified HtH1 were produced by Charles River Deutschland (Kisslegg, Germany). The immunization process was carried out in accordance with Markl and Winter (*J. Comp. Physiol.* 159B (1989), 139-151).

4. Limited proteolysis and isolation of the fragments

The limited proteolysis was carried out at 37°C in 0.13 M glycine/NaOH, pH 9.6 by addition of one of the following enzymes (Sigma, Deisenhofen, Germany), which were dissolved in 0.1 M NH_4HCO_3 , pH 8.0: *Staphylococcus aureus* V8 protease type XVII (8400), papain type II from papaya milk (P-3125), bovine pancreas elastase type IV (E-0258), chymotrypsin and trypsin. The haemocyanin concentration was between 1 and 10 mg/ml. The final concentration of the enzyme was 2% (weight/weight). The proteolysis was ended after 5 hours by freezing to -20°C. The HPLC process was carried out on a device from Applied Biosystems (BAI, Bensheim, Germany) equipped with a model 1000S Diode Array detector. The proteolytic fragments were introduced on to a small Mono-Q anion exchanger column (Pharmacia, Freiburg, Germany), which had been equilibrated with 0.02 M Tris/HCl, pH 8.0, and were eluted with a linear sodium chloride gradient (0.0 M – 0.5 M CaCl) in the same buffer at a flow rate of 1 ml/min. Alternatively, the proteolytic fragments were isolated by cutting out the bands from native PAGE gels (Markl et al., 1979) J. Comp. Physiol. **133** B, 167-175, after they had first been inversely stained with the Roti-White system (Roth, Karlsruhe, Germany) in accordance with Fernandez-Patron et al. (1995) Anal. Biochem. **224**, 203-211. For subsequent cleavage with a second enzyme, the fragments isolated were first dialysed overnight against 0.13 M glycine/NaOH, pH 9.6 to remove NaCl.

5. Amino acid sequence analysis

The proteins obtained by the HPLC process were denatured in SDS-containing sample buffer and separated by SDS-PAGE (Laemmli, 1970, supra; 7.5 % polyacrylamide). To prevent blocking of the NH_2 terminus, 0.6% (weight/weight) thioglycolic acid was added to the cathode buffer (Walsh et al., Biochemistry **27** (1988), 6867-6876). The protein bands were transferred by electro-transfer to ProBlot membranes (Applied Biosystems, Germany) in a vertical blotting chamber (25 mM borate buffer, pH 8.8, containing 2 mM EDTA; 10 min/100 mA, 15 min/200 mA, 12 h/300 mA). Detection of the individual polypeptides on the membranes was carried out with Ponceau S stain. The polypeptide bands of interest were cut out and sequenced in a 477A protein sequencing device from Applied Biosystems. The amounts of polypeptides applied to the sequencing device were in the lower pmol range.

6. cDNA cloning and sequence analysis

A lambda-cDNA expression library was established from poly(A⁺)-RNA from *Haliotis* mantle tissue using the vector Lambda ZAP Express[®] in accordance with the manufacturer's instructions (Stratagene, Heidelberg, Germany). The clones were isolated using HtH-specific rabbit antibodies. The nucleotide sequencing was carried out on both strands using the Taq Dye deoxy Terminator[®] system. The sequences were arranged with the software CLUSTAL W (1.7)[®] and TREEVIEW[®] (Thompson et al., Nucl. Acids Res. 22 (1994), 4673-4680).

Example 1:

Isolation of HtH and separation of two different types (HtH1 and HtH2)

The haemolymph was obtained from adult abalones. The blood cells were removed by centrifugation and the haemocyanin was then sedimented by ultracentrifugation. The blue haemocyanin pellet was dissolved again in "stabilization buffer" (pH 7.4) and examined by electron microscopy (figure 1a). It comprised mainly typical di-decamers, accompanied by a small content of decamers and tridecamers. Denaturing in 2% SDS in the presence of reducing substances and subsequent SDS-PAGE separation resulted in a single band, which corresponded to the polypeptide with an apparent molecular weight of 370 kDa, which is only slightly below the apparent subunit weight of KLH (figure 1b). Complete dissociation of the oligomers and of the di-decamers into the native polypeptides (subunits) was achieved by overnight dialysis of HtH against "dissociation buffer" (pH 9.6). The native PAGE method, which was used on these samples, showed a main and a secondary component (figure 1c). Crossed immunoelectrophoresis (crossed IE) using polyclonal rabbit antibodies generated against purified whole HtH showed two components which are immunologically different but show the classical reaction of being partly immunologically identical (figure 1d). Their preparative isolation (figure 1e-i) showed that they are subunits of two different HtH types, called HtH1 and HtH2, and the patterns of the native PAGE and crossed IE methods could be assigned to each individually (figure 1c, d).

The separation of HtH1 and HtH2 was carried out by the method of selective dissociation according to Harris et al., 1995, *supra*. In ammonium molybdate/polyethylene glycol, HtH1 in the oligomer state (di-decamer) was completely stable, while HtH2 dissociated completely into the subunits (figure 1e). This allowed quantitative sedimentation of HtH1 in an ultracentrifuge, while the majority of the HtH2 remained in the supernatant. Large amounts of HtH1 were purified to homogeneity from the redissolved pellet by gel filtration chromatography, which also resulted in small amounts of pure HtH2 (figure 1f). The fractions were investigated by native PAGE (figure 1g) and crossed IE (figure 1h, i). The process of selective dissociation of HtH2 removed all the tri-decamer from the samples, which suggests that the latter are built up from HtH2, but not from HtH1 (figure 1e). The selective dissociation behaviour of HtH2 and also the ability to form aggregates which are larger than *in vivo* di-decamers correspond to the properties of KLH2. Conversely, the stability of HtH1 under these conditions and its inability to assemble into aggregates larger than di-decamers resemble the behaviour of KLH1. This feature of being related is demonstrated further by the reaction of anti-KLH1 and anti-KLH2 antibodies against the two HtH types (figure 1j-m).

Example 2:

Analysis of the organization of the HtH1 subunit

The eight functional units (FUs, often called "functional domains") which form a mollusc haemocyanin subunit differ in primary structure and show no immunological cross-reactivity, as emerged from crossed IE. In the case of the purified HtH1 subunit (Figure 1g, h), small concentrations of five different proteases (elastase, V8 protease, papain, trypsin and chymotrypsin) which had cleaved the peptide bonds between adjacent FUs of KLH1 and KLH2 were used (Gebauer et al., 1994, *supra*, Söhnngen et al., 1997, *supra*). The cleavage products were investigated by crossed IE and SDS-PAGE (Fig. 2). Elastase treatment produces eight individual FUs, deduced from the number of different immunoprecipitation peaks in the crossed IE (Fig. 2a) and with the apparent molecular weight of approx. 50 kDa of the main portion of the cleavage products in SDS-PAGE (Fig. 2b). A further precipitation peak was recognized as FU dimer, which was formed by incomplete cleavage of the segment ab (Fig. 2a). By an HPLC process with a Mono-Q column (Fig. 3a), two of the elastase cleavage products

were obtained in a sufficient purity to allow their clear assignment to two of the eight precipitation peaks (Fig. 2c, d) by "crossed-line IE". The other four proteases had different cleavage patterns, which comprised mixtures of individual FUs and larger fragments containing two, three or more FUs (e.g. Fig. 2e, f). Many of them were concentrated to a sufficient amount by the HPLC process (Fig. 3b-e) to allow their identification in their corresponding SDS-PAGE and crossed IE patterns. A number of these components were sequenced N-terminally by blot transfer of SDS gels on ProBlot® membranes (Table 1). The results were compared with the N-terminal sequences which had been obtained from the apparently orthologous protein in *Megathura crenulata*, KLH1 (Table I), the complete FU arrangement of which is available (Söhngen et al., 1997, supra; cf. Fig. 5b). The result of the entire batch led to the determination of the complete FU arrangement within the HtH1 subunit (Fig. 2a).

In particular, cleavage of the HtH1 subunit (1-abcdefgh) with V8 protease resulted in four precipitation peaks in the crossed IE (Fig. 2e). The SDS-PAGE showed five different fragments (Fig. 2f): 220 kDa (5 FUs), 185 kDa (4 FUs), 100 kDa (2 FUs), 55 kDa (1 FU) and 46 kDa (1 FU). The 100 kDa fragment was isolated by the HPLC method (Fig. 3b) and identified by N-terminal sequencing as 1-ab, since the sequence was identical to that of the intact subunit (Table I). In the "crossed-line" IE process, 1-ab fused with three precipitation peaks of the elastase cleavage pattern. On the basis of the evaluation, they represent fragments 1-ab, 1-a and 1-b (Fig. 2g). However, it remained unclear which peak represents 1-a and which 1-b. In a second step, the 1-ab purified by HPLC was cleaved by elastase into its component FUs, from which one could be eluted by the native PAGE gel strip method and was assigned to the elastase pattern by the "crossed-line" IE method (Fig. 2h) and sequenced N-terminally. This component had the same N-terminal sequence as the whole subunit and was therefore identical to 1-a. The second FU of the 100 kDa fragment is thus 1-b (Fig. 2a; Table I). HPLC-purified 1-c and 1-h were also obtained (Fig. 3b), identified by N-terminal sequence similarities with the corresponding FUs in KLH1 (Table I) and assigned by the "crossed-line" IE method to their corresponding precipitation peaks in the elastase pattern (Fig. 2i, j). 1-a, 1-b, 1-c and 1-h were furthermore identified (Fig. 2a). Using papain for subunit cleavage, five different peaks were obtained in the crossed IE method (Fig. 2k). A 100 kDa fragment (2 FUs) was purified from such a sample by the HPLC method (Fig. 3c), and, according to the "crossed-line" IE method, contained the FU 1-h already identified and one of the four

FUs still not identified and therefore must be 1-gh (Fig. 2k, 3c). In fact, this fragment had an N-terminal sequence which showed similarities with KLH1-g (Table I). For further confirmation, the HPLC-purified fragment 1-gh was cleaved into its constituent FUs with elastase, from which 1-g was purified and identified by N-terminal sequencing. It was assigned to its peak in the elastase cleavage pattern by the "crossed-line" IE method (Fig. 2l).

The 220 kDa fragment from the V8 protease cleavage (Fig. 2e, f) was purified by HPLC (Fig. 3b) and in the "crossed-line" IE method fused with 1-h, 1-g and three peaks of the elastase cleavage pattern which have not yet been identified. The 185 kDa fragment was furthermore obtained in a sufficient purity (Fig. 2e, f; 3b), and it was shown that it comprised the same components with the exception of 1-h. This suggested that the 22 kDa and the 185 kDa fragment are 1-defgh and 1-defg respectively. In fact, the N-terminal sequence was practically identical and furthermore showed similarity with KLH1-d (Table I). Cleavage of the HtH1 subunit with trypsin resulted in a large number of components in the molecular weight range of one or two FUs (Fig. 2m). Several of the components were concentrated in HPLC fractions (Fig. 3d). A 100 kDa fragment proved to be particularly useful since it had the same N-terminal sequence as the fragment 1-defg from the v8 protease cleavage (Table I); the 100 kDa fragment should therefore be 1-de. In the "crossed-line" IE method, this component fused with two of the three FU peaks of the elastase cleavage pattern not yet identified (Fig. 2n), which should therefore be 1-d and 1-e, and thus left a single possibility for 1-f. The "crossed-line" IE method also showed that FU 1-f was furthermore present in the 1-de fraction (Fig. 2n). The identification of 1-f was confirmed by cleavage of the subunit with chymotrypsin (Fig. 2o) and a subsequent HPLC process (Fig. 3e). This cleavage gave, inter alia, a 95 kDa fragment (2 FUs) which fused with 1-g and a second peak (Fig. 2p) in the "crossed-line" IE method and could therefore be either 1-gh (which could be ruled out since 1-h had already been identified) or 1-fg (which seems appropriate on the basis of the further peak in question, which was identical to the remaining candidate). In fact, this fragment showed a new N-terminal sequence which is similar to KLH1-f in a certain manner. The last problem was now to assign the two remaining FU peaks to 1-d and 1-e. This was achieved using HPLC-isolated FUs from samples in which the subunit had been cleaved with elastase. (Fig. 2c, d; 3a). The more acidic component in the crossed IE method was deduced as 1-d from its N-terminal sequence, which is identical to that of 1-defgh (Fig.

2c, Table I), while the more basic component of the 1-d/1-g pair had a new N-terminal sequence (Table I) and therefore had to be 1-e (Fig. 2a). The structure of the functional units of subunit HtH1 was thus clarified.

Example 3:

Comparison of the molecular weights and N-terminal sequences of the biochemically isolated functional units (FUs) from HtH1 and KLH1. The various FUs, each with an intact binuclear copper-binding site, were liberated from their larger unit as globular segments by limited proteolysis; cf. the section "Isolation and analysis of the units from HtH1". The KLH1 data were obtained from Söhnngen et al., *supra*. The assignment as an actual unit was done on the basis of the molecular weight and the immunological properties (cf. Fig. 2). The unusually low molecular weight of isolated HtH1-d could mean that a large peptide was split off C-terminally.

TABLE 1

Functional unit	Weight (kDa)	N-terminal sequence
HtH1-a	53	DNV VR KDVSHLTDDEVQ
KLH1-a	50	ENL VR KDVERL
HtH1-b	48	?
KLH1-b	45	?
HtH1-c	46	FEDEKHSLR IR KNVDSLTPPEENTNERLR
KLH1-c	45	KVPRSRLL IR KNVDRLTPSE
HtH1-d	40	VEEVTGASH IR KNLNDLNTGEM
KLH1-d	50	EVTSANR IR KNIENLS
HtH1-e	49	ILDHDHEEEIL VR KNIIDLSP
KLH1-e	50	?
HtH1-f	50	KLNSRKHTPNR VR HELSSLSSRDIASLKA
KLH1-f	45	HHLSXNK VR HDLSTL
HtH1-g	45	DHQSGSIAGSG VR KDVNTLTKAETDNLRE
KLH1-g	45	SSMAGHF VR KDINTLTP
HtH1-h	55	DEHHDDRLLADVLR IR KEVDFLSLQEANAIDK
KLH1-h	60	HEDHHEDIL VR KNIHSL

Example 4:**Cloning of haemocyanin cDNA**

1. For cloning the cDNA of haemocyanin, mRNA was isolated from the mantle tissue of the particular mollusc. The first cDNA strand was obtained by reverse transcription with Oligo(dT) as a primer. The second strand was obtained conventional synthesis with random primers. The cDNA obtained in this way was cloned in a lambda expression vector to form a cDNA expression library. Using an anti-haemocyanin antibody, the library was searched under suitable conditions, positive clones being obtained. These positive clones were isolated, sequenced and characterized.

2. A cDNA probe was prepared from the N-terminal region of a positive clone obtained, and the cDNA library was searched with this. The positive clones obtained were in turn isolated, sequenced and characterized.
3. To obtain sequences arranged still further to 5', another expression library was established from cDNA, this being obtained with the aid of a combination of haemocyanin-specific and "random" primers. This cDNA library was searched with cDNA probes which correspond to the "N-terminal" regions of the positive clones obtained under (2.). The positive clones obtained were isolated, sequenced and characterized.

Example 5:

Cloning of haemocyanin genes

Genomic DNA was isolated by standard methods. The PCR reaction was carried out with the aid of haemocyanin-specific primers in order to amplify the gene sections of the haemocyanins of interest. The amplification products obtained were cloned in a suitable vector (for example pGem T or pGem T easy (Promega, Mannheim) sequenced and characterized.

Example 6:

Recombinant expression of haemocyanin

A PCR reaction was carried out with a cDNA clone which contains the coding sequence for HtH-1d in order to amplify specifically the coding sequence of the domain 1d.

Synthetically prepared oligonucleotides were used as primers.

Primer 1 (upstream) comprises six nucleotides of the end of the domain HtH-1c, an *SacI* cleavage site and 12 nucleotides of the end of the domain HtH-1d.

Primer 2 (downstream) comprises six nucleotides of the start of the domain HtH-1e, an *SalI* cleavage site and an HtH1-d-specific sequence.

PCR conditions:

2	min	95°C
30	sec	95°C
30	sec	55°C
1	min	72°C
35	cycles	
10	min	72°C

The amplification product was cloned in the pGEM T easy PCR cloning vector (Promega) in XL-1 Blue (Stratagene). After isolation of the recombinant plasmid and restriction with *SacI* and *SalI*, the cDNA of domain 1d could be isolated. The expression vector pQE30 (Qiagen) was also restricted with the corresponding enzymes.

The ligation was then carried out between the Hth-1d-cDNA (restricted with *SacI* and *SalI*) and pQE (restricted with *SacI* and *SalI*). Directed cloning of the cDNA which codes for Hth-1d in an expression vector is thus possible. The expression of Hth1-d in pQE in XL-1 Blue is carried out in accordance with the manufacturer's instructions. The expression of further Hth1, Hth2 or KLH1 or KLH2 domains can be carried out analogously.

Preliminary Amendment -1-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

WHAT IS CLAIMED IS:

1. Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(a) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),

Preliminary Amendment -2-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),

Preliminary Amendment -3-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerate to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;

Preliminary Amendment -4-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and
- (g) combinations of several of the DNA sequences described under (a) to (f).

2. Nucleic acid molecule according to claim 1, **characterized in that** the hybridization described under (b) or (d) is carried out under stringent conditions.

3. Nucleic acid molecule according to claim 1,
characterized in that the nucleic acid molecule
described under (e) is at least 80% homologous to one
of the nucleic acid sequences described under (a).

Preliminary Amendment -5-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

4. Nucleic acid molecule according to claim 1, **characterized in that** the nucleic acid molecule described under (e) is at least 90 % homologous to one of the nucleic acid sequences described under (a).

5. Nucleic acid molecule according to claim 1, **characterized in that** the nucleic acid molecule described under (e) is at least 95 % homologous to one of the nucleic acid sequences described under (a).

6. Nucleic acid molecule according to claim 1,
characterized in that it is a deoxyribonucleic acid
molecule.

7. Construct comprising a nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(a) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),

Preliminary Amendment -6-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),

[illegible]

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),

Preliminary Amendment -9-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

and

(g) combinations of several of the DNA sequences described under (a) to (f)

8. Construct according to claim 7, further comprising a promoter which is suitable for expression control, the nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof being under the control of the promoter.

9. Construct according to claim 7, further comprising a nucleic acid sequence which codes for an antigen and is coupled directly to the nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof.

10. Construct according to claim 9, wherein the antigen is selected from: tumour antigens, virus antigens and antigens of bacterial or parasitic pathogens.

11. Construct according to claim 7, wherein the construct comprises at least a part of a vector, the vector being selected from: bacteriophages, adenoviruses, vaccinia viruses, baculoviruses, SV40 virus and retroviruses.

12. Construct according to claim 7, wherein the

Preliminary Amendment -12-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;

Preliminary Amendment -13-
 Clean Copy of Amendments
 Markl, et al.
 § 371 Patent Application of PCT/EP00/02410
 filed September 17, 2001

- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and
- (g) combinations of several of the DNA sequences described under (a) to (f).

14. Host cell according to claim 13, **characterized in that** the prokaryotic host cell is selected from E. coli and Bacillus subtilis.

Preliminary Amendment -14-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

15. Host cell according to claim 13, **characterized in that** the eukaryotic host cell is selected from yeast cells, plant cells, insect cells and mammalian cells, preferably from CHO cells, COS cells and HeLa cells.

16. Process for the preparation of a haemocyanin polypeptide, wherein a nucleic acid molecule and/or a construct comprising said nucleic acid molecule is expressed in a suitable host cell and the protein is isolated, if appropriate, wherein said nucleic acid molecule comprising a nucleic acid molecule comprises a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(a) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),

SEO ID NO:2 (HtH1 domain b),

SEQ ID NO:3 (HtH1 domain c),

SEQ ID NO:4 (HtH1 domain d),

SEQ ID NO:5 (HtH1 domain e),

SEQ ID NO:6 (HtH1 domain f),

SEQ ID NO:7 (HtH1 domain g),

SEQ ID NO: 8 (HtH1 domain h),

SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),

Preliminary Amendment -16-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

(b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence

according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;

- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin;
and
- (g) combinations of several of the DNA sequences described under (a) to (f).

Preliminary Amendment -18-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

that the haemocyanin polypeptide prepared is modified naturally or chemically.

18. Process according to claim 17, **characterized in that** the modification is a crosslinking or a covalent bonding to an antigen.

19. Process according to claim 16, **characterized in that** the expression is carried out in a host cell.

20. Haemocyanin polypeptide, comprising an amino acid sequence which is coded by one or more of a nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(a) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),

Preliminary Amendment -19-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),

- 20 -

of PCT/EP00/02410

Preliminary Amendment -21-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

counter-strand of a nucleic acid sequence
according to (a) and code for a polypeptide which
has the immunological properties of at least one
domain of a haemocyanin;

(c) nucleic acid sequences which on the basis of the
genetic code are degenerated to the DNA sequences
defined under (a) and (b) and code for a
polypeptide which has the immunological properties
of at least one domain of a haemocyanin;

(d) nucleic acid sequences which hybridize with one
of the nucleic acid sequences described under (a)
to (c) and the counter-strand of which codes for a
polypeptide which has the immunological properties
of at least one domain of a haemocyanin;

(e) nucleic acid sequences which are at least 60%
homologous to one of the nucleic acid sequences
described under (a);

(f) variants of the sequences described under (a) to
(d), the variants containing additions, deletions,
insertions or inversions with respect to the
sequences described under (a) to (d) and coding
for a polypeptide which has the immunological
properties of at least one domain of haemocyanin;
and

(g) combinations of several of the DNA sequences
described under (a) to (f).

SEQ ID NO:25 (HtH1 domain a + signal peptide),
SEQ ID NO:26 (HtH1 domain b),
SEQ ID NO:27 (HtH1 domain c),
SEQ ID NO:28 (HtH1 domain d),
SEQ ID NO:29 (HtH1 domain e),
SEQ ID NO:30 (HtH1 domain f),
SEQ ID NO:31 (HtH1 domain g),
SEQ ID NO:32 (HtH1 domain h),
SEQ ID NO:33 (partial HtH2 domain b),
SEQ ID NO:34 (HtH2 domain c),
SEQ ID NO:35 (HtH2 domain d),
SEQ ID NO:36 (HtH2 domain e),
SEQ ID NO:37 (HtH2 domain f),
SEQ ID NO:38 (HtH2 domain g),
SEQ ID NO:39 (HtH2 domain h),
SEQ ID NO:40 (partial KLH1 domain b),
SEQ ID NO:41 (KLH1 domain c),
SEQ ID NO:42 (partial KLH1 domain d),
SEQ ID NO:43 (partial KLH1 domain e),
SEQ ID NO:44 (KLH2 domain b),
SEQ ID NO:45 (KLH2 domain c),
SEQ ID NO:46 (partial KLH2 domain d),
SEQ ID NO:47 (KLH2 domain g),
SEQ ID NO:48 (partial KLH2 domain h),
SEQ ID NO:63 (HtH1 domain a' + signal peptide),
SEQ ID NO:64 (HtH1 domain h'),
SEQ ID NO:65 (partial HtH2 domain a),

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

```

SEQ ID NO:66 (HtH2 domain b'),
SEQ ID NO:67 (HtH2 domain d'),
SEQ ID NO:68 (HtH2 domain e'),
SEQ ID NO:69 (partial KLH1 domain b'),
SEQ ID NO:70 (KLH1 domain e'),
SEQ ID NO:71 (KLH1 domain f),
SEQ ID NO:72 (KLH1 domain g),
SEQ ID NO:73 (KLH1 domain h),
SEQ ID NO:74 (KLH2 domain b'),
SEQ ID NO:75 (KLH2 domain c'),
SEQ ID NO:76 (KLH2 domain d'),
SEQ ID NO:77 (KLH2 domain e),
SEQ ID NO:78 (KLH2 domain f),
SEQ ID NO:79 (KLH2 domain g'),

```

or a fragment of one of these sequences which has the immunological properties of at least one domain of a haemocyanin.

22. Recombinant haemocyanin polypeptide, obtainable by a process for the preparation of a haemocyanin polypeptide, wherein a nucleic acid molecule and/or a construct comprising said nucleic acid molecule is expressed in a suitable host cell and the protein is isolated, if appropriate, wherein said nucleic acid molecule comprising a nucleic acid molecule comprises a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

Preliminary Amendment -24-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

(a) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),

Preliminary Amendment -25-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

```

SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),
SEQ ID NO:80 (HtH1 domain a" + signal peptide),
SEQ ID NO:81 (HtH1 domain b"),
SEQ ID NO:82 (HtH1 domain c"),
SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),

```

Preliminary Amendment -26-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerated to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences

(f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and

23. Recombinant haemocyanin polypeptide according to claim 22, **characterized in that** it comprises the sequences SEQ ID NO: 25 to 32 and is haemocyanin 1 from *Haliotis tuberculata*, it being possible for the sequence with SEQ ID NO:25 to be replaced by SEQ ID NO:63 and/or SEQ ID NO:32 to be replaced by SEQ ID NO:64.

25. Recombinant haemocyanin polypeptide according to claim 23, **characterized in that** it has an apparent

Preliminary Amendment -28-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

molecular weight of 370 kDa in SDS-PAGE under
reducing conditions.

26. Recombinant haemocyanin polypeptide according to
claim 24, **characterized in that** it has an apparent
molecular weight of 370 kDa in SDS-PAGE under
reducing conditions.

27. Recombinant haemocyanin polypeptide according to
claim 21, **characterized in that** the haemocyanin
polypeptide comprises either the sequences SEQ ID NO:
40 to 43 or the sequences SEQ ID NO:40 to 43 and SEQ
ID NO:71 to 73 and is KLH1 from *Megathura crenulata*,
it being possible in each case the for sequence with
SEQ ID NO:40 to be replaced by SEQ ID NO:66 and/or
SEQ ID NO:43 to be replaced by SEQ ID NO:70.

28. Recombinant haemocyanin polypeptide according to
claim 21, **characterized in that** the haemocyanin
polypeptide comprises either the sequences SEQ ID NO:
44 to 48 or the sequences SEQ ID NO:44 to 46, 77, 78,
47, 48 and is KLH2 from *Megathura crenulata*, in being
possible in each case for the sequence with SEQ ID
NO:44 to be replaced by SEQ ID NO:74, SEQ ID NO:45 to
be replaced by SEQ ID NO:75, SEQ ID NO:46 to be
replaced by SEQ ID NO:76 and/or SEQ ID NO:47 to be
replaced by SEQ ID NO:79.

29. Recombinant haemocyanin polypeptide according to
claim 20, **characterized in that** it is bonded
covalently to viruses, virus constituents, bacteria,

Preliminary Amendment -29-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

bacteria constituents, DNA, DNA constituents,
inorganic or organic molecules, such as e.g.
carbohydrates, peptides and/or glycoproteins.

30. Recombinant haemocyanin polypeptide according to
claim 20, **characterized in that** the haemocyanin
polypeptide is non-glycosylated.

31. Recombinant haemocyanin polypeptide according to
claim 20, **characterized in that** the haemocyanin
polypeptide is glycosylated.

32. Pharmaceutical composition, comprising a nucleic
acid molecule and/or a construct comprising said
nucleic acid molecule and physiologically tolerated
additives, wherein said nucleic acid molecule
comprises a nucleic acid sequence which codes for a
haemocyanin, a haemocyanin domain or a functional
fragment thereof with the immunological properties of
at least one domain of a haemocyanin, the nucleic
acid sequence being selected from:

(a) nucleic acid sequences which are selected from
the group consisting of the DNA sequences shown
below or the corresponding RNA sequences or which
contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),

SEQ ID NO:2 (HtH1 domain b),

SEQ ID NO:3 (HtH1 domain c),

SEQ ID NO:4 (HtH1 domain d),

Preliminary Amendment -30-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

SEQ ID NO:5 (HtH1 domain e),
 SEQ ID NO:6 (HtH1 domain f),
 SEQ ID NO:7 (HtH1 domain g),
 SEQ ID NO: 8 (HtH1 domain h),
 SEQ ID NO:9 (partial HtH2 domain b),
 SEQ ID NO:10 (HtH2 domain c),
 SEQ ID NO:11 (HtH2 domain d),
 SEQ ID NO:12 (HtH2 domain e),
 SEQ ID NO:13 (HtH2 domain f),
 SEQ ID NO:14 (HtH2 domain g),
 SEQ ID NO:15 (HtH2 domain h),
 SEQ ID NO:16 (partial KLH1 domain b),
 SEQ ID NO:17 (KLH1 domain c),
 SEQ ID NO:18 (KLH1 domain d),
 SEQ ID NO:19 (partial KLH1 domain e),
 SEQ ID NO:20 (KLH2 domain b),
 SEQ ID NO:21 (KLH2 domain c),
 SEQ ID NO:22 (partial KLH2 domain d),
 SEQ ID NO:23 (KLH2 domain g),
 SEQ ID NO:24 (partial KLH2 domain h),
 SEQ ID NO:49 (HtH1 domain a' + signal peptide),
 SEQ ID NO:50 (partial HtH2 domain a),
 SEQ ID NO:51 (HtH2 domain b'),
 SEQ ID NO:52 (HtH2 domain d'),
 SEQ ID NO:53 (HtH2 domain e'),
 SEQ ID NO:54 (KLH1 domain e'),
 SEQ ID NO:55 (KLH1 domain f),
 SEQ ID NO:56 (KLH1 domain g),
 SEQ ID NO:57 (KLH2 domain b'),
 SEQ ID NO:58 (KLH2 domain c'),
 SEQ ID NO:59 (KLH2 domain d'),

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),

Preliminary Amendment -34-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),
SEQ ID NO:61 (KLH2 domain f),
SEQ ID NO:62 (KLH2 domain g'),

Preliminary Amendment -36-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

counter-strand of a nucleic acid sequence
according to (a) and code for a polypeptide which
has the immunological properties of at least one
domain of a haemocyanin;

(c) nucleic acid sequences which on the basis of the
genetic code are degenerated to the DNA sequences
defined under (a) and (b) and code for a
polypeptide which has the immunological properties
of at least one domain of a haemocyanin;

(d) nucleic acid sequences which hybridize with one
of the nucleic acid sequences described under (a)
to (c) and the counter-strand of which codes for a
polypeptide which has the immunological properties
of at least one domain of a haemocyanin;

(e) nucleic acid sequences which are at least 60%
homologous to one of the nucleic acid sequences
described under (a);

(f) variants of the sequences described under (a) to
(d), the variants containing additions, deletions,
insertions or inversions with respect to the
sequences described under (a) to (d) and coding
for a polypeptide which has the immunological
properties of at least one domain of haemocyanin;
and

(g) combinations of several of the DNA sequences
described under (a) to (f).

Preliminary Amendment -37-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

35. Pharmaceutical composition according to claim 34, **characterized in that** it is used as an antiparasitic composition, antiviral composition or as an antitumour composition.

36. Pharmaceutical composition according to claim 34, **characterized in that** it is used for treatment of one of the following diseases: schistosomiasis, high blood pressure, surface bladder carcinomas, epithelial carcinomas, ovarian carcinoma, mammary carcinoma, bronchial carcinoma and colorectal carcinoma.

37. Pharmaceutical composition according to claim 34, **characterized in that** it is used as a vaccine.

38. Pharmaceutical composition according to claim 34, **characterized in that** it is used for prevention of cocaine abuse.

39. Use of a haemocyanin polypeptide as a carrier substance for medicaments, wherein said haemocyanin polypeptide comprises an amino acid sequence which is coded by one or more of the nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(a) nucleic acid sequences which are selected from

Preliminary Amendment -38-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

the group consisting of the DNA sequences shown
below or the corresponding RNA sequences or which
contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),

Preliminary Amendment -41-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

(f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and

(g) combinations of several of the DNA sequences described under (a) to (f).

40. Liposome, comprising a nucleic acid molecule , a construct comprising said nucleic acid molecule and/or a haemocyanin polypeptide encoded by said nucleic acid molecule, wherein said nucleic acid molecule comprises a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(a) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),

SEQ ID NO:2 (HtH1 domain b),

SEQ ID NO:3 (HtH1 domain c),

SEQ ID NO:4 (HtH1 domain d),

SEQ ID NO:5 (HtH1 domain e),

SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),
SEQ ID NO:14 (HtH2 domain g),
SEQ ID NO:15 (HtH2 domain h),
SEQ ID NO:16 (partial KLH1 domain b),
SEQ ID NO:17 (KLH1 domain c),
SEQ ID NO:18 (KLH1 domain d),
SEQ ID NO:19 (partial KLH1 domain e),
SEQ ID NO:20 (KLH2 domain b),
SEQ ID NO:21 (KLH2 domain c),
SEQ ID NO:22 (partial KLH2 domain d),
SEQ ID NO:23 (KLH2 domain g),
SEQ ID NO:24 (partial KLH2 domain h),
SEQ ID NO:49 (HtH1 domain a' + signal peptide),
SEQ ID NO:50 (partial HtH2 domain a),
SEQ ID NO:51 (HtH2 domain b'),
SEQ ID NO:52 (HtH2 domain d'),
SEQ ID NO:53 (HtH2 domain e'),
SEQ ID NO:54 (KLH1 domain e'),
SEQ ID NO:55 (KLH1 domain f),
SEQ ID NO:56 (KLH1 domain g),
SEQ ID NO:57 (KLH2 domain b'),
SEQ ID NO:58 (KLH2 domain c'),
SEQ ID NO:59 (KLH2 domain d'),
SEQ ID NO:60 (KLH2 domain e),

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (c) nucleic acid sequences which on the basis of the genetic code are degenerate to the DNA sequences defined under (a) and (b) and code for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (d) nucleic acid sequences which hybridize with one of the nucleic acid sequences described under (a) to (c) and the counter-strand of which codes for a polypeptide which has the immunological properties of at least one domain of a haemocyanin;
- (e) nucleic acid sequences which are at least 60% homologous to one of the nucleic acid sequences described under (a);
- (f) variants of the sequences described under (a) to (d), the variants containing additions, deletions, insertions or inversions with respect to the sequences described under (a) to (d) and coding for a polypeptide which has the immunological properties of at least one domain of haemocyanin; and
- (g) combinations of several of the DNA sequences

Preliminary Amendment -45-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

described under (a) to (f).

41. Liposome according to claim 40, **characterized in that** the liposome furthermore comprises cell recognition molecules.

42. Antibodies, obtainable by immunization of a test animal with a recombinant haemocyanin polypeptide comprising an amino acid sequence which is coded by one or more of the nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(a) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),

Preliminary Amendment -46-

Clean Copy of Amendments

Markl, et al.

§ 371 Patent Application of PCT/EP00/02410

filed September 17, 2001

SEQ ID NO:11 (HtH2 domain d),
 SEQ ID NO:12 (HtH2 domain e),
 SEQ ID NO:13 (HtH2 domain f),
 SEQ ID NO:14 (HtH2 domain g),
 SEQ ID NO:15 (HtH2 domain h),
 SEQ ID NO:16 (partial KLH1 domain b),
 SEQ ID NO:17 (KLH1 domain c),
 SEQ ID NO:18 (KLH1 domain d),
 SEQ ID NO:19 (partial KLH1 domain e),
 SEQ ID NO:20 (KLH2 domain b),
 SEQ ID NO:21 (KLH2 domain c),
 SEQ ID NO:22 (partial KLH2 domain d),
 SEQ ID NO:23 (KLH2 domain g),
 SEQ ID NO:24 (partial KLH2 domain h),
 SEQ ID NO:49 (HtH1 domain a' + signal peptide),
 SEQ ID NO:50 (partial HtH2 domain a),
 SEQ ID NO:51 (HtH2 domain b'),
 SEQ ID NO:52 (HtH2 domain d'),
 SEQ ID NO:53 (HtH2 domain e'),
 SEQ ID NO:54 (KLH1 domain e'),
 SEQ ID NO:55 (KLH1 domain f),
 SEQ ID NO:56 (KLH1 domain g),
 SEQ ID NO:57 (KLH2 domain b'),
 SEQ ID NO:58 (KLH2 domain c'),
 SEQ ID NO:59 (KLH2 domain d'),
 SEQ ID NO:60 (KLH2 domain e),
 SEQ ID NO:61 (KLH2 domain f),
 SEQ ID NO:62 (KLH2 domain g'),
 SEQ ID NO:80 (HtH1 domain a" + signal peptide),
 SEQ ID NO:81 (HtH1 domain b"),
 SEQ ID NO:82 (HtH1 domain c"),

Preliminary Amendment -47-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

SEQ ID NO:83 (HtH1 domain d"),
SEQ ID NO:84 (HtH1 domain e"),
SEQ ID NO:85 (HtH1 domain f"),
SEQ ID NO:86 (HtH1 domain g"),
SEQ ID NO:87 (HtH1 domain h"),
SEQ ID NO:88 (partial HtH2 domain a"),
SEQ ID NO:89 (HtH2 domain b"),
SEQ ID NO:90 (HtH2 domain c"),
SEQ ID NO:91 (HtH2 domain d"),
SEQ ID NO:92 (HtH2 domain e"),
SEQ ID NO:93 (HtH2 domain f"),
SEQ ID NO:94 (HtH2 domain g"),
SEQ ID NO:95 (HtH2 domain h"),
SEQ ID NO:96 (partial KLH1 domain b"),
SEQ ID NO:97 (KLH1 domain c"),
SEQ ID NO:98 (KLH1 domain d"),
SEQ ID NO:99 (KLH1 domain e"),
SEQ ID NO:100 (KLH1 domain f"),
SEQ ID NO:101 (KLH1 domain g"),
SEQ ID NO:102 (KLH2 domain b"),
SEQ ID NO:103 (KLH2 domain c"),
SEQ ID NO:104 (KLH2 domain d"),
SEQ ID NO:105 (KLH2 domain e"),
SEQ ID NO:106 (KLH2 domain f"),
SEQ ID NO:107 (KLH2 domain g"),
SEQ ID NO:108 (partial KLH2 domain h");

- (b) nucleic acid sequences which hybridize with the counter-strand of a nucleic acid sequence according to (a) and code for a polypeptide which has the immunological properties of at least one

Preliminary Amendment -49-
Clean Copy of Amendments
Markl, et al.
§ 371 Patent Application of PCT/EP00/02410
filed September 17, 2001

A. bringing cell DNA and/or cell protein into contact with a probe comprising a nucleic acid molecule and/or the antibody obtainable by immunization of a test animal with a recombinant haemocyanin polypeptide comprising an amino acid sequence which is coded by one or more of said nucleic acid molecules, wherein said nucleic acid molecule comprises a nucleic acid sequence which codes for a haemocyanin, a haemocyanin domain or a functional fragment thereof with the immunological properties of at least one domain of a haemocyanin, the nucleic acid sequence being selected from:

(a) nucleic acid sequences which are selected from the group consisting of the DNA sequences shown below or the corresponding RNA sequences or which contain these:

SEQ ID NO:1 (HtH1 domain a + signal peptide),
SEQ ID NO:2 (HtH1 domain b),
SEQ ID NO:3 (HtH1 domain c),
SEQ ID NO:4 (HtH1 domain d),
SEQ ID NO:5 (HtH1 domain e),
SEQ ID NO:6 (HtH1 domain f),
SEQ ID NO:7 (HtH1 domain g),
SEQ ID NO: 8 (HtH1 domain h),
SEQ ID NO:9 (partial HtH2 domain b),
SEQ ID NO:10 (HtH2 domain c),
SEQ ID NO:11 (HtH2 domain d),
SEQ ID NO:12 (HtH2 domain e),
SEQ ID NO:13 (HtH2 domain f),

Preliminary Amendment -50-
 Clean Copy of Amendments
 Markl, et al.
 § 371 Patent Application of PCT/EP00/02410
 filed September 17, 2001

SEQ ID NO:14 (HtH2 domain g),
 SEQ ID NO:15 (HtH2 domain h),
 SEQ ID NO:16 (partial KLH1 domain b),
 SEQ ID NO:17 (KLH1 domain c),
 SEQ ID NO:18 (KLH1 domain d),
 SEQ ID NO:19 (partial KLH1 domain e),
 SEQ ID NO:20 (KLH2 domain b),
 SEQ ID NO:21 (KLH2 domain c),
 SEQ ID NO:22 (partial KLH2 domain d),
 SEQ ID NO:23 (KLH2 domain g),
 SEQ ID NO:24 (partial KLH2 domain h),
 SEQ ID NO:49 (HtH1 domain a' + signal peptide),
 SEQ ID NO:50 (partial HtH2 domain a),
 SEQ ID NO:51 (HtH2 domain b'),
 SEQ ID NO:52 (HtH2 domain d'),
 SEQ ID NO:53 (HtH2 domain e'),
 SEQ ID NO:54 (KLH1 domain e'),
 SEQ ID NO:55 (KLH1 domain f),
 SEQ ID NO:56 (KLH1 domain g),
 SEQ ID NO:57 (KLH2 domain b'),
 SEQ ID NO:58 (KLH2 domain c'),
 SEQ ID NO:59 (KLH2 domain d'),
 SEQ ID NO:60 (KLH2 domain e),
 SEQ ID NO:61 (KLH2 domain f),
 SEQ ID NO:62 (KLH2 domain g'),
 SEQ ID NO:80 (HtH1 domain a" + signal peptide),
 SEQ ID NO:81 (HtH1 domain b"),
 SEQ ID NO:82 (HtH1 domain c"),
 SEQ ID NO:83 (HtH1 domain d"),
 SEQ ID NO:84 (HtH1 domain e"),
 SEQ ID NO:85 (HtH1 domain f"),

- 53 -

Markl, et al.

filed September 17, 2001

colorectal carcinoma.

090360Z JUL 78 070034N 152034E

- 55 -

- 55 -

- 55 -

- 55 -

Fig. 1a-f




Fig. 1g-m




Fig. 2a-h








Fig. 2i-p





5/29

Fig. 3a-c



6/29

Fig. 3d-e



7/29

Figur 4

cDNA-Sequenz in Verbindung mit Intronstruktur des HtH1

Domäne a

GGCTTGTTTCAGTTTCTACTCGTCGCCCTTGTGGCGGGGGCTGGAGCAGACAAACGTCGTCAG
AAGGACGCTGAGTCACCTCACGGATGACGAGGTGCAAGCTCTCCACGGCGCCCTCCRTGAC
CTCACTGCATCTACAGGGCCTCTGAGTTTCGAAGACATAACATCTTACCATGCCGACACAG
CGTCGTGTGACTACAAGGGACGGAAGATCGCCTGCTGTGTCCACGGTATGCCAGTTTCCC
CTTCTGGGCACAGGGCATATGTCTGTCCTCAAGCCGAGCGGGCACTGTTGTCCAAACGGAAGACT
GTCCGGAATGCCCTTACTGGGACTGGACGCAAAACGCTGACTCACTTACCATCTCTTGTGACTG
AACCCATCTACATTGACAGTAAAGGTGGAAAGGCTCAACCAACTACTGGTACCGGGCGGA
GATAGCGTTTCATCAATAAGGAGACTGCGCGAGCTGTAGATGATCGCCTATTTCGAGAAGGTG
GAGCCTGGTCACTACACACATCTTATGGAGACTGTCCTCGACGCTCTCGAACAGGACGAAT
TCTGTAAATTTGAAATCCAGTTTCGAGTTGGGCTCATAATGCTATCCATTACTTGGTTGGCGG
TAATTTTGAATATTCAATGTCAAACCTTGGGAATACACCTCCTACGACCCCATCTTCTTCCTC
CACCCTCCCAATGCAATGGACTGTGCACATGAACCTCGCTCACCAGCAACTCCALCCCTTCAA
AGATCCCAATGCAATGGACTGTGCACATGAACCTCGCTCACCAGCAACTCCALCCCTTCAA
CAGGGACAGCAATCCAGTCCAGCTCACAAAGGACCACTCGACACCTGCTGACCTCTTTGAT
TACAAACAACCTTGGATACAGCTACGACAGCTTAAACCTGAATGGAAATGACGCCAGAACAGC
TGAAAACAGAACTAGACGAACGCCACTCCAAAGAAGGTGCGTTTGCAAGCTTCCGACTCAG
TGGCTTTGGGGGTTCTGCCAACGTTGTTGTCTATGCATGTGTCCCTGATGATGATCCACGC
AGTGATGACTACTGCGAGAAAGCAGGCGACTTCTTCATTCTTGGGGGTCALAGCGAAATGC
CGTGGAGATTCTACAGACCCCTTCTTCTATGATGTAACCTGAAGCGGTACATCACCTTGGAGT
CCCGCTAAGTGGCCACTACTATGTGAAAACAGAACTCTTCAGCGTGAATGGCACAGCACTT
TCACCTGATCTTCTTCCTCAACCAACTGTTGCCCTACCGACCTGGGAAAG

Domäne b

GTCACTTGGACCCACCTGTGCATCATCGCCACGATGACGATCTTATTGTTTCGAAAAATAT
AGATCATTGACTCGTGAAGAGGAATACGAGCTAAGGATGGCTCTGGAGAGATTCCAGGCG
GACACATCCGTTGATGGGTACCGAGGTACAGTAGAGTACCATGGCCTTCCCTGCTCGTTGTC
CACGACCAGATGCAAAAGTCAGGTTCCGCTGTTGTATGCATGGCATGGCATCCTTCCCTCA
CTGGCACCGGCTGTTTCGTTACCCAGGTGGAAGATGCTCTTGTACGGCGTGGATCGCCTATC
GGTGTTCCTTATTGGGACTGGACAAAACCTATGACTCACCTTCCAGACTTGGCATCAAATG
AGACGTACGTAGACCCGATGACATACACATCATAATCCATTCTTCAATGCAATATATC
TTTTGAGGAGGGACACCATCACACGAGCAGGATGATAGATTGCAAACTGTTTGCCCCAGTC
GCTTTTGGGGAGCATTCCCATCTGTTTGATGGAATCCTGTACGCATTTGAGCAGGAAGATT
TCTGCGACTTTGAGATTGAGTTTGAAGTTAGTCCATAATTCTATTTCATGCGTGGATAGGCGG
TTCCGAAGATTACTCCATGGCCACCCTGCATTACACAGCCTTTGACCCCATTTTCTACCTT
CATCATTCCAATGTCGATCGTCTATGGGCAATCTGGCAAGCTCTTCAATCAGGAGACACA
AGCCATATCAAGCCCACTGTGCACAGTCTGTGGAACAGTTGCCAATGAAGCCATTTGCTTT
CCCATCACCTCTTAACAACAACGAGAAGACACATAGTCATTTCAGTCCCGACTGACATTTAT
GACTACGAGGAAGTGCTGCACTACAGCTACGATGATCTAACGTTTGGTGGGATGAACCTTG
AAGAAATAGAAGAAGCTATACATCTCAGACAACAGCATGAACGAGTCTTCGCGGGGATTTCT
CCTTGCTGGAATAGGAACATCTGCACTTGTGTGACATTTTTCATAAATAAACCGGGGAACCAA
CCACTCAAGAGCTGGAGATATTGCCATTCTTGGTGGTGCCAAGGAAATGCCTTGGGCGTTTG
ACCGCTTGTATAAGGTGCAAAATACTGACTCATTGAAGACACTTCTCTCGATCTCGATGG
AGATTATGAAGTCACTTTTAAATTCATGATATGCACGGAAACGCTCTTGATACGGACCTG
ATTCCACACGACGACGAGTGTGTTTCTGAGCCAGCTCACC

WO 00/55192

PCT/EP00/02410

8/29

Intron b/c

GTAAGTAAATTTACAAATTTGGTGTCTCTAACTATCCTAAGTATTCAATCGTTAGCGTG
TACCTATCTGCATAATGCAATACCCTGACTCCATATAAGTATAGTATATTTACTCTGGTCG
AAACAAACAAATTGAAAACAAGAGTGGACGTGCTGTTATGATTTCTTTTTCATTCTTGGT
TCGTTGTGTAATGCCACAGCCAGCAATTCAGATATATAGCGACGGTCTATGAATACTCCA
GTCTGGACCAGACAATCGTGTGGAATGGTTTAGGCACATTATATCAAATTCATTGTTGAAG
ATATGAGTTATGAGGTCACAATGTTGCTTGTACCCCGTGTCACTAGTGACGTCATTTCA
TGACTGAAATCTCTTCAACGCCGTTTAGCAATAATAGGCTCAGTAGTATTCAACCAATTAC
AATCAGTAGAAATTTCTCTATACTATTCTTATGTTGCATCCTGATATCCCTATGCAAAAT
TAGTCLTCTAATATAATCATTTTCGATAAATACTTTGGGCAACAAATCAATGTAACATCT
ATTTTCTTTTCAG

Domäne c

CTACCTTTGAGGATGAAAAGCACAGCTTACGAATCAGAAAAATGTCGACAGCTTGACTCC
TGAAGAAACAAATGAACGCGTAAAGCCCTGGAGCTTCTTGAAAATGATCATACTGCAGGT
GGATTCAATCAGCTTGGCGCCTTCCATGGAGAGCCTAAATGGTGCCCTAATCCTGAAGCGG
AGCACAAGGTTGCATGCTGTGTTTCATGGCATGGCTGTTTTCCCTCATTGGCACAGGCTTCT
TGCTCTCCAGGCGGAGAATGCTCTTAGAAAGCATGGGTACAGTGGTGCTCTACCATACTGG
GATTGGACTCGCCCCCTTTCCCAACTTCTGATCTGGTTAGTCATGAGCAGTATACAGATC
CTTCCGACCATCAGCTGAAGCATAAACCCTGGTTCAATGGCCACATCGATACAGTAAATCA
GGATACCACCAGAAGCGTACGGGAGGATCTTTATCAACAACCTGAATTTGGACATTTTCAGG
GATATTGCTCAACAAGTCCTCTTAGCATTAGAACAAGATGACTTCTGTTTCGTTTGAAGTGC
AGTATGAGATTTCCCATAAATTTTATCCATGCACCTGTAGGAGGAACCGACGCTTATGGCAT
GGCATCGCTGAGATATACAGCATAACGATCCAAATGCTTTTTCTTGATCATTTCAACACCGGAC
AGGATCTGGGCTATTTGGCAATCCCTGCAAAAATACAGAGGCAAACCGTACAACACTGCCA
ACTGCGCCATAGAATCTATGAGAAGGCCCTGCAACCATTTGGACTAAGCAGTGCCATTAA
CCCTGACAGAATCACCAGAGAGCATGCTATCCCGTTTGATGTCTTCAACTATAGAGATAAC
CTTCATTACGTATATGATACCCTGGAATTTAATGGTTTGTGATTTCAACACTTGATAGAG
AGCTGGAAAAAATCAAGAGTCACGAAAGAGTATTTGCTGGATTCTTGCTGTGCGGGGATTAA
AAATCTGCTCTTGTGAAATTCGAAGTTGTACTCCACCTGATAATTGTCAAAAGCAGGG
GAGTTTTATCTACTCGGGGACGAAAACGAGATGGCTTGGGCCCTATGACCGACTTTTCAAGT
ATGATATTACTCAGGTTCTGGAAGCAAACCATCTACACTTCTATGATCATCTCTTCTCATCG
CTACGAAGTCTTTGATCTTAAAGGAGTGAGTTTGGGAACTGACCTGTTCCACACTGCAAAAT
GTGGTACATGATTCCGGCACAG

Intron c/d

GTACGTGGATTTGATTACATAGCAATGCTATATGATTTCAAGTAATTACAACCTCAAGTCAT
GTAGCCGTTTTAGATTGCATTACATCAAAACAGCATTGGATTAAATGGGGGATTGTCCAGG
CCGCATTATGTTGCATTCCGAAAATAGTTTGTGTCCAGTGTCCACGTTTAAALATTALACCA
TTTTAATCATATTAGGGATAATTTTAAATAGATGTTTATAGTGCTTTATTTTCATATTGTTACA
GTGGACAGTCACCAAGGACATATTTTACTCTATAGATACACAAACACCPATTAAACCCCTG
CTTTGGAAAGTCTAACTTTTTCCCCACAG

Domäne d

GCACCCGTGATCGTGATAACTACGTTGAAGAAGTTACTGGGGCCAGTCATATCAGGAAGAA
TTTGAACGACCTCAATACCGGAGAAATGGAAGCCCTTAGAGCTGCTTTCTGCAATATTCAG
GACGACGGAACATATGAATCTATTGCCAGTACCATGGCAACCAGGCAAAATGTCAATTGA
ATGATCATAATATTGCGTGTGTGTCATGGTATGCCTACCTTCCCCCAGTGGCACAGACT
GTATGTGGTTCAAGGTGGAGAATGCTCTCTAALACAGGGGATCTGGTGTGGCTGTTCTTAC

WO 00/55192

PCT/EP00/02410

9/29

TGGGAGTGGACTGCTCCCATAGACCATCTACCTCATTTTCATTGATGATGCAACATACTTCA
ATTCCCGACAACAGCGGTACGACCCTAACCCCTTTCTTCAGGGGAAAGGTTACTTTTGAAAA
CGCAGTCACAACAAGGGACCCACAAGCCGGGCTCTTCACTCAGATTATATGTATGAGAAT
GTTTTACTTGCCTGGAGCAGGAAAATTATTTGTGACTTTGAAATTGAGTTTGGAGCTTGTTC
ATAACGCACTTTCATTCCATGCTGGGAGGTAAAGGGCAGTACTCCATGTCCTCCCTGGACTA
TTCTGCGTTTGTATCCCGTCTTCTTCTACATCATGCCAACACGGACAGACTGTGGGCAATC
TGGCAGGAACACTACAAAGATTCCGAGAACTGCCTTATGAAGAAGCGAACTGTGCAATCAACC
TCATGCATCAACCACTGAAGCCGTTTCAGTGATCCACATGAGAATCAGACAAATGTCACTTT
GAAATACTCAAAACCACAGGACGGATTTCGACTACCAGAACCCTTCGGATACAAGTATGAC
AACCTTGAGTTCCATCACTTATCTATCCCAAGTCTTGATGCTACCCTGAAGCAAGGAGAA
ATCAGCAGAGAGTGTGTTGCGGGCTTCCTTCTCATAACATAGGAACTTCTGCTGACATAAC
TATCTACATATGTCTGCCTGACGGGCGGCGTGGCAATGACTGCAGTCATGAGGCGGGAACA
TTCTATATCCTCGGAGGCGAAACAGAGATGCCTTTTATCTTTGACCGTTTGTATATAATTG
AATCACCACCAACTGCAACAGTTAGGAGTCAAGCTGCATGGTGGAGTTTTTGAAGTGGG
GCTTGAGATCAAGGCATACAACGGTTCCCTATCTGGATCCCCATACCTTTGATCCAACATC
ATCTTTGAACCTGGAACAG

Intron d/e

GTAATGCCATCTTAATACAGTTGCTTCGTTAAATTATATATGTTGCTTTACAACACCATAC
CTTGAATTGAGGTAATACATCACTTGATATTGATAATGTAATGGTAATTGTTCTTGTGTTGT
AAACCCGTTTCTGGGGTGTGTTATTCATATCCACCTGGTGGATAGTGAGTAAACACATTG
GTTTAATATGGGTATCTAATGGACAGTGAAGTGTGCTGGCTAGGCAGATACCTTGCTTTCT
GTGAATGGAGGTAGTAGAAAGGGGTTTTGATGATTGCAG

Domäne e

ATACCCATATCTTGGACCACGACCATGAGGAAGAGATACTTGTGAGGAAGAATATAATTGA
TTTGAGCCCAAGGGAGAGGGTTTTCTCTAGTCAAAGCTTTGCAAAGAATGAAGAATGATCGC
TCCGCTGATGGGTACCAAGCCATTGCTCTTTCCATGCCCTGCCACCCTCTGTCCCAATC
CATCTGCAGCTCACCGTTATGCTTGTGTCCATGGCATGGCTACATTTCCCCAGTGGCA
CAGACTGTACACTGTTTCAGGTTTCAGGATGCCCTGAGGAGACATGGTTCACTTGTGTTGTTATT
CCTTACTGGGACTGGACAAAACCAAGTCACAGGTTACCCGAGCTTCTTTCTTCAGCAACAT
TTTATCATCCAATCCGGAATATTAATATTTCAAATCCATTCTCGGGGCTGACATGGAATT
TGAAGGACCGGGCGTTTCATACAGAGAGGCACATAAACTACTGAGCGCCTGTTTTCAGTGGG
GATCATGACGGATACCACAACCTGGTTCTTCGAACTGTTCTCTTTGCTTTGGAACAGGAAG
ATTAAGTGGGATTTTGAATACAAATTTGAGATAGCCCATATGGCATCCACACATGGATTGG
TGGAAGCGCAGTATATGGCATGGGACACCTTCACTATGCATCATATGATCCAAATTTTCTAC
ATCCACCATTTCACAGACGGACAGAAATATGGGCTATTTGGCAAGAGCTGCAGAAGTACAGGG
GTCTATCTGGTTTCGGAAGCAAACTGTGCCATTGAACATATGAGAACACCCTTGAAGCCTTT
CAGCTTTGGGGCCACCCTACAATTTGAATAGTCATACGCAAGAATATTCAAAGCCTGAGGAC
ACGTTTGAATATAAGAAAGTTTGGATACAGATATGATAGTCTGGAATTGGAGGGGCGATCAA
TTTCTCGCATTTGATGAATTTATCCAGCAGAGACAGGAGAAAGACAGAACTTTTGCAGGGTT
CCTCCTTAAGGTTTTTGGTACATCCGCATCTGTGTCAATGCAAGTTTGCAGAGTTGATCAC
ACCTGTAAAGATGCGGGCTATTTCACTATTCTGGGAGGATCAGCCGAAATGCCATGGGCAT
TCGACAGGCTTTATAAGTATGACATTACTAAACTCTTCACGACATGAACCTGAGGCACGA
GGACACTTTCTCTATAGACGTAACATCAAGTCTTACAATGGAACAGTACTCTCGGGAGAC
CTCATTCAGACGCCCCCTCATTATATTTGTACCTGGACGCC

Intron e/f

GTGAGTACCTGTTTGCCTAAGACTTCTGTAGGCTAAAGTGTAAAGAAATATCAATTAATT
TCAATTCACCCAAACTTGAAAACGGTACCTATATAGGTTAACTTTTTGTCTACAGTAACT
GAACATACCTACACATTTTCATGAATGATCTCTCAATATTTTCCACCAACAG

WO 00/55192

PCT/EP00/02410

10/29

Domäne f

ATAAACTCAACTCACGGAAACATACACCTAACAGAGTCCGCCATGAGCTAAGTAGCCTTAG
TTCCCGTGACATAGCAAGCTTGAAGGCAGCTTTGACAAAGCCTTCAACATGATAATGGGACT
GATGGTTATCAAGCTATTGCTGCCTTCCATGGCGTTCTTGGCAGTGCCACGAGCCATCTG
GACGTGAG

Intron f(1)

GTAAATTTACAGAGCTTTATGAAGTGTGTTTCAGAGTGAAGAGACCAAGATATACTTATACC
CAAACTAGCTAGCAACAGACGATTTCACTTGTTCGGACACTTTGTATTATACGTTGGAT
CCCAAGGTAAACGGAAACGTAACCGAGAATCAGTCCGTAAAGTGAGTGAGTGAGTTTGGGG
CTTAAAGTGCAGCTCAGCAATACCCAGCTATGTGGCGACTCTCAGATTTACTGCTGGAGG
AGAACCTACATAGCCCGGTTTAAACCGGTGTGGTATGTAGTAAGACCAGCGCGGCATGGCTG
GTATCTGACGGACGAAGGGTGGCGCTGCACGTATTCAGTGGTACAACACTGCACCCCAAT
TTCACCGACCGGAGAAGTCTTCCCTTCGGAGATATCGCCTGCCTTCCACGGGATTCGA
ACTCGGTGACCTTCAAGCCAGCGCGCTTCTAGCGGGGGCGATTAGAGGTTNAAGGCCGACG
GCTCTACCACTTAACTATCCCCGGCCCCACTCCTGACGGAAATGTTTATAATTCAGCCT
TTGTTTTCTTATTAACACTCTTGGCAGATTTTCTATAGATAATGGATTACATGTAGACA
GTCTCCCATTTGTTGTAAGTGTAGTCAAGAGTTAGAATCTGAATACATTCTCCAAGATGGA
TCAAGGAAAACAAATTAATTACTTGATGTTGCAG

Domäne f(2)

ATCGCCTGTTGCATCCACGGCATGGCGACGTTTCCTCACTGGCACC GGTTGTACACTCTGC
AGTTGGAGCAAGCGCTGCGCAGACACGGGTCCAGTGTTGCTGTTCCATACTGGGACTGGAC
CAAGCCAATCACCGAAGTCCACACATTTCTGACAGACGGAGAATATTATGACGTTTGGCAA
AATGCCGTCTTGGCCAATCCGTTTGAAGAGGTTATGTGAAAATTAAAGATGCATTTACGG
TGAGAAATGTCCAGGAAAGTCTGTTCAAAATGTCAAGTTTTGGAAAGCACTCGCTTCTGTT
TGACCAGGCTTTTGTGGCTCTTGAACAACTGACTACTGTGACTTCGAAGTTCAGTTTGAA
GTGATGCATAACACGATCCATTATCTCGTAGGAGGGCGTCAAACGTACGCCTTCTCCTCTC
TCGAGTATTCCTCATACGATCCAATCTTCTTTATTCACCACTCGTTTGTGACAAAATATG
GGCTGTATGGCAAGAAGTGCAGAGCAGGAGACATCTACAGTTTGAACAGCTGATTGTGCT
GTGGGCCCTCATGGGTGAGGCAATGAGGCCCTTCAACAAGGATTTCAACCACAACCTCGTTCA
CCAAGAAGCAAGCAGTCCCTAATACAGTATTTGATTATGAAGATCTTGGCTATAACTATGA
CAACCTTGAAATCAGTGGTTTAACTTAAATGAGATCGAGGCGTTAATAGCAAAACGCAAG
TCACATGCTAGAGTCTTTGCTGGGTTTCTGTTGTTTGGATTAGGAACCTTCGGCTGATATAC
ATCTGGAAATTTGCAAGACATCGGAAAACCTGCCATGATGCTGGTGTGATTTTCATCCTTGG
AGGTTCTGCAGAGATGCATTGGGCATACAAACCGCCTCTACAAGTATGACATTACAGAAGCA
TTGCAGGAATTTGACATCAACCCTGAAGATGTTTTCCATGCTGATGAACCATTTTCTCTGA
GGCTGTGGGTTGTGCTGTGAATGGAAGTGTCAATCCATCGTCTCATCTTCACCAGCCAAC
GATAATCTATGAACAGGCGAAG

Intron f/g

GTGAGATATATGCAATTTGAATGTTGTCCAGATGCGTTGTTTACATTTATATGCTTGGAAAT
TGTCTGAACGAATACAGTGGGAATAACCAAAAGCTGAAAATAAAAAGATATATACTTCAT
TCTGAATTTGTGAGTATTGCTGACCCAAAACACGTTATCCATGTGACACTATATTTGCC
TTTCTGAATCTGAGACTGCGTTATGTTTCTAATAATCACGAAATATGGTATACAGGTTGTG
TATCTGTAGAATACCCAAGGCAGAAATTTAAAGGCTCACACCCTGTTTAAATACAG

PCT/EP00/02410

11/29

Domäne $\mathbb{C}(1)$

ATCACCATGACGACCATCAGTCGGGAAGCATAGCAGGATCCGGGGTCCGCAAGGACGTGAA
CACCTTGACTAAGGCTGAGACCGACAACCTGAGGGAGGCGCTGTGGGGTGTTCATGGCAGAC
CACGGTCCCAATGGCTTTCAAGCTATTGCTGCTTTCCATGGAAAACCAGCTTTGTGTCCCA
TGCCTGATGGCCACAACCTACTCATGTTGTACTCACGGCATGGCTACCTTCCACACTGGCA
TCGCTCTTACACCAAGCAGATGGAGGATGCAATGAGGGCGCATGGGTCTCATGTCGGCCTG
CCGCTACTGGGACTGGACTGCTGCCTTCACCCACCTGCCAACACTGGTCAACGACACGGACA
ACAACCCCTTCCAAAT

Inten 5 (2)

GTAAGAGCGGGGTAGGGATGGGGTGGTAGGGGGTGGGTTGTTCTATTACTTCCCGCTTCA
 TTGTATGAAATGGATAACCTTGGCTGCATCCCAATTGCGTGATCGATTCTCTTTCGATTCA
 CTCGTGCGATTAGACTGCCTTATTTACTATAGTAGTTAGAATGTTGCTCAGTGCGCCGTTA
 AACAACTAATACACAAAACCGCATTGTGTTTTATATGGTCACTCTACTGTTTATCACGTATA
 TGTATGTTCCGACTCACTGGTTGGTGCGTACCATTCTACTGTCACACTGAGAGCCAATGTT
 CTCGATGTGTGAAATGTTTGAAAGCCGTTTCTACATAATATTGCAGGAATACCATTGTAG
 AATGTAGTCAAAACAGGTAAACAATCTGTTAGTGAGCCCAGTTCGAGGTTGCGTTGTAGGGTG
 TAGTCCAAACAGGTAGGCGAGTCCATAAGCATAGTTTTTAAGCATTTTAGATCATCTATAATT
 AACCATCATGGTTAGCCGCTATGTTTAGTTTAACTCCAGTATAAGTTAGAAGTGTATATTC
 GAAGGGAAGTGAGTAAATCCTTATTCCTTGACTACCATTATAGATTTCCCAATGACTCC
 ATTCAACTCCTAACTTTCACATCACTGCTCTCTTCAACAG

Domäne $\zeta(2)$

GGACACATTGATTATCTCAATGTCAGCACAACTCGATCTCCCCGAGACATGCTGTTCAACG
ACCCCGAGCATGGATCAGAGTCGTTCTTCTACAGACAAGTCCTCTTAGCTCTGGAACAAAC
TGATTTCTGCAAATTCGAAGTTTCAGTTTGAGATAACCCACAATGCCATCCATTCCTGGACA
GGTGGCCACAGCCCCCTACGGAATGTCCACTCTCGACTTCACTGCCTACGATCCTCTCTTCT
GGCTTCAACCACTCCAACACCGACAGAATCTGGGCTGTCTGGCAAGCTTTGCAAGAATACAG
AGGACTTCCATACAACCATGCCAATTGTGAGATCCAGGCAATGCAAACGCCCTTGAGGCCCT
TTCAGTGACGATATCAACCACAACCCAGTCACAAAGGCTAACGCCGAAGCCATTAGATGTCT
TCGAGTATAATCGGTTGAGCTTCCAGTACGACAACCTCATCTTCCATTGGATACAGTATTCC
GGAACCTTGATCGCGTGCTTGAAGAAAGAAAGGAGGAGGACAGAATATTTGCTGCCTTCCTT
CTCAGTGGGAATCAAGCGTAGTGCTGATGTAGTGTTTCGACATATGCCAGCCAGAACACGAAT
GTGTGTTTCGCAGGGACTTTTGCGATTTTGGGAGGGGAGCTAGAAATGCCCTGGTCCTTCGA
CAGACTGTTCCTCATGATATCAACCAAGGTGATGAAGCAGCTACACCTGAGGCATGACTCT
GACTTTACCTTCTCAGGTTGAAGATTGTCTGGCACCGACACCGAGCTTCTTCAGACAGTG
TCAAAGCACCAACTATTGAATTTGAACCGGGCG

Intron g/h

GTGAGTACGACAGGCATTTCTAGTAAAAACCTACTTTTGGTAAAAGGTTTCGAGAAATCACT
TGAAGCAACAACATGATTTTGTAAACGCTATTACACGTGAACATGTCACACCCGGTGATGC
CGTTTAAATGGACATGCCTCTGTTAATGAPAGGGGTAAGTACATGTGTATGGGGATGGGATG
GGAGCCACCTGTCCCAATTTTCATAGGTCCCTAGGATCCCAAGTTGCGTAGGAATCCCCTGAT
TAATGCCTTGTGAATTCCTCCTGGAATTGTCCTGGCCCAATTTTTACAAACCCGCCCGA
TATACCTTGGAAATLATTGGGGCCTAAGGGTGGGGCTTTTAAAGGACCAAGAACCCAACTAA
ACCCCAACCCATTTTTTCCCAACCCATTCCAGGTTTTGTTTTTACCAATAAAGGTTTCCA
CTTTGAGGAACAACCTTTAAGGTTCTTTTTTCAGGCTTTTTTTCTTTTCTGGGAATTCCAAT
TCCGGGGGAACAAAAATACATATATTACACAGCCTTTGGTCAAATTTATATATTTCGGAC
TTCATGTCATAGGTTTGTCTTTCTTCCTACACAG

WO 00/55192

PCT/EP00/02410

12/29

Domäne h

TGCACAGAGGGCGGAAACCACGAAGATGAACACCATGATGACAGACTCGCAGATGTCCTGAT
CAGGAAAGAAGTTGACTTCCTCTCCCTGCAAGAGGGCCAAACGCAATTAAGGATGCCACTGTAC
AAGCTCCAGAATGACGACAGTAAAGGGGGCTTTGAGGGCCATAGCTGGCTATCACGGGTATC
CTAATATGTGTCCAGAAAGAGGTACCGACAAAGTATCCCTGCTGTGTCCACGGAATGCCCCG
GTTCCCCCACTGGCACCAGCCTGCATACCATTGAGATGGAGAGAGCTCTGAAAAACCATGGC
TCTCCCAATGGGCATTTCCTTACTGGGATTGGACAAAGAGATGTGAGATCTTCCATCTTTCT
TTGGAGATTCCAGCAACAACAACCCCTTTCTACAAATATTACATCCGGGGGCGTGCAGCAGCA
AACAACCAGGGGACATTTAATCAGAGACTCTTTAATCAAACCAAGTTTGGTGAATTTGATTAC
CTATATTACCTAACTCTGCAAGTCCTGGAGGAAAACCTCGTACTGTGACTTTGAAGTTTCAGT
ATGAGATCCTCCATAACGCCGTCCTACTCCTGGCTTGGAGGAACTGGAAAGTATTCCATGTC
TACCCTGGAGCATTCGSCCTTTGACCCCTGTCTTCATGATTCAACCACTCGAGTTTGGATAGA
ATCTGGATCCTTTGGGCAGAAAGTTGCATAAGATAAGAATGAAGCCTTACTACGCATTGGATT
GTGCTGGCGACAGACTTATGAAAGACCCCCCTGCATCCCTTCAACTACGAAACCGTTAATGA
AGATGAATTCACCCGCATCAACTCTTTCCCAAGCATACTGTTTGACCACTACAGGTTCAAC
TATGAATACGATAACATGAGAATCAGGGGTGAGGACATACATGAACCTGAAGAGGTAATTC
AGGAATTAAGAAACAAAGATCGCATATTTGCTGGTTTTGTTTTGTTGTCGGGCTTACGGATATC
AGCTACAGTGAAAGTATTCATTTCATTCGAAAAACGATACAAGTCACGAAAGTATGACAGGA
GAATTTGCAGTTTTTGGGAGGTGAGAAGGAGATGCCGTGGGCATATGAAAGAATGCTGAAT
TGGACATCTCCGATGCTGTACACAAGCTTCACGTGAAGATGAAGACATCCGTTTTAGAGT
GGTTGTTACTGCCTACAAACGGTGACGTTGTTACCACAGGCTGTCTCAGCCATTTCATCGTC
CACCGTCCAGCCCATGTGGCTCACGACATCTTGGTAATCCCAAGTAGGTGCGGGCCATGACC
TTCCGCTAAAGTCGTAGTAAAGAGCGGCACCAAGTCGAGTTTACACCAATAGATTGCTC
GGTGAACAAAGCAATGGTGGAGCTGGGGCAGCTATACTGCTATGGCTAAATGCATCGTTCCC
CCTTTCTCTTACCACGGCTTTGAACTGGACAAAGTCTACAGCGTCGATCACGGAGACTACT
ACATTGCTGCAGGTACCCACGCGTTGTGTGAGCAGAACCTCAGGCTCCACATCCACGTTGA
ACACGAGTAG

3' UTR

TTCACAG

Intron UTR

GTGAGGAGAAGGCCCCAGGCTAGCAGGGCAATGGATGAAGGAAATAGGGGCAAGGGGAATA
GCAGTTACACCATCGACATTTCCAACCTCCTCAGAACTAATATATAGCCTTAATACAACC
AGCCAGACTCAACGGGCGAGCCGGGGTGGGGGGATTGGTGGTGGCTGTTTCAGACCAGGG
TGCAAAATATCAGTGCGCAATCAACATGTTGCGTGTGAGACACTGACACAGCAGTCATTG
AACCTGCAGACCCATAACAGGAAATGGGGGCAGATACGATCAAGACAGTGTAAATAGGG
ATAAGTAGGCATATGCAACCACCTGATGGAAATGAAAAGGGGTAAAGTTTAAACCCCGGCTA
CCAAAGGTCCAATGGTTTCCTTAACCCAGCTTACGCTATCCCTCTAATTTTCAGTATTGAGCT
GATTTCTGTGAGTTTCATGTAACTGTATACTTTCTGTATTATTACAG

3' UTR

GTTGCTATGCCGACTGCGCTATATTGGTGAACGAGACGATGAGGACATCTCTGAAAGAGTT
CGCCAAAGTGATGTGTAGGTACCGGAAGTATTGTTGAGCTAACAATATGATGATTTCLAAAT
GACTTGGCGCTCTAGGACAAAGACATAATTCATCAGCACCCCTGTGCACCAACTCTTTGTTT
GCTGCAACGCTCTGACAAGCGACACGTCAATCAACAAGCTGTTCAAACCTCAAGTGGATGTA
ACTAGAATCGTTGGGGCCATCGTTCACAAAGTATTGACAGATGTCACACATGATGGCGAGAA
ACACTTTAGAATTTTAAATGACCTAGAGTGACTTGTAAATATGTAAATATATTCTTCAAAG
ACTCAGCTGAACATATTGTTGGATAACACATCAATCCCTCAACAAAATGCTTTATCTTCAC
ATGGATGTATGTAATGTGGCCGGCAATAAAGTATATATATGTATAAAAA

A

WO 00/55192

PCT/EP00/02410

13/29

Figur 5

Abgeleitete Primärstruktur des HtH1

Signalpeptid

LVQFLLVAGAGA

Domäne a

DNVVRKDVSHLTDDDEVQALHGALHDVTASTGPLSFEDITSYHAAPASCDYKGRKIACCVHG
MPSPFVWHRAYVVOAERALLSKRKTVMGMPYWDWTQTLTHLPSLVTEPIYIDSKGGKAQNTY
WYRGEIAFINKKTARAVDDRLFEKVEPGHYTHLMTVLDALQDEFCKFETIQFELAHNAIH
YLVGGKFEYSMSNLEYTSYDPIFFLHRSNVDRLFAIWQRLQELRGKNPNAMDCAHSLAHQQ
LQPFNRDSNPVQLTKDHSTPADLFDYKQLGYSYDSLNLNGMTPEQLKTELDERHRSKERAFA
SFRLSGFGGSANVVVYACVPDDDDPRSDDYCEKAGDFFILGGQSEMPWRFYRPFYDVTAV
HHLGVPLSGHYVVKTELFVNGTALSPDLLPQPTVAYRPGK

Domäne b

GHLDPVHHRHDDDLIVRKNI DHLTREEEYELRMALERFOADTSVDGYQATVEYHGLPARC
PRPDAKVRFACCMHGMASFPHWHRLFVTQVEDALVRRGSPIGVPYWDWTKPMTHLPDLASN
ETYVDPYGHTRHNPFNANISFEEGGHHTSRMIDSKLFAPVAFGEHSHLFDGILYAFEQED
FCDFEIQFELVHNSIHAWIGGSESDYSMATLHYTAFDPIFYLHHSNVDRLWAIWQALQIRRH
KPYQAHCAQSVEQLPMKPFAPPSPLNNEKTHSHSVPTDIYDYEEVLHYSYDDLTFGGMNL
EEIEBAIHRLRQCHERVFAGFLLAGIGTSALVDIFINKPGNQPLKAGDIALGGAKEMPWAF
DRLYKVEITDSLKTLSLDVDGDYEVTFKIHDMHGNAIDTDLI PHAAVVSEPAH

Domäne c

PTFEDEKHSRLRIRKNVDSLTPETNELRKALELLENDHTAGGFNQLGAFHGEPKWCNPPEA
EHKVACCVHGMVFPWHRLALQENALRKHGYSYGALPYWDWTRPLSQLPDLVSHEQYTD
PSDHHVKHNPWFNGHIDTVNQDTRSVREDLYQQPEFGHFTDIAQOVLLALEQDDFCSEFV
QYEISHNFIALVGGTDAYGMASLRYTAYDPIFFLHHSNTDRIWAIWQSLQYRGKPYNTA
NCAIESMRRPLQPFGLSSAINPDRTREHAI PFDVFNRYRDNLHYVYDTLEFNGLSISQLDR
ELEKIKSHERVFAGFLLSGIKKSALVKFEVCTPPDNCHKAGEFYLLGDENEMAWAYDRLEK
YDITQVLEANHLHFYDHLFIRYEVFDLKGVS LGTDLFHTANVVHDSGT

Domäne d

GTRDRDNYVEEVTGASHIRKNLNDLNTGEMESLRAAFLHIQDDGTYESIAQYHGKPGKCQL
NDHNIACCVHGMPTFPQWHRLYVQVENALLNRGSGVAVPYWEWTAPIDHLPHFIDDATYF
NSRQORYDPNPFTRGKVT FENAVTTRDPQAGLPNSDYMYENVLLALEQENYCDFETIQFELV
HNALHSM LGGKGQYSMSLLDYSAFDPVFFLHHANTDRLWAIWQELQRFREL PYEEANCAN
LMHQLKPFSDPHENHDNVTLYSKPQDGFQYQNHFGYKYDNLEFHLSIPSLDATLKQRR
NHDRVFAGFLLHNIGTSADITIYICLPDGRGNDSCSEAGTFYILGGGETEMPFIFDRLYKF
EITKPLQQLGVKLHGGVFELBLEIKAYNGSYLDPHTFDPTIIFEPGT

Domäne e

VHRRGNGHEDEHHDDRDLADVLIRKEVDFLSLQEANAKDALYKLQNDSSKGGFEAIAGYHGY
PNMCPERGTDKYPCCVHGMVPVFPWHRLHTIQMERALKNHGSPMGIPYWDWTKKMSSSPSF
FGDSSNNMNPYKYVIRGVQHETTRDVNQRLFNQTKFGEFDYLYYLTLOVLENSYCDFEVQ
YEILHNAVHWSLGGTGQYSMSTLEYSAFDPVFMIIHSSLDRIWILWQKLQKIRMKPYVALD
CAGDRMLMKDPLHPFNYETVNEDEFTRINSFPSILFDHYRFNYEYDNMIRGQDIHELEEV
QELRNKDRI FAGFVLSGLRISATVKVFIHSHKNDTSHEEYAGEFAVLGGGEKEMPWAYERMLK
LDISDAVHKLHKVDEDIRFVVVYATYNGDVVTRLSQPFIVHRPAHVAHDILVIVPGAGHD
LPPKVVVKSGLKVEFTPIDSSVNKAMVELGSYTAMAKCIVPPFSYHGFE LDKVYSVDHGDY
YIAAGTHALCEONRLRHHVHEH

WO 00/55192

PCT/EP00/02410

15/29

Figur 6

cDNA-Sequenz in Verbindung mit Intronstruktur des HtH2

Domäne b

CACAGACTGTTGCTCAGCCAGGTGGAAGATGCTCTGATCAGGCGAGGATCGCCTATAGGGG
 TCCCCTACTGGGACTGGACTCAGCCTATGGCGCATCTCCAGGACTTGCAGACAACGCCAC
 CTATAGAGATCCCATCAGCGGGGACAGCAGACACAACCCCTTCCACGATGTTGAAGTTGCC
 TTTGAAATGGACGTACAGAACGTCACCCAGATAGTAGATTGTTTGAAACACCTTTATTG
 GCALACATACGCGTCTCTTCGACAGTATAGTCTATGCTTTTGAGCAGGAGGACTTCTGGA
 TTTTGAAAGTTCAATTTGAGATGACCCATAATATATTCACGCCTGGATTGGTGGCGGGGAG
 AAGTATTCATGTCCTTCTCTACACTACACAGCCTTCGACCCCTATCTTCTACCTTCGTCAC
 CCAACACTGACCGGCTCTGGGCAATTTGGCAAGCGTTGCAGATACGAAGAACAGGCCTTA
 CAAGGCTCATTTGTGCTTGGTCTGAGGAACGCCAGCCTCTCAAACCTTTGCGCTTCAGTTCC
 CCACTGAACACCAACGAACCAACCTACGAAACCTCGGTGCCACCAACGTTTACGACTACG
 AAGGAGTCCTTGGCTATACTTATGATGACCTCAACTTCGGGGGCATGGACCTGGGTACGCT
 TGAGGAATACATCCAGAGGCAGAGACAGAGAGACAGGACCTTTGCTGGTTTCTTTCTGTCA
 CATATTGGTACATCAGCGAATGTTGAAATCATTTATAGACCATGGGACTCTTCATACCTCCG
 TGGGCACGTTTGGCTGTTCTTGGCGGAGAGAAAGGAGATGAAATGGGGATTTGACCGTTTGT
 CAAATATGAGATTACAGATGAACAGGCAACTTAATCTCCGTGCTGATGATGTTTTTCAGC
 ATCTCTGTTAAAGTAACTGATGTTGATGGCAGTGAGCTGTCTCTGAACTCATCCCATCTG
 CTGCTATCATCTTCGAACGAAGCCATA

Intron b/c

GTAAGTAGCTACCTGTTTATTCAATTTTTTCGCTTTGCCAATCAATTCATTCAGCTTGAAA
 TTCAATAAATTGTGTTTTGCATGGCTGAAACCAATTTGAACTCTTTTCTTTCTCAGGTG
 AACTCAAATAAATAATCACTAATTGTTATGCACGCGGCTAGGGCATACATACTATATCCAC
 ATCGGTATCTCAAAATGCAAAACAAATTTGTCTTATTTCCGTTGGGACAAAGCAACCCCTT
 TCCTGTAATCTTGCCTTTGGCATCCACTGGAATTAATGTTGACTGGTAATTTGATACTGGCT
 CTCTTCTTGCATAGAGTTAATATCTATAGTTTGTAAATCTTTATGATTTTGCTATTTATAT
 TTGACAGCATGCTATAGACACCCTAGACTATTGTATAGCCACTTGTATTGTTTTTCCATT
 TATTATTTATAACAGAACATGGCTTGTAATTTTTTATTTACCTTCCAG

Domäne c

TTGACCATCAGGACCCGCGATCATGACACAATCATTAGGAAAAATGTTGATAATCTTACACC
 CGAGGAAATTAATTCTCTGAGGCGGGCAATGGCAGACCTTCAATCAGACAAACCGCCGCT
 GGATTCCAGCAAATTGCTGCTTTTCACGGGGAAACCCAAATGGTGCCCAAGTCCCGATGCTG
 AGAAGAAGTTCTCTGCTGTGTCCATGGAATGGCTGTCTTCCCTCACTGGCACAGACTCCT
 GACCGTGCAAGGCGAGAATGCCCTGAGAAAGCATGGATGTCTCGGAGCTCTCCCTACTGG
 GACTGGACTCGGCCCTGTCTCACCTACCTGATTTGGTTTTGGTAAGTAGCAGAACTACAC
 CGATGCCATATTCCACCGTGGAAGCCCGAAACCCCTGGTACAGCGGCCATATTGATACAGT
 TGGTGTGACACACAAAGAAGCGTCCGTCAAGAAGTGTATGAAGCTCCTGGATTTGGCCAT
 TATACTGGGGTGGCTAAGCAAGTGCTTCTGGCTTTGGAGCAGGATGACTTCTGTGATTTTG
 AAGTCCAGTTTGGATAGCTCACAAATTCATTCACGCTCTTGTGGCGGGAAGCGAGCCATA
 TGGTATGGCGTCACTCCGTTACACTACTTATGATCCAATTTTCTACCTCCATCATTTCTAAC
 ACTGCAGAGACTCTGGGCTATATGGCAGGCTCTACAAAAGTACAGGGGCAACCTTACAATT
 CGGCCAATCGGCCATTGCTTCTATGAGAAAACCCCTACAACCCTTTGGTCTGACTGATGA
 GATCAACCCGGATGATGAGACAAGACAGCATGTCTTCTTCCAGTGCTCTTGATTCAAG
 AACAACTTCAATTATGAATATGACACCCTTGACTTCAACGGACTATCAATCTCCAGCTGG
 ACCGTGAACTGTCACGGAGAAAGTCTCATGACAGAGTATTTGCCGGATTTTGTGCTGCATGG

WO 00/55192

PCT/EP00/02410

16/29

TATTCAGCAGTCTGCACTAGTTAAATTCTTTGTCTGCAAATCAGATGATGACTGTGACCAC
 TATGCTGGTGAATTCTACATCCTTGGTGATGAAGCTGAAATGCCATGGGGCTATGATCGTC
 TTTACAAATATGAGATCACTGAGCAGCTCAATGCCCTGGATCTACACATCGGAGATAGATT
 CTTTCATCAGATACGAAGCGTTTGATCTTCATGGTACAAGTCTTGGAAGCAACATCTTCCCC
 AACCTTCTGTCTATACATGACGAAGGGGACG

Intron c/d

GTGAGAACATTGATAATAGTTCAAATGAAGTATATCCGATTCAAGCTGTGCGATACAAGATG
 AGATACATAATCACAATGTTTGTATTAGATATCTCTCTTAATTTAATGCCGCTTTTATCAA
 TATTCGAGCAATCCTTCAGCAACATACACCAGCAATGTTTCATCAACAGACTATATTATT
 TAATCTTTTAAAAATCCTTTTCTGTTGTTATAAATACTTAAAGTATCGAATTCCTTGAATG
 CGTCTTCTCTGCAAGCATATAGTTAAGTTGTTGTGTTTCTCTGTCTAG

Domäne d

GTCACCATCAGGCTGACGAGTACGACGAAGTTGTAAGTCTGCAAGCCACATCAGAAAGAA
 TTTAAAGATCTGTCAAAGGGAGAAGTAGAGAGCCTAAGGTCTGCCTTCCTGCAACTTCAG
 AACGACGGAGTCTATGAGAATATTGCCAAGTTCCACGGCAAGCCTGGGTTGTGTGATGATA
 ACGGTGCGAAGGTTGCCTGTTGTGTCCATGGAATGCCACCTTCCCCCAGTGGCACAGGCT
 CTATGTCCTCCAGGTGGAGAATGCTTTGCTGGAGAGAGGATCTGCCGTCTCTGTSCCATAC
 TGGGACTGGACTGAAACATTTACAGAGCTGCCATCTTTGATTGCTGAGGCTACCTATTTCA
 ATTCCCCTCAACAAACGTTTGACCCTAATCCTTTCTTCAGAGGTAAATCAGTTTGTGAAA
 TGCTGTTACAACACGTGATCCCCAGCCTGAGCTGTACGTTAACAGGTACTACTACCAAAC
 GTCATGTTGGTTTTTGAACAGGACAACACTACTGCGACTTCGAGATACAGTTTGAGATGGTTC
 ACAATGTTCTCCATGCTTGGCTTGGTGGAGAGCTACTTATTCTATTTCTTCTCTTGATTA
 TTCTGCATTGCAACCTGTGTTTTCTTCCACCATGCGAACACAGATAGATTGTGGGCCATC
 TGGCAGGAGCTGCAGAGGTACAGGAAGAAGCCATACAATGAAGCGGATTGTGCCATTAACC
 TAATGCGCAAACCTCTACATCCCTTCGACAACAGTGATCTCAATCATGATCCTGTAACCTT
 TAAATACTCAAAACCCACTGATGGCTTTGACTACCAGAACAACCTTTGGATACAAGTATGAC
 AACCTTGAGTTCAATCATTTTCAGTATTCCGAGGCTTGAAGAAATCATTGCTATTAGACAAC
 GTCAAGATCGTGTGTTTGCAGGATTCCCTCCTTCACAACATTGGGACATCCGCAACTTGTGA
 GATATTGCTCTGTGTCCCTACCACCAGCGGTGAGCAAACTGTGAAAACAAAGCCGGAACA
 TTTGCCGTACTCGGAGGAGAAACAGAGATGGCGTTTCATTTTGACAGACTCTACAGGTTTG
 ACATCAGTGAAACACTGAGGGACCTCGGCATACAGCTGGACAGCCATGACTTTGACCTCAG
 CATCAAGATTCAAGGAGTAAATGGATCCTACCTTGATCCACACATCCTGCCAGAGCCATCC
 TTGATTTTTGTGCCTGGTTCAAGT

Intron d/e

AAGAAAGTTTCACTGTCTAAATCTTTTTTTATGATAGAGGGTAGAGAAGTGGAGACAATGT
 GACAATATATTGAATAAAGTTGTTTAAATTTATAACTCTCATAAGTTCATATTATGCTGA
 AGCTGTAGCCATCTATAACTGTGTAACATGAAATGTTAAGACATTAACTAATACTTCAG
 CTGATAACAAAACAATGTTAATACATACGTCAATGTAACATTTCTTATCTTTAGGTTATA
 GCATAAACACTTCAGAGATACAGTGACGAAAACCTCTATTTAAATATTTTCAGGT

Domäne e

TCTTTCCCTGCGTCTGATGGGCATTTCAGATGACATCCTTGTGAGAAAAGAAGTGAACAGCC
 TGACAACCAGGGAGACTGCATCTCTGATCCATGCTCTGAAAAGTATGCAGGAAGACCATTC
 ACCTGACGGGTTCCAAGCCATTGCCTCTTTCCATGCTCTGCCACCACTCTGCCCTTCACCA
 TCTGCAAGCTCACCGTTATGCTTGTGTGTCACGGCATGGCTACATTTCCCCAGTGGCACA
 GATTGTACACTGTACAGTTCCAGGATGCACTGAGGAGACATGGAGCTACGGTAGGTGTACC
 GTATTGGGATTGGCTGCGACCGCAGTCTCACCTACCAGAGCTTGTCAACCATGGAGACATAC

WO 00/55192

17/29

PCT/EP00/02410

CATGATATTTGGAGTAACAGAGATTTCCCCAATCCTTTCTACCAAGCCAAATATTGAGTTTG
AAGGAGAAACATTACAACAGAGAGAGAGAGTCAATTGCAGACAAACTTTTTGTCAAAGGTGG
ACACGTTTTTGTATAAACTGGTTCTTCAAACAAGCCATCCTAGCGCTGAGCAGGAAAACCTAC
TGTGACTTTGAGATTCACTTTGAAATTTCTTCAACAACGGCGTTACACAGTGGGTGGGAGGCA
GTCGTACCTACTCTATCGGACATCTTCATTACGCATTCTACGACCCTCTTTTCTACCTTCA
CCATTTCCAGACAGACCGTATTTGgGCAATCTGGCAAGAAGCTCCAGGAACAGAGAGGGGCTC
TCGGGTGATGAGGCTCACTGTGCTCTCGAGCAATGAGAGAACCATTGAAGCCTTTCAAGCT
TCGGCGCTCCTTATAACTGGGAATCAGCTCACACAGGATTTCTCCCGACCCGAGGACACCTT
CGACTACAGGAAGTTTGGTTATGATATGACAATTTAGAAATTCCTGGGAAATGTCAGTTGCT
GAACTGGATCAATACATTATTGAACATCAAGAAAATGATAGAGTATTCGCTGGGTTCTCTGT
TGAGTGGATTCCGAGGTTCCGCATCAGTTAATTTCCAGGTTTGTAGAGCTGATTCCACATG
TCAGGATGCTGGGTACTTCACCGTTCTTGGTGGCAGTGTGAGATGGCGTGGGCATTTGAC
AGGCTTTACAAATATGACATTACTGAAACTCTGGAGAAAATGCACCTTCGATATGATGATG
ACTTCACAATCTCTGTCACTCTGACCGCCAACAACGGAAGTGTCTGAGCAGCAGTCTAAT
CCCAACACCCGAGTGTCAATTTCCAGCGGGGACATC

Intron e/f

AAGTAGTAAACTGCTCAGATTGTTTTTCATAATTACTCCACTATTAAGTAAAAAGTACTAGT
AATTCAATAGTACTGTTCCACAGAGAAATGTAACACAATAGACCACAGAGTCCATTTGTTAA
ACGCTTTTGGCTTGGTAAGTCTGAGGTTTTTGGTGACTGATGGAAGCTAATATATATTTTG
ACAG

Domäne f(1)

GTGACATAAATACCAGGAGCATGTCACCGAACCGTGTTCCCGTGAGCTGAGCGATCTGTC
TGCGAGGGACCTGTCTAGTCTCAAGTCTGCTCTGCGAGACCTACAGGAGGATGATGGCCCC
AACGGATACCAGGCTCTTGACAGCCTTCCATGGGCTACCAGCAGGCTGCCATGATAGCCGGG
GAAATGAGAT

Intron f

ATATTTAAAGTATTTTATCTTACGCATGACCCCTGACCCCTATTATTTTTTTPATCCTATGAT
GAAACATTTACTTAGACTGGCTTGTGAGCCCCAGGCAAAATGCACTGTAAAAATACACTGA
CAGAGGATTAGGCATTCTTGGGAGTACTGTATAGTTAGTTGCATACATATTAGCGTTCCCT
CACTAAAACGAATCTCTGAATGCTATCAATTAAGATCATGATGCTTTGATTGTGTCTACT
GTATTTAAATGTTGTTAAGATTTGCAATTACAATATACACAAACACGTTTCTGCACTCTC
GGAGAATGCAATCTTTTCGTTGTACGCGTCTGTTTTCATATTTTTTATGCACTGTAGTTTGCAC
TACTTAGCGTCCAAATAAATCCATTACAAAATCACACAAACAAACGATTTTAGGAATGTGA
CTGTAGCTGCAACGAATATACCTGATCCTTTCTTGTTCAGAT

Domäne f(2)

CGCATGTTGCATTACAGGGATGCCGACCTTCCCCAGTGGCACAGACTGTACACCCTGCAG
TTGGAGATGGCTCTGAGGAGACATGGATCATCTGTCCCATCCCCTACTGGGACTGGACAA
AGCCTATCTCCGAACCTCCCTCGCTCTTCAACAGCCCTGAGTATTATGACCCATGGCATGA
TGCTGTGGTAAACAAACCCATTCTCCAAAGGTTTTGTCAAATTTGCLAATACCTACACAGTA
AGAGACCCACAGGAGATGCTGTTCCAGCTTTGTGAACATGGAGAGTCAATCCTCTATGAGC
AACTCTTCTTGTCTTTGAGCAAACCGACTACTGTGATTTTGGAGGTACAGTTTGGAGTCTC
CCATAACGTGATCCACTACCTTGTGGTGGAGCTCAGACCTACGCATTGTCTTCTCTGCAT
TATGCCCTCCTACGACCCATTCTTCTTTATACACCATTCCTTTGTGGATAAGATGTGGGTAG
TATGGCAAGCTCTTCAAAGAGGAGGAACCTTCCATACAAAGCGAGCTGACTGTgCTGTCAA
CCTAATGACTAAACCAATGAGGCCATTTGACTCCGATATGAATCAGAACCCATTACAAAG
ATGCACGCGATTTCCCAACACACTCTATGACTCCGAGACACTGTACTACAGCTACGATAATC
TCGAAATAGGTGGCAGGAATCTCGACCAGCTTCAGGCTGAAATTGACAGAAGCAGAAGCCA

WO 00/55192

PCT/EP00/02410

18/29

CGATCGCGTTTTTGGCTGGATTCTTGCTTCGTGGAATCGGAACTTCTGCTGATGTCAGGTTT
 TGGATTTGTAGAAATGAAATGACTGCCACAGGGGTGGAATAATTTTCATCTTAGGTGGAG
 CCAAGGAAATGCCATGGTCATTTGACAGAACTTCAAGTTTGATATCACCCATGTACTCGA
 GAATGCTGGCATTAGCCCAGAGGACGTGTTTGATGCTGAGGAGCCATTTTATATCAAGGTT
 GAGATCCATGCTGTTAACAAGACCATGATACCGTCGTCTGTGATCCCAGCCCCAACTATCA
 TCTATTCTCCTGGGGAAG

Intron f/g

GTGAGAGAACCAGTAATAGCTACTGTCTACAAAGAATGTGTTTCATTTAAAGACCTGACTGT
 AGGCCGATGGCTGCTGTCTATCTCCTCCGCCTCCTCCTCCTGTTCCCTCCTCCGAAGGGGTCA
 GCTTCAGGTTCTCTTGCCAATATGCCAAGCAGACCTCCTGAGCAGGCAGTATATATACGTA
 AGGGAAAGCAAGTATGGACCATCGCGCGGCATGTAGAGATACAATGATCAGCTGTCTGCTGT
 TCCACTCCTGTGACACAATGAGATAAACATGAATACAGTATTACTCAGCAGCGTTTCCAATT
 TTTCAACCCTCGTATTTTATTAATAAAAGGAATTTTAAATATATTTTCTCCTTGTGAAATA
 TTTTAGTAACGTGTTAATCGATATAGAGTGGAGTAGTGACGCTTTATTTTCGGTTCATTCTCG
 AAACAAAAATATAATAGTCCACTGAACTCTCTTAAATTGTTTTTACAACCTTCAACTGCCA
 CAGACGTAATCCCTCACGTTATTTTGAGCTGACAACGTGTTGAATTGAGTGTGTTCCGAAT
 TCTAATAAAGCATGTATATATTTACGTCTCATGCAAGTAATATATGTTTTACTGATGACGT
 CACTTGGGTGACCACTGATTTAGTTCCTTTGTGATAATTGCAGTTTCTGTTGTACAGGGGAC
 GGTGGGGAAGCCAGGTTCCCTCCTGTGACGCTGAATATCCCGTTTGAATCCCCCACATGGGT
 ACAAGTGTGATGCCTATTTCTGGTGTCCCCACCGTGATATTGCTGGAATAAGTGGCTTA
 ATACCATATACACTCACTCTATTGTACACTACTGCCACCGGCTCACACCTCTGATGCTTC
 TGTTCATCCAG

Domäne g(1)

GTCGCGCTGCTGACAGTGCGCACTCTGCCAACATTGCTGGCTCTGGGGTGAGGAAGGACGT
 CACGACCCTCACTGTGTCTGAGACCGAGAACCTAAGACAGGCTCTTCAAGGTGTCTATCGAT
 GATACTGGTCCCAATGGTTACCAAGCAATAGCATCCTTCCACGGAAGTCCCTCCAATGTGCG
 AGATGAACGGCCGCAAGGTTGCCTGTTGTGCTCACG

Intron g(1)

GTAATTAATGGATGTGAAGTCAATGTCCGAGGGTATAATAAGGATTTAAATACTTCAGTCG
 TGTAATACTGTATGACATGTGTATTGGATGGTGTAGGTATTACAGGTTATAAGGCCAGTGT
 GTGTTGGGACGGTTACTTTCCCTGCACTAGTAATAAGCATTGTATTTAGCTAGCTTTTATCA
 TATAACTTTAGTTTCAGGTTTGGCAATTGAAATCGAAATTTTCTTTTCAATTTCAAGGTTA
 TCGCACTCGTGTGTNAGAAATAGTTACTATGCTGCATTGAGAATAACACTATAGTAATAAAG
 CATATCATACAGTAAGAATAACACTATAGTAATAAAGTATATCATNCAGTAAGAATGTCAT
 TGTATGATAAATAGGTTATCACACTCGTGTGTTTTAGARTGGTTACTATCCCAGGAATAAC
 CACTATGTATTACATGTATATTGGGCAGTGTAAGTAGTAGCATTGTATATTAAATCAGTAT
 ATCGTGCTTCAAAACACCAGGATATATGGGGTATACAGTGGGCAGTGTAAGTAGCAACATT
 GTATATTAAATCAGTATATCGTACTTCAAAACACCAGGATTATGGGGTATACAGTGGGCAG
 TGTAAAGTAGTAGCATTGTATATTAAATCAGTATATCGTACTTCAAAACACCAGGATATAAT
 TCAGTATATCGTGCTTCAAAACACCAGGATATAATTCAGTATATCGTGCTTCAAAACACCA
 GGATATATGGGATATACAGTGCGGGTTTGCATACAACCTCCACCCTTTACAG

Domäne g(2)

GTATGGCCTCCTTCCACACTGGCACAGACTGTATGTGAAGCAGATGGAAGATGCCCTGGC
 TGACCACGGGTACATATCGGCATCCCTTACTGGGACTGGACAACCTGCCTTCACAGAGTTA
 CCGGCCCTTGTACAGACTCCGAGAACAAATCCCTTCCATGAG

WO 00/55192

PCT/EP00/02410

19/29

Intron g(2)

GTCAGTTT TAGTCTCCTGTCTGAGCTAACGATACCAATTTCTCTATTTTCGAGAACCACGATG
 ACGAGAAAACAAGCAATATAGATATAGATGCAGTATAGATCAAGTTAATGAATTTCATTGCT
 ATATGTTTGGCTTGTAAATAAACTTTAAGAAAACGAGAGCATGCACACAAATGAAACAAACAA
 TTATGTGTTTGATAGGAATATGATATATGTATTTGGGGGCTGACGTGAGCAGGGTTGAAGG
 GACAGTTTACATTGTCAGTAACACTGGGAGTATTCTTTGATCCACAATATATAGTTTCATT
 GTGTTACAGCAGTTACAACATAACATTATATCATACATTACGTCTGTAACATGCTTCTTTTGTG
 CTCTTTTGCCAG

Domäne g(3)

GGTCGCATTGATCATCTCGGTGTAACCACGTCACGTTCCCCCAGAGACATGCTGTTTAAAG
 ACCCAGAGCAAGGATCAGAGTCGTTCTTCTATAGACAAGTCCTCCTGGCTTTGGAGCAGAC
 TGACTACTGCCAGTTCGAAGTCCAGTTTGAGCTGACCCACAACGCCATTCACTCCTGGACA
 GGTGGACGTAGCCCTTACGGAATGTGACCCCTCGAGTTTCACAGCCTACGATCCTCTCTCT
 GGCTTCACCACTCCAACACCGACAGAACTCTGGGCTGTCTGGCAAGCACTGCAGAAATACCG
 AGGACTCCCATACAAACGAAGCACACTGTGAATCCAGGTTCTGAACAGCCCTTGAGGCCA
 TTCAACGATGACATCAACCACAATCCAATCACCAGACTAATGCCAGGCCCTATCGATTTCAT
 TTGATTATGAGAGGCTTAACTATCAGTATGACACCCTTAGCTTCCATGGTAAGAGCATCCC
 TGAACCTGAATGACCTGCTCGAGGAAAGAAAAGAGAAAGAGAGAACATTTGCTGCTTCTCT
 CTTGCTGGGAATCGGTTGCAGTGCTGATGCTCTCTTTGACATCTGCCGCCCCAATGGTGACT
 GTGTCTTTGCAGGAACCTTTGCTGTGCTGGGAGGGGAGCTAGAAATGCCCTTGGTCTCTCGA
 CAGACTGTTCCGCTATGACATCACCAGAGTCATGAATCAGCTCCATCTCCAGTATGATTCA
 GATTTTCAGTTTTCAGGGTGAAGCTTGTGTCACCAATGGCACTGAGCTTTCATCAGACCTTC
 TCAAGTCACCAACAATTGAACATGAACCTTG

Intron g/h

GTATGTTATCTTATCATCAAATGTGTGATCAGATACTGGAGACGTTTTCATATTAACCTTGG
 TCAGCATTAGTTGATGATTTTGGTGCGATGTTGACGACAAGGAGTCAAGCATTAAACACATT
 CAACACATCTTTAATCTGATATGAGAAGGGAATAAATTGATCCAGTATTGATGATTGAAGT
 TAGATTAAACAGTGAAAGATATACCAGTTTTGATAATCGTATAAAACAGTAGCAGAATTGTA
 TCGTGAAAACATAAATGTGGGAAGGCGAACGCCAAGCAGATTTTAGATTACGATCGTGTGCT
 AGAATAATTCACAATAACCCAGACGTCGGAATGTGGTTGTCTATGGCAATGGTTACGATT
 AATTGCTAACATGCACGATTTACCTATTTCA

Domäne h

AGCCACAGAGGACCAGTTGAAGAAACAGAACTCACTCGCCAACATACTGACGGCAATGCA
 CACTTTTCATCGTAAGGAAGTTGATTCGCTGTCCCTGGATGAAGCAAACAACCTTGAAGAATG
 CCCTTTACAAGCTACAGAACGACCACAGTCTAACGGGATACGAAGCAATCTCTGGTTACCA
 TGGATACCCCAATCTGTGTCCGGAAGAGGCGATGACAAAATACCCCTGCTGCGTCCCCGG
 ATGGGCATCTTTTCTTACTGGCACAGACTCTTGACCATTCAACTGGAAGAGCTCTTGAGC
 ACAATGGTGCAGTCTTGGTGTTCCTTACTGGGACTGGAACAAGGACCTGTCTGCTCACTGCC
 GCGTCTCTTCTCCGACTCCAGCAACAACAAATCCCTACTTCAAGTACCACATCGCCGGTSTT
 GGTCAAGACACCGTCAGAGAGCCAACTAGTCTTATATATAACCAGCCCCAAATCCATGGTT
 ATGATTATCTCTATTACCTAGCATTGACCACGCTTGAAGAAAACAATTACTGGGACTTTGA
 GGTTCAGTATGAGATCCTCCACAACGCCGTCCACTCCTGGCTTGGAGGATCCAGAAAGTAT
 TCCATGTCTACCCCTGGAGTATTCGGCCCTTTGACCCTGTCTTTATGATCCTTCACTCGGCTC
 TAGACAGACTTTGGATCATCTGGCAAGAACTTCAGAAGATCAGGAGAAAGCCCTACAACCTT
 CGCTAAATGTGCTTATCATATGATGGTAGAGCCACTGGCGCCCTTCAGCTATCCATCTATC
 AACCAGGACGAGTTCACCCGTGCCAACTCCAAGCCTTCTACAGTTTTTTGACAGCCATAAGT

WO 00/55192

PCT/EP00/02410

20/29

TCGGCTACCATTACGATAACCTGAATGTTAGAGGTCACAGCATCCAAGAACTCAACACAAT
CATCAATGACTTGAGAAACACAGACAGAATCTACGCAGGATTTGTTTTGTCAGGCATCGGT
ACGCTCTGCTAGTGTCAAGATCTATCTCCGAACAGATGACAATGACGAAGAAGTTGGAACCTT
TCACTGTCCTGGGAGGAGAGAGGGGAAATGCCATGGGCCTACGAGCGAGTTTTCAAGTATGA
CATCACAGAGGTTGCAGATAGACTTAAAATTAAGTTATGGGGACACCCTTTAACTTCCGGA
ACTGGAGATCACATCCTTACGAATGGAATCGGTGGTAAACAAGAGCCTACCCAAATCCTTT
CATCATCTACAGACCTGCCAATCATGACTACGATGTTCTTGTTATCCCAAGTANGGAAGAAA
CCTTCACATCCCTCCCAAAGTTGTCTGTCAGAAAGGCACCCGCATCGAGTTCCACCCAGTC
GATGATTCAGTTACGAGACCAAGTTGTTGATCTTGGAAGCTACACTGCACTCTTCAACTGTG
TGGTACCACCGTTTCACATACCACGGATTGGAAGTGAACCACGTCTATTCTGTCAAGCCTGG
TGACTACTATGTTACTGGACCCACGAGAGACCTTTGCCAGAATGCAGATGTCAGGATTCAT
ATCCATGTTGAGGATGAGTAA

3' UTR

CGCAACAGGT

Intron UTR

GAGATAAGAAAACCCTTCTAACAGTAATACGACACCACATTACAGCTTAAACATGATTGCCA
TCGATGTTTTTCATGTGTAGTATACGCTTTTCAGTTCTACATAATTTTTGTTTTTCAAATCAA
GTTTAGCAAATGAATCTATCACTGGAAAATAGGGTAGGGTAGCCAAGTGGTTAAAGCGGTG
ACTGATCACGCCAAAGACGAGTGTCTAACCTGCATGGGTACAAAAGTGAAGACCATTGCT
GGTGTCTACCGCCGTAATATTGTTTTTAGTATTGCTAAAACCTTATACTCACCCATGCGCTG
TAAAAGTGAATAATAATCATATTTCAACAAAAGCACAAAACCATTTTCATTTTCATGAAAG
CCTCTTGTTTCACCTGAAAGACGCAAGAGACAATAGTTCCCTAACATTATTTTCAGACATTG
GAAATGTCCTGCACGTGTAAACCATATATCCTTTGAAATTTTTACGACTGCATCGTATACA
ATTTATGATATAAATTTAAACCTTTAT

3' UTR

TTCTTGGTCTCCACATATTCACATATCAGCACCAAATGGTTTTCGAAGGACATTGGCGTTCT
TCTCTGGCAATGCATTTCAATACAACATTGAAAATGACTTCAGCATATCAGTGTGCTTCGA
ACGTGTTCCGGAAGTACTCAAATGTGCTATGACTGAATTATTGTACATACATAACTTATTG
ATGTTCAATAAATAAATGTTGAAACGAAAAAAAAAAAAAAAAAAAAA

Figur 7

Abgeleitete Primärstruktur des HtH2

Domäne b

HRLFVTOVEDALIRRGSPIGVPYWDWTQPMALPGLADNATYRDPI SGDSRHNPFDHVEVA
FENGRTERHPDSRLFEQPLFGKHTRLFDSIVYAFEQEDFCDFEVQFEMTHNNIHA WIGGGE
KYSMSSLHYTAFDPIFYLRHSNTDRLWAIWQALQIRNRNPYKAHCAWSEERQPLKPFASFSS
PLNNNEKTYENSVPNTNVYDYEGVLGYTYDDLNFEGGMDLGQLEEYIQRQRQRDRTFAGFFLS
HIGTSANVEIIIDHGTLSVGTFAVLGGEKEMKWGFDRLYKYEITDELRLNLNRADDVFS
ISVKVTDVDGSELSSSELIPSAAIIFERSH

Domäne c

IDHQDPHHDITIRKNVDNLTPEEINSLRRAMADLQSDKTAGGFQOIAAFHGE PKWCPSDA
EKKPSCCVHGMVFPWHRLTVQGENALRKHGCLGALPYWDWTRPLSHLPDLVLVSSRTT
PMPYSTVEARNPWYSGHIDTVGVDTTRSQRQELYEAPGFGHYTGVAQVLLALEQDDFCDF
EVQFEIAHNFIHALVGGSEPYGMASLRYTTYDPIFYLRHSNTDRLWAIWQALQYRGKPYN
SANCAIASMRKPLQPFGLTDEINPDDETROHAPFVSVDYKNNFNFEYDTLDFNGLSISQL
DRELSRRKSHDRVFAGFLLHGIQQSALVKFFVCKSDDDCDHYAGEFYILGDEAEMPWGVDYR
LYKYEITEQLNALDLHIGDRFFIRYEAFDLHGTSLGSNIFPKPSVIHDEGA

Domäne d

GHHQADEYDEVVTAASHIRKNLKDLSKGEVESLRS AFLQLQNDGVYENIAKPHGKPGLCDD
NGRKVACCVHGMPTFPQWHRLYVLQVENALLERGS AVSVPYWDWTETFTELPSLIAEATYF
NSRQQTDFDPNPFGRKISFENAVTTRDPQPELYVNRYYYQNVMLVFEQDNYCDFEIQFEMV
HNVLHAWLGGRATYSSISLDYSADFVPVFFLHHANTDRLWAIWQELQRYRKKPYNADCAIN
LMRKPLHFPDNDLNHDPVTFKYSKPTDGFQYQNNFGYKYDNLEFNHFSIPRLESIIRIQ
RQDRVFAGFLLHNIQTSATVLIIFVCVPTTSGEQNCENKAGTEAVLGGETEMAFHFDRLYRF
DISETLRDLGIQLDSHDFDLSIKIQGVNGSYLDPHILPEPSLIIFVPGSS

Domäne e

SFLRPDGHSDDI LVRKEVNSLTRETASLIHALKSMQEDHSPDGFQAIASFHALPPLCPSP
SAAHRYACCVHGMATFPQWHRLYTVQFQDALRRHGATVGVPYWDWLRPQSHLPPELVMTET
HDIWSNRDFPNPFYQANIEFEGENIT TEREVIADKLFVKGGHVFDKLVLTQTSHPSAEQENY
CDFEIQFEILHNGVHTWVGGSRTYSIGHLHYAFYDPLFYLRHHTQTDRIWAIWQELQEQGL
SGDEAHCALEQMREPLKPFSGAPYNWNQLTQDFSRPEDTFDYRKFGYEYDNLEFLGMSVA
ELDQYIIIEHQENDRVFAGFLLSGFGGSASVNFQVCRADSTCQDAGYFTVLGGS AEMAWAFD
RLYKYDITETLEKMLRYDDDFITISVSLTANNGTVLSSSLIPTPSVIFORGH

Domäne f

RDINTRSMSPNRVRRELSDL SARDLSSLSKALRDLOEDDGPNQYQALAAFHGLPAGCHDSR
GNEIACCIHGMPTFPQWHRLYTLQLEMALRRHGSSVAIPYWDWTKPISELPSLFTSPEYYD
PWHDAVVNNPFSKGFVKFANTYTVRDPQEMLFQLCENGESILYEQTLLALEQTDYCDFEVQ
FEVLHNVIHYLVGGROTALSSSLHYASYDFFFFIHHSFVDKMWVWQALQKRRLPYKRA
CAVNLMTKPMRPFDSDMNQNPFTKMHAVPNTLYDYETLYYSYDNLEIGGRNL DQLQAEIDR

GAHRGPVEETEVTQRQHTDGNAHFHRKEVDSLSLDEANNLKNALYKLQNDHSLTGYEAISGY
HGYPNLCPEEGDDKIPLLRPRMGIFPYWHRLTIQLERALEHNGALLGVPYWDWNKDLSSL
PAFFSDSSNNNPYFKYHIAGVGHDVTREPTSLIYNQPGIHGYDYLYYLALTLEENNYWDF
EVQYEILHNAVHWSLGGSSQKYSMSTLEYSADFVFMILHSGLDRLWI IWQELQKIRRPYN
FAKCAHYHMEPLAPFSYPSINQDEFTRANSPSTVFD SHKFGYHYDNLNVRGHSIQELNT
IINDLRNTDRIYAGFVLSGIGTSASVKIYLRTDDNDEEVGTF TVLGGGEREMPWAYERVFKY
DITEDVARDLKIKLWGHPLTSGTGDHILTNIGGKQEPTQILSSSTDLPIMTTMFLLSQXGR
NLHIIPPKVVVKKGTRIEFHVPVDDSTRPVVDLGSYALFNCCVVPFFTYHGFELNHVYSVKP
GDYYVTGPTRDLCQNAADVRIHIHVEDE

Figur 8

cDNA-Sequenz in Verbindung mit Intronstruktur des KLH1

Domäne b

GGCCTACCGTACTGGGACTGGACTGAACCCATGACACACATTCCGGGTCTGGCAGGAAACA
 AACTTTATGTGGATTCTCATGGTGCATCCCACACAAATCCTTTTCATAGTTCAGTGATTGC
 ATTTGAAGAAAATGCTCCCCACACCAAAAGACAAATAGATCAAAGACTCTTTAAACCGCT
 ACCTTTGGACACCACACAGACCTGTTCAACCAGATTTTGTATGCCTTTGAACAAGAAGATT
 ACTGTGACTTTGAAGTCCAATTTGAGATTACCCATAACACGATTTCACGCTTGGACAGGAGG
 AAGCGAACATTTCTCAATGTGCTCCCTACATTACACAGCTTTGATCCTTTGTTTACTTT
 CACCATTCTAACGTTGATCGTCTTTGGGCGCTTTGGCAAGCCTTACAGATGAGACGGCATA
 AACCTTACAGGGGCCACTGCGCCATATCTCTGGAACATATGCATCTGAAACCATTGCGCTT
 TTCATCTCCCTTAACAATAACGAAAGACTCATGCCAATGCCATGCCAAACAAGATCTAC
 GACTATGAAAATGTCTCCATTACACATACGAAGATTTAACATTTGGAGGCATCTCTCTGG
 AAAACATAGAAAAGATGATCCACGAAAACCAGCAAGAAGACAGAATATATGCCGGTTTTCT
 CCTGGCTGGCATACTGACTTCAGCAAATGTTGATATCTTCATTAAAACTACCGATTCCGTG
 CAACATAAGGCTGGAACATTTGCAGTGCTCGGTGGAAGCAAGGAAATGAAGTGGGGATTTG
 ATCGCGTTTTTCAAGTTTGACATCACGCACGTTTTTGAAGATCTCGATCTCACTGCTGATGG
 CGATTTTCGAAGTTACTGTTGACATCACTGAAGTCGATGGAACCTAACTTGCATCCAGTCTT
 ATCCACATGCTTCTGTCTTCGTGAGCATGCACGTGGTAAGCTGAATAGAG

Intron b/c

GTTTTGTAATAATTATGTAGAATTCTTTACCTCAGAATAAGATGAGGTCACATGGGTTTTG
 CAAAACATTACGTTCGAATTAATATTAATAATACCGGACCTCCACTGGTACATATTTAT
 CTTTATAACGATAATAGCGATGATGATGATGATGATGATGATGATGATGATGATGATAATG
 ATGATGCCGGTATTGCACGTAATCCAGCCGACTTAGATGACACCCTAAGGGTGCAGAAAGT
 ATAACAATTAGATTGCGTTTGCATCTGTGTATGCGTGTGCTTTAAACCAAAAGTCAAAATAA
 AAGTGCAAAACCTTAGTTTATTCATTTGATAGAGCCTTTTACGATAAGAACAATGTAATAA
 ATTAGAACATAACTGAAACCTCCGAAAGAAGGCCTGTTTGTCAAGAGAGGTATCGACATGA
 TTGACTTATAAACCTGTGCTTCTATATTTTGGAACTGTCCACTTTCTTGTGTGTGTA
 TAATCACATCGCACTATGGCTGCAAGACGTGTACGAGTACACTATATACTTACCTAATGAC
 CAACCACAAGGCTGGCTTTGTTAATATTTGTTATTTTACAGAAATAAACACAGAATTCCAGC
 ATTTGGCTGGTGTATTTAGCAAAACACCGATATGACACTCATGTTTTATTACATTTTTTTT
 AG

Domäne c

TTAAATTTGACAAAGTGCCAAAGGAGTCTGCTTATTTCGAAAAATGTAGACCGTTTGAGCCC
 CGAGGAGATGAATGAACCTTCGTAAAGCCCTAGCCTTACTGAAAGAGGACAAAAGTGCCGGT
 GGATTTTCAGCAGCTTGGTGCATTCCATGGGGAGCCAAAATGGTGTCTAGTCCCGAAGCAT
 CTAAAAAATTTGCCTGCTGTGTTACCGCATGTCTGTGTTCCCTCACTGGCATCGACTGTT
 GACGGTTTCAGAGTGAAAATGCTTTGAGACGACATGGCTACGATGGAGCTTTGCCGTACTGG
 GATTGGACCTCTCCTCTTAATCACTTCCCGAAGTGGCAGATCATGAGAAGTACGTCGACC
 CTGAAGATGGGGTAGAGAAGCATAACCTTGGTTGATGGTCATATAGATACAGTCGACAA
 AACAAACAAGAAGTGTTCAGAAATAACTCTTCGAACAGCCTGAGTTTGGTCATTATACA
 AGCATTGCCAAACAAGTACTGCTAGCGTTGGAACAGGACAATTTCTGTGACTTTGAAATCC
 AATATGAGATTGCCCATTAACATACATCCATGCACTTGTAGGAGGCGCTCAGCCTTATGGTAT
 GGCATCGCTTCGCTACACTGCTTTTGATCCACTATTCTACTTGCATCACTCTAATACAGAT
 CGTATATGGGCAATATGGCAGGCTTTACAGAAGTACAGAGGAAAACCGTACAACGTTGCTA
 ACTGTGCTGTTACATCGATGAGAGAACCTTTGCAACCATTTGGCCTCTCTGCCAATATCAA
 CACAGACCATGTAACCAAGGAGCATTCAGTGCCATTCAACGTTTTTGTATTACAAGACCAAT

WO 00/55192

PCT/EP00/02410

24/29

TTCAATTATGAATATGACACTTTGGAATTTAACGGTCTCTCAATCTCTCAGTTGAATAAAA
AGCTCGAAGCGATAAAGAGCCAAGACAGCTTCTTTGCAGGCTTCCTGTTATCTGGTTTCAA
GAAATCATCTCTTGTAAATTCAATATTTGCACCGATAGCAGCAACTGTCACCCCGCTGGA
GAGTTTTACCTTCTGGGTGATGAAAACGAGATGCCATGGGCATACGATAGAGTCTTCAAT
ATGACATAACCGAAAACTCCACGATCTAAAGCTGCATGCAGAAGACCACTTCTACATTGA
CTATGAAGTATTTGACCTTAAACCAGCAAGCCTGGGAAAAGATTTGTTCAAGCAGCCTTCA
GTCATTTCATGAACCAAGAATAG

Intron c/d

GTACTTGTTATATGTTTCGAATATTGCCGATACCTTCAATATATATACTTTATCAAAGTAA
TTGATTAATCTGAAGTAATTTTCCTTTCCAGTAGAGATTGAGTTGATACAACAAGAATTGC
CCCTGTTGTATGTCACCTTATTTTCATCAAACGATTGGAAGTGAGCTGTCCATGCCACAT
GGGGTCTCTGTAACCTTCTCGTATGGGGTATAGATTATATAGACGTGGCAGACCTTACGTA
TAACTAATATTTGTGTAATGTGCTTTCAG

Domäne d

GTCACCATGAAGGCGAAGTATATCAAGCTGAAGTAACTTCTGCCAACCGTATTGCAAAAAA
CATTGAAAATCTGAGCCTTGGTGAAGTCTGAGAGCTGCCTTCCTGGAAATTGAA
AACGATGGAACTTACGAATCAATAGCTAAATTCCATGGTAGCCCTGGTTTGTGCCAGTTAA
ATGGTAACCCCATCTCTTGTGTGTCATGGCATGCCAACTTTCCCTCACTGGCACAGACT
GTACGTGGTTGTGCTTGAGAATGCCCTCCTGAAAAAAGGATCATCTGTAGCTGTTCCCTAT
TGGGACTGGACAAAACGAATCGAACATTTACCTCACCTGATTTTCAGACGCCACTTACTACA
ATTCCAGGCAACATCACTATGAGACAAAACCCATTCCATCATGGCAAAATCACACACGAGAA
TGAAACTCACTAGGGATCCCAAGGACAGCCTCTCCATTTCAGACTACTTTTACGAGCAG
GTCCTTTACGCCCTTGGAGCAGGATAACTTCTGTGATTTTCGAGATTTCAGTTGGAGATATTAC
ACAATGCATTGCATTCTTTACTTGGTGGCAAAGGTAAATATTCCATGTCAAACCTTGATTA
CGCTGCTTTTGTATCCTGTGTTCTTCCTTCATCACGCAACGACTGACAGAATCTGGGCAATC
TGGCAAGACCTTCAGAGGTTCCGAAAACGGCCATACCGAGAAGCGAATTGCGCTATCCAAT
TGATGCACACGCCACTCCAGCCGTTTGATAAGAGCGACAACAATGACGAGGCAACGAAAAC
GCATGCCACTCCACATGATGTTTTGAATATCAAACAGCTTTGGTTATGCTTACGATAAT
CTGGAACCTGAATCACTACTCGATTCCCTCAGCTTGATCACATGCTGCPAGAAAGAAAAGGC
ATGACAGAGTATTCGCTGGCTTCCTCCCTCACAAATATTGGAACATCTGCCGATGGCCATGT
ATTTGTATGTCTCCCAACTGGGGAACACACGAAGGACTGCAGTCATGAGGCTGGTATGTTT
TCCATCTTAGGCGGTCAAACGGAGATGTCTTTGTATTTGACAGACTTTACAAACTTGACA
TAACTAAAGCCTTGAAAAAGAACGGGTGTGCACCTGCAAGGGGATTTGATCTGGAAATTGA
GATTACGGCTGTGAATGGATCTCATCTAGACAGTCATGTCCACTCTCCCACTATACTG
TTTGAGGCGCGGAACAG

Intron d/e

GTAATATTTTGTCACTGTAACCAACAACCTGCAGTCTATTTTGCAATTACGATAATAACAA
TTTTTGAATATATCTTTATTAPAGCAAAGSTTTCTAGAGACAAACAGCCGGCTCIAATTA
TTTTTTCGAACCTTACGCTTGAGTAAAGATCTGCAAATGGCAACCCTACCTATACTATTAA
AATATAATGTTACATTCTGATCTGAATGTTTAAATAATCACTTCATATTCTGTTGCGAG

Domäne e

ATTCTGCCCCACACAGATGATGGACACACTGAACCAGTGATGATTGCAAGATATCACACA
ATTGGACAAGCGTCAACAACCTGTCAGTGGTGAAGCCCTCGAGTCCATGAAAGCCGACCA
TCATCTGATGGGTTCCAGGCAATCGCTTCCTTCCATGCTCTTCCTCCTCTTTGTCCATCAC
CAGCTGCTTCAAAGAGGTTTGGCTGCTGCGTCCATGGCATGCCAACCTTCCCGCAATG

Figur 9

Abgeleitete Primärstruktur des KLH1

Domäne b

GLPYWDWTEPMTHIPGLAGNKTYVDSHGASHTNPFHSSVIAFEENAPHTKRQIDQRLFKPA
TFGHHTDLFNQILYAFEQEDYCDFEVQFEITHNTIHAWTGGSEHFSMSSLHYTAFDPLFYF
HHSNVDRLLWAVWQALQMRRHKPYRAHCAISLEHMLKPFAPSSPLNNNEKTHANAMPNKIV
DYENVLHYTYEDLTFGGISLENIEKMIHENQQEDRIYAGFLLAGIRTSANVDIFIKTDSV
QHKAGTFAVLGGSKEMKWGFDRVFKFDITHVLKDLDLTADGDFEVTVDITEVDGTKLASSL
IPHASVIREHARGKLNK

Domäne c

VKFDKVPRSRILIRKNVDRLSPEEMNELRKALALLKEDKSAGGFQQLGAFHGEPKWCPSP
SKKFACCVHGMSTFPHWRLLTVQSENALRRHGYDGAALPYWDWTSPLNHLPELADHEKYVD
PEDGVEKHNPWFDDGHIDTVDKTTTTRSVQNKLFEOPEFGHYTSIAKQVLLALEQDNFCDFEI
QYEIAHNYTHALVGGAPYGMASLRYTAFDPLFYLLHHSNTDRIWAIWQALQKYRGKPYNVA
NCAVTSMREPLQPFGLSANINTDHTVKEHSVPFNVFDYKTNFNYEYDTLEFNGLSISOLNK
KLEAIKSQDRFFAGFLLSGFKKSSLVKFNICTDSSNCHPAGEFYLLGDENEMPWAYDRVFK
YDITEKLHDLKLHAEDHFIYIDYEVFDLKPASLGKDLFKQPSVIHEPRI

Domäne d

GHHEGEVYQAEVTSANRIRKNINLSLGELESLRAAFLEIENDGTYESIAKFHSGSPGLCQL
NGNPISCCVHGMPTFPHWRLLYVVVVENALLKKGSSVAVPYWDWTKRIEHLPHLISDATYY
NSRQHMYETNPFHKGKITHENEITTRDPKDSLPHSDYFYEQVLYALEQDNFCDFEIQLEIL
HNAHSLGKGGKYSMSNLDYAAFDPVFFLHATTDRIWAIWQDLQRFKRKPYREANCAIQ
LMHTPLQPFDKSDNNDEATKTHATPHDGFYQNSFGYAYDNLELNHYSIPOLDHMLQERKR
HDRVFAFGLLHNIGTSADGHVFCVCLPTGEHTKDCSHEAGMFSILGGQTEMSFVFDRLYKLD
ITKALKKNGVHLQGDFFLEIEITAVNGSHLDSHVIHSPTILFEAG

Domäne e

DSAHTDDGHTEPVMIRKDITQLDKRQQLSLVKALESMKADHSSDGFQAIASFHALPPLCP
PAASKRFACCVHGMPTFPQWRLLYTVQFQDSLKKGAVVGLPYWDWTLPR

26/29

Figur 10

cDNA-Sequenz in Verbindung mit Intronstruktur des KLH2

Domäne b

GGCCTGCCCTACTGGGATTGGACCATGCCAATGAGTCATTTGCCAGAACTGGCTACAAGTG
 AGACCTACCTCGATCCAGTTACTGGGGAACTAATAACAACCCTTTCCATCACGCCCAAGT
 GGCGTTTGAATAATGGTGTAAACAAGCAGGAATCCTGATGCCAAACTTTTTATGAAACCACT
 TACGGAGACCACACTTACCTCTTCGACAGCATGATCTACGCATTTGAGCAGGAAGACTTCT
 GCGACTTTGAAGTCCAATATGAGCTCACGCATAATGCAATACATGCATGGGTTGGAGGCAG
 TGAATAAGTATTCAATGTCTTCTCTTCACTacacTGCTTTTGATCCTATATTTTACCTCCAT
 CACTCAAAATGTTGATCGTCTCTGGGCCATTTGGCAAGCTCTTCAAAATCAGGAGAGGCAAGT
 CTTACAAGGCCCACTGCGCCTCGTCTCAAGAAAGAGAACCATTAAAGCCTTTTGCATTTCAG
 TTCCCCACTGAACAACAACGAGAAAACGTACCACAACCTCTGTCCCCACTAACGTTTATGAC
 TATGTGGGAGTTTTGCACATATCGATATGATGACCTTCAGTTTGGCGGTATGACCATGTTCAG
 AACTTGAGGAATATATTTACAAGCAGACACAACATGATAGAACCCTTTGCAGGATTCTTCCT
 TTCATATATTGGAACATCAGCAAGCGTAGATATCTTCATCAATCGAGAAGGTCATGATAAA
 TACAAAGTGGGAAGTTTTGTAGTACTTGGTGGATCCAAAGAAATGAAATGGGGCTTTGATA
 GAATGTACAAGTATGAGATCACTGAGGCTCTGAAGACGCTGAATGTTGCASTGGATGATGG
 GTTCAGCATTACTGTTGAGATCACCGATGTTGATGGATCTCCCCCATCTGCAGATCTCATT
 CCACCTCCTGCTATAATCTTTGaACGTGGTCTaTG

Intron 2b/c

AGGTATTTAAAAAAGTAATAAAAACCaTATTTTCGAATGCGCTTTATGAAATATCGTGTGAC
 TGGTTCTTTAGTTTACATGGAGTGTAAACAACATGCTCCATCAGTTGACATATACTGCTCAC
 ACAAGTAAGGGATATTTGATAATGATAACAAATATAATCAAAGCGGTTATACTATCAAGA
 CTTATTACATAATTACAGGTGAAGGGAGGTGTGATCGTGTTCAGTATCAGGTTGAGGCC
 AGAGAAGTCCCAAGTTTGAGTCTTGCAAGAAGATGATGTTTAGGCATGGGGTCGAATCACCAA
 AATCACATGACTTCAATAACGGGTTGGACCACCTCGAGCGACgATGCAAGCAGTAGAGCGT
 CTACGCATGCTCCTGATAAGGCGACCAATCTGTTTCTGGGGAATCAGtCGCCACTCCTCTT
 GTAGTGCCACGCTCATTTCTGCTACGGTCTGGGTACCTGCTATCGGgTCTTGATCCGTAT
 CCCAAGGATGTCCCACACATGTTCAAgGTGAGAGGTGGGGAAACATCGCTGGCCACGGTaA
 GGtCTGAATTTGATGCCGTTGAAAGTGAAGCTCTGACAACcTGAGCATGGtGAGCTCTGACG
 TTGTCGTCCTGAAAGATGAATcCAGCTcCaTGaCAGCGAGCAAaGGGCAGGACGTGTTGGT
 CAATGCAGTTGTCTCTGCAGTACACACCTGTCACTCGCCACTCACAAAGCGTGTAGATCTGT
 ACGACCAGTCATGGAGATCCCAGCCCACATCATAACGGACCCCTATCCATACCGATCATGA
 GCCACCATAGCAGCGTCTTGATGACGTTCTCCCTGTGCGCTCGACATCCTcACACGGCCAA
 AAGGAACGTGGACTCGTCACTGAACATGACATTAGCCAACCTGGCACTTGTCCACCGCTGA
 TGTTGGCGAGACCATTCCAGTCGAGCTCTTCGGTGTCTGGCTTTTCATCGATAACACGACGT
 AAGGTCTGCGGGGCTGCAAGACGGCTCTATGCAAGGCGATTTTCGGATTGTCTGGGTGCTAAC
 TCTGATCCCAGGTGCCTGCTGAAGTTGATGCTGGATCTGTGTGGCATTGAGATGGCGATTC
 CTTAGGACTGTGGAGATGATGAATCGATCTTGACTTATGGTGGTGACATTAGGACGTGGGG
 TTCGTGTCTTATCCTGCACTCTTCCAGTTGTTTCGGTGACGCTCTGGTACCGGCTGATTAC
 TGACTGAGAATATCCATCTGCCGTGCGACATGAGCCTGTGTTGGCCCAGCCTGAAGCATTG
 CAATCGCCAGAGACGCTCTTCAAAAGTCATTTCGACGCATGGtTTTCTGTTCAAAATGACA
 GCGTAAACAGtTTTTGGtGCTTTTATGCTTCCCAAGAGCATGAAAAACACGTTCTATgGG
 TCGtGCACACCTTACATGACAAGtGtGAAAAGTGACTTGcACCCCTTGTgGtGTTCCGATG
 CACACTCTGTTTACGTACTGATGCGATTTGGCGTCTAAACATGTTTTGGCGCTCTAAACATG
 TTTTCTGTCATGATTCATATACTATTTTTGTATATTCTGGCATCAAACCAACTACAGTG
 AAATATATTTCAATATCCCCTACTTTGTGTGAGTAGTATAGATCACTGCAGACAACATATA

WO 00/55192

PCT/EP00/02410

27/29

GACAAAtGCAgtTaCaCCGTCAACAATCCCAGTCATTAATTATGATGaCaCTTCCACACATA
GfGTcAGTgATTGTAAATTCAaCTGTACACACTTTTCCCGTGAACATTcAGGATCTATATGA
CTAAATATATAACATTAGTATACGTGCAGTTTTGTATCGCTACGACATTGTTGTAACCTCT
TGTTTAATCATTTaACAG

Domäne c

CTGATGCCAAAGaCTTTGgCCATAGCAGAAAAATCAGgAAAAGcCGTTGATTcTcTGACAGT
CgAAGAACAAAaCTTCGTTGAGgCGAGcTATGgCAGATcTACAGGACGACAAAACATCAGGG
GGTTTCCAGCAGATTGCAGCATTCCACGGGAGAACCAAAATGGTGTCCAAGCCCCgAAGCGG
AGAAAAAATTTGCATGCTGTGTTTCATGGAATGGCTGTTTTCCCTCACTGGCACAGATTGCT
GACAGTTCAAGGAGAAAAATGCTCTGAGGAAACATGGCTTTACTGGTGGACTGCCCTACTGG
GACTGGACTCGATCAATGAGCGCCCTTCCACATTTTGTGCTGATCCTACTTACAATGATG
CTATTTCCAGCCAGGAAGAAGATAAACCATGGCATCATGGTCACATAGACTCTGTGGGGCA
TGATACTACAAGAGATGTGCGTGATGATCTTTATCAATCTCCTGGTTTTCGGTCACTACACA
GATATTGCACAACAAGTCCTTCTGGCCTTTGAGCAGGACAGTTTTCTGTGATTTTGAGGTAC
AATTTGAAATTGCCCATAATTTTCATACATGCACTGATTGGTGGTAACGAACCATACAGTAT
GTCATCTTTGAGGTATACTACATACGATCCAATCTTCTTCTGCACTCCAGTACAGAC
CGACTTTGGGCCATCTGGCAAGCAATCACTAGTGCGGCCCGCCTGCAGGTCGACCATAAGGG
AGAGCTCCCAACGCgtTGGAtGCAATCT

Domäne g

ATGGCTGTGTTTTCCGCACTGGCACAGACTGTTTGTGAAACAGATGGAGGACGCACTTGCTG
CTCATGGAGCTCATATTGGCATACCATACTGGGATTGGACAAGTGCGTTTTAGTCATCTGCC
CGCCCTAGTGACTGACCACGAGAACAATCCCTTCCACCAC

Intron g(2)

GTATGTGTCAAATCGTTTTAGGAACTGCCTTATCCATTTTACAATTACGAGTACAAAATGA
AAACGGAAACTGTGTGACCTCGAAAAGTGCAATCTTTAAAGGATGCAATGTACACAATAAA
ATGCTCCGATCAAAGCGATGGCTAGAAATCATTTTCCCTCTAATTCCCTTTACACAGCT
CGGTTGTTTTTAAGTAGGAACAAGTCTCTGCAAAAACATCACAAATAAAGAGAACACAGAA
AAAACCTCATTCTCGTTTTCTGTATTCCGAAAATGAAATTTACAATTTCTTTTCATTTATAG

Domäne g

GGCCATATTGGTCATCTGAATGTGGATACATCTCGATCTCCAAGAGACATGCTGTTTTAATG
ATCCTGAACAAGGCTCAGAATCATTCCTTCTACAGACAGGTTCTCTTGACTCTAGAACAGAC
AGACTTCTGCCAATTTGAAGTTCACTTTGAACTTACACACAATGCCATCCACTCTTGGACT
GGAGGACATACTCCATATGGAATGTCATCACTGGAATATACAGCATATGATCCACTCTTTT
ATCTCCACCATTCCAACACTGATCGTATCTGGGCCATCTGGCAGGCACTCCAGAAATATAG
AGGTCTTCCATACAACGCAGCTCACTGCGATATccaagtctgaacaacctcTTAAACCA
TTCAGCGAGTCCAGGAATCCAAACCCAGTCACCAGAGCCAATTCTAGGGCCGTTGATTCTAT
TTGATTATGAGAAATTCaATTATCAATATGACACACTTACCTTCCACGGACTTTCTATCCC
AGAACTTGATGCCATGCTTCAAGAGAGAAAGAAGGAAGAGAGAACATTTGCAGCCTTCCTG
TTGCACGGATTGCGGCCAGTGCTGATGTTTCGTTTGATGTCTGCACACCTGATGGTCATT
GTGCCTTTGCTGGAACCTTCGCGGTACTTGGTGGGGAGCTTGAGATGCCCTGGTCCTTTGA
AAGATTGTTCCGTTACGATATCACAAAGGTTCTCAAGCAGATGAATCTTCACTATGATTCT
GAGTTCCACTTTGAGTTGAAGATTGTTGGCACAGATGGAACAGAACTGCCATCGGATCGTA
TCAAGAGCCCTACCATTGAACACCATGGAGGAG

WO 00/55192

PCT/EP00/02410

28/29

Intron g/h

GTATGTTTTGAGATCCACATAATCTTCTACCCTGTCTCATTTCTAATGCTCTTCAATACAC
AATTTATATAGCCTTTGAGCTTCAGATGTATTACGGACAGGCATTACAGTATACATGTAAT
ATGGTTTTCTGCTATTTGCAAAAATTGTGTCCTATCTCTGTTTCAGATCATCATGGCGGTGA
CACCTAG

Domäne h

GTCACGATCACAGTGAACGTCACGATGGATTTTTTCAGGAAGGAAGTCGGTTCCTGTCCCT
GGATGAAGCCAATGACCTTAAAAATGCACTGTACAAGCTGCAGAATGATCAGGGTCCCAAT
GGATATGAATCAATAGCCGGTTACCATGGCTATCCATTCCTCTGCCCTGAACATGGTGAAG
ACCAGTACGCATGCTGTGTCCACGGAATGCCTGTATTTCCACATTGGCACAGACTTCATAC
AATCCAGTTTGAGAGAGCTCTCAAAGAACATGGTTCTCATTTGGGTCTGCCATACTGGGAC
TGGAC

Figur 11

Abgeleitete Primärstruktur von KLH2

Domäne b

GLPYWDWTMPMSHLP ELATSETYLD PVTGETKNNPFFHHAQVAFENGVT SRNPDAKLFMKPT
YGDHTYLFDSMIYAFEQEDFCDFEVQYELTHNAIHAWVGGSEKYSMSSSLHYTAFDPIFYLLH
HSNVDRLWAIWQALQIRRGKSYKAHCASSQEREPLKPPAFSSPLNNNEKTYHNSVPTNVYD
YVGVLHYRYDDLQFGGMTMSELEEYIHKQTQHDRTFAGFFLSYIGTSASVDIFINREGHDK
YKVGSFVVLGGSKEMKWGPFDRMYKYEITEALKTLNVAVDGGSITVEITDVGSPPSADLI
PPPAIIFERGH

Domäne c

DAKDFGHSRKIRKA VD SLTVEEQTS LRRAMADLQDDKTSGGFFQOIAAFHGEPKWCPSPEAS
KKFACCVHGM AVEFPHWHRLLTVOGENALRKHGFTGGLPYWDWTRSMSALPHFVADPTYNDA
ISSQEEDNPWHHGHIDSVGHDTTRDVRDDLYQSPGFGHYTDIAQQVLLAFEQDSFCDFEVQ
FEIAHNFIHALIGGNEPYSMSLLRYTTYDPIFFLHHSSTDRLWAIWQALQKYRGKPYNTAN
CAIASMRKPLQPFGLDSVINPDDETREHSVPFRVFDYKNNFDYEVESLAFNGLSIAQLDRE
LQRRKSHDRVFAGFLLHEIGQSAKHNVSDCDHYAGEFYILGDEAEMPWRYDRVYKYEITQQ
LHDLDLHVGDNFFLKYEAFDLNGGSLGGSIFSQPSVIFEPAGMF

Domäne d

GSHQADEYREAVTSASHIRKNIRDLS EGEIESIRSAFLOIQKEGIYENIAKFHGKPGLC EH
DGHVACCVHGMPTFPHWHRLYVLQVENALLERGS AVAVPYWDWTLPR

Domäne g

MAVEFPHWHRLFVKQMEDALAAHGAHIGIPYWDWTS AFSHLPALVTDHENNPFHHGHIGHLN
VDTSRSPRDMLFNDPEQGSSEFFYRQVLLTLEQTDFCQFEVQFELTHNAIHSWTGGHTPYG
MSSLEYTAYDPLFYLLHHSNTDRIWAIWQALQKYRGCLPYNAAHCDIQVLKQPLKPFSESRNP
NPVTRANSRAVDSFDYEKFNYQYDTLTFHGLSIPELDAMLQERKKEERTFAAFLHLHGFGAS
ADV SFDVCTPDGHCAFAGTFAVLGGELEMPWSFERLFRYDITKVLKQMNLYDSEFHFELK
IVGTDGTELP SDRIKSPTIEHHGG

Domäne h

GHDHSE RHDGFFRKEVGSLSLDEANDLKNALYKLQNDQGPNGYESIAGYRGYPFLCP EHG E
DQYACCVHGM PVFPHWHRLHTIQFERALKEHGSHLGLPYWDW

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare:

That my residence, post office address and citizenship are as stated below next to my name.

That I verify believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: **NUCLEIC ACID MOLECULE COMPRISING A NUCLEIC ACID SEQUENCE CODING FOR A HAEMOCYANIN** the specification of which (check one)

☒ is attached hereto.

☐ was filed on _____ as Application, Serial No. _____ and was amended on _____ (if applicable).

That I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

That I acknowledge the duty to disclose information known to be material to patentability of this application in accordance with Title 37, Code of Federal Regulations §1.56(a).

That I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate on this invention having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)**Priority Claimed**

PCT/EP00/02410 Europe 17 March 2000
(Number) (Country) (Day/Month/Year Filed)

☒ ☐
Yes No

199 11 971.6 Germany 17 March 1999
(Number) (Country) (Day/Month/Year Filed)

☒ ☐
Yes No

199 39 578.0 Germany 20 August 1999
(Number) (Country) (Day/Month/Year Filed)

☒ ☐
Yes No

That I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

United States Application(s)

(Application Serial No.) (Filing Date) (Status)-(Patented, pending, abandoned)

(Application Serial No.) (Filing Date) (Status)-(Patented, pending, abandoned)

(Application Serial No.) (Filing Date) (Status)-(Patented, pending, abandoned)

That all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

I hereby appoint the following attorneys, with full power of substitution and revocation, to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith and request that all correspondence and telephone calls in respect to this application be directed to: WELSH & KATZ, LTD., 120 South Riverside Plaza, 22nd Floor, Chicago, Illinois 60606-3913, Telephone No.: (312) 655-1500:

AttorneyRegistration No.

A. Sidney Katz
 Richard L. Wood
 Jerold B. Schnayer
 Eric C. Cohen
 Joseph R. Marcus
 Gerald S. Schur
 Gerald T. Shekleton
 James A. Scheer
 Daniel R. Cherry
 Kathleen A. Rheintgen
 Edward P. Gamson
 Thomas W. Tolpin
 Shannon L. Nebolsky
 Mitchell J. Weinstein
 Charles R. Krikorian

24,003
 22,839
 28,903
 27,429
 25,060
 22,053
 27,466
 29,434
 29,054
 34,044
 29,381
 27,600
 41,217
 37,963
 40,687

Full name of sole or one joint inventor:

Inventor's signature:

Date:

Residence and Post Office Address:

Jürgen MARKL

M. Markl
 2. Oct. 01

An der Mahlsteig 12

55296 Gau-Bischofsheim

GERMANY

Germany

Citizenship:

Full name of additional joint inventor, if any:

Inventor's signature:

Date:

Residence and Post Office Address:

Benjamin ALTENHEIN

B. Altenhein
 4. 10. 01

Elasser Platz 7 ELSAESSER PLATZ 7

65195 Weisbaden

GERMANY

Germany

Citizenship:

SEQUENCE LISTING

<110> Biosyn Arzneimittel GmbH

<120> Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin

<130> PCT1153-01966

<140>

<141>

<160> 108

<170> PatentIn Ver. 2.1

<210> 1

<211> 1269

<212> DNA

<213> Haliotis tuberculata

<400> 1

```

ggcttggttca gtttctactc gtcgcccttg tggcgggggc tggagcagac aacgtcgtca 60
gaaaggacgt gagtcacctc acggatgacg aggtgcaagc tctccacggc gccctccatg 120
acgtcactgc atctacaggg cctctgagtt tccaagacat aacatcttac catgccgcac 180
cagcgtcgtg tgactacaag ggacggaaga tcgcctgctg tgtccacggg atgcccagtt 240
tccccttctg gcacagggca tatgtcgtcc aagccgagcg ggcactgttg tccaaacgga 300
agactgtcgg aatgccttac tgggactgga cgcaaacgct gactcactta ccatctcttg 360
tgactgaacc catctacatt gacagtaaag gtggaaaggc tcaaaccaac tactggtacc 420
gcggcgagat agcgttcatc aataagaaga ctgcgcgagc tgtagatgat cgcctattcg 480
agaaggtgga gcctgggtcac tacacacatc ttatggagac tgtcctcgac gctctcgaac 540
aggacgaatt ctgtaaattt gaaatccagt tcgagttggc tcataatgct atccattact 600
tgggttggcgg taaatttgaa tattcaatgt caaacttgga atacacctcc tacgacccca 660
tcttcttctc ccaccactcc aacggttgacc gcctcttcgc catctggcag cgtcttcagg 720
aactgcgagg aaagaatccc aatgcaatgg actgtgcaca tgaactcgct caccagcaac 780
tccaaccctt caacagggac agcaatccag tcagctcac aaaggaccac tcgacacctg 840
ctgacctctt tgattacaaa caacttggat acagctacga cagcttaaac ctgaatggaa 900
tgacgccaga acagctgaaa acagaactag acgaacgcca ctccaaagaa cgtgcgtttg 960
caagcttccg actcagtggc tttggggggt ctgccaacgt tgttgtctat gcatgtgtcc 1020
ctgatgatga tccacgcagt gatgactact gcgagaaagc aggcgacttc ttcattcttg 1080
ggggtcaaag cgaaatgccg tggagattct acagaccctt cttctatgat gtaactgaag 1140
cggtagatca cttggagtc ccgctaagtg gccactacta tgtgaaaaca gaactcttca 1200
gcgtgaatgg cacagcactt tcacctgata ttcttctca accaactggt gcctaccgac 1260
ctgggaaag                                     1269

```

<210> 2

<211> 1257

<212> DNA

<213> Haliotis tuberculata

<400> 2

```

gtcaccttga cccacctgtg catcatcgcc acgatgacga tcttattggt cgaaaaaata 60
tagatcattt gactcgtgaa gaggaatacg agctaaggat ggctctggag agattccagg 120
ccgacacatc cgttgatggg taccaggcta cagtagagta ccatggcctt cctgctcgtt 180
gtccacgacc agatgcaaaa gtcagggttcg cctgttgatg gcatggcatg gcatccttcc 240
ctcactggca ccggctgttc gttacccagg tggaaagatgc tcttgtagcg cgtggatcgc 300
ctatcgggtg tcttatttgg gactggacaa aacctatgac tcaccttcca gacttggcat 360

```

2

caaatgagac	gtacgtagac	ccgtatggac	atacacatca	taatccattc	ttcaatgcaa	420
atatatcttt	tgaggaggga	caccatcaca	cgagcaggat	gatagattcg	aaactgtttg	480
ccccagtcgc	ttttggggag	cattcccatc	tgtttgatgg	aatcctgtac	gcatttgagc	540
aggaagattt	ctgcgacttt	gagattcagt	ttgagttagt	ccataattct	attcatgcgt	600
ggataggcgg	ttccgaagat	tactccatgg	ccaccctgca	ttacacagcc	tttgacccca	660
ttttctacct	tcatcattcc	aatgtcgatc	gtctatgggc	aatctggcaa	gctcttcaaa	720
tcaggagaca	caagccatat	caagcccact	gtgcacagtc	tgtggaacag	ttgccaatga	780
agccattttg	tttcccatca	cctcttaaca	acaacgagaa	gacacatagt	cattcagtc	840
cgactgacat	ttatgactac	gaggaagtgc	tgcactacag	ctacgatgat	ctaacgtttg	900
gtgggatgaa	ccttgaagaa	atagaagaag	ctatacatct	cagacaacag	catgaacgag	960
tcttcgcggg	atttctcctt	gctggaatag	gaacatctgc	acttggtgac	attttcataa	1020
ataaaccggg	gaaccaacca	ctcaaagctg	gagatattgc	cattcttggg	ggtgccaaag	1080
aaatgccttg	ggcgtttgac	cgcttggtata	aggtcgaaat	aactgactca	ttgaagacac	1140
tttctctcga	tgctgatgga	gattatgaag	tcacttttaa	aattcatgat	atgcacggaa	1200
acgctcttga	tacggacctg	attccacacg	cagcagttgt	ttctgagcca	gctcacc	1257

<210> 3

<211> 1242

<212> DNA

<213> *Haliotis tuberculata*

<400> 3

ctacctttga	ggatgaaaag	cacagcttac	gaatcagaaa	aatgtcgac	agcttgactc	60
ctgaagaaac	aatgaactg	cgtaaagccc	tggagcttct	tgaaaatgat	catactgcag	120
gtggattcaa	tcagcttggc	gccttccatg	gagagcctaa	atgggtgccct	aatcctgaag	180
cggagcacia	ggttgcattg	tgtgttcattg	gcattggctgt	tttccctcat	tggcacaggc	240
ttcttgctct	ccaggcggag	aatgctctta	gaaagcatgg	gtacagtggg	gctctaccat	300
actgggattg	gactcgcccc	ctttcccaac	ttcctgatct	ggttagtcat	gagcagtata	360
cagatccttc	cgaccatcac	gtgaagcata	acccgtgggt	caatggccac	atcgatacag	420
taaatcagga	taccaccaga	agcgtacggg	aggatcttta	tcaacaacct	gaatttggac	480
atttcacgga	tattgctcaa	caagtcctct	tagcattaga	acaagatgac	ttctgttcgt	540
ttgaagtgca	gtatgagatt	tcccataatt	ttatccatgc	acttgtagga	ggaaccgacg	600
cttatggcat	ggcatcgctg	agatatacag	catacgatcc	aatctttttc	ttgcatcatt	660
caaacaccga	caggatctgg	gctattttgg	aatccttgca	aaaatacaga	ggcaaacctg	720
acaacactgc	caactgcgcc	atagaatcta	tgagaaggcc	cctgcaacca	tttggactaa	780
gcagtgccat	taaccctgac	agaatcacca	gagagcatgc	tatcccggtt	gatgtcttca	840
actatagaga	taaccttcat	tacgtatatg	ataccctgga	atttaattgg	ttgtcgattt	900
cacaacttga	tagagagctg	gaaaaaatca	agagtcacga	aagagtattt	gctggattct	960
tgctgtcggg	gattaaaaaa	tctgctcttg	tgaaattcga	agtttgact	ccacctgata	1020
attgtcataa	agcaggggag	ttttatctac	tgggggacga	aaacgagatg	gcttgggcct	1080
atgaccgact	tttcaagtat	gatattactc	aggttctgga	agcaaaccat	ctacacttct	1140
atgatcatct	cttcattcgc	tacgaagtct	ttgatcttaa	aggagtgagt	ttgggaactg	1200
acctgttcca	cactgcaaat	gtggtacatg	attccggcac	ag		1242

<210> 4

<211> 1239

<212> DNA

<213> *Haliotis tuberculata*

<400> 4

gcacccgtga	tcgtgataac	tacgttgaag	aagttactgg	ggccagtcac	atcaggaaga	60
atttgaacga	cctcaatacc	ggagaaatgg	aaagccttag	agctgctttc	ctgcatattc	120
aggacgacgg	aacatatgaa	tctattgccc	agtaccatgg	caaaccaggc	aatgtcaaat	180
tgaatgatca	taatattgcg	tggttggtcc	atggatagcc	taccttcccc	cagtggcaca	240
gactgtatgt	ggttcagggtg	gagaatgctc	tctaaacag	gggatctggg	gtggctgttc	300
cttactggga	gtggactgct	cccatagacc	atctacctca	tttcattgat	gatgcaacat	360
acttcaattc	ccgacaacag	cggtacgacc	ctaacccttt	cttcagggga	aaggttactt	420

3

ttgaaaacgc	agtcacaaca	agggacccac	aagccgggct	cttcaactca	gattatatgt	480
atgagaatgt	tttacttgca	ctggagcagg	aaaattattg	tgactttgaa	attcagtttg	540
agcttggtca	taacgcactt	cattccatgc	tgggaggtaa	agggcagtac	tccatgtcct	600
ccctggacta	ttctgcgttt	gatcccgctt	tcttcctaca	tcatgccaac	acggacagac	660
tgtgggcaat	ctggcaggaa	ctacaaagat	tccgagaact	gccttatgaa	gaagcgaact	720
gtgcaatcaa	cctcatgcat	caaccactga	agccgttcag	tgatccacat	gagaatcacg	780
acaatgtcac	tttgaaatac	tcaaaaccac	aggacggatt	cgactaccag	aaccacttcg	840
gatacaagta	tgacaacctt	gagttccatc	acttatctat	cccaagtctt	gatgctaccc	900
tgaagcaaag	gagaaatcac	gacagagtgt	ttgcgggctt	ccttcctcat	aacataggaa	960
cttctgctga	cataactatc	tacatatgtc	tgcttgacgg	acggcggtggc	aatgactgca	1020
gtcatgaggc	gggaacattc	tatatcctcg	gaggcgaaac	agagatgcct	tttatctttg	1080
accgtttgta	taaatttgaa	atcaccaaac	cactgcaaca	gttaggagtc	aagctgcatg	1140
gtggagtttt	cgaactggag	cttgagatca	aggcatacaa	cggttcctat	ctggatcccc	1200
atacctttga	tccaactatc	atctttgaac	ctggaacag			1239

<210> 5

<211> 1260

<212> DNA

<213> *Haliotis tuberculata*

<400> 5

ataccatata	cttggaccac	gaccatgagg	aagagatact	tgtcaggaag	aatataattg	60
atttgagccc	aaggagagag	gtttctctag	tcaaagcttt	gcaaagaatg	aagaatgac	120
gctccgctga	tgggtaccaa	gccattgcct	ctttccatgc	cctgccacca	ctctgtccca	180
atccatctgc	agctcacctg	tatgcttgct	gtgtccatgg	catggctaca	tttccccagt	240
ggcacagact	gtacactggt	caggttcagg	atgccctgag	gagacatggt	tcacttggtg	300
gtattcctta	ctgggactgg	acaaaaccag	tcaacgagtt	acccgagctt	ctttcttcag	360
caacatttta	tcatccaatc	cggaaatatta	atatttcaaa	tccattcctc	ggggctgaca	420
tagaatttga	aggaccgggc	gttcatacag	agaggcacat	aaatactgag	cgctgttttc	480
acagtgggga	tcatgacgga	taccacaact	ggttcttcga	aactgttctc	tttgctttgg	540
aacaggaaga	ttactgcgat	tttgaaatac	aatttgagat	agcccataat	ggcatccaca	600
catggattgg	tgggaagcga	gtatatggca	tgggacacct	tcactatgca	tcatatgac	660
caattttcta	catccaccat	tcacagacgg	acagaatatg	ggctatttgg	caagagctgc	720
agaagtacag	gggtctatct	ggttcggaag	caaactgtgc	cattgaacat	atgagaacac	780
ccttgaagcc	tttcagcttt	gggccaccct	acaatttgaa	tagtcatacg	caagaatatt	840
caaagcctga	ggacacgttt	gactataaga	agtttggata	cagatatgat	agtctggaat	900
tggagggggc	atcaatttct	cgcattgatg	aacttatcca	gcagagacag	gagaaagaca	960
gaacttttgc	agggttcctc	cttaaagggt	ttggtacatc	cgcactctgt	tcattgcaag	1020
tttgacagag	tgatcacacc	tgtaaagatg	cgggctatct	cactattctg	ggaggatcag	1080
ccgaaatgcc	atgggcattc	gacaggcttt	ataagtatga	cattactaaa	actcttcacg	1140
acatgaacct	gaggcacgag	gacactttct	ctatagacgt	aactatcacg	tcttacaatg	1200
gaacagtact	ctcgggagac	ctcattcaga	cgcctcccat	tatatttgta	cctggacgcc	1260

<210> 6

<211> 1251

<212> DNA

<213> *Haliotis tuberculata*

<400> 6

ataaactcaa	ctcacggaaa	catacaccta	acagagtcog	ccatgagcta	agtagcctta	60
gttcccgtga	catagcaagc	ttgaaggcag	ctttgacaag	ccttcaacat	gataatggga	120
ctgatgggta	tcaagctatt	gctgccttcc	atggcgcttc	tgcgcagtg	cacgagccat	180
ctggacgtga	gatcgctgt	tgcatccacg	gcattggcgac	gtttcctcac	tggcaccggg	240
tgtacactct	gcagttggag	caagcgctgc	gcagacacgg	gtccagtgtt	gctgttccat	300
actgggactg	gaccaagcca	atcaccgaac	tgccacacat	tctgacagac	ggagaatatt	360
atgacgtttg	gcaaaatgcc	gtcttggcca	atccgtttgc	aagagggtat	gtgaaaatta	420
aagatgcatt	tacggtgaga	aatgtccagg	aaagtctgtt	caaaatgtca	agtttttgaa	480

4

agcactcgct	tctgtttgac	caggctttgt	tggctcttga	acaaactgac	tactgtgact	540
tcgaagttca	gtttgaagt	atgcataaca	cgatccatta	tctcgtagga	gggcgtcaaa	600
cgtacgcctt	ctcctctctc	gagtattcct	catacgatcc	aatcttcttt	attcaccact	660
cgtttgttga	caaaatatgg	gctgtatggc	aagaactgca	aagcaggaga	catctacagt	720
ttagaacagc	tgattgtgct	gtgggcctca	tgggtcaggc	aatgaggcct	ttcaacaagg	780
atttcaacca	caactcgttc	accaagaagc	acgcagtcct	taatacagta	tttgattatg	840
aagatcttgg	ctataactat	gacaaccttg	aaatcagtg	tttaaaactta	aatgagatcg	900
aggcgttaat	agcaaaacgc	aagtcacatg	ctagagtctt	tgctgggttc	ctgttgtttg	960
gattaggaac	ttcggtgat	atacatctgg	aaatttgcaa	gacatcgga	aactgccatg	1020
atgctgggtg	gattttcatc	cttgagggtt	ctgcagagat	gcattgggca	tacaaccgcc	1080
tctacaagta	tgacattaca	gaagcattgc	aggaatttga	catcaaccct	gaagatgttt	1140
tccatgctga	tgaaccattt	ttcctgaggc	tgtcggttgt	tgctgtgaat	ggaactgtca	1200
ttccatcgct	tcattcttcac	cagccaacga	taatctatga	accaggcgaa	g	1251

<210> 7

<211> 1209

<212> DNA

<213> *Haliotis tuberculata*

<400> 7

atcaccatga	cgaccatcag	tcgggaagca	tagcaggatc	cgggggtccgc	aaggacgtga	60
acaccttgac	taaggctgag	accgacaacc	tgaggggaggc	gctgtgggggt	gtcatggcag	120
accacgggtcc	caatggcttt	caagctattg	ctgctttcca	tggaaaacca	gctttgtgtc	180
ccatgcctga	tgcccacaac	tactcatgtt	gtactcacgg	catggctacc	ttcccacact	240
ggcatcgctt	ctacaccaag	cagatggagg	atgcaatgag	ggcgcatggg	tctcatgtcg	300
gcctgcccta	ctgggactgg	actgctgcct	tcacccacct	gccaacactg	gtcaccgaca	360
cggacaacaa	ccccttccaa	catggacaca	ttgattatct	caatgtcagc	acaactcgat	420
ctccccgaga	catgctgttc	aacgaccccg	agcatggatc	agagtcgttc	ttctacagac	480
aagtcctctt	agctctggaa	caaactgatt	tctgcaaatt	cgaagttcag	tttgagataa	540
cccacaatgc	catccattcc	tggaacaggtg	gccacagccc	ctacggaatg	tccactctcg	600
acttcaactgc	ctacgatcct	ctcttctggc	ttcaccactc	caacaccgac	agaatctggg	660
ctgtctggca	agctttgcaa	gaatacacag	gacttccata	caaccatgcc	aattgtgaga	720
tccaggcaat	gaaaacgccc	ctgaggcctt	tcagtgcga	tatcaaccac	aaccagtgca	780
caaaggctaa	cgcgaagcca	ttagatgtgt	tcgagtataa	tcggttgagc	ttccagtacg	840
acaacctcat	cttccatgga	tacagtattc	cggaaacttga	tcgcgtgctt	gaagaaagaa	900
aggaggagga	cagaatatatt	gctgccttcc	ttctcagtgg	aatcaagcgt	agtgtctgatg	960
tagtgttcga	catatgccag	ccagaacacg	aatgtgtgtt	cgcaggggact	tttgcgattt	1020
tgggagggga	gctagaaatg	ccctggctct	tcgacagact	gttccgctat	gatatcacca	1080
aggtgatgaa	gcagctacac	ctgaggcatg	actctgactt	taccttcagg	gtgaagattg	1140
tcggcaccga	cgaccacgag	cttcccttcag	acagtgtcaa	agcaccaact	attgaatttg	1200
aaccgggcg						1209

<210> 8

<211> 1535

<212> DNA

<213> *Haliotis tuberculata*

<400> 8

tgcacagagg	cggaaaccac	gaagatgaac	accatgatga	cagactcgca	gatgtcctga	60
tcaggaaaga	agttgacttc	ctctccctgc	aagaggccaa	cgcaattaag	gatgcactgt	120
acaagctcca	gaatgacgac	agtaaagggg	gctttgaggc	catagctggc	tatcacgggt	180
atcctaatat	gtgtccagaa	agaggtagcg	acaagtatcc	ctgctgtgtc	cacggaatgc	240
ccgtgttccc	ccactggcac	cgctgcata	ccattcagat	ggagagagct	ctgaaaaacc	300
atggctctcc	aatgggcatt	ccttactggg	attggacaaa	gaagatgtcg	agtcttccat	360
ctttcttttg	agattccagc	aacaacaacc	ctttctacaa	atattacatc	cggggcgctgc	420
agcacgaaac	aaccagggac	attaatcaga	gactctttaa	tcaaaccaag	tttggtgaat	480
ttgattacct	atattacct	actctgcaag	tcttgaggga	aaactcgtag	tgtgactttg	540

5

aagttcagta	tgagatcctc	cataacgccg	tccactcctg	gcttggagga	actggaaagt	600
attccatgtc	taccctggag	cattcggcct	ttgaccctgt	cttcatgatt	caccactcga	660
gtttggatag	aatctggatc	ctttggcaga	agttgcaaaa	gataagaatg	aagccttact	720
acgcattgga	ttgtgctggc	gacagactta	tgaaagaccc	cctgcatccc	ttcaactacg	780
aaaccggttaa	tgaagatgaa	ttcaccgcga	tcaactcttt	ccaagcata	ctgtttgacc	840
actacaggtt	caactatgaa	tacgataaca	tgagaatcag	gggtcaggac	atacatgaac	900
ttgaagaggt	aattcaggaa	ttaagaaaca	aagatcgcac	atttgctggt	tttgttttgt	960
cgggcttacg	gatatcagct	acagtgaaag	tattcattca	ttcgaaaaac	gatacaagtc	1020
acgaagaata	tgcaggagaa	tttgcagttt	tgggaggtga	gaaggagatg	ccgtgggcat	1080
atgaaagaat	gctgaaattg	gacatctccg	atgctgtaca	caagcttcac	gtgaaagatg	1140
aagacatccg	ttttagatg	gttgttactg	cctacaacgg	tgacgttggt	accaccaggc	1200
tgtctcagcc	attcatcgtc	caccgctccg	cccattgtggc	tcacgacatc	ttggtaatcc	1260
cagtagggtgc	gggccatgac	cttcgccta	aagtcgtagt	aaagagcggc	accaaagtgc	1320
agttttacacc	aatagattcg	tcggtgaaca	aagcaatggt	ggagctgggc	agctatactg	1380
ctatggctaa	atgcatcggt	ccccctttct	cttaccacgg	ctttgaaactg	gacaaagtct	1440
acagcgtcga	tcacggagac	tactacattg	ctgcaggtac	ccacgcgttg	tgtgagcaga	1500
acctcaggct	ccacatccac	gtggaacacg	agtag			1535

<210> 9

<211> 1003

<212> DNA

<213> Haliotis tuberculata

<400> 9

cacagactgt	tcgtcaccca	ggtggaagat	gctctgatca	ggcgaggatc	gcctataggg	60
gtccccact	gggactggac	tcagcctatg	gcgcctctcc	caggacttgc	agacaacgcc	120
acctatagag	atcccatcag	cggggacagc	agacacaacc	ccttccacga	tgttgaagtt	180
gcctttgaaa	atggacgtac	agaacgtcac	ccagatagta	gattgtttga	acaaccttta	240
tttgggcaaac	atacgcgtct	cttcgacagt	atagtctatg	cttttgagca	ggaggacttc	300
tgcgattttg	aagttcaatt	tgagatgacc	cataataata	ttcacgcctg	gattgggtggc	360
ggcgagaagt	attccatgtc	ttctctacac	tacacagcct	tcgaccctat	cttctacctt	420
cgtcactcca	acactgaccg	gctctgggca	atttggcaag	cgttgcagat	acgaagaaac	480
aggcettaca	aggetcattg	tgcttgggtct	gaggaacgcc	agcctctcaa	acctttcgcc	540
ttcagttccc	cactgaacaa	caacgaaaaa	acctacgaaa	actcgggtgcc	caccaacggt	600
tacgactacg	aaggagtcc	tggtctatact	tatgatgacc	tcaacttcgg	gggcatggac	660
ctgggtcagc	ttgaggaata	catccagagg	cagagacaga	gagacaggac	ctttgctggt	720
ttctttctgt	cacgatttgg	tacatcagcg	aatgttgaaa	tcattataga	ccatgggact	780
cttcatacct	ccgtgggcac	gtttgctgtt	cttggcggag	agaaggagat	gaaatgggga	840
tttgaccggt	tgtacaaata	tgagattaca	gatgaactga	ggcaacttaa	tctccgtgct	900
gatgatgttt	tcagcatctc	tgtaaagta	actgatgttg	atggcagtg	gctgtcctct	960
gaactcatcc	catctgctgc	tatcatcttc	gaacgaagcc	ata		1003

<210> 10

<211> 1251

<212> DNA

<213> Haliotis tuberculata

<400> 10

ttgaccatca	ggaccgcgat	catgacacaa	tcattaggaa	aaatgttgat	aatcttacac	60
ccgaggaaat	taattctctg	aggcgggcaa	tggcagacct	tcaatcgagac	aaaaccgccg	120
gtggattcca	gcaaatgtgt	gcttttcacg	gggaacccaa	atggtgccca	agtcgccgatg	180
ctgagaagaa	gttctcctgc	tgtgtccatg	gaatggctgt	cttccctcac	tggcacagac	240
tcttgaccgt	gcaaggcgag	aatgccttga	gaaagcatgg	atgtctcgga	gctctccctt	300
actgggactg	gactcggccc	ctgtctcacc	tacctgattt	ggtttttggt	agtagcagaa	360
ctacaccgat	gccatattcc	accgtggaag	cccgaaaccc	ctggtacagc	ggccatattg	420
atacagttgg	tgttgacaca	acaagaagcg	tccgtcaaga	actgtatgaa	gctcctggat	480
ttggccatta	tactgggggtc	gctaagcaag	tgcttctggc	tttggagcag	gatgacttct	540

6

```
gtgatttttga agtccagttt gagatagctc acaatttcat tcaagctctt gtcggcgga 600
gcgagccata tggatggcg tcaactcgtt acactactta tgatccaatt ttctacctcc 660
atcattctaa cactgacaga ctctgggcta tatggcaggc tctacaaaag tacaggggca 720
aaccttacaa ttccgccaac tgcgccattg cttctatgag aaaacccta caacctttg 780
gtctgactga tgagatcaac ccggatgatg agacaagaca gcatgctgtt cctttcagt 840
tctttgatta caagaacaac ttcaattatg aatatgacac ccttgacttc aacggactat 900
caatctccca gctggaccgt gaactgtcac ggagaaagtc tcatgacaga gtatttgccg 960
gattttttgct gcatgggtatt cagcagctctg cactagttaa attctttgtc tgcaaatcag 1020
atgatgactg tgaccactat gctgggtgaat tctacatcct tgggtgatgaa gctgaaatgc 1080
catgggggcta tgatcgtctt taaaaatatg agatcactga gcagctcaat gccctggatc 1140
tacacatcgg agatagattc ttcacatgat acgaagcgtt tgatcttcat ggtacaagtc 1200
ttggaagcaa catcttcccc aaaccttctg tcatacatga cgaaggggca g 1251
```

<210> 11

<211> 1244

<212> DNA

<213> *Haliotis tuberculata*

<400> 11

```
gtcaccatca ggctgacgag tacgacgaag ttgtaactgc tgcaagccac atcagaaaaga 60
atttaaaaga tctgtcaaaag ggagaagtag agagcctaag gtctgccttc ctgcaacttc 120
agaacgacgg agtctatgag aatattgcca agttccacgg caagcctggg ttgtgtgatg 180
ataacggteg caaggttgcc tgttgtgtcc atggaatgcc cacctcccc cagtggcaca 240
ggctctatgt cctccagggtg gagaatgctt tgctggagag aggatctgcc gtctctgtgc 300
catactggga ctggactgaa acatttacag agctgccatc ttgattgct gaggctacct 360
atttcaattc ccgtcaacaa acgtttgacc ctaatccttt ctacagaggt aaaatcagtt 420
ttgagaatgc tgttacaaca cgtgatcccc agcctgagct gtacgttaac aggtactact 480
acaaaaacgt catgtttggtt tttgaacagg acaactactg cgacttcgag atacagtttg 540
agatggttca caatgttctc catgcttggtc ttgggtggaag agctacttat tctatttctt 600
ctcttgatta ttctgcattc gacctgtgtt ttttccttca ccatgcgaac acagatagat 660
tgtggggccat ctggcaggag ctgcagaggt acaggaagaa gccatacaat gaagcggatt 720
gtgccattaa cctaattgcgc aaacctctac atcccttcga caacagtgat ctcaatcatg 780
atcctgtaac ctttaataac tcaaaaccca ctgatggctt tgactaccag aacaactttg 840
gatacaagta tgacaacctt gagttcaatc atttcagtat tcccaggctt gaagaaatca 900
ttcgtattag acaacgtcaa gatcgtgtgt ttgcaggatt cctccttcac aacattggga 960
catccgcaac tgttgagata ttcgtctgtg tccctaccac cagcgggtgag caaaaactgtg 1020
aaaacaaagc cggaacattt gccgtactcg gaggagaaac agagatggcg ttctattttg 1080
acagactcta caggtttgac atcagtgaag cactgaggga cctcggcata cagctggaca 1140
gccatgactt tgacctcagc atcaagattc aaggagtaaa tggatcctac cttgatccac 1200
acatcctgcc agagccatcc ttgatttttg tgcttggttc aagt 1244
```

<210> 12

<211> 1255

<212> DNA

<213> *Haliotis tuberculata*

<400> 12

```
tctttcctgc gtctgatgg gcattcagat gacatccttg tgagaaaaga agtgaacagc 60
ctgacaacca gggagactgc atctctgatc catgctctga aaagtatgca ggaagaccat 120
tcacctgacg ggttccaagc cattgcctct ttccatgctc tgccaccact ctgcccttca 180
ccatctgcag ctaccgttta tgcttgctgt gtccacggca tggctacatt tccccagtgg 240
cacagattgt aactgttaca gttccaggat gcactgagga gacatggagc tacggtaggt 300
gtaccgtatt gggattggct gcgaccgcag tctcacctac cagagcttgt caccatggag 360
acataccatg atatttgagg taacagagat tcccccaatc ctttctacca agccaatatt 420
gagtttgaag gagaaaacat tacaacagag agagaagtca ttgcagacaa actttttgtc 480
aaagggtggac acgttttttg taaactgggt cttcaaacaa gccatcctag cgctgagcag 540
gaaaactact gtgacttttg gattcagttt gaaattcttc acaacggcgt tcacacgtgg 600
```

7

gtcggaggca	gtcgtacct	ctctatcgga	catcttcatt	acgcattcta	cgacctctt	660
ttctaccttc	accatttcca	gacagaccgt	atttgggcaa	tctggcaaga	actccaggaa	720
cagagagggc	tctcgggtga	tgaggctcac	tgtgctctcg	agcaaataag	agaaccattg	780
aagcctttca	gcttcggcgc	tccttataac	tggaaatcagc	tcacacagga	tttctcccga	840
cccgaggaca	ccttcgacta	caggaagttt	ggttatgaat	atgacaattt	agaattcctg	900
ggaatgtcag	ttgctgaact	ggatcaatac	attattgaac	atcaagaaaa	tgatagagta	960
ttcgctgggt	tctgttgag	tggattcgga	ggttccgcac	cagttaattt	ccagggtttgt	1020
agagctgatt	ccacatgtca	ggatgctggg	tacttcaccg	ttcttgggtg	cagtgtctgag	1080
atggcgtggg	catttgacag	gctttacaaa	tatgacatta	ctgaaactct	ggagaaaatg	1140
caccttcgat	atgatgatga	cttcacaatc	tctgtcagtc	tgaccgcca	caacggaact	1200
gtcctgagca	gcagtcta	cccaacaccg	agtgtcatat	tccagcgggg	acatc	1255

<210> 13

<211> 1248

<212> DNA

<213> *Haliotis tuberculata*

<400> 13

gtgacataaa	taccaggagc	atgtcaccga	accgtgttcg	ccgtgagctg	agcgatctgt	60
ctgcgaggga	cctgtctagt	ctcaagtctg	ctctgcgaga	cctacaggag	gatgatggcc	120
ccaacggata	ccaggctctt	gcagccttcc	atgggctacc	agcaggctgc	catgatagcc	180
ggggaaatga	gatcgcgatg	tgcattcacg	ggatgccgac	cttccccag	tggcacagac	240
tgtacacct	gcagttggag	atggctctga	ggagacatgg	atcatctgtc	gccatccctt	300
actgggactg	gacaaagcct	atctccgaac	tccctcgtct	cttcaccagc	cctgagtatt	360
atgacccatg	gcatgatgct	gtggtaaaca	accattcttc	caaagggttt	gtcaaatttg	420
caaataccta	cacagtaaga	gacccacagg	agatgctgtt	ccagctttgt	gaacatggag	480
agtcaatcct	ctatgagcaa	actcttcttg	ctcttgagca	aaccgactac	tgtgattttg	540
aggtacagtt	tgaggctctc	cataacgtga	tccactacct	tgttgggtgga	cgtcagacct	600
acgcattgtc	ttctctgcat	tatgcctcct	acgacccatt	cttctttata	caccattcct	660
ttgtggataa	gatgtgggta	gtatggcaag	ctcttcaaaa	gaggaggaaa	cttccataca	720
agcgagctga	ctgtgctgtc	aacctaatga	ctaaaccaat	gaggccattt	gactccgata	780
tgaatcagaa	cccattcaca	aagatgcacg	cagttcccaa	cacactctat	gactacgaga	840
cactgtacta	cagctacgat	aatctcgaaa	taggtggcag	gaatctcgac	cagcttcagg	900
ctgaaattga	cagaagcaga	agccacgatc	gcgtttttgc	tggattcttg	cttcgtggaa	960
tccgaacttc	tgctgatgtc	aggtttttga	tttgtagaaa	tgaaaatgac	tgccacaggg	1020
gtggaataat	tttcatctta	ggtggagcca	aggaaatgcc	atgggtcattt	gacagaaaact	1080
tcaagtttga	tatcacccat	gtactcgaga	atgctggcat	tagcccagag	gacgtgtttg	1140
atgctgagga	gccattttat	atcaaggttg	agatccatgc	tgtaacaag	accatgatac	1200
cgctgtctgt	gatcccagcc	ccaactatca	tctattctcc	tggggaag		1248

<210> 14

<211> 1207

<212> DNA

<213> *Haliotis tuberculata*

<400> 14

gtcgcgctgc	tgacagtgcg	cactctgcca	acattgctgg	ctctgggggtg	aggaaggagc	60
tcacgacct	cactgtgtct	gagaccgaga	acctaagaca	ggctcttcaa	ggtgtcatcg	120
atgatactgg	tccaatgggt	taccaagcaa	tagcatcctt	ccacggaagt	cctccaatgt	180
gcgagatgaa	cggccgcaag	gttgccctgtt	gtgctcacgg	tatggcctcc	ttcccacact	240
ggcacagact	gtatgtgaag	cagatggaag	atgccctggc	tgaccacggg	tcacatatcg	300
gcacccctta	ctgggactgg	acaactgcct	tcacagagtt	acccgcctct	gtcacagact	360
ccgagaacaa	tcccttccat	gagggctcgca	ttgatcatct	cggtgtaacc	acgtcacgtt	420
ccccagaga	catgctgttt	aacgaccag	agcaaggatc	agagtcgttc	ttctatagac	480
aagtcctcct	ggctttggag	cagactgaet	actgccagtt	cgaagtccag	tttgagctga	540
cccacaacgc	cattcactcc	tggacaggtg	gacgtagccc	ttacggaatg	tcgacctcgc	600
agttcacagc	ctacgatcct	ctcttctggt	ttcaccactc	caacaccgac	agaatctggg	660

8

ctgtctggca	agcactgcag	aaataccgag	gactcccata	caacgaagca	caactgtgaaa	720
tccaggttct	gaaacagccc	ttgaggccat	tcaacgatga	catcaaccac	aatccaatca	780
ccaagactaa	tgccaggcct	atcgattcat	ttgattatga	gaggtttaac	tatcagtatg	840
acacccttag	cttccatggt	aagagcatcc	ctgaactgaa	tgacctgctc	gaggaaagaa	900
aaagagaaga	gagaacatct	gctgccttcc	ttcttcgtgg	aatcgggtgc	agtgtgtgatg	960
tcgtctttga	catctgccgg	cccaatgggtg	actgtgtctt	tgcaggaacc	tttgctgtgc	1020
tgggagggga	gctagaaatg	cetttggtcct	tcgacagact	gttccgctat	gacatcacca	1080
gagtcatgaa	tcagctccat	ctccagtatg	attcagattt	cagtttcagg	gtgaagcttg	1140
ttgccacca	tggcactgag	ctttcatcag	accttctcaa	gtcaccaaca	attgaacatg	1200
aacttgg						1207

<210> 15

<211> 1546

<212> DNA

<213> *Haliotis tuberculata*

<400> 15

agcccacaga	ggaccagttg	aagaaacaga	agtcactcgc	caacatactg	acggcaatgc	60
acacttttcat	cgtaaggaag	ttgattcgct	gtccctggat	gaagcaaaaca	acttgaagaa	120
tgccctttac	aagctacaga	acgaccacag	tctaacggga	tacgaagcaa	tctctggtta	180
ccatggatac	cccaatctgt	gtccggaaga	aggcgatgac	aaaatacccc	tgctgcgtcc	240
cgggatgggc	atctttcctt	actggcacag	actcttgacc	attcaactgg	aaagagctct	300
tgagcacaat	ggtgcactgc	ttggtgttcc	ttactgggac	tggaaacaagg	acctgtcgtc	360
actgccggcg	ttcttctccg	actccagcaa	caacaatccc	tacttcaagt	accacatcgc	420
cgggtgttgg	cacgacaccg	tcagagagcc	aactagtctt	atatataacc	agccccaat	480
ccatggttat	gattatctct	attacctagc	attgaccacg	cttgaagaaa	acaattactg	540
ggacttttgag	gttcagtatg	agatcctcca	caacgccgtc	cactcctggc	ttggaggatc	600
ccagaagtat	tccatgtcta	ccctggagta	ttcggccttt	gacctgtctt	ttatgatcct	660
tcactcgggt	ctagacagac	tttggtatcat	ctggcaagaa	cttcagaaga	tcaggagaaa	720
gccctacaac	ttcgctaaat	gtgcttatca	tatgatggaa	gagccactgg	cgcccttcag	780
ctatccatct	atcaaccagg	acgagttcac	ccgtgccaac	tccaagcctt	ctacagtttt	840
tgacagccat	aagtccggct	accattacga	taacctgaat	gttagaggtc	acagcatcca	900
agaactcaac	acaatcatca	atgacttgag	aaacacagac	agaatctacg	caggatttgt	960
tttgtcaggc	atcggtacgt	ctgctagtgt	caagatctat	ctccgaacag	atgacaatga	1020
cgaagaagtt	ggaactttca	ctgtcctggg	aggagagagg	gaaatgccat	gggcctacga	1080
gcgagttttc	aagtatgaca	tcacagaggt	tgcagataga	cttaaaatta	agttatgggg	1140
acacccttta	acttccggaa	ctggagatca	catccttacg	aatggaatcg	gtggtaaaca	1200
agagcctacc	caaatccttt	catcatctac	agacctgcca	atcatgacta	cgatgttctt	1260
gttatccag	tanggaagaa	accttcacat	ccctcccaaa	gttgctgtca	agaaaggcac	1320
ccgcatcgag	ttccacccag	tcgatgatcc	agttacgaga	ccagttgttg	atcttggaag	1380
ctacactgca	ctcttcaact	gtgtggtacc	accgttcaca	taccacggat	tcgaactgaa	1440
ccacgtctat	tctgtcaagc	ctggtgacta	ctatgttact	ggacccacga	gagacctttg	1500
ccagaatgca	gatgtcagga	ttcatatcca	tgttgaggat	gagtaa		1546

<210> 16

<211> 967

<212> DNA

<213> *Megathura crenulata*

<400> 16

ggcctaccgt	actgggactg	gactgaaccc	atgacacaca	ttccgggtct	ggcaggaaac	60
aaaacttatg	tggattctca	tggtgcaccc	cacacaaatc	cttttcatag	ttcagtgatt	120
gcatttgaag	aaaatgctcc	ccacaccaaa	agacaaatag	atcaaagact	ctttaaaccc	180
gtacactttg	gacaccacac	agacctgttc	aaccagattt	tgtatgcctt	tgaacaagaa	240
gattactgtg	actttgaagt	ccaatttgag	attacccata	acacgattca	cgcttgagca	300
ggaggaagcg	aacattttct	aatgtcgtcc	ctacattaca	cagctttcga	tcctttgttt	360
tactttcacc	attctaactg	tgatcgtctt	tgggcccgtt	ggcaagcctt	acagatgaga	420

9

cggcataaac	cctacagggc	ccactgcgcc	atatctctgg	aacatatgca	tctgaaacca	480
ttcgcccttt	catctcccct	taacaataac	gaaaagactc	atgccaatgc	catgccaaac	540
aagatctacg	actatgaaaa	tgtcctccat	tacacatacg	aagatttaac	atttggaggc	600
atctctctgg	aaaacataga	aaagatgac	cacgaaaacc	agcaagaaga	cagaatatat	660
gccggttttc	tcctggctgg	catacgtact	tcagcaaatg	ttgatatctt	cattaaaact	720
accgattccg	tgcaacataa	ggctggaaca	tttgagtgcc	tcggtggaag	caaggaaatg	780
aagtggggat	ttgatcgctg	tttcaagttt	gacatcacgc	acgttttgaa	agatctcgat	840
ctcactgctg	atggcgattt	cgaagttact	gttgacatca	ctgaagtcga	tggaaactaaa	900
cttgcaccca	gtctttattcc	acatgcttct	gtcattcgtg	agcatgcacg	tggtaagctg	960
aatagag						967

<210> 17

<211> 1242

<212> DNA

<213> Megathura crenulata

<400> 17

ttaaatttga	caaagtgcc	aggagtcgtc	ttattcgaaa	aaatgtagac	cgtttgagcc	60
ccgaggagat	gaatgaactt	cgtaaagccc	tagccttact	gaaagaggac	aaaagtgccg	120
gtggatttca	gcagcttggt	gcattccatg	gggagccaaa	atgggtgtcct	agtcccgaag	180
catctaaaaa	atttgccctg	tgtgttcacg	gcattgtctgt	gttccctcac	tggcatcgac	240
tgttgacggt	tcagagtga	aatgctttga	gacgacatgg	ctacgatgga	gctttgccgt	300
actgggattg	gacctctcct	cttaatcacc	ttcccgaact	ggcagatcat	gagaagtacg	360
tcgaccctga	agatggggta	gagaagcata	acccttggtt	cgatgggtcat	atagatacag	420
tcgacaaaac	aacaacaaga	agtgttcaga	ataaactctt	cgaacagcct	gagtttggtc	480
attatacaag	cattgccaaa	caagtactgc	tagcgttggg	acaggacaat	ttctgtgact	540
ttgaaatcca	atatgagatt	gcccataact	acatccatgc	acttgtagga	ggcgctcagc	600
cttatgggtat	ggcatcgctt	cgtacactg	cttttgatcc	actattctac	ttgcatcact	660
ctaatacaga	tcgtatatgg	gcaatatggc	aggctttaca	gaagtacaga	ggaaaaccgt	720
acaacgttgc	taactgtgct	gttacatcga	tgagagaacc	tttgcaacca	tttggcctct	780
ctgccaatat	caacacagac	catgtaacca	aggagcattc	agtgccattc	aacgtttttg	840
attacaagac	caatttcaat	tatgaatatg	acactttgga	atttaacggt	ctctcaatct	900
ctcagttgaa	taaaaagctc	gaagcgataa	agagccaaga	caggttcttt	gcaggcttcc	960
tgttatctgg	tttcaagaaa	tcattctctg	ttaaattcaa	tatttgacc	gatagcagca	1020
actgtcacc	cgtgggagag	ttttaccttc	tgggtgatga	aaacgagatg	ccatgggcat	1080
acgatagagt	cttcaaatat	gacataaccg	aaaaactcca	cgatctaaag	ctgcatgcag	1140
aagaccactt	ctacattgac	tatgaagtat	ttgaccttaa	accagcaagc	ctgggaaaag	1200
atttgttcaa	gcagccttca	gtcattcatg	aaccaagaat	ag		1242

<210> 18

<211> 1236

<212> DNA

<213> Megathura crenulata

<400> 18

gtcaccatga	aggcgaagta	tatcaagctg	aagtaacttc	tgccaaccgt	attcgaaaaa	60
acattgaaaa	tctgagcctt	ggtgaactcg	aaagtctgag	agctgccttc	ctggaaattg	120
aaaacgatgg	aacttacgaa	tcaatagcta	aattccatgg	tagccctggg	ttgtgccagt	180
taaatggtaa	ccccatctct	tgttgtgtcc	atggcatgcc	aactttccct	cactggcaca	240
gactgtacgt	ggttgtcggt	gagaatgccc	tcctgaaaaa	aggatcatct	gtagctgttc	300
cctattggga	ctggacaaaa	cgaatcgaac	atttacctca	cctgatttca	gacgccactt	360
actacaattc	caggcaacat	cactatgaga	caaaccatt	ccatcatggc	aaaatcacac	420
acgagaatga	aatcactact	agggatccca	aggacagcct	cttccattca	gactactttt	480
acgagcaggt	cctttacgcc	ttggagcagg	ataacttctg	tgatttcgag	attcagttgg	540
agatattaca	caatgcattg	cattctttac	ttgggtggca	aggtaaatat	tccatgtcaa	600
accttgatta	cgtgtctttt	gatcctgtgt	tcttccttca	tcacgcaacg	actgacagaa	660
tctgggcaat	ctggcaagac	cttcagaggt	tccgaaaacg	gccataccga	gaagcgaatt	720

<400> 21						
ctgatgccaa	agactttggc	catagcagaa	aaatcaggaa	agccgttgat	tctctgacag	60
tcgaagaaca	aacttcgttg	aggcgagcta	tggcagatct	acaggacgac	aaaacatcag	120
ggggtttcca	gcagattgca	gcattccacg	gagaaccaaa	atgggtgtcca	agccccgaag	180
cggagaaaaa	atttgcattg	tgtgttcatt	gaatggctgt	tttccctcac	tggcacagat	240
tgctgacagt	tcaaggagaa	aatgctctga	ggaaacatgg	ctttactggt	ggactgccct	300

<400> 24						
gtcacgatca	cagtgaacgt	cacgatggat	ttttcaggaa	ggaagtcggt	tcctctgtccc	60
tggatgaagc	caatgacctt	aaaaatgcac	tgtacaagct	gcagaatgat	caggggtccca	120
atggatatga	atcaatagcc	ggttaccatg	gctatccatt	cctctgccct	gaacatggtg	180
aagaccagta	cgcctgctgt	gtccacggaa	tgctgtatt	tcacattgg	cacagacttc	240
atacaatcca	gtttgagaga	gctctcaaag	aacatggttc	tcatttgggt	ctgccatact	300

<400> 25																
Leu	Val	Gln	Phe	Leu	Leu	Val	Ala	Leu	Val	Ala	Gly	Ala	Gly	Ala	Asp	
1				5					10					15		
Asn	Val	Val	Arg	Lys	Asp	Val	Ser	His	Leu	Thr	Asp	Asp	Glu	Val	Gln	
			20					25					30			
Ala	Leu	His	Gly	Ala	Leu	His	Asp	Val	Thr	Ala	Ser	Thr	Gly	Pro	Leu	
		35					40					45				
Ser	Phe	Glu	Asp	Ile	Thr	Ser	Tyr	His	Ala	Ala	Pro	Ala	Ser	Cys	Asp	
	50					55					60					
Tyr	Lys	Gly	Arg	Lys	Ile	Ala	Cys	Cys	Val	His	Gly	Met	Pro	Ser	Phe	
65					70					75					80	
Pro	Phe	Trp	His	Arg	Ala	Tyr	Val	Val	Gln	Ala	Glu	Arg	Ala	Leu	Leu	
				85					90					95		
Ser	Lys	Arg	Lys	Thr	Val	Gly	Met	Pro	Tyr	Trp	Asp	Trp	Thr	Gln	Thr	
			100					105					110			
Leu	Thr	His	Leu	Pro	Ser	Leu	Val	Thr	Glu	Pro	Ile	Tyr	Ile	Asp	Ser	
		115					120					125				
Lys	Gly	Gly	Lys	Ala	Gln	Thr	Asn	Tyr	Trp	Tyr	Arg	Gly	Glu	Ile	Ala	
	130					135					140					
Phe	Ile	Asn	Lys	Lys	Thr	Ala	Arg	Ala	Val	Asp	Asp	Arg	Leu	Phe	Glu	
145					150					155					160	
Lys	Val	Glu	Pro	Gly	His	Tyr	Thr	His	Leu	Met	Glu	Thr	Val	Leu	Asp	
				165					170					175		
Ala	Leu	Glu	Gln	Asp	Glu	Phe	Cys	Lys	Phe	Glu	Ile	Gln	Phe	Glu	Leu	
			180					185					190			
Ala	His	Asn	Ala	Ile	His	Tyr	Leu	Val	Gly	Gly	Lys	Phe	Glu	Tyr	Ser	
		195					200					205				
Met	Ser	Asn	Leu	Glu	Tyr	Thr	Ser	Tyr	Asp	Pro	Ile	Phe	Phe	Leu	His	
	210					215					220					
His	Ser	Asn	Val	Asp	Arg	Leu	Phe	Ala	Ile	Trp	Gln	Arg	Leu	Gln	Glu	
225					230					235					240	

Gly 1	His	Leu	Asp	Pro 5	Pro	Val	His	His	Arg 10	His	Asp	Asp	Asp	Leu 15	Ile
Val	Arg	Lys	Asn 20	Ile	Asp	His	Leu	Thr 25	Arg	Glu	Glu	Glu	Tyr 30	Glu	Leu
Arg	Met	Ala 35	Leu	Glu	Arg	Phe	Gln 40	Ala	Asp	Thr	Ser	Val 45	Asp	Gly	Tyr
Gln 50	Ala	Thr	Val	Glu	Tyr	His 55	Gly	Leu	Pro	Ala	Arg 60	Cys	Pro	Arg	Pro
Asp 65	Ala	Lys	Val	Arg	Phe 70	Ala	Cys	Cys	Met	His 75	Gly	Met	Ala	Ser	Phe 80

His Ala Leu Val Gly Gly Thr Asp Ala Tyr Gly Met Ala Ser Leu Arg
195 200 205

16

Tyr Thr Ala Tyr Asp Pro Ile Phe Phe Leu His His Ser Asn Thr Asp
 210 215 220

Arg Ile Trp Ala Ile Trp Gln Ser Leu Gln Lys Tyr Arg Gly Lys Pro
 225 230 235 240

Tyr Asn Thr Ala Asn Cys Ala Ile Glu Ser Met Arg Arg Pro Leu Gln
 245 250 255

Pro Phe Gly Leu Ser Ser Ala Ile Asn Pro Asp Arg Ile Thr Arg Glu
 260 265 270

His Ala Ile Pro Phe Asp Val Phe Asn Tyr Arg Asp Asn Leu His Tyr
 275 280 285

Val Tyr Asp Thr Leu Glu Phe Asn Gly Leu Ser Ile Ser Gln Leu Asp
 290 295 300

Arg Glu Leu Glu Lys Ile Lys Ser His Glu Arg Val Phe Ala Gly Phe
 305 310 315 320

Leu Leu Ser Gly Ile Lys Lys Ser Ala Leu Val Lys Phe Glu Val Cys
 325 330 335

Thr Pro Pro Asp Asn Cys His Lys Ala Gly Glu Phe Tyr Leu Leu Gly
 340 345 350

Asp Glu Asn Glu Met Ala Trp Ala Tyr Asp Arg Leu Phe Lys Tyr Asp
 355 360 365

Ile Thr Gln Val Leu Glu Ala Asn His Leu His Phe Tyr Asp His Leu
 370 375 380

Phe Ile Arg Tyr Glu Val Phe Asp Leu Lys Gly Val Ser Leu Gly Thr
 385 390 395 400

Asp Leu Phe His Thr Ala Asn Val Val His Asp Ser Gly Thr
 405 410

<210> 28

<211> 413

<212> PRT

<213> Haliotis tuberculata

<400> 28

Gly Thr Arg Asp Arg Asp Asn Tyr Val Glu Glu Val Thr Gly Ala Ser
 1 5 10 15

His Ile Arg Lys Asn Leu Asn Asp Leu Asn Thr Gly Glu Met Glu Ser
 20 25 30

Leu Arg Ala Ala Phe Leu His Ile Gln Asp Asp Gly Thr Tyr Glu Ser
 35 40 45

Ile Ala Gln Tyr His Gly Lys Pro Gly Lys Cys Gln Leu Asn Asp His
 50 55 60

Glu Ile Ala His Asn Gly Ile His Thr Trp Ile Gly Gly Ser Ala Val
195 200 205

```
<400> 30
His Lys Leu Asn Ser Arg Lys His Thr Pro Asn Arg Val Arg His Glu
 1               5               10               15
Leu Ser Ser Leu Ser Ser Arg Asp Ile Ala Ser Leu Lys Ala Ala Leu
      20               25               30
Thr Ser Leu Gln His Asp Asn Gly Thr Asp Gly Tyr Gln Ala Ile Ala
    35               40               45
```

SEQUENCE LISTING

<110> Biosyn Arzneimittel GmbH

<120> Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin

<130> PCT1153-01966

<140>

<141>

<160> 108

<170> PatentIn Ver. 2.1

<210> 1

<211> 1269

<212> DNA

<213> *Haliotis tuberculata*

<400> 1

```
ggcttggttca gtttctactc gtcgcccttg tggcgggggc tggagcagac aacgtcgtca 60
gaaaggacgt gagtcacctc acggatgacg aggtgcaagc tctccacgac gccctccatg 120
acgtcactgc atctacaggg cctctgagtt tcgaagacat aacatcttac catgccgcac 180
cagcgtcgtg tgactacaag ggacggaaga tcgctgctg tgtccacggt atgccagtt 240
tccccttctg gcacagggca tatgtcgtcc aagccgagcg ggcactgttg tccaaacgga 300
agactgtcgg aatgccttac tgggactgga cgcaaacgct gactcactta ccatctcttg 360
tgactgaacc catctacatt gacagtaaag gtggaaaggc tcaaaccaac tactggtacc 420
gcggcgagat agcgttcatc aataagaaga ctgcgcgagc tgtagatgat cgcctattcg 480
agaagggtgga gcctgggtcac tacacacatc ttatggagac tgtcctcgac gctctcgaac 540
aggacgaatt ctgtaaattt gaaatccagt tcgagttggc tcataatgct atccattact 600
tgggtggcgg taaatttgaa tattcaatgt caaacttgga atacacctcc tacgacccca 660
tcttcttctc ccaccactcc aacggttgacc gcctcttcgc catctggcag cgtcttcagg 720
aactgcgagg aaagaatccc aatgcaatgg actgtgcaca tgaactcgct caccagcaac 780
tccaaccctt caacagggac agcaatccag tcagctcac aaaggaccac tcgacacctg 840
ctgacctctt tgattacaaa caacttggat acagctacga cagcttaaac ctgaatggaa 900
tgacgccaga acagctgaaa acagaactag acgaacgcca ctccaaagaa cgtgcgtttg 960
caagcttcg actcagtggc tttgggggtt ctgccaacgt tgttgtctat gcatgtgtcc 1020
ctgatgatga tccacgcagt gatgactact gcgagaaagc aggcgacttc ttcatcttg 1080
ggggtcaaag cgaaatgcg tggagattct acagaccctt cttctatgat gtaactgaag 1140
cggtagatca cttggagtc ccgctaagtg gccactacta tgtgaaaaca gaactcttca 1200
gcgtgaatgg cacagcactt tcacctgac ttcttctca accaactggt gcctaccgac 1260
ctgggaaag
```

<210> 2

<211> 1257

<212> DNA

<213> *Haliotis tuberculata*

<400> 2

```
gtcaccttga cccacctgtg catcatcgcc acgatgacga tcttattggt cgaaaaaata 60
tagatcattt gactcgtgaa gaggaatacg agctaaggat ggctctggag agattccagg 120
ccgacacatc cgttgatggg taccaggcta cagtagagta ccatggcctt cctgctcgtt 180
gtccacgacc agatgcaaaa gtcagggttcg cctgttgtat gcatggcatg gcatccttcc 240
ctcactggca ccggtgttc gttaccacagg tggaaagatgc tcttgtagcg cgtggatcgc 300
ctatcggtgt tccttattgg gactggacaa aacctatgac tcaccttcca gacttggcat 360
```


3

ttgaaaacgc	agtcacaaca	agggaaccac	aagccgggct	cttcaactca	gattatatgt	480
atgagaatgt	tttacttgca	ctgggagcagg	aaaattattg	tgactttgaa	attcagtttg	540
agcttggtta	taacgcactt	cattccatgc	tgggaggtaa	agggcagtac	tccatgtcct	600
ccctggacta	ttctgcgttt	gateccgtct	tcttcctaca	tcatgccaac	acggacagac	660
tgtgggcaat	ctggcaggaa	ctacaaagat	tccgagaact	gccttatgaa	gaagcgaact	720
gtgcaatcaa	cctcatgcat	caaccactga	agccgttcag	tgatccacat	gagaatcacg	780
acaatgtcac	tttgaaatac	tcaaaaccac	aggacggatt	cgactaccag	aaccacttcg	840
gatacaagta	tgacaacctt	gagttccatc	acttatctat	cccaagtctt	gatgctaccc	900
tgaagcaaag	gagaaatcac	gacagagtgt	ttgcgggctt	ccttcttcat	aacataggaa	960
cttctgctga	cataactatc	tacatatgtc	tgccctgacg	acggcgtggc	aatgactgca	1020
gtcatgaggc	gggaacattc	tatatcctcg	gaggcgaaac	agagatgcct	tttatctttg	1080
accgtttgta	taaatttgaa	atcaccaaac	cactgcaaca	gttaggagtc	aagctgcatg	1140
gtggagtttt	cgaactggag	cttgagatca	aggcatacaa	cggttccctat	ctggatcccc	1200
atacctttga	tccaactatc	atctttgaac	ctggaacag			1239

<210> 5

<211> 1260

<212> DNA

<213> *Haliotis tuberculata*

<400> 5

atacccatat	cttggaccac	gaccatgagg	aagagatact	tgtcaggaag	aatataattg	60
atcttgagccc	aagggagagg	gtttctctag	tcaaagcttt	gcaaagaatg	aagaatgac	120
gtcccgctga	tgggtaccaa	gccattgcct	ctttccatgc	cctgccacca	ctctgtccca	180
atccatctgc	agctcacctg	tatgcttgct	gtgtccatgg	catggctaca	tttcccaggt	240
ggcacagact	gtacactggt	caggttcagg	atgccttgag	gagacatggt	tcacttggtg	300
gtattcctta	ctgggactgg	acaaaaccag	tcaacgagtt	acccgagctt	ctttcttcag	360
caacatttta	tcateccaatc	cggaaatatta	atatttcaaa	tccattcctc	ggggctgaca	420
tagaatttga	aggaccgggc	gttcatacag	agaggcacat	aaatactgag	cgccgtgttc	480
acagtgggga	tcatgacgga	taccacaact	ggttcttcga	aactgttctc	tttgctttgg	540
aacaggaaga	ttactgcat	tttgaaatac	aatttgagat	agcccataat	ggcatccaca	600
catggattgg	tgggaagcgca	gtatatggca	tgggacacct	tcactatgca	tcatatgac	660
caattttcta	catccaccat	tcacagacgg	acagaatatg	ggctatttgg	caagagctgc	720
agaagtacag	gggtctatct	ggttcggaag	caaactgtgc	cattgaacat	atgagaacac	780
ccttgaaagcc	tttcagcttt	gggccaccct	acaatttgaa	tagtcatacg	caagaatatt	840
caaagcctga	ggacacgttt	gactataaga	agtttgata	cagatatgat	agtctggaat	900
tggagggggcg	atcaattttct	cgcattgatg	aacttatcca	gcagagacag	gagaaagaca	960
gaacttttgc	agggttcctc	cttaaagggt	ttggtacatc	cgcactctgtg	tcattgcaag	1020
tttgacagagt	tgatcacacc	tgtaaagatg	cgggctatct	cactattctg	ggaggatcag	1080
ccgaaatgcc	atgggcattc	gacaggcttt	ataagtatga	cattactaaa	actcttcacg	1140
acatgaacct	gaggcacgag	gacactttct	ctatagacgt	aactatcacg	tcttacaatg	1200
gaacagtact	ctcgggagac	ctcattcaga	cgcctcccat	tatatttgta	cctggacgcc	1260

<210> 6

<211> 1251

<212> DNA

<213> *Haliotis tuberculata*

<400> 6

ataaactcaa	ctcacggaaa	catacaccta	acagagtccg	ccatgagcta	agtagcctta	60
gttcccgtga	catagcaagc	ttgaaggcag	ctttgacaag	ccttcaacat	gataatggga	120
ctgatgggtta	tcaagctatt	gctgccttcc	atggcggtcc	tgcgcagtgc	cacgagccat	180
ctggacgtga	gatcgctgt	tgcattccacg	gcattggcgac	gtttcctcac	tggcaccgggt	240
tgtacactct	gcagttggag	caagcgctgc	gcagacacgg	gtccagtgtt	gctgttccat	300
actgggactg	gaccaagcca	atcaccgaac	tgccacacat	tctgacagac	ggagaatatt	360
atgacgtttg	gcaaaatgcc	gtcttgccca	atccgtttgc	aagagggttat	gtgaaaatta	420
aagatgcatt	tacggtgaga	aatgtccagg	aaagtctgtt	caaaatgtca	agttttggaa	480

4

agcactcgct	tctgtttgac	caggctttgt	tggtctcttga	acaaactgac	tactgtgact	540
tcgaagttca	gtttgaagtg	atgcataaca	cgatccatta	tctcgtagga	gggcgtcaaa	600
cgtacgcctt	ctcctctctc	gagtattcct	catacgatcc	aatcttcttt	attcaccact	660
cgtttgttga	caaaatatgg	gctgtatggc	aagaactgca	aagcaggaga	catctacagt	720
ttagaacagc	tgattgtgct	gtgggcctca	tggttcaggc	aatgaggcct	ttcaacaagg	780
atttcaacca	caactcgttc	accaagaagc	acgcagtccc	taatacagta	tttgattatg	840
aagatcttgg	ctataactat	gacaaccttg	aaatcagtgg	tttaaaactta	aatgagatcg	900
aggcggtta	agcaaaacgc	aagtcacatg	ctagagtctt	tgctgggttc	ctgttgtttg	960
gattaggaac	ttcggctgat	atacatctgg	aaatttgcaa	gacatcggaa	aactgccatg	1020
atgctgggtg	gatttttcac	cttggagggt	ctgcagagat	gcattgggca	tacaaccgcc	1080
tctacaagta	tgacattaca	gaagcattgc	aggaatttga	catcaaccct	gaagatgttt	1140
tccatgctga	tgaaccattt	ttcctgaggc	tgctcggttg	tgctgtgaat	ggaactgtca	1200
ttccatcgct	tcattcttcac	cagccaacga	taatctatga	accaggcgaa	g	1251

<210> 7

<211> 1209

<212> DNA

<213> *Haliotis tuberculata*

<400> 7

atcaccatga	cgaccatcag	tcgggaagca	tagcaggatc	cgggggtccgc	aaggacgtga	60
acaccttgac	taaggctgag	accgacaacc	tgaggggaggc	gctgtggggg	gtcatggcag	120
accacggtcc	caatggcttt	caagctattg	ctgctttcca	tgaaaaacca	gctttgtgtc	180
ccatgcctga	tggecacaac	tactcatgtt	gtactcacgg	catggctacc	ttcccacact	240
ggcatcgctt	ctacaccaag	cagatggagg	atgcaatgag	ggcgcagggg	tctcatgtcg	300
gcctgcccta	ctgggactgg	actgctgcct	tcaccacact	gccaacactg	gtcaccgaca	360
cggacaacaa	cccccttcaa	catggacaca	ttgattatct	caatgtcagc	acaactcgat	420
ctccccgaga	catgctgttc	aacgaccccc	agcatggatc	agagtcggtc	ttctacagac	480
aagtcctctt	agctctggaa	caaactgatt	tctgcaaatt	cgaagttcag	tttgagataa	540
cccacaatgc	catccattcc	tggaacagg	gccacagccc	ctacggaatg	tccactctcg	600
acttcactgc	ctacgatect	ctcttctggc	ttcaccactc	caacaccgac	agaatctggg	660
ctgtctggca	agctttgcaa	gaatacagag	gacttccata	caaccatgcc	aattgtgaga	720
tccaggcaat	gaaaacgccc	ctgaggcctt	tcagtgacga	tatcaaccac	aaccagtgca	780
caaaggctaa	cgcgaaagcca	ttagatgtgt	tcgagtataa	tcggtttgagc	ttccagtagc	840
acaacctcat	cttccatgga	tacagtattc	cggaaacttga	tcgcgtgctt	gaagaaagaa	900
aggaggagga	cagaatattt	gctgccttcc	ttctcagtgg	aatcaagcgt	agtgtctgatg	960
tagtggttcga	catatgccag	ccagaacacg	aatgtgtgtt	cgcaggggact	tttgcgattt	1020
tgggagggga	gctagaaatg	ccctggctct	tcgacagact	gttccgctat	gatatcacca	1080
aggtgatgaa	gcagctacac	ctgaggcatg	actctgactt	taccttcagg	gtgaagattg	1140
tcggcaccca	cgaccacgag	cttcccttcag	acagtgtcaa	agcaccaact	attgaatttg	1200
aaccgggcg						1209

<210> 8

<211> 1535

<212> DNA

<213> *Haliotis tuberculata*

<400> 8

tgcacagagg	cggaaaccac	gaagatgaac	accatgatga	cagactcgca	gatgtcctga	60
tcaggaaaga	agttgacttc	ctctccctgc	aagaggccaa	cgcaattaag	gatgcactgt	120
acaagctcca	gaatgacgac	agtaaagggg	gctttgaggc	catagctggc	tatcacgggt	180
atcctaatat	gtgtccagaa	agaggtaccg	acaagtatcc	ctgctgtgtc	cacggaatgc	240
ccgtgttccc	ccactggcac	cgcttgcata	ccattcagat	ggagagagct	ctgaaaaacc	300
atgggtctcc	aatgggcatt	ccttactggg	attggacaaa	gaagatgtcg	agtcttccat	360
ctttcttttg	agattccagc	aacaacaacc	ctttctacaa	atattacatc	cggggcgctgc	420
agcacgaaac	aaccagggac	attaatcaga	gactctttta	tcaaaccaag	tttggtgaat	480
ttgattacct	atattaccta	actctgcaag	tcctggagga	aaactcgtac	tgtgactttg	540

5

aagttcagta	tgagatcctc	cataacgccg	tcactcctg	gcttggagga	actggaaagt	600
attccatgtc	taccctggag	cattcggcct	ttgaccctgt	cttcatgatt	caccactcga	660
gtttggatag	aatctggatc	ctttggcaga	agttgcaaaa	gataagaatg	aagccttact	720
acgcattgga	ttgtgctggc	gacagactta	tgaaagaccc	cctgcatccc	ttcaactacg	780
aaaccgttaa	tgaagatgaa	ttcaccgcga	tcaactcttt	ccaagcata	ctgtttgacc	840
actacagggt	caactatgaa	tacgataaca	tgagaatcag	gggtcaggac	atacatgaac	900
ttgaagaggt	aattcaggaa	ttaagaaaca	aagatcgcat	atttgcctgt	tttgttttgt	960
cgggcttacg	gatatcagct	acagtgaag	tattcattea	ttcgaaaaac	gatacaagtc	1020
acgaagaata	tgcaggagaa	tttgagcttt	tgaggaggtg	gaaggagatg	ccgtgggcat	1080
atgaaagaat	gctgaaattg	gacatctccg	atgctgtaca	caagcttcac	gtgaaagatg	1140
aagacatccg	ttttagagtg	gttggttactg	cctacaacgg	tgacgttggt	accaccaggc	1200
tgtctcagcc	attcatcgtc	caccgtccag	cccatgtggc	tcacgacatc	ttggtaatcc	1260
cagtaggtgc	gggccatgac	cttcgcgcta	aagtcgtagt	aaagagcggc	accaaagtgc	1320
agtttacacc	aatagattcg	tcggtgaaca	aagcaatggg	ggagctgggc	agctatactg	1380
ctatggctaa	atgcatcggt	ccccctttct	cttaccacgg	ctttgaactg	gacaaagtct	1440
acagcgtcga	tcacggagac	tactacattg	ctgcagggtac	ccacgcgttg	tgtgagcaga	1500
acctcaggct	ccacatccac	gtggaacacg	agtag			1535

<210> 9
 <211> 1003
 <212> DNA
 <213> Haliotis tuberculata

<400> 9						
cacagactgt	tcgtcaccca	ggtggaagat	gctctgatca	ggcgaggatc	gcctataggg	60
gtccctact	gggactggac	tcagcctatg	gcgcatctcc	caggacttgc	agacaacgcc	120
acctatagag	atcccatcag	cggggacagc	agacacaacc	ccttccacga	tggtgaagtt	180
gcctttgaaa	atggacgtac	agaacgtcac	ccagatagta	gattgtttga	acaaccttta	240
tttggcaaac	atacgcgtct	cttcgacagt	atagtctatg	cttttgagca	ggaggacttc	300
tgcgattttg	aagttcaatt	tgagatgacc	cataataata	ttcacgcctg	gattggtggc	360
ggcgagaagt	attccatgtc	ttctctacac	tacacagcct	tcgaccctat	cttctacctt	420
cgtcactcca	acactgaccg	gctctgggca	atgttgcaag	cgttgcagat	acgaagaaac	480
aggccttaca	aggctcattg	tgcttgggtct	gaggaacgcc	agcctctcaa	acctttcgcc	540
ttcagttccc	cactgaacaa	caacgaaaaa	acctacgaaa	actcggtgcc	caccaacggt	600
tacgactacg	aaggagtcct	tggtctatact	tatgatgacc	tcaacttcgg	gggcatggac	660
ctgggtcagc	ttgaggaata	catccagagg	cagagacaga	gagacaggac	ctttgctggg	720
ttctttctgt	cacatattgg	tacatcagcg	aatgttgaaa	tcattataga	ccatgggact	780
cttcatacct	ccgtgggcac	gtttgctggt	cttgccggag	agaaggagat	gaaatgggga	840
tttgaccgtt	tgtacaaata	tgagattaca	gatgaactga	ggcaacttaa	tctccgtgct	900
gatgatgttt	tcagcatctc	tgttaaagta	actgatgttg	atggcagtga	gctgtcctct	960
gaactcatcc	catctgctgc	tatcatcttc	gaacgaagcc	ata		1003

<210> 10
 <211> 1251
 <212> DNA
 <213> Haliotis tuberculata

<400> 10						
ttgaccatca	ggaccgcgat	catgacacaa	tcattaggaa	aatgtttgat	aatcttacac	60
ccgaggaaat	taattctctg	aggcgggcaa	tggcagacct	tcaatcagac	aaaaccgccg	120
gtggattcca	gcaaattgct	gcttttcacg	gggaacccaa	atggtgcccc	agtcccgatg	180
ctgagaagaa	gttctcctgc	tgtgtccatg	gaatggctgt	cttccctcac	tggcacagac	240
tcctgaccgt	gcaaggcgag	aatgccctga	gaaagcatgg	atgtctcgga	gctctccctt	300
actgggactg	gactcggccc	ctgtctcacc	tacctgattt	ggttttggta	agtagcagaa	360
ctacaccgat	gccatattcc	accgtggaag	cccgaacccc	ctggtacagc	ggccatattg	420
atacagttgg	tgttgacaca	acaagaagcg	tcggtcaaga	actgtatgaa	gctcctggat	480
ttggccatta	tactgggggtc	gctaagcaag	tgcttctggc	tttggagcag	gatgacttct	540

6

gtgatttttga	agtccagttt	gagatagctc	acaatttcat	tcacgctctt	gtcggcggaa	600
gcgagccata	tggtatggcg	tcactccgtt	acactactta	tgatccaatt	ttctacctcc	660
atcattctaa	cactgacaga	ctctgggcta	tatggcaggc	tctacaaaag	tacaggggca	720
aaccttacia	ttccgccaac	tgcgccattg	cttctatgag	aaaacccta	caaccctttg	780
gtctgactga	tgagatcaac	ccggatgatg	agacaagaca	gcatgctgtt	cctttcagtg	840
tctttgatta	caagaacaac	ttcaattatg	aatatgacac	ccttgacttc	aacggactat	900
caatctccca	gctggaccgt	gaactgtcac	ggagaaagtc	tcatgacaga	gtattttgccg	960
gattttttgt	gcatgggtatt	cagcagctctg	cactagttaa	attctttgtc	tgcaaatcag	1020
atgatgactg	tgaccactat	gctgggtgaat	tctacatcct	tggtgatgaa	gctgaaatgc	1080
catgggggcta	tgatcgtctt	tacaaatatg	agatcactga	gcagctcaat	gccctggatc	1140
tacacatcgg	agatagattc	ttcatcagat	acgaagcgtt	tgatcttcat	ggtacaagtc	1200
ttggaagcaa	catcttcccc	aaaccttctg	tcatacatga	cgaaggggca	g	1251

<210> 11

<211> 1244

<212> DNA

<213> *Haliotis tuberculata*

<400> 11

gtcaccatca	ggctgacgag	tacgacgaag	ttgtaactgc	tgcaagccac	atcagaaaga	60
atttaaaaga	tctgtcaaag	ggagaagtag	agagcctaag	gtctgccttc	ctgcaacttc	120
agaacgacgg	agtctatgag	aatattgcca	agttccacgg	caagcctggg	ttgtgtgatg	180
ataacggteg	caaggttgcc	tgttggtgct	atggaatgcc	caccttcccc	cagtggcaca	240
ggctctatgt	cctccagggt	gagaatgctt	tgctggagag	aggatctgcc	gtctctgtgc	300
catactggga	ctggactgaa	acatttacag	agctgccatc	tttgattgct	gaggctacct	360
atttcaattc	ccgtcaacaa	acgtttgacc	ctaatecttt	cttcagaggt	aaaatcagtt	420
ttgagaatgc	tgttacaaca	cgtgatcccc	agcctgagct	gtacgttaac	aggtactact	480
accaaaccgt	catgtttggt	tttgaacagg	acaactactg	cgacttcgag	atacagtttg	540
agatggttca	caatgtttct	catgcttggc	ttggtggaag	agctacttat	tctattttct	600
ctcttgatta	ttctgcattc	gacctgtgtg	ttttccttca	ccatgcgaac	acagatagat	660
tgtggggccat	ctggcaggag	ctgcagaggt	acaggaagaa	gccatacaat	gaagcggatt	720
gtgccattaa	cctaattgcg	aaacctctac	atcccttcga	caacagtgat	ctcaatcatg	780
atcctgtaac	ctttaaatat	tcaaaaccca	ctgatggctt	tgactaccag	aacaactttg	840
gatacaagta	tgacaacctt	gagttcaatc	atttcagtat	tcccaggctt	gaagaaatca	900
ttcgtattag	acaacgtcaa	gatcgtgtgt	ttgcaggatt	cctccttcac	aacattggga	960
catccgcaac	tgttgagata	ttcgtctgtg	tcctaccac	cagcgggtgag	caaaactgtg	1020
aaaacaaagc	cggaaacattt	gcggtactcg	gaggagaaac	agagatggcg	tttcattttg	1080
acagactcta	caggtttgac	atcagtgaat	cactgaggga	cctcggcata	cagctggaca	1140
gccatgactt	tgacctcagc	atcaagattc	aaggagtaaa	tgatcctac	cttgatccac	1200
acatcctgcc	agagccatcc	ttgatttttg	tgcttggttc	aagt		1244

<210> 12

<211> 1255

<212> DNA

<213> *Haliotis tuberculata*

<400> 12

tctttcctgc	gtcctgatgg	gcattcagat	gacatccttg	tgagaaaaga	agtgaacagc	60
ctgacaacca	gggagactgc	atctctgata	catgctctga	aaagtatgca	ggaagaccat	120
tcacctgacg	ggttccaagc	cattgcctct	ttccatgctc	tgccaccact	ctgcccttca	180
ccatctgcag	ctcaccgtta	tgttggtgtg	gtccacggca	tggtacatt	tccccagtg	240
cacagattgt	acactgtaca	gttccaggat	gcactgagga	gacatggagc	tacggtaggt	300
gtaccgtatt	gggattggct	gcgaccgcag	tctcacctac	cagagcttgt	caccatggag	360
acataccatg	atattttggag	taacagagat	ttccccaatc	ctttctacca	agccaatatt	420
gagtttgaag	gagaaaacat	tacaacagag	agagaagtca	ttgcagacaa	actttttgtc	480
aaagggtggac	acgttttttg	taaactgggt	cttcaaacaa	gccatcctag	cgctgagcag	540
gaaaactact	gtgactttga	gatttcagtt	gaaattcttc	acaacggcgt	tcacacgtgg	600

7

gtcggaggca	gtcgtaccta	ctctatcgga	catcttcatt	acgcattcta	cgaccctctt	660
ttctaccttc	accattttcca	gacagaccgt	atctgggcaa	tctggcaaga	actccaggaa	720
cagagagggc	tctcgggtga	tgaggctcac	tgtgctctcg	agcaaataag	agaaccattg	780
aagcctttca	gcttcggcgc	tccttataac	tggaaatcagc	tcacacagga	tttctcccga	840
cccagaggaca	ccttcgacta	caggaagttt	ggttatgaat	atgacaattt	agaattcctg	900
ggaatgtcag	ttgctgaact	ggatcaatac	attattgaac	atcaagaaaa	tgatagagta	960
ttcgtctgggt	tcctgttgag	tggattcgga	ggttccgcat	cagttaattt	ccagggtttgt	1020
agagctgatt	ccacatgtca	ggatgctggg	tacttcaccg	ttcttggtgg	cagtgtctgag	1080
atggcgtggg	catttgacag	gctttacaaa	tatgacatta	ctgaaactct	ggagaaaatg	1140
caccttcgat	atgatgatga	cttcacaatc	tctgtcagtc	tgaccgccaa	caacggaact	1200
gtcctgagca	gcagtcta	cccaacaccg	agtgtcatat	tccagcgggg	acatc	1255

<210> 13

<211> 1248

<212> DNA

<213> *Haliotis tuberculata*

<400> 13

gtgacataaa	taccaggagc	atgtcaccga	accgtgttcg	ccgtgagctg	agcgatctgt	60
ctgcgaggga	cctgtctagt	ctcaagtctg	ctctgcgaga	cctacaggag	gatgatggcc	120
ccaacggata	ccaggctctt	gcagccttcc	atgggctacc	agcaggctgc	catgatagcc	180
ggggaaatga	gatcgcatgt	tgcattcacg	ggatgccgac	cttccccag	tggcacagac	240
tgtacaccct	gcagttggag	atggctctga	ggagacatgg	atcatctgtc	gccatcccct	300
actgggactg	gacaaagcct	atctccgaac	tcccctcgt	cttcaccagc	cctgagtatt	360
atgacccatg	gcatgatgct	gtggtaaaca	accattctc	caaaggtttt	gtcaaatttg	420
caaataccta	cacagtaaga	gaccacaggg	agatgctgtt	ccagctttgt	gaacatggag	480
agtcaatcct	ctatgagcaa	actcttcttg	ctcttgagca	aaccgactac	tgtgattttg	540
aggtacagtt	tgaggctctc	cataacgtga	tccactacct	tgttggtgga	cgtcagacct	600
acgcattgtc	ttctctgcat	tatgctcct	acgaccatt	cttctttata	caccattcct	660
ttgtggataa	gatgtgggta	gtatggcaag	ctcttcaaaa	gaggaggaaa	cttccataca	720
agcgagctga	ctgtgctgtc	aacctaatga	ctaaaccaat	gaggccattt	gactccgata	780
tgaatcagaa	cccattcaca	aagatgcacg	cagttcccaa	cacactctat	gactacgaga	840
cactgtacta	cagctacgat	aatctcgaaa	taggtggcag	gaatctcgac	cagcttcagg	900
ctgaaattga	cagaagcaga	agccacgatc	gcgtttttgc	tggattcttg	cttcgtggaa	960
tcggaacttc	tgtgtgatgtc	aggtttttgga	tttgtagaaa	tgaaaatgac	tgccacaggg	1020
gtggaataat	tttcatctta	ggtggagcca	aggaaatgcc	atggtcattt	gacagaaact	1080
tcaagtttga	tatcaccat	gtactcgaga	atgctggcat	tagcccagag	gacgtgtttg	1140
atgctgagga	gccattttat	atcaagggtg	agatccatgc	tgttaacaag	accatgatac	1200
cgctgtctgt	gatcccagcc	ccaactatca	tctattctcc	tggggaag		1248

<210> 14

<211> 1207

<212> DNA

<213> *Haliotis tuberculata*

<400> 14

gtcgcgctgc	tgacagtgcg	cactctgcc	acattgctgg	ctctgggggtg	aggaaggacg	60
tcacgacctt	cactgtgtct	gagaccgaga	acctaagaca	ggctcttcaa	ggtgtcatcg	120
atgatactgg	tcccaatggg	taccaagcaa	tagcatcctt	ccacggaagt	cctccaatgt	180
gcgagatgaa	cggccgcaag	gttgccctgtt	gtgctcacgg	tatggcctcc	ttcccaact	240
ggcacagact	gtatgtgaag	cagatggaag	atgccctggc	tgaccacggg	tcacatatcg	300
gcatccctta	ctgggactgg	acaactgcct	tcacagagtt	acccgccctt	gtcacagact	360
ccgagaacaa	tcccttccat	gagggtcgca	ttgatcatct	cggtgtaacc	acgtcacgtt	420
ccccagaga	catgctgttt	aacgacccag	agcaaggatc	agagtctgtc	ttctatagac	480
aagtctctct	ggctttggag	cagactgact	actgccagtt	cgaagtccag	tttgagctga	540
cccacaacgc	cattcactcc	tggacaggtg	gacgtagccc	ttacggaatg	tcgaccctcg	600
agttcacagc	ctacgatcct	ctcttctggc	ttcaccactc	caacaccgac	agaatctggg	660

<400> 16						
ggcctaccgt	actgggactg	gactgaaccc	atgacacaca	ttccgggtct	ggcaggaaac	60
aaaacttatg	tggattctca	tgggtgatcc	cacacaaatc	cttttcatag	ttcagtgatt	120
gcatttgaag	aaaatgctcc	ccacaccaa	agacaaatag	atcaaagact	ctttaaaccc	180
gctacctttg	gacaccacac	agacctgttc	aaccagattt	tgtatgcctt	tgaacaagaa	240
gattactgtg	actttgaagt	ccaatttgag	attacccata	acacgattca	cgcttggaca	300
ggaggaagcg	aacattttctc	aatgtcgtcc	ctacattaca	cagctttcga	tcctttgttt	360
tactttcacc	attctaacgt	tgatcgtctt	tggggcgttt	ggcaagcctt	acagatgaga	420

9

cggcataaac	cctacagggc	ccactgcgcc	atatctcttg	aacatatgca	tctgaaacca	480
ttcgcccttt	catctccct	taacaataac	gaaaagactc	atgccaatgc	catgccaaac	540
aagatctacg	actatgaaaa	tgctctccat	tacacatacg	aagatttaac	atttggaggc	600
atctctcttg	aaaacataga	aaagatgatc	cacgaaaacc	agcaagaaga	cagaatatat	660
gccggttttc	tcctggctgg	catacgtact	tcagcaaattg	ttgatatact	cattaaaact	720
accgattccg	tgcaacataa	ggctggaaca	tttgcaagtgc	tcggtggaag	caaggaaatg	780
aagtggggat	ttgatcgctg	tttcaagttt	gacatcacgc	acgtttttgaa	agatctcgat	840
ctcactgctg	atggcgattt	cgaagttact	gttgacatca	ctgaagtcga	tggaaactaaa	900
cttgcatcca	gtcttattcc	acatgcttct	gtcattcctg	agcatgcacg	tggttaagctg	960
aatagag						967

<210> 17

<211> 1242

<212> DNA

<213> Megathura crenulata

<400> 17

ttaaatttga	caaagtgcc	aggagtcgtc	ttattcgaaa	aaatgtagac	cgtttgagcc	60
ccgaggagat	gaatgaactt	cgtaaagccc	tagccttact	gaaagaggac	aaaagtgccg	120
gtggatttca	gcagcttggt	gcattccatg	gggagccaaa	atggtgtcct	agtcccgaag	180
catctaaaaa	atttgccctg	tgtgttcacg	gcatgtctgt	gttccttcac	tggcatcgac	240
tgttgacggg	tcagagtga	aatgctttga	gacgacatgg	ctacgatgga	gctttgccgt	300
actgggattg	gacctctcct	cttaatcacc	ttcccgaact	ggcagatcat	gagaagtacg	360
tcgaccctga	agatggggta	gagaagcata	acccttggtt	cgatgggtcat	atagatacac	420
tcgacaaaac	aacaacaaga	agtgttcaga	ataaactcct	cgaacagcct	gagtttggtc	480
attatacaag	cattgccaaa	caagtactgc	tagcgttgga	acaggacaat	ttctgtgact	540
ttgaaatcca	atatgagatt	gcccataact	acatccatgc	acttgtagga	ggcgctcagc	600
cttatgggat	ggcatcgctt	cgctacactg	cttttgatcc	actattctac	ttgcatcact	660
ctaatacaga	tcgtatatgg	gcaatatggc	aggctttaca	gaagtacaga	ggaaaaccgt	720
acaacgttgc	taactgtgct	gttacatcga	tgagagaacc	tttgcaacca	tttggcctct	780
ctgccaatat	caacacagac	catgtaacca	aggagcattc	agtgccattc	aacgtttttg	840
attacaagac	caatttcaat	tatgaatatg	acactttgga	atttaacggg	ctctcaatct	900
ctcagttgaa	taaaaagctc	gaagcgataa	agagccaaga	caggttcctt	gcaggcttcc	960
tgttatctgg	tttcaagaaa	tcctctcttg	ttaaattcaa	tatttgccac	gatagcagca	1020
actgtcaccc	cgctgggag	ttttaccttc	tgggtgatga	aaacgagatg	ccatgggcat	1080
acgatagagt	cttcaaatat	gacataaccg	aaaaactcca	cgatctaaag	ctgcatgcag	1140
aagaccactt	ctacattgac	tatgaagtat	ttgaccttaa	accagcaagc	ctgggaaaag	1200
atttgttcaa	gcagccttca	gtcattcatg	aaccaagaat	ag		1242

<210> 18

<211> 1236

<212> DNA

<213> Megathura crenulata

<400> 18

gtcaccatga	aggcgaagta	tatcaagctg	aagtaacttc	tgccaaccgt	attcgaaaaa	60
acattgaaaa	tctgagcctt	ggtgaactcg	aaagtctgag	agctgccttc	ctggaaattg	120
aaaacgatgg	aacttacgaa	tcaatagcta	aattccatgg	tagccctggg	ttgtgccagt	180
taaatggtaa	ccccatctct	tgttggtgct	atggcatgcc	aactttccct	cactggcaca	240
gactgtacgt	ggttgtcggt	gagaatgccc	tcctgaaaaa	aggatcatct	gtagctgttc	300
cctattggga	ctggacaaaa	cgaatcgaac	atttacctca	cctgatttca	gacgccactt	360
actacaattc	caggcaacat	cactatgaga	caaaccattt	ccatcatggc	aaaatcacac	420
acgagaatga	aatcactact	agggatccca	aggacagcct	cttccattca	gactactttt	480
acgagcaggt	cctttacgcc	ttggagcagg	ataacttctg	tgatttcgag	attcagttgg	540
agatattaca	caatgcattg	cattctttac	ttgggtggcaa	aggtaaatat	tccatgtcaa	600
accttgatta	cgctgctttt	gatcctgtgt	tcttccctca	tcacgcaacg	actgacagaa	660
tctgggcaat	ctggcaagac	cttcagaggt	tccgaaaacg	gccataccga	gaagcgaatt	720

<400>	21						
ctgatgccaa	agactttggc	catagcagaa	aaatcaggaa	agccgttgat	tctctgacag	60	
tcgaagaaca	aacttcgttg	aggcgagcta	tggcagatct	acaggacgac	aaaacatcag	120	
ggggtttcca	gcagattgca	gcattccacg	gagaacccaaa	atgggtgtcca	agccccgaag	180	
cggagaaaaa	atttgcatgc	tgtgttcatg	gaatggctgt	tttccctcac	tggcacagat	240	
tgctgacagt	tcaaggagaa	aatgctctga	ggaaacatgg	ctttactggg	ggactgccct	300	

11

```
actgggactg gactcgatca atgagcgccc ttccacattt tgttgetgat cctacttaca 360
atgatgctat ttccagccag gaagaagata acccatggca tcatgggtcac atagactctg 420
ttgggcatga tactacaaga gatgtgcgtg atgatcttta tcaatctcct ggtttcgggc 480
actacacaga tattgcacaa caagtccttc tggcctttga gcaggacagt ttctgtgatt 540
ttgaggtaca atttgaaatt gcccataatt tcatacatgc actgattggg ggtaacgaac 600
catacagtat gtcacatctt aggtatacta catacagatc aatcttcttc ttgcaccact 660
ccagtacaga ccgacttttg gccatctggc aagcaatcac tagtgcgggc gcctgcaggt 720
cgaccataag ggagagctcc caacgcgttg gatgcaatct 760
```

<210> 22
<211> 323
<212> DNA
<213> Megathura crenulata

```
<400> 22
gttcacacca ggctgatgaa tatcgtgagg cagtaacaag cgctagccac ataagaaaaa 60
atatccggga cctctcagag ggagaaattg agagcatcag atctgctttc ctccaaattc 120
aaaaagaggg tatatatgaa aacattgcaa agttccatgg aaaaccagga ctttgtgaac 180
atgatggaca tcctgttgct tgttgtgtcc atggcatgcc cacctttccc cactggcaca 240
gactgtacgt tcttcaggtg gagaatgcgc tcttagaacg agggctctgca gttgctgttc 300
cttactggga ctggacccta cct 323
```

<210> 23
<211> 988
<212> DNA
<213> Megathura crenulata

```
<400> 23
atggctgtgt ttccgcactg gcacagactg tttgtgaaac agatggagga cgcacttgct 60
gctcatggag ctcatatttg cataccatac tgggattgga caagtgcgtt tagtcatctg 120
cccgccctag tgactgacca cgagaacaat cccttccacc acggccatat tgggtcatctg 180
aatgtggata catctcgatc tccaagagac atgctgttta atgatcctga acaaggctca 240
gaatcattct tctacagaca ggttctcttg actctagaac agacagactt ctgccaatth 300
gaagttcagt ttgaacttac acacaatgcc atccactctt ggactggagg acatactcca 360
tatggaatgt catcactgga atatacagca tatgatccac tcttttatct ccaccattcc 420
aacactgacg gtatctgggc catctggcag gcaactccaga aatatagagg tcttccatac 480
aacgcagctc actgcgatat ccaagttctg aaacaacctc ttaaaccatt cagecgagtcc 540
aggaatccaa acccagtcac cagagccaat tctagggccg ttgattcatt tgattatgag 600
aaattcaatt atcaatatga cacacttacc ttccacggac tttctatccc agaacttgat 660
gccatgcttc aagagagaaa gaaggaagag agaacatttg cagccttccg gttgcacgga 720
tttggcgcca gtgctgatgt ttcgtttgat gtctgcacac ctgatggcca ttgtgccttt 780
gctggaacct tcgcggtact tgggtggggag cttgagatgc cctgggtcctt tgaaagattg 840
ttcggttacg atatcacaaa ggttctcaag cagatgaatc ttcactatga ttctgagttc 900
cactttgagt tgaagattgt tggcacagat ggaacagaac tgccatcgga tcgtatcaag 960
agccctacca ttgaacacca tggaggag 988
```

<210> 24
<211> 310
<212> DNA
<213> Megathura crenulata

```
<400> 24
gtcacgatca cagtgaacgt cacgatggat ttttcaggaa ggaagtcggt tccctgtccc 60
tggaatgaag caatgacctt aaaaatgcac tgtacaagct gcagaatgat cagggtccca 120
atggatatga atcaatagcc gggtaccatg gctatccatt cctctgccct gaacatgggt 180
aagaccagta cgcattgctg gtccacggaa tgccctgtatt tccacattgg cacagacttc 240
atacaatcca gtttgagaga gctctcaaa aacatggttc tcaattgggt ctgccatact 300
```

gggactggac

310

<210> 25

<211> 422

<212> PRT

<213> *Haliotis tuberculata*

<220>

<221> SIGNAL

<222> (1) . . (15)

<400> 25

Leu Val Gln Phe Leu Leu Val Ala Leu Val Ala Gly Ala Gly Ala Asp
1 5 10 15

Asn Val Val Arg Lys Asp Val Ser His Leu Thr Asp Asp Glu Val Gln
20 25 30

Ala Leu His Gly Ala Leu His Asp Val Thr Ala Ser Thr Gly Pro Leu
35 40 45

Ser Phe Glu Asp Ile Thr Ser Tyr His Ala Ala Pro Ala Ser Cys Asp
50 55 60

Tyr Lys Gly Arg Lys Ile Ala Cys Cys Val His Gly Met Pro Ser Phe
65 70 75 80

Pro Phe Trp His Arg Ala Tyr Val Val Gln Ala Glu Arg Ala Leu Leu
85 90 95

Ser Lys Arg Lys Thr Val Gly Met Pro Tyr Trp Asp Trp Thr Gln Thr
100 105 110

Leu Thr His Leu Pro Ser Leu Val Thr Glu Pro Ile Tyr Ile Asp Ser
115 120 125

Lys Gly Gly Lys Ala Gln Thr Asn Tyr Trp Tyr Arg Gly Glu Ile Ala
130 135 140

Phe Ile Asn Lys Lys Thr Ala Arg Ala Val Asp Asp Arg Leu Phe Glu
145 150 155 160

Lys Val Glu Pro Gly His Tyr Thr His Leu Met Glu Thr Val Leu Asp
165 170 175

Ala Leu Glu Gln Asp Glu Phe Cys Lys Phe Glu Ile Gln Phe Glu Leu
180 185 190

Ala His Asn Ala Ile His Tyr Leu Val Gly Gly Lys Phe Glu Tyr Ser
195 200 205

Met Ser Asn Leu Glu Tyr Thr Ser Tyr Asp Pro Ile Phe Phe Leu His
210 215 220

His Ser Asn Val Asp Arg Leu Phe Ala Ile Trp Gln Arg Leu Gln Glu
225 230 235 240

13

Pro	His	Trp	His	Arg	Leu	Phe	Val	Thr	Gln	Val	Glu	Asp	Ala	Leu	Val	85	90	95
Arg	Arg	Gly	Ser	Pro	Ile	Gly	Val	Pro	Tyr	Trp	Asp	Trp	Thr	Lys	Pro	100	105	110
Met	Thr	His	Leu	Pro	Asp	Leu	Ala	Ser	Asn	Glu	Thr	Tyr	Val	Asp	Pro	115	120	125
Tyr	Gly	His	Thr	His	His	Asn	Pro	Phe	Phe	Asn	Ala	Asn	Ile	Ser	Phe	130	135	140
Glu	Glu	Gly	His	His	His	Thr	Ser	Arg	Met	Ile	Asp	Ser	Lys	Leu	Phe	145	150	155
Ala	Pro	Val	Ala	Phe	Gly	Glu	His	Ser	His	Leu	Phe	Asp	Gly	Ile	Leu	165	170	175
Tyr	Ala	Phe	Glu	Gln	Glu	Asp	Phe	Cys	Asp	Phe	Glu	Ile	Gln	Phe	Glu	180	185	190
Leu	Val	His	Asn	Ser	Ile	His	Ala	Trp	Ile	Gly	Gly	Ser	Glu	Asp	Tyr	195	200	205
Ser	Met	Ala	Thr	Leu	His	Tyr	Thr	Ala	Phe	Asp	Pro	Ile	Phe	Tyr	Leu	210	215	220
His	His	Ser	Asn	Val	Asp	Arg	Leu	Trp	Ala	Ile	Trp	Gln	Ala	Leu	Gln	225	230	235
Ile	Arg	Arg	His	Lys	Pro	Tyr	Gln	Ala	His	Cys	Ala	Gln	Ser	Val	Glu	245	250	255
Gln	Leu	Pro	Met	Lys	Pro	Phe	Ala	Phe	Pro	Ser	Pro	Leu	Asn	Asn	Asn	260	265	270
Glu	Lys	Thr	His	Ser	His	Ser	Val	Pro	Thr	Asp	Ile	Tyr	Asp	Tyr	Glu	275	280	285
Glu	Val	Leu	His	Tyr	Ser	Tyr	Asp	Asp	Leu	Thr	Phe	Gly	Gly	Met	Asn	290	295	300
Leu	Glu	Glu	Ile	Glu	Glu	Ala	Ile	His	Leu	Arg	Gln	Gln	His	Glu	Arg	305	310	315
Val	Phe	Ala	Gly	Phe	Leu	Leu	Ala	Gly	Ile	Gly	Thr	Ser	Ala	Leu	Val	325	330	335
Asp	Ile	Phe	Ile	Asn	Lys	Pro	Gly	Asn	Gln	Pro	Leu	Lys	Ala	Gly	Asp	340	345	350
Ile	Ala	Ile	Leu	Gly	Gly	Ala	Lys	Glu	Met	Pro	Trp	Ala	Phe	Asp	Arg	355	360	365
Leu	Tyr	Lys	Val	Glu	Ile	Thr	Asp	Ser	Leu	Lys	Thr	Leu	Ser	Leu	Asp	370	375	380

His Ala Leu Val Gly Gly Thr Asp Ala Tyr Gly Met Ala Ser Leu Arg
195 200 205

Tyr	Thr	Ala	Tyr	Asp	Pro	Ile	Phe	Phe	Leu	His	His	Ser	Asn	Thr	Asp
	210					215					220				
Arg	Ile	Trp	Ala	Ile	Trp	Gln	Ser	Leu	Gln	Lys	Tyr	Arg	Gly	Lys	Pro
225					230					235					240
Tyr	Asn	Thr	Ala	Asn	Cys	Ala	Ile	Glu	Ser	Met	Arg	Arg	Pro	Leu	Gln
				245					250					255	
Pro	Phe	Gly	Leu	Ser	Ser	Ala	Ile	Asn	Pro	Asp	Arg	Ile	Thr	Arg	Glu
			260					265					270		
His	Ala	Ile	Pro	Phe	Asp	Val	Phe	Asn	Tyr	Arg	Asp	Asn	Leu	His	Tyr
		275					280					285			
Val	Tyr	Asp	Thr	Leu	Glu	Phe	Asn	Gly	Leu	Ser	Ile	Ser	Gln	Leu	Asp
	290					295					300				
Arg	Glu	Leu	Glu	Lys	Ile	Lys	Ser	His	Glu	Arg	Val	Phe	Ala	Gly	Phe
305					310					315					320
Leu	Leu	Ser	Gly	Ile	Lys	Lys	Ser	Ala	Leu	Val	Lys	Phe	Glu	Val	Cys
				325					330					335	
Thr	Pro	Pro	Asp	Asn	Cys	His	Lys	Ala	Gly	Glu	Phe	Tyr	Leu	Leu	Gly
			340					345					350		
Asp	Glu	Asn	Glu	Met	Ala	Trp	Ala	Tyr	Asp	Arg	Leu	Phe	Lys	Tyr	Asp
		355					360					365			
Ile	Thr	Gln	Val	Leu	Glu	Ala	Asn	His	Leu	His	Phe	Tyr	Asp	His	Leu
	370					375					380				
Phe	Ile	Arg	Tyr	Glu	Val	Phe	Asp	Leu	Lys	Gly	Val	Ser	Leu	Gly	Thr
385					390					395					400
Asp	Leu	Phe	His	Thr	Ala	Asn	Val	Val	His	Asp	Ser	Gly	Thr		
				405					410						

```
<210> 28
<211> 413
<212> PRT
<213> Haliotis tuberculata
```

```

<400> 28
Gly Thr Arg Asp Arg Asp Asn Tyr Val Glu Glu Val Thr Gly Ala Ser
 1           5           10           15
His Ile Arg Lys Asn Leu Asn Asp Leu Asn Thr Gly Glu Met Glu Ser
          20           25           30
Leu Arg Ala Ala Phe Leu His Ile Gln Asp Asp Gly Thr Tyr Glu Ser
          35           40           45
Ile Ala Gln Tyr His Gly Lys Pro Gly Lys Cys Gln Leu Asn Asp His
 50           55           60

```

17

Asn Ile Ala Cys Cys Val His Gly Met Pro Thr Phe Pro Gln Trp His
65 70 75 80

Arg Leu Tyr Val Val Gln Val Glu Asn Ala Leu Leu Asn Arg Gly Ser
85 90 95

Gly Val Ala Val Pro Tyr Trp Glu Trp Thr Ala Pro Ile Asp His Leu
100 105 110

Pro His Phe Ile Asp Asp Ala Thr Tyr Phe Asn Ser Arg Gln Gln Arg
115 120 125

Tyr Asp Pro Asn Pro Phe Phe Arg Gly Lys Val Thr Phe Glu Asn Ala
130 135 140

Val Thr Thr Arg Asp Pro Gln Ala Gly Leu Phe Asn Ser Asp Tyr Met
145 150 155 160

Tyr Glu Asn Val Leu Leu Ala Leu Glu Gln Glu Asn Tyr Cys Asp Phe
165 170 175

Glu Ile Gln Phe Glu Leu Val His Asn Ala Leu His Ser Met Leu Gly
180 185 190

Gly Lys Gly Gln Tyr Ser Met Ser Ser Leu Asp Tyr Ser Ala Phe Asp
195 200 205

Pro Val Phe Phe Leu His His Ala Asn Thr Asp Arg Leu Trp Ala Ile
210 215 220

Trp Gln Glu Leu Gln Arg Phe Arg Glu Leu Pro Tyr Glu Glu Ala Asn
225 230 235 240

Cys Ala Ile Asn Leu Met His Gln Pro Leu Lys Pro Phe Ser Asp Pro
245 250 255

His Glu Asn His Asp Asn Val Thr Leu Lys Tyr Ser Lys Pro Gln Asp
260 265 270

Gly Phe Asp Tyr Gln Asn His Phe Gly Tyr Lys Tyr Asp Asn Leu Glu
275 280 285

Phe His His Leu Ser Ile Pro Ser Leu Asp Ala Thr Leu Lys Gln Arg
290 295 300

Arg Asn His Asp Arg Val Phe Ala Gly Phe Leu Leu His Asn Ile Gly
305 310 315 320

Thr Ser Ala Asp Ile Thr Ile Tyr Ile Cys Leu Pro Asp Gly Arg Arg
325 330 335

Gly Asn Asp Cys Ser His Glu Ala Gly Thr Phe Tyr Ile Leu Gly Gly
340 345 350

Glu Thr Glu Met Pro Phe Ile Phe Asp Arg Leu Tyr Lys Phe Glu Ile
355 360 365

18

Thr Lys Pro Leu Gln Gln Leu Gly Val Lys Leu His Gly Gly Val Phe
370 375 380

Glu Leu Glu Leu Glu Ile Lys Ala Tyr Asn Gly Ser Tyr Leu Asp Pro
385 390 395 400

His Thr Phe Asp Pro Thr Ile Ile Phe Glu Pro Gly Thr
405 410

<210> 29

<211> 420

<212> PRT

<213> Haliotis tuberculata

<400> 29

Asp Thr His Ile Leu Asp His Asp His Glu Glu Glu Ile Leu Val Arg
1 5 10 15

Lys Asn Ile Ile Asp Leu Ser Pro Arg Glu Arg Val Ser Leu Val Lys
20 25 30

Ala Leu Gln Arg Met Lys Asn Asp Arg Ser Ala Asp Gly Tyr Gln Ala
35 40 45

Ile Ala Ser Phe His Ala Leu Pro Pro Leu Cys Pro Asn Pro Ser Ala
50 55 60

Ala His Arg Tyr Ala Cys Cys Val His Gly Met Ala Thr Phe Pro Gln
65 70 75 80

Trp His Arg Leu Tyr Thr Val Gln Val Gln Asp Ala Leu Arg Arg His
85 90 95

Gly Ser Leu Val Gly Ile Pro Tyr Trp Asp Trp Thr Lys Pro Val Asn
100 105 110

Glu Leu Pro Glu Leu Leu Ser Ser Ala Thr Phe Tyr His Pro Ile Arg
115 120 125

Asn Ile Asn Ile Ser Asn Pro Phe Leu Gly Ala Asp Ile Glu Phe Glu
130 135 140

Gly Pro Gly Val His Thr Glu Arg His Ile Asn Thr Glu Arg Leu Phe
145 150 155 160

His Ser Gly Asp His Asp Gly Tyr His Asn Trp Phe Phe Glu Thr Val
165 170 175

Leu Phe Ala Leu Glu Gln Glu Asp Tyr Cys Asp Phe Glu Ile Gln Phe
180 185 190

Glu Ile Ala His Asn Gly Ile His Thr Trp Ile Gly Gly Ser Ala Val
195 200 205

Tyr Gly Met Gly His Leu His Tyr Ala Ser Tyr Asp Pro Ile Phe Tyr
 210 215 220
 Ile His His Ser Gln Thr Asp Arg Ile Trp Ala Ile Trp Gln Glu Leu
 225 230 235 240
 Gln Lys Tyr Arg Gly Leu Ser Gly Ser Glu Ala Asn Cys Ala Ile Glu
 245 250 255
 His Met Arg Thr Pro Leu Lys Pro Phe Ser Phe Gly Pro Pro Tyr Asn
 260 265 270
 Leu Asn Ser His Thr Gln Glu Tyr Ser Lys Pro Glu Asp Thr Phe Asp
 275 280 285
 Tyr Lys Lys Phe Gly Tyr Arg Tyr Asp Ser Leu Glu Leu Glu Gly Arg
 290 295 300
 Ser Ile Ser Arg Ile Asp Glu Leu Ile Gln Gln Arg Gln Glu Lys Asp
 305 310 315 320
 Arg Thr Phe Ala Gly Phe Leu Leu Lys Gly Phe Gly Thr Ser Ala Ser
 325 330 335
 Val Ser Leu Gln Val Cys Arg Val Asp His Thr Cys Lys Asp Ala Gly
 340 345 350
 Tyr Phe Thr Ile Leu Gly Gly Ser Ala Glu Met Pro Trp Ala Phe Asp
 355 360 365
 Arg Leu Tyr Lys Tyr Asp Ile Thr Lys Thr Leu His Asp Met Asn Leu
 370 375 380
 Arg His Glu Asp Thr Phe Ser Ile Asp Val Thr Ile Thr Ser Tyr Asn
 385 390 395 400
 Gly Thr Val Leu Ser Gly Asp Leu Ile Gln Thr Pro Ser Ile Ile Phe
 405 410 415
 Val Pro Gly Arg
 420

<210> 30

<211> 417

<212> PRT

<213> *Haliotis tuberculata*

<400> 30

His Lys Leu Asn Ser Arg Lys His Thr Pro Asn Arg Val Arg His Glu
 1 5 10 15
 Leu Ser Ser Leu Ser Ser Arg Asp Ile Ala Ser Leu Lys Ala Ala Leu
 20 25 30
 Thr Ser Leu Gln His Asp Asn Gly Thr Asp Gly Tyr Gln Ala Ile Ala
 35 40 45

Ala	Phe	His	Gly	Val	Pro	Ala	Gln	Cys	His	Glu	Pro	Ser	Gly	Arg	Glu
50						55					60				
Ile	Ala	Cys	Cys	Ile	His	Gly	Met	Ala	Thr	Phe	Pro	His	Trp	His	Arg
65					70					75					80
Leu	Tyr	Thr	Leu	Gln	Leu	Glu	Gln	Ala	Leu	Arg	Arg	His	Gly	Ser	Ser
				85					90					95	
Val	Ala	Val	Pro	Tyr	Trp	Asp	Trp	Thr	Lys	Pro	Ile	Thr	Glu	Leu	Pro
			100					105					110		
His	Ile	Leu	Thr	Asp	Gly	Glu	Tyr	Tyr	Asp	Val	Trp	Gln	Asn	Ala	Val
		115					120					125			
Leu	Ala	Asn	Pro	Phe	Ala	Arg	Gly	Tyr	Val	Lys	Ile	Lys	Asp	Ala	Phe
	130					135					140				
Thr	Val	Arg	Asn	Val	Gln	Glu	Ser	Leu	Phe	Lys	Met	Ser	Ser	Phe	Gly
145					150					155					160
Lys	His	Ser	Leu	Leu	Phe	Asp	Gln	Ala	Leu	Leu	Ala	Leu	Glu	Gln	Thr
				165					170					175	
Asp	Tyr	Cys	Asp	Phe	Glu	Val	Gln	Phe	Glu	Val	Met	His	Asn	Thr	Ile
			180					185					190		
His	Tyr	Leu	Val	Gly	Gly	Arg	Gln	Thr	Tyr	Ala	Phe	Ser	Ser	Leu	Glu
		195					200					205			
Tyr	Ser	Ser	Tyr	Asp	Pro	Ile	Phe	Phe	Ile	His	His	Ser	Phe	Val	Asp
	210					215					220				
Lys	Ile	Trp	Ala	Val	Trp	Gln	Glu	Leu	Gln	Ser	Arg	Arg	His	Leu	Gln
225					230					235					240
Phe	Arg	Thr	Ala	Asp	Cys	Ala	Val	Gly	Leu	Met	Gly	Gln	Ala	Met	Arg
				245					250					255	
Pro	Phe	Asn	Lys	Asp	Phe	Asn	His	Asn	Ser	Phe	Thr	Lys	Lys	His	Ala
			260					265					270		
Val	Pro	Asn	Thr	Val	Phe	Asp	Tyr	Glu	Asp	Leu	Gly	Tyr	Asn	Tyr	Asp
		275					280					285			
Asn	Leu	Glu	Ile	Ser	Gly	Leu	Asn	Leu	Asn	Glu	Ile	Glu	Ala	Leu	Ile
	290					295					300				
Ala	Lys	Arg	Lys	Ser	His	Ala	Arg	Val	Phe	Ala	Gly	Phe	Leu	Leu	Phe
305					310					315					320
Gly	Leu	Gly	Thr	Ser	Ala	Asp	Ile	His	Leu	Glu	Ile	Cys	Lys	Thr	Ser
				325					330					335	
Glu	Asn	Cys	His	Asp	Ala	Gly	Val	Ile	Phe	Ile	Leu	Gly	Gly	Ser	Ala
			340					345					350		

Gln Val Leu Leu Ala Leu Glu Gln Thr Asp Phe Cys Lys Phe Glu Val
165 170 175

22


```
<400> 33
His Arg Leu Phe Val Thr Gln Val Glu Asp Ala Leu Ile Arg Arg Gly
  1          5          10          15
Ser Pro Ile Gly Val Pro Tyr Trp Asp Trp Thr Gln Pro Met Ala His
          20          25          30
Leu Pro Gly Leu Ala Asp Asn Ala Thr Tyr Arg Asp Pro Ile Ser Gly
          35          40          45
Asp Ser Arg His Asn Pro Phe His Asp Val Glu Val Ala Phe Glu Asn
          50          55          60
Gly Arg Thr Glu Arg His Pro Asp Ser Arg Leu Phe Glu Gln Pro Leu
  65          70          75          80
```

25

Phe Gly Lys His Thr Arg Leu Phe Asp Ser Ile Val Tyr Ala Phe Glu
85 90 95

Gln Glu Asp Phe Cys Asp Phe Glu Val Gln Phe Glu Met Thr His Asn
100 105 110

Asn Ile His Ala Trp Ile Gly Gly Gly Glu Lys Tyr Ser Met Ser Ser
115 120 125

Leu His Tyr Thr Ala Phe Asp Pro Ile Phe Tyr Leu Arg His Ser Asn
130 135 140

Thr Asp Arg Leu Trp Ala Ile Trp Gln Ala Leu Gln Ile Arg Arg Asn
145 150 155 160

Arg Pro Tyr Lys Ala His Cys Ala Trp Ser Glu Glu Arg Gln Pro Leu
165 170 175

Lys Pro Phe Ala Phe Ser Ser Pro Leu Asn Asn Asn Glu Lys Thr Tyr
180 185 190

Glu Asn Ser Val Pro Thr Asn Val Tyr Asp Tyr Glu Gly Val Leu Gly
195 200 205

Tyr Thr Tyr Asp Asp Leu Asn Phe Gly Gly Met Asp Leu Gly Gln Leu
210 215 220

Glu Glu Tyr Ile Gln Arg Gln Arg Gln Arg Asp Arg Thr Phe Ala Gly
225 230 235 240

Phe Phe Leu Ser His Ile Gly Thr Ser Ala Asn Val Glu Ile Ile Ile
245 250 255

Asp His Gly Thr Leu His Thr Ser Val Gly Thr Phe Ala Val Leu Gly
260 265 270

Gly Glu Lys Glu Met Lys Trp Gly Phe Asp Arg Leu Tyr Lys Tyr Glu
275 280 285

Ile Thr Asp Glu Leu Arg Gln Leu Asn Leu Arg Ala Asp Asp Val Phe
290 295 300

Ser Ile Ser Val Lys Val Thr Asp Val Asp Gly Ser Glu Leu Ser Ser
305 310 315 320

Glu Leu Ile Pro Ser Ala Ala Ile Ile Phe Glu Arg Ser His
325 330

<210> 34

<211> 417

<212> PRT

<213> Haliotis tuberculata

<400> 34

Ile Asp His Gln Asp Pro His His Asp Thr Ile Ile Arg Lys Asn Val
1 5 10 15

27

Gly Phe Leu Leu His Gly Ile Gln Gln Ser Ala Leu Val Lys Phe Phe
325 330 335

Val Cys Lys Ser Asp Asp Asp Cys Asp His Tyr Ala Gly Glu Phe Tyr
340 345 350

Ile Leu Gly Asp Glu Ala Glu Met Pro Trp Gly Tyr Asp Arg Leu Tyr
355 360 365

Lys Tyr Glu Ile Thr Glu Gln Leu Asn Ala Leu Asp Leu His Ile Gly
370 375 380

Asp Arg Phe Phe Ile Arg Tyr Glu Ala Phe Asp Leu His Gly Thr Ser
385 390 395 400

Leu Gly Ser Asn Ile Phe Pro Lys Pro Ser Val Ile His Asp Glu Gly
405 410 415

Ala

<210> 35
<211> 415
<212> PRT
<213> Haliotis tuberculata

<400> 35
Gly His His Gln Ala Asp Glu Tyr Asp Glu Val Val Thr Ala Ala Ser
1 5 10 15

His Ile Arg Lys Asn Leu Lys Asp Leu Ser Lys Gly Glu Val Glu Ser
20 25 30

Leu Arg Ser Ala Phe Leu Gln Leu Gln Asn Asp Gly Val Tyr Glu Asn
35 40 45

Ile Ala Lys Phe His Gly Lys Pro Gly Leu Cys Asp Asp Asn Gly Arg
50 55 60

Lys Val Ala Cys Cys Val His Gly Met Pro Thr Phe Pro Gln Trp His
65 70 75 80

Arg Leu Tyr Val Leu Gln Val Glu Asn Ala Leu Leu Glu Arg Gly Ser
85 90 95

Ala Val Ser Val Pro Tyr Trp Asp Trp Thr Glu Thr Phe Thr Glu Leu
100 105 110

Pro Ser Leu Ile Ala Glu Ala Thr Tyr Phe Asn Ser Arg Gln Gln Thr
115 120 125

Phe Asp Pro Asn Pro Phe Phe Arg Gly Lys Ile Ser Phe Glu Asn Ala
130 135 140

Val 145	Thr	Thr	Arg	Asp	Pro 150	Gln	Pro	Glu	Leu	Tyr 155	Val	Asn	Arg	Tyr	Tyr 160
Tyr	Gln	Asn	Val	Met 165	Leu	Val	Phe	Glu	Gln 170	Asp	Asn	Tyr	Cys	Asp 175	Phe
Glu	Ile	Gln	Phe 180	Glu	Met	Val	His	Asn 185	Val	Leu	His	Ala	Trp 190	Leu	Gly
Gly	Arg	Ala 195	Thr	Tyr	Ser	Ile	Ser 200	Ser	Leu	Asp	Tyr	Ser 205	Ala	Phe	Asp
Pro	Val 210	Phe	Phe	Leu	His	His 215	Ala	Asn	Thr	Asp	Arg 220	Leu	Trp	Ala	Ile
Trp 225	Gln	Glu	Leu	Gln	Arg 230	Tyr	Arg	Lys	Lys	Pro 235	Tyr	Asn	Glu	Ala	Asp 240
Cys	Ala	Ile	Asn 245	Leu	Met	Arg	Lys	Pro	Leu 250	His	Pro	Phe	Asp	Asn 255	Ser
Asp	Leu	Asn	His 260	Asp	Pro	Val	Thr	Phe 265	Lys	Tyr	Ser	Lys	Pro 270	Thr	Asp
Gly	Phe	Asp 275	Tyr	Gln	Asn	Asn	Phe 280	Gly	Tyr	Lys	Tyr	Asp 285	Asn	Leu	Glu
Phe 290	Asn	His	Phe	Ser	Ile	Pro 295	Arg	Leu	Glu	Glu	Ile 300	Ile	Arg	Ile	Arg
Gln 305	Arg	Gln	Asp	Arg	Val 310	Phe	Ala	Gly	Phe	Leu 315	Leu	His	Asn	Ile	Gly 320
Thr	Ser	Ala	Thr 325	Val	Glu	Ile	Phe	Val	Cys 330	Val	Pro	Thr	Thr	Ser 335	Gly
Glu	Gln	Asn	Cys 340	Glu	Asn	Lys	Ala	Gly 345	Thr	Phe	Ala	Val	Leu 350	Gly	Gly
Glu	Thr 355	Glu	Met	Ala	Phe	His	Phe 360	Asp	Arg	Leu	Tyr	Arg 365	Phe	Asp	Ile
Ser 370	Glu	Thr	Leu	Arg	Asp	Leu 375	Gly	Ile	Gln	Leu	Asp 380	Ser	His	Asp	Phe
Asp 385	Leu	Ser	Ile	Lys	Ile 390	Gln	Gly	Val	Asn	Gly 395	Ser	Tyr	Leu	Asp	Pro 400
His	Ile	Leu	Pro 405	Glu	Pro	Ser	Leu	Ile	Phe 410	Val	Pro	Gly	Ser	Ser 415	

<210> 36

<211> 418

<212> PRT

<213> *Haliotis tuberculata*

<400> 36

Ser	Phe	Leu	Arg	Pro	Asp	Gly	His	Ser	Asp	Asp	Ile	Leu	Val	Arg	Lys
1				5					10					15	
Glu	Val	Asn	Ser	Leu	Thr	Thr	Arg	Glu	Thr	Ala	Ser	Leu	Ile	His	Ala
			20					25					30		
Leu	Lys	Ser	Met	Gln	Glu	Asp	His	Ser	Pro	Asp	Gly	Phe	Gln	Ala	Ile
		35					40					45			
Ala	Ser	Phe	His	Ala	Leu	Pro	Pro	Leu	Cys	Pro	Ser	Pro	Ser	Ala	Ala
	50					55					60				
His	Arg	Tyr	Ala	Cys	Cys	Val	His	Gly	Met	Ala	Thr	Phe	Pro	Gln	Trp
65					70					75					80
His	Arg	Leu	Tyr	Thr	Val	Gln	Phe	Gln	Asp	Ala	Leu	Arg	Arg	His	Gly
				85					90					95	
Ala	Thr	Val	Gly	Val	Pro	Tyr	Trp	Asp	Trp	Leu	Arg	Pro	Gln	Ser	His
			100					105					110		
Leu	Pro	Glu	Leu	Val	Thr	Met	Glu	Thr	Tyr	His	Asp	Ile	Trp	Ser	Asn
		115					120					125			
Arg	Asp	Phe	Pro	Asn	Pro	Phe	Tyr	Gln	Ala	Asn	Ile	Glu	Phe	Glu	Gly
	130					135					140				
Glu	Asn	Ile	Thr	Thr	Glu	Arg	Glu	Val	Ile	Ala	Asp	Lys	Leu	Phe	Val
145					150					155					160
Lys	Gly	Gly	His	Val	Phe	Asp	Lys	Leu	Val	Leu	Gln	Thr	Ser	His	Pro
				165					170					175	
Ser	Ala	Glu	Gln	Glu	Asn	Tyr	Cys	Asp	Phe	Glu	Ile	Gln	Phe	Glu	Ile
			180					185					190		
Leu	His	Asn	Gly	Val	His	Thr	Trp	Val	Gly	Gly	Ser	Arg	Thr	Tyr	Ser
		195					200					205			
Ile	Gly	His	Leu	His	Tyr	Ala	Phe	Tyr	Asp	Pro	Leu	Phe	Tyr	Leu	His
	210					215					220				
His	Phe	Gln	Thr	Asp	Arg	Ile	Trp	Ala	Ile	Trp	Gln	Glu	Leu	Gln	Glu
225					230					235					240
Gln	Arg	Gly	Leu	Ser	Gly	Asp	Glu	Ala	His	Cys	Ala	Leu	Glu	Gln	Met
				245					250					255	
Arg	Glu	Pro	Leu	Lys	Pro	Phe	Ser	Phe	Gly	Ala	Pro	Tyr	Asn	Trp	Asn
			260					265					270		
Gln	Leu	Thr	Gln	Asp	Phe	Ser	Arg	Pro	Glu	Asp	Thr	Phe	Asp	Tyr	Arg
		275					280					285			
Lys	Phe	Gly	Tyr	Glu	Tyr	Asp	Asn	Leu	Glu	Phe	Leu	Gly	Met	Ser	Val
	290					295					300				

```

<400> 37
Arg Asp Ile Asn Thr Arg Ser Met Ser Pro Asn Arg Val Arg Arg Glu
  1              5              10              15

Leu Ser Asp Leu Ser Ala Arg Asp Leu Ser Ser Leu Lys Ser Ala Leu
      20              25              30

Arg Asp Leu Gln Glu Asp Asp Gly Pro Asn Gly Tyr Gln Ala Leu Ala
      35              40              45

Ala Phe His Gly Leu Pro Ala Gly Cys His Asp Ser Arg Gly Asn Glu
      50              55              60

Ile Ala Cys Cys Ile His Gly Met Pro Thr Phe Pro Gln Trp His Arg
  65              70              75              80

Leu Tyr Thr Leu Gln Leu Glu Met Ala Leu Arg Arg His Gly Ser Ser
      85              90              95

Val Ala Ile Pro Tyr Trp Asp Trp Thr Lys Pro Ile Ser Glu Leu Pro
      100              105              110

Ser Leu Phe Thr Ser Pro Glu Tyr Tyr Asp Pro Trp His Asp Ala Val
      115              120              125

```

Val	Asn	Asn	Pro	Phe	Ser	Lys	Gly	Phe	Val	Lys	Phe	Ala	Asn	Thr	Tyr
130						135					140				
Thr	Val	Arg	Asp	Pro	Gln	Glu	Met	Leu	Phe	Gln	Leu	Cys	Glu	His	Gly
145					150					155					160
Glu	Ser	Ile	Leu	Tyr	Glu	Gln	Thr	Leu	Leu	Ala	Leu	Glu	Gln	Thr	Asp
				165					170					175	
Tyr	Cys	Asp	Phe	Glu	Val	Gln	Phe	Glu	Val	Leu	His	Asn	Val	Ile	His
			180					185					190		
Tyr	Leu	Val	Gly	Gly	Arg	Gln	Thr	Tyr	Ala	Leu	Ser	Ser	Leu	His	Tyr
		195					200					205			
Ala	Ser	Tyr	Asp	Pro	Phe	Phe	Phe	Ile	His	His	Ser	Phe	Val	Asp	Lys
	210					215						220			
Met	Trp	Val	Val	Trp	Gln	Ala	Leu	Gln	Lys	Arg	Arg	Lys	Leu	Pro	Tyr
225					230					235					240
Lys	Arg	Ala	Asp	Cys	Ala	Val	Asn	Leu	Met	Thr	Lys	Pro	Met	Arg	Pro
				245					250					255	
Phe	Asp	Ser	Asp	Met	Asn	Gln	Asn	Pro	Phe	Thr	Lys	Met	His	Ala	Val
			260					265					270		
Pro	Asn	Thr	Leu	Tyr	Asp	Tyr	Glu	Thr	Leu	Tyr	Tyr	Ser	Tyr	Asp	Asn
		275					280					285			
Leu	Glu	Ile	Gly	Gly	Arg	Asn	Leu	Asp	Gln	Leu	Gln	Ala	Glu	Ile	Asp
	290					295					300				
Arg	Ser	Arg	Ser	His	Asp	Arg	Val	Phe	Ala	Gly	Phe	Leu	Leu	Arg	Gly
305					310					315					320
Ile	Gly	Thr	Ser	Ala	Asp	Val	Arg	Phe	Trp	Ile	Cys	Arg	Asn	Glu	Asn
				325					330					335	
Asp	Cys	His	Arg	Gly	Gly	Ile	Ile	Phe	Ile	Leu	Gly	Gly	Ala	Lys	Glu
			340					345					350		
Met	Pro	Trp	Ser	Phe	Asp	Arg	Asn	Phe	Lys	Phe	Asp	Ile	Thr	His	Val
		355					360					365			
Leu	Glu	Asn	Ala	Gly	Ile	Ser	Pro	Glu	Asp	Val	Phe	Asp	Ala	Glu	Glu
	370					375					380				
Pro	Phe	Tyr	Ile	Lys	Val	Glu	Ile	His	Ala	Val	Asn	Lys	Thr	Met	Ile
385					390					395					400
Pro	Ser	Ser	Val	Ile	Pro	Ala	Pro	Thr	Ile	Ile	Tyr	Ser	Pro	Gly	Glu
				405					410					415	

```
<210> 38
<211> 402
<212> PRT
<213> Haliotis tuberculata
```

<400> 38

Gly Arg Ala Ala Asp Ser Ala His Ser Ala Asn Ile Ala Gly Ser Gly
1 5 10 15

Val Arg Lys Asp Val Thr Thr Leu Thr Val Ser Glu Thr Glu Asn Leu
20 25 30

Arg Gln Ala Leu Gln Gly Val Ile Asp Asp Thr Gly Pro Asn Gly Tyr
35 40 45

Gln Ala Ile Ala Ser Phe His Gly Ser Pro Pro Met Cys Glu Met Asn
50 55 60

Gly Arg Lys Val Ala Cys Cys Ala His Gly Met Ala Ser Phe Pro His
65 70 75 80

Trp His Arg Leu Tyr Val Lys Gln Met Glu Asp Ala Leu Ala Asp His
85 90 95

Gly Ser His Ile Gly Ile Pro Tyr Trp Asp Trp Thr Thr Ala Phe Thr
100 105 110

Glu Leu Pro Ala Leu Val Thr Asp Ser Glu Asn Asn Pro Phe His Glu
115 120 125

Gly Arg Ile Asp His Leu Gly Val Thr Thr Ser Arg Ser Pro Arg Asp
130 135 140

Met Leu Phe Asn Asp Pro Glu Gln Gly Ser Glu Ser Phe Phe Tyr Arg
145 150 155 160

Gln Val Leu Leu Ala Leu Glu Gln Thr Asp Tyr Cys Gln Phe Glu Val
165 170 175

Gln Phe Glu Leu Thr His Asn Ala Ile His Ser Trp Thr Gly Gly Arg
180 185 190

Ser Pro Tyr Gly Met Ser Thr Leu Glu Phe Thr Ala Tyr Asp Pro Leu
195 200 205

Phe Trp Leu His His Ser Asn Thr Asp Arg Ile Trp Ala Val Trp Gln
210 215 220

Ala Leu Gln Lys Tyr Arg Gly Leu Pro Tyr Asn Glu Ala His Cys Glu
225 230 235 240

Ile Gln Val Leu Lys Gln Pro Leu Arg Pro Phe Asn Asp Asp Ile Asn
245 250 255

His Asn Pro Ile Thr Lys Thr Asn Ala Arg Pro Ile Asp Ser Phe Asp
260 265 270

33

Tyr Glu Arg Phe Asn Tyr Gln Tyr Asp Thr Leu Ser Phe His Gly Lys
 275 280 285

Ser Ile Pro Glu Leu Asn Asp Leu Leu Glu Glu Arg Lys Arg Glu Glu
 290 295 300

Arg Thr Phe Ala Ala Phe Leu Leu Arg Gly Ile Gly Cys Ser Ala Asp
 305 310 315 320

Val Val Phe Asp Ile Cys Arg Pro Asn Gly Asp Cys Val Phe Ala Gly
 325 330 335

Thr Phe Ala Val Leu Gly Gly Glu Leu Glu Met Pro Trp Ser Phe Asp
 340 345 350

Arg Leu Phe Arg Tyr Asp Ile Thr Arg Val Met Asn Gln Leu His Leu
 355 360 365

Gln Tyr Asp Ser Asp Phe Ser Phe Arg Val Lys Leu Val Ala Thr Asn
 370 375 380

Gly Thr Glu Leu Ser Ser Asp Leu Leu Lys Ser Pro Thr Ile Glu His
 385 390 395 400

Glu Leu

<210> 39
 <211> 515
 <212> PRT
 <213> *Haliotis tuberculata*

<400> 39
 Gly Ala His Arg Gly Pro Val Glu Glu Thr Glu Val Thr Arg Gln His
 1 5 10 15

Thr Asp Gly Asn Ala His Phe His Arg Lys Glu Val Asp Ser Leu Ser
 20 25 30

Leu Asp Glu Ala Asn Asn Leu Lys Asn Ala Leu Tyr Lys Leu Gln Asn
 35 40 45

Asp His Ser Leu Thr Gly Tyr Glu Ala Ile Ser Gly Tyr His Gly Tyr
 50 55 60

Pro Asn Leu Cys Pro Glu Glu Gly Asp Asp Lys Ile Pro Leu Leu Arg
 65 70 75 80

Pro Arg Met Gly Ile Phe Pro Tyr Trp His Arg Leu Leu Thr Ile Gln
 85 90 95

Leu Glu Arg Ala Leu Glu His Asn Gly Ala Leu Leu Gly Val Pro Tyr
 100 105 110

34

Trp	Asp	Trp	Asn	Lys	Asp	Leu	Ser	Ser	Leu	Pro	Ala	Phe	Phe	Ser	Asp	
		115					120					125				
Ser	Ser	Asn	Asn	Asn	Pro	Tyr	Phe	Lys	Tyr	His	Ile	Ala	Gly	Val	Gly	
	130					135					140					
His	Asp	Thr	Val	Arg	Glu	Pro	Thr	Ser	Leu	Ile	Tyr	Asn	Gln	Pro	Gln	
145					150					155					160	
Ile	His	Gly	Tyr	Asp	Tyr	Leu	Tyr	Tyr	Leu	Ala	Leu	Thr	Thr	Leu	Glu	
				165					170					175		
Glu	Asn	Asn	Tyr	Trp	Asp	Phe	Glu	Val	Gln	Tyr	Glu	Ile	Leu	His	Asn	
			180					185					190			
Ala	Val	His	Ser	Trp	Leu	Gly	Gly	Ser	Gln	Lys	Tyr	Ser	Met	Ser	Thr	
		195					200					205				
Leu	Glu	Tyr	Ser	Ala	Phe	Asp	Pro	Val	Phe	Met	Ile	Leu	His	Ser	Gly	
	210					215					220					
Leu	Asp	Arg	Leu	Trp	Ile	Ile	Trp	Gln	Glu	Leu	Gln	Lys	Ile	Arg	Arg	
225					230					235					240	
Lys	Pro	Tyr	Asn	Phe	Ala	Lys	Cys	Ala	Tyr	His	Met	Met	Glu	Glu	Pro	
				245					250					255		
Leu	Ala	Pro	Phe	Ser	Tyr	Pro	Ser	Ile	Asn	Gln	Asp	Glu	Phe	Thr	Arg	
			260					265					270			
Ala	Asn	Ser	Lys	Pro	Ser	Thr	Val	Phe	Asp	Ser	His	Lys	Phe	Gly	Tyr	
		275					280					285				
His	Tyr	Asp	Asn	Leu	Asn	Val	Arg	Gly	His	Ser	Ile	Gln	Glu	Leu	Asn	
	290					295					300					
Thr	Ile	Ile	Asn	Asp	Leu	Arg	Asn	Thr	Asp	Arg	Ile	Tyr	Ala	Gly	Phe	
305					310					315					320	
Val	Leu	Ser	Gly	Ile	Gly	Thr	Ser	Ala	Ser	Val	Lys	Ile	Tyr	Leu	Arg	
				325					330					335		
Thr	Asp	Asp	Asn	Asp	Glu	Glu	Val	Gly	Thr	Phe	Thr	Val	Leu	Gly	Gly	
			340					345					350			
Glu	Arg	Glu	Met	Pro	Trp	Ala	Tyr	Glu	Arg	Val	Phe	Lys	Tyr	Asp	Ile	
		355					360					365				
Thr	Glu	Val	Ala	Asp	Arg	Leu	Lys	Ile	Lys	Leu	Trp	Gly	His	Pro	Leu	
	370					375					380					
Thr	Ser	Gly	Thr	Gly	Asp	His	Ile	Leu	Thr	Asn	Gly	Ile	Gly	Gly	Lys	
385					390					395					400	
Gln	Glu	Pro	Thr	Gln	Ile	Leu	Ser	Ser	Ser	Thr	Asp	Leu	Pro	Ile	Met	
				405					410					415		

Gly 1	Leu	Pro	Tyr	Trp 5	Asp	Trp	Thr	Glu	Pro 10	Met	Thr	His	Ile	Pro 15	Gly
Leu	Ala	Gly	Asn 20	Lys	Thr	Tyr	Val	Asp 25	Ser	His	Gly	Ala	Ser 30	His	Thr
Asn	Pro	Phe 35	His	Ser	Ser	Val	Ile 40	Ala	Phe	Glu	Glu	Asn 45	Ala	Pro	His
Thr	Lys 50	Arg	Gln	Ile	Asp	Gln 55	Arg	Leu	Phe	Lys	Pro 60	Ala	Thr	Phe	Gly
His 65	His	Thr	Asp	Leu	Phe 70	Asn	Gln	Ile	Leu	Tyr 75	Ala	Phe	Glu	Gln	Glu 80
Asp	Tyr	Cys	Asp	Phe 85	Glu	Val	Gln	Phe	Glu 90	Ile	Thr	His	Asn	Thr 95	Ile
His	Ala	Trp	Thr 100	Gly	Gly	Ser	Glu	His 105	Phe	Ser	Met	Ser	Ser 110	Leu	His
Tyr	Thr	Ala 115	Phe	Asp	Pro	Leu	Phe 120	Tyr	Phe	His	His	Ser 125	Asn	Val	Asp
Arg	Leu 130	Trp	Ala	Val	Trp	Gln 135	Ala	Leu	Gln	Met	Arg 140	Arg	His	Lys	Pro
Tyr 145	Arg	Ala	His	Cys	Ala 150	Ile	Ser	Leu	Glu	His 155	Met	His	Leu	Lys	Pro 160

Val	Lys	Phe	Asp	Lys	Val	Pro	Arg	Ser	Arg	Leu	Ile	Arg	Lys	Asn	Val
1				5					10					15	
Asp	Arg	Leu	Ser	Pro	Glu	Glu	Met	Asn	Glu	Leu	Arg	Lys	Ala	Leu	Ala
			20					25					30		
Leu	Leu	Lys	Glu	Asp	Lys	Ser	Ala	Gly	Gly	Phe	Gln	Gln	Leu	Gly	Ala
		35					40					45			
Phe	His	Gly	Glu	Pro	Lys	Trp	Cys	Pro	Ser	Pro	Glu	Ala	Ser	Lys	Lys
	50					55					60				
Phe	Ala	Cys	Cys	Val	His	Gly	Met	Ser	Val	Phe	Pro	His	Trp	His	Arg
65					70					75					80

Trp Gln Asp Leu Gln Arg Phe Arg Lys Arg Pro Tyr Arg Glu Ala Asn
225 230 235 240

```

<400> 43
Asp Ser Ala His Thr Asp Asp Gly His Thr Glu Pro Val Met Ile Arg
  1          5          10          15
Lys Asp Ile Thr Gln Leu Asp Lys Arg Gln Gln Leu Ser Leu Val Lys
          20          25          30
Ala Leu Glu Ser Met Lys Ala Asp His Ser Ser Asp Gly Phe Gln Ala
          35          40          45
Ile Ala Ser Phe His Ala Leu Pro Pro Leu Cys Pro Ser Pro Ala Ala
  50          55          60
Ser Lys Arg Phe Ala Cys Cys Val His Gly Met Pro Thr Phe Pro Gln
  65          70          75          80

```

Ser Tyr Ile Gly Thr Ser Ala Ser Val Asp Ile Phe Ile Asn Arg Glu
225 230 235 240

<400> 45															
Asp	Ala	Lys	Asp	Phe	Gly	His	Ser	Arg	Lys	Ile	Arg	Lys	Ala	Val	Asp
1				5					10					15	
Ser	Leu	Thr	Val	Glu	Glu	Gln	Thr	Ser	Leu	Arg	Arg	Ala	Met	Ala	Asp
			20					25					30		
Leu	Gln	Asp	Asp	Lys	Thr	Ser	Gly	Gly	Phe	Gln	Gln	Ile	Ala	Ala	Phe
		35					40					45			
His	Gly	Glu	Pro	Lys	Trp	Cys	Pro	Ser	Pro	Glu	Ala	Glu	Lys	Lys	Phe
	50					55					60				
Ala	Cys	Cys	Val	His	Gly	Met	Ala	Val	Phe	Pro	His	Trp	His	Arg	Leu
65					70					75					80
Leu	Thr	Val	Gln	Gly	Glu	Asn	Ala	Leu	Arg	Lys	His	Gly	Phe	Thr	Gly
				85					90					95	
Gly	Leu	Pro	Tyr	Trp	Asp	Trp	Thr	Arg	Ser	Met	Ser	Ala	Leu	Pro	His
			100					105					110		
Phe	Val	Ala	Asp	Pro	Thr	Tyr	Asn	Asp	Ala	Ile	Ser	Ser	Gln	Glu	Glu
		115					120					125			
Asp	Asn	Pro	Trp	His	His	Gly	His	Ile	Asp	Ser	Val	Gly	His	Asp	Thr
	130					135					140				
Thr	Arg	Asp	Val	Arg	Asp	Asp	Leu	Tyr	Gln	Ser	Pro	Gly	Phe	Gly	His
145					150					155					160
Tyr	Thr	Asp	Ile	Ala	Gln	Gln	Val	Leu	Leu	Ala	Phe	Glu	Gln	Asp	Ser
				165					170					175	

43

Ile Arg Ser Ala Phe Leu Gln Ile Gln Lys Glu Gly Ile Tyr Glu Asn
 35 40 45
 Ile Ala Lys Phe His Gly Lys Pro Gly Leu Cys Glu His Asp Gly His
 50 55 60
 Pro Val Ala Cys Cys Val His Gly Met Pro Thr Phe Pro His Trp His
 65 70 75 80
 Arg Leu Tyr Val Leu Gln Val Glu Asn Ala Leu Leu Glu Arg Gly Ser
 85 90 95
 Ala Val Ala Val Pro Tyr Trp Asp Trp Thr Leu Pro Arg
 100 105

<210> 47
 <211> 329
 <212> PRT
 <213> Megathura crenulata

<400> 47
 Met Ala Val Phe Pro His Trp His Arg Leu Phe Val Lys Gln Met Glu
 1 5 10 15
 Asp Ala Leu Ala Ala His Gly Ala His Ile Gly Ile Pro Tyr Trp Asp
 20 25 30
 Trp Thr Ser Ala Phe Ser His Leu Pro Ala Leu Val Thr Asp His Glu
 35 40 45
 Asn Asn Pro Phe His His Gly His Ile Gly His Leu Asn Val Asp Thr
 50 55 60
 Ser Arg Ser Pro Arg Asp Met Leu Phe Asn Asp Pro Glu Gln Gly Ser
 65 70 75 80
 Glu Ser Phe Phe Tyr Arg Gln Val Leu Leu Thr Leu Glu Gln Thr Asp
 85 90 95
 Phe Cys Gln Phe Glu Val Gln Phe Glu Leu Thr His Asn Ala Ile His
 100 105 110
 Ser Trp Thr Gly Gly His Thr Pro Tyr Gly Met Ser Ser Leu Glu Tyr
 115 120 125
 Thr Ala Tyr Asp Pro Leu Phe Tyr Leu His His Ser Asn Thr Asp Arg
 130 135 140
 Ile Trp Ala Ile Trp Gln Ala Leu Gln Lys Tyr Arg Gly Leu Pro Tyr
 145 150 155 160
 Asn Ala Ala His Cys Asp Ile Gln Val Leu Lys Gln Pro Leu Lys Pro
 165 170 175

[illegible]

<400> 51
gttacagagg cccagctcc ctctcggat gctcacctcg ccgtcaggaa ggatatcaac 60
catctgacac gcgaggaggt gtacgagctg cgcagagcta tggagagatt ccaggccgac 120
acatccgttg atgggtacca ggctacggtt gagtatcacg gcttacctgc tcgatqtcca 180

46

ttccccgagg	ccacaaatag	gttcgcctgt	tgcattccacg	gcattggcgac	attccctcat	240
tggcacagac	tggtcgtcac	ccaggtggaa	gatgctctga	tcaggcgagg	atcgccata	300
gggggtccct	actgggactg	gactcagcct	atggcgcatc	tcccaggact	tgcagacaac	360
gccacctata	gagatcccat	cagcggggac	agcagacaca	accccttcca	cgatgttgaa	420
gttgcccttg	aaaatggacg	tacagaacgt	caccagata	gtagattgtt	tgaacaacct	480
ttatttggca	aacatacgcg	tctcttcgac	agtatagtct	atgcttttga	gcaggaggac	540
ttctgcgatt	ttgaagttca	atctgagatg	accataata	atattcacgc	ctggattggt	600
ggcggcgaga	agtattccat	gtcttctcta	cactacacag	ccttcgaccc	tatcttctac	660
cttcgctact	ccaacactga	cgggctctgg	gcaatttggc	aagcgttgca	gatacgaaga	720
aacaggcctt	acaaggctca	ttgtgcttgg	tctgaggaa	gccagcctct	caaacccttc	780
gccttcagtt	ccccactgaa	caacaacgaa	aaaacctacg	aaaactcggg	gcccaccaac	840
gtttacgact	acgaaggagt	ccttggtctat	acttatgatg	acctcaactt	cgggggcatg	900
gacctgggtc	agcttgagga	atacatccag	aggcagagac	agagagacag	gacctttgct	960
ggtttctttc	tgtcacatat	tggtacatca	gcgaatgttg	aatcattat	agaccatggg	1020
actcttcata	cctccgtggg	cacgtttgct	gttcttggcg	gagagaagga	gatgaaatgg	1080
ggatttgacc	gtttgtacaa	atatgagatt	acagatgaac	tgaggcaact	taatctccgt	1140
gctgatgatg	ttttcagcat	ctctgttaaa	gtaactgatg	ttgatggcag	tgagctgtcc	1200
tctgaactca	tcccatctgc	tgctatcatc	ttcgaacgaa	gccata		1246

<210> 52

<211> 1242

<212> DNA

<213> *Haliotis tuberculata*

<400> 52

gtcaccatca	ggctgacgag	tacgacgaag	ttgtaactgc	tgcaagccac	atcagaaaga	60
atttaaaaga	tctgtcaaag	ggagaagtag	agagcctaag	gtctgccttc	ctgcaacttc	120
agaacgacgg	agtctatgag	aatattgcca	agttccacgg	caagcctggg	ttgtgtgatg	180
ataacggtcg	caagggttgc	tggtgtgtcc	atggaatgcc	caccttcccc	cagtggcaca	240
ggctctatgt	cctccagggtg	gagaatgctt	tgctggagag	aggatctgcc	gtctctgtgc	300
catactggga	ctggactgaa	acattttacag	agctgccatc	tttgattgct	gaggctacct	360
atltcaatlc	cgttcaacaa	acgtttgacc	ctaatecttt	cttcagaggt	aaaatcagtt	420
ttgagaatgc	tggtacaaca	cgtgatcccc	agcctgagct	gtacgttaac	aggtactact	480
accaaaacgt	catgttggtt	tttgaacagg	acaactactg	cgacttcgag	atacagtttg	540
agatggttca	caatgttctc	catgcttggc	ttgggtggaag	agctacttat	tctatttctt	600
ctcttgatta	ttctgcattc	gacctgtgtg	ttttccttca	ccatgcgaac	acagatagat	660
tgtggggccat	ctggcaggag	ctgcagaggt	acaggaagaa	gccatacaat	gaagcggatt	720
gtgccattaa	cctaattgcgc	aaacctctac	atcccttcga	caacagtgat	ctcaatcatg	780
atcctgtaac	ctttaaatac	tcaaaaccca	ctgatggctt	tgactaccag	aacaactttg	840
gatacaagta	tgacaacctt	gagttcaate	atltcagtat	tcccaggctt	gaagaaatca	900
ttcgtattag	acaacgtcaa	gatcgtgtgt	ttgcaggatt	cctccttcac	aacattggga	960
catccgcaac	tgttgagata	ttcgtctgtg	tccctaccac	cagcgggtgag	caaaactgtg	1020
aaaacaaagc	cggaaacattt	gccgtactcg	gaggagaaac	agagatggcg	tttcattttg	1080
acagactcta	caggtttgac	atcagtgaac	cactgagggg	cctcggcata	cagctggaca	1140
gccatgactt	tgacctcagc	atcaagatlc	aaggagtaaa	tggaatcctac	cttgatccac	1200
acatcctgcc	agagccatcc	ttgatttttg	tgcttggttc	aa		1242

<210> 53

<211> 1257

<212> DNA

<213> *Haliotis tuberculata*

<400> 53

gttcttttcc	gcgtcctgat	gggcattcag	atgacatcct	tgtgagaaaa	gaagtgaaca	60
gcctgacaac	caggagagact	gcattctctga	tccatgctct	gaaaagtatg	cagggaagacc	120
attcacctga	cgggttccaa	gccattgcct	ctttccatgc	tctgccacca	ctctgccctt	180
caccatctgc	agctcacctg	tatgcttgc	gtgtccacgg	catggctaca	tttccccagt	240

47

ggcacagatt	gtacactgta	cagttccagg	atgcaactgag	gagacatgga	gctacggtag	300
gtgtaccgta	ttgggattgg	ctgcgaccgc	agtctcacct	accagagctt	gtcaccatgg	360
agacatacca	tgatatttgg	agtaacagag	atttcccca	tcctttctac	caagccaata	420
ttgagtttga	aggagaaaac	attacaacag	agagagaagt	cattgcagac	aaactttttg	480
tcaaaggtgg	acacgttttt	gataaaactgg	ttcttcaaac	aagccatcct	agcgctgagc	540
aggaaaacta	ctgtgacttt	gagattcagt	ttgaaattct	tcacaacggc	gttcacacgt	600
gggtcggagg	cagtcgtacc	tactctatcg	gacatcttca	ttacgcattc	taagaccctc	660
ttttctacct	tcaccatttc	cagacagacc	gtatttgggc	aatctggcaa	gaactccagg	720
aacagagagg	gctctcgggt	gatgaggctc	actgtgctct	cgagcaaattg	agagaacat	780
tgaagccttt	cagcttcggc	gctccttata	actggaatca	gctcacacag	gattttctccc	840
gacccgagga	caccttcgac	tacaggaagt	ttggttatga	atatgacaat	ttagaattcc	900
tgggaatgtc	agttgctgaa	ctggatcaat	acattattga	acatcaagaa	aatgatagag	960
tattcgtctg	gttctctgtt	agtggattcg	gaggttccgc	atcagttaat	ttccagggtt	1020
gtagagctga	ttccacatgt	caggatgctg	ggtacttcac	cgttcttggg	ggcagtgtct	1080
agatggcgtg	ggcatttgac	aggctttaca	aatatgacat	tactgaaact	ctggagaaaa	1140
tgcaccttcg	atatgatgat	gacttcacaa	tctctgtcag	tctgaccgcc	aacaacggaa	1200
ctgtcctgag	cagcagtcta	atcccaacac	cgagtgtcat	attccagcgg	ggacatc	1257

<210> 54

<211> 1257

<212> DNA

<213> Megathura crenulata

<400> 54

attctgcccc	cacagatgat	ggacacactg	aaccagtgat	gattcgcaaa	gatatacacac	60
aattggacaa	gcgtcaacaa	ctgtcactgg	tgaagccct	cgagtccatg	aaagccgacc	120
attcatctga	tgggttccag	gcaatcgctt	ccttccatgc	tcttctctct	ctttgtccat	180
caccagctgc	ttcaaagagg	tttgcggtgt	gcgtccatgg	catggcaacg	ttcccacaat	240
ggcacgcgtc	gtacacagtc	caattccaag	attctctcag	aaaacatggg	gcagtcgttg	300
gacttccgta	ctgggaactg	accctacctc	gttctgaatt	accagagctc	ctgaccgtct	360
caactattca	tgaccgggag	acaggcgag	atataccaaa	tccatttatt	ggttctaaaa	420
tagagtttga	aggagaaaac	gtacatacta	aaagagatat	caatagggat	cgtctcttcc	480
agggatcaac	aaaaacacat	cataactggg	ttattgagca	agcactgctt	gctcttgaa	540
aaaccaacta	ctgcgacttc	gaggttcagt	ttgaaattat	gcataatggg	gttcatacct	600
gggttggagg	caaggagccc	tatggaattg	gccatctgca	ttatgcttcc	tatgatccac	660
ttttctacat	ccatcactcc	caaactgatc	gtatttgggc	tatatggcaa	tcgttgcagc	720
gtttcagagg	actttctgga	tctgaggcta	actgtgctgt	aaatctcatg	aaaactcctc	780
tgaagccttt	cagctttgga	gcaccatata	atcttaatga	tcacacgcac	gattttctca	840
agcctgaaga	tacattcgac	taccaaaagt	ttggatacat	atatgacact	ctggaatttg	900
cagggtggtc	aattcgtggc	attgaccata	ttgtccgtaa	caggcaggaa	cattcaaggg	960
tctttgcggg	attcttgctt	gaaggatttg	gcacctctgc	cactgtcgat	ttccagggtc	1020
gtcgcacagc	gggagactgt	gaagatgcag	ggtacttcac	cgtgttgagg	gggtgaaaa	1080
aaatgccttg	ggcctttgat	cggctttaca	agtacgacat	aacagaaacc	ttagacaaga	1140
tgaaccttcg	acatgacgaa	atcttccaga	ttgaagtaac	cattacatcc	taagatggaa	1200
ctgtactcga	tagtggcctt	attccacac	cgtcaatcat	ctatgatect	gtctatc	1257

<210> 55

<211> 1254

<212> DNA

<213> Megathura crenulata

<400> 55

atgatattag	ttcgcaccac	ctgtcgtctca	acaagggttcg	tcatgatctg	agtacactga	60
gtgagcgaga	tattggaagc	cttaaatatg	ctttgagcag	cttgcaggca	gatacctcag	120
cagatgggtt	tgctgccatt	gcatecttcc	atgggtctgcc	tgccaaatgt	aatgacagcc	180
acaataacga	ggtggcatgc	tgtatccatg	gaatgcctac	attccccac	tggcacagac	240
tctacacctt	ccaatttgag	caagctctaa	gaagacatgg	ctctagtgtg	gcagttacct	300

48

```

actgggactg gacaaagcca atacataata ttccacatct gtccacagac aaagaatact 360
acgatgtctg gagaaataaa gtaatgccaa atccatttgc ccgaggggat gtccctcac 420
acgatacata cacggtaaga gacgtccaag aaggcctgtt ccacctgaca tcaacgggtg 480
aacactcagc gcttctgaat caagctcttt tggcgctgga acagcacgac tactgcgatt 540
ttgcagtcca gtttgaagtc atgcacaaca caatccatta cctagtggga ggacctcaag 600
tctattcttt gtcacccctt cattatgctt catatgatcc gatcttcttc atacaccact 660
cctttgtaga caagggttgg gctgtctggc aggctcttca agaaaagaga ggccctccat 720
cagaccgtgc tgactgcgct gttagtctga tgactcagaa catgaggcct ttccattacg 780
aaattaacca taaccagttc accaagaaac atgcagttcc aaatgatgtt tccaagtacg 840
aactcctggg ttacagatac gacaatctgg aaatcgggtg catgaatttg catgaaattg 900
aaaaggaaat caaagacaaa cagcaccatg tgagagtgtt tgcaggggtc ctccctcacg 960
gaattagaac ctgagctgat gtccaattcc agatttgtaa aacatcagaa gattgtcacc 1020
atggaggcca aatcttcgtt cttgggggga ctaaagagat ggccctgggt tataaccgtt 1080
tattcaagta cgatattacc catgctcttc atgacgcaca catcactcca gaagacgtat 1140
tccatccctc tgaaccattc ttcacaaagg tgtcagtgac agccgtcaac ggaacagttc 1200
ttccggcttc aatcctgcat gcaccaacca ttatctatga acctggtctc ggtg 1254

```

<210> 56

<211> 509

<212> DNA

<213> Megathura crenulata

<400> 56

```

accatcacga agatcatcat tcttcttcta tggctggaca tgggtgtcaga aaggaaatca 60
acacacttac cactgcagag gtggacaatc tcaaagatgc catgagagcc gtcattggcag 120
accacgggtc aaatggatac caggctatag cagcggtcca tggaaaccca ccaatgtgcc 180
ctatgccaga tggaaagaat tactcgtgtt gtacacatgg catggctact tccccctact 240
ggcacagact gtacacaaaa cagatggaag atgccttgac cgcccatggt gccagagtcg 300
gccttcctta ctgggacggg acaactgect ttacagcttt gccactttt gtccagatg 360
aagaggacaa tcctttccat catggtcaca tagactattt gggagtggat acaactcgg 420
cgccccgaga caagttgttc aatgatccag agcgaggatc agaatcgttc ttctacaggc 480
aggttctctt ggctttggag cagacagat 509

```

<210> 57

<211> 943

<212> DNA

<213> Megathura crenulata

<400> 57

```

ggcctgccct actgggattg gaccatgccaa atgagtcatt tgccagaact ggctacaagt 60
gagacctacc tcgatccagt tactggggaa actaaaaaca accctttcca tcacgcccaa 120
gtggcgtttg aaaatgggtg aacaagcagg aatcctgatg ccaaactttt tatgaaacca 180
acttacggag accacactta cctcttcgac agcatgatct acgcatttga gcaggaagac 240
ttctgcgact ttgaagtcca atatgagctc acgcataatg caatacatgc atgggttgg 300
ggcagtga aaatattcaat gtcttctctt cactacactg cttttgatcc tatattttac 360
ctccatcact caaatgttga tegtctctgg gccatttggc aagctcttca aatcaggaga 420
ggcaagtctt acaaggccca ctgcgcctcg tctcaagaaa gagaaccatt aaagcctttt 480
gcattcagtt cccactgaa caacaacgag aaaacgtacc acaactctgt cccactaac 540
gtttatgact atgtgggagt tttgcactat cgatatgatg accttcagtt tggcggtatg 600
accatgtcag aacttgagga atatattcac aagcagacac aacatgatag aacctttgca 660
ggattcttcc ttccatatat tggaaacatca gcaagcgtag atatcttcat caatcgagaa 720
ggtcatgata aatacaaaagt ggggaagtttt gtagtacttg gtggatccaa agaaatgaaa 780
tggggctttg atagaatgta caagtatgag atcactgagg ctctgaagac gctgaatgtt 840
gcagtggatg atgggttcag cattactgtt gagatcaccg atgttgatgg atctcccca 900
tctgcagatc tcattccacc tcctgctata atctttgaac gtg 943

```

gttcacacca	ggctgatgaa	tatcgtgagg	cagtaacaag	cgctagecac	ataagaaaaa	60
atatccggga	cctctcagag	ggagaaattg	agagcatcag	atctgctttc	ctccaaattc	120
aaaaagaggg	tatatatgaa	aacattgcaa	agttccatgg	aaaaccagga	ctttgtgaac	180
atgatggaca	tcttgttgct	tgttgtgtcc	atggcatgcc	cacctttccc	cactggcaca	240
gactgtacgt	tcttcaggtg	gagaatgcgc	tcttagaacg	agggtctgca	gttgctgttc	300
cttactggga	ctggaccgag	aaagctgact	ctctgccatc	attaatcaat	gatgcaactt	360
atttcaattc	acgatcccag	acctttgatc	ctaatccttt	cttcagggga	catattgcct	420
tcgagaatgc	tgtgacgtcc	agagatcctc	agccagaact	atggggacaat	aaggacttct	480
acgagaatgt	catgctggct	cttgagcaag	acaacttctg	tgactttgag	attcagcttg	540
agctgataca	caacgccctt	cattctagac	ttggaggaag	ggctaataac	tccctttcgt	600
ctcttgatta	taccgcattt	gatectgtat	ttttccttca	ccatgcaaac	gttgacagaa	660
tctggggccat	ctggcaggac	ttgcagagat	atagaaagaa	accatacaat	gaggctgact	720
gcgcagtcaa	cgagatgcgt	aaacctcttc	aaccatttaa	taaccagaa	cttaacagtg	780
attccatgac	gcttaaacac	aacctccac	aagacagttt	tgattatcaa	aaccgcttca	840
ggtaccaata	tgaataacct	caatttaacc	acttcagcat	acaaaagcta	gaccaaacta	900
ttcaggetag	ataacaacac	gcagagttt	ttgctggctt	tattcttcac	aacattggga	960
catctgctgt	tgtagatatt	tatatttgcg	tggaacaagg	aggagaaaca	aactgcaaga	1020
caaaggcggg	ttccttcacg	attctggggg	gagaacaaga	aatgccattc	cactttgacc	1080
gcttgtaaca	atttgacata	acgtctgtct	tgcataaact	tggtgttccc	ttggacggac	1140
atggattcga	catcaaagtt	gacgtcagag	ctgtcaatgg	atcgcatctt	gatcaacaca	1200
tcctcaacga	accgagtctg	ctttttgttc	ctgggtgaacg	taagaatata	tattatg	1257

<210> 60
 <211> 1239
 <212> DNA
 <213> Megathura crenulata

<400> 60
 atgggctttc acaacataat cttgtgcgaa aagaagtaag ctctcttaca acactggaga 60
 aacatttttt gaggaagact ctcaagaaca tgcaagcaga tgattctcca gacggatata 120
 aagctattgc ttctttccac gctttgcctc ctctttgtcc aagtcacatc gctgcacata 180
 gacacgcttg ttgcctccat ggtatggcta ccttccctca gtggcacaga ctctacacag 240
 ttcagttcga agattctttg aaacgacatg gttctattgt cggacttcca tattgggatt 300
 ggctgaaacc gcagtctgca ctccctgatt tgggtgacaca ggagacatac gagcacctgt 360
 tttcacacaa aaccttccca aatccgttcc tcaaggcaaa tatagaattt gagggagagg 420
 gagtaacaac agagagggat gttgatgctg aacacctctt tgcaaaagga aatctggttt 480
 acaacaactg gttttgcaat caggcactat atgcactaga acaagaaaat tactgtgact 540
 ttgaaatata gttcgaaatt ttgcataatg gaattcattc atggggttga ggatcaaaga 600
 cccattcaat aggtcatctt cattacgcac catacgatcc actgttctat atccaccatt 660
 cgcagacaga tgcattttgg gctatctggc aagctctcca ggagcacaga ggtctttcag 720
 ggaaggaagc acactgcgcc ctggagcaaa tgaaagaccc tctcaaacct ttcagctttg 780
 gaagtcccta taatttgaac aaacgcactc aagagttctc caagcctgaa gacacatttg 840
 attatcaccc attcgggtat gagtatgatt cctcgaatt tgttggcatg tctgtttcaa 900
 gtttacataa ctatataaaa caacaacagg aagctgatag agtcttcgca ggattccttc 960
 ttaaaggatt tggacaatca gcatccgtat cgtttgatat ctgcagacca gaccagagtt 1020
 gccaaagaagc tggatacttc tcagttctcg gtggaagttc agaaatgccg tggcagtttg 1080
 acaggcttta caagtacgac attacaaaaa cgttgaaaga catgaaactg cgatacgatg 1140
 acacatttac catcaagggt cacataaagg atatagctgg agctgagttg gacagcgatc 1200
 tgattccaac tccttctgtt ctcttgaag aaggaaagc 1239

<210> 61
 <211> 1251
 <212> DNA
 <213> Haliotis tuberculata

<400> 61
 atgggatcaa tgtacgtcac gttgggtcgta atcggattcg tatggaacta tctgaactca 60
 ccgagagaga tctcgccagc ctgaaatctg caatgaggtc tctacaagct gacgatgggg 120
 tgaacggtta tcaagccatt gcatcattcc acggtctccc ggcttcttgt catgatgatg 180
 agggacatga gattgcctgt tgtatccacg gaatgccagt attcccacac tggcacaggc 240
 tttacaccct gcaaatggac atggctctgt tatctcacgg atctgctgtt gctattccat 300
 actgggactg gaccaaacct atcagcaaac tgctgatct ctccaccagc cctgaatatt 360
 acgatccttg gagggatgca gttgtcaata atccatttgc taaaggctac attaaatccg 420
 aggacgtta cacggttagg gatcctcagg acattttgta ccacttgcag gacgaaacgg 480
 gaacatctgt tttgtagat caaactcttt tagccttaga gcagacagat ttctgtgatt 540
 ttgaggttca atttgaggtc gtccataatg ctattcacta ctgtgtgggt ggtcgacaag 600
 tttatgctct ttcttctcaa cactatgctt catatgacct agccttcttt attcatcact 660
 cctttgttga caaaatatgg gcagtctggc aagctctgca aaagaagaga aagcgctcct 720
 atcataaagc ggatttgtct cttaacatga tgaccaaac aatgcgacca tttgcacacg 780
 atttcaatca caatggattc acaaaaatgc acgcagtccc caacactcta tttgactttc 840
 aggacctttt ctacacgtat gacaacttag aaattgctgg catgaatgtt aatcagtttg 900
 aagcggaaat caaccggcga aaaagccaaa caagagtctt tgccgggttc cttctacatg 960
 gcattggaag atcagctgat gtacgatttt ggatttgcaa gacagctgac gactgccacg 1020
 catctggcat gatctttatc ttaggaggtt ctaaagagat gcaactgggc tatgacagga 1080
 actttaataa cgacatcacc caagctttga aggtcagtc cataccacct gaagatgtgt 1140
 ttgacactga tgctcctttc ttcattaaag tggaggtcca tgggtgtaaac aagactgctc 1200
 tccatcttc agctatccca gcacctacta taatctactc agctggtgaa g 1251

Leu	Thr	His	Leu	Pro	Ser	Leu	Val	Thr	Glu	Pro	Ile	Tyr	Ile	Asp	Ser
		115					120					125			
Lys	Gly	Gly	Lys	Ala	Gln	Thr	Asn	Tyr	Trp	Tyr	Arg	Gly	Glu	Ile	Ala
	130					135					140				
Phe	Ile	Asn	Lys	Lys	Thr	Ala	Arg	Ala	Val	Asp	Asp	Arg	Leu	Phe	Glu
145					150					155					160
Lys	Val	Glu	Pro	Gly	His	Tyr	Thr	His	Leu	Met	Glu	Thr	Val	Leu	Asp
				165					170					175	
Ala	Leu	Glu	Gln	Asp	Glu	Phe	Cys	Lys	Phe	Glu	Ile	Gln	Phe	Glu	Leu
			180					185					190		
Ala	His	Asn	Ala	Ile	His	Tyr	Leu	Val	Gly	Gly	Lys	Phe	Glu	Tyr	Ser
		195					200					205			
Met	Ser	Asn	Leu	Glu	Tyr	Thr	Ser	Tyr	Asp	Pro	Ile	Phe	Phe	Leu	His
	210					215					220				
His	Ser	Asn	Val	Asp	Arg	Leu	Phe	Ala	Ile	Trp	Gln	Arg	Leu	Gln	Glu
225					230					235					240
Leu	Arg	Gly	Lys	Asn	Pro	Asn	Ala	Met	Asp	Cys	Ala	His	Glu	Leu	Ala
				245					250					255	
His	Gln	Gln	Leu	Gln	Pro	Phe	Asn	Arg	Asp	Ser	Asn	Pro	Val	Gln	Leu
			260					265					270		
Thr	Lys	Asp	His	Ser	Thr	Pro	Ala	Asp	Leu	Phe	Asp	Tyr	Lys	Gln	Leu
		275					280					285			
Gly	Tyr	Ser	Tyr	Asp	Ser	Leu	Asn	Leu	Asn	Gly	Met	Thr	Pro	Glu	Gln
	290					295					300				
Leu	Lys	Thr	Glu	Leu	Asp	Glu	Arg	His	Ser	Lys	Glu	Arg	Ala	Phe	Ala
305					310					315					320
Ser	Phe	Arg	Leu	Ser	Gly	Phe	Gly	Gly	Ser	Ala	Asn	Val	Val	Val	Tyr
				325					330					335	
Ala	Cys	Val	Pro	Asp	Asp	Asp	Pro	Arg	Ser	Asp	Asp	Tyr	Cys	Glu	Lys
			340					345					350		
Ala	Gly	Asp	Phe	Phe	Ile	Leu	Gly	Gly	Gln	Ser	Glu	Met	Pro	Trp	Arg
		355					360					365			
Phe	Tyr	Arg	Pro	Phe	Phe	Tyr	Asp	Val	Thr	Glu	Ala	Val	His	His	Leu
	370					375					380				
Gly	Val	Pro	Leu	Ser	Gly	His	Tyr	Tyr	Val	Lys	Thr	Glu	Leu	Phe	Ser
385					390					395					400
Val	Asn	Gly	Thr	Ala	Leu	Ser	Pro	Asp	Leu	Leu	Pro	Gln	Pro	Thr	Val
				405					410					415	

<400> 64																
Val 1	His	Arg	Gly	Gly 5	Asn	His	Glu	Asp	Glu 10	His	His	Asp	Asp	Arg 15	Leu	
Ala	Asp	Val	Leu 20	Ile	Arg	Lys	Glu	Val 25	Asp	Phe	Leu	Ser	Leu 30	Gln	Glu	
Ala	Asn	Ala 35	Ile	Lys	Asp	Ala	Leu 40	Tyr	Lys	Leu	Gln	Asn 45	Asp	Asp	Ser	
Lys	Gly 50	Gly	Phe	Glu	Ala	Ile 55	Ala	Gly	Tyr	His	Gly 60	Tyr	Pro	Asn	Met	
Cys 65	Pro	Glu	Arg	Gly	Thr 70	Asp	Lys	Tyr	Pro	Cys 75	Cys	Val	His	Gly	Met 80	
Pro	Val	Phe	Pro	His 85	Trp	His	Arg	Leu	His 90	Thr	Ile	Gln	Met	Glu 95	Arg	
Ala	Leu	Lys	Asn 100	His	Gly	Ser	Pro	Met 105	Gly	Ile	Pro	Tyr	Trp 110	Asp	Trp	
Thr	Lys 115	Lys	Met	Ser	Ser	Leu	Pro 120	Ser	Phe	Phe	Gly	Asp 125	Ser	Ser	Asn	
Asn 130	Asn	Pro	Phe	Tyr	Lys	Tyr 135	Tyr	Ile	Arg	Gly	Val 140	Gln	His	Glu	Thr	
Thr 145	Arg	Asp	Val	Asn	Gln 150	Arg	Leu	Phe	Asn	Gln 155	Thr	Lys	Phe	Gly	Glu 160	
Phe	Asp	Tyr	Leu	Tyr 165	Tyr	Leu	Thr	Leu	Gln 170	Val	Leu	Glu	Glu	Asn 175	Ser	
Tyr	Cys	Asp	Phe 180	Glu	Val	Gln	Tyr	Glu 185	Ile	Leu	His	Asn	Ala 190	Val	His	
Ser	Trp	Leu 195	Gly	Gly	Thr	Gly	Gln 200	Tyr	Ser	Met	Ser	Thr 205	Leu	Glu	His	
Ser	Ala 210	Phe	Asp	Pro	Val	Phe 215	Met	Ile	His	His	Ser 220	Ser	Leu	Asp	Arg	
Ile 225	Trp	Ile	Leu	Trp	Gln 230	Lys	Leu	Gln	Lys	Ile 235	Arg	Met	Lys	Pro	Tyr 240	

54

Ala Met Glu Arg Phe Gln Ala Asp Thr Ser Val Asp Gly Tyr Gln Ala
35 40 45

Pro Val Phe Phe Leu His His Ala Asn Thr Asp Arg Leu Trp Ala Ile
 210 215 220
 Trp Gln Glu Leu Gln Arg Tyr Arg Lys Lys Pro Tyr Asn Glu Ala Asp
 225 230 235 240
 Cys Ala Ile Asn Leu Met Arg Lys Pro Leu His Pro Phe Asp Asn Ser
 245 250 255
 Asp Leu Asn His Asp Pro Val Thr Phe Lys Tyr Ser Lys Pro Thr Asp
 260 265 270
 Gly Phe Asp Tyr Gln Asn Asn Phe Gly Tyr Lys Tyr Asp Asn Leu Glu
 275 280 285
 Phe Asn His Phe Ser Ile Pro Arg Leu Glu Glu Ile Ile Arg Ile Arg
 290 295 300
 Gln Arg Gln Asp Arg Val Phe Ala Gly Phe Leu Leu His Asn Ile Gly
 305 310 315 320
 Thr Ser Ala Thr Val Glu Ile Phe Val Cys Val Pro Thr Thr Ser Gly
 325 330 335
 Glu Gln Asn Cys Glu Asn Lys Ala Gly Thr Phe Ala Val Leu Gly Gly
 340 345 350
 Glu Thr Glu Met Ala Phe His Phe Asp Arg Leu Tyr Arg Phe Asp Ile
 355 360 365
 Ser Glu Thr Leu Arg Asp Leu Gly Ile Gln Leu Asp Ser His Asp Phe
 370 375 380
 Asp Leu Ser Ile Lys Ile Gln Gly Val Asn Gly Ser Tyr Leu Asp Pro
 385 390 395 400
 His Ile Leu Pro Glu Pro Ser Leu Ile Phe Val Pro Gly Ser
 405 410

<210> 68

<211> 419

<212> PRT

<213> *Haliotis tuberculata*

<400> 68

Ser Ser Phe Leu Arg Pro Asp Gly His Ser Asp Asp Ile Leu Val Arg
 1 5 10 15

Lys Glu Val Asn Ser Leu Thr Thr Arg Glu Thr Ala Ser Leu Ile His
 20 25 30

Ala Leu Lys Ser Met Gln Glu Asp His Ser Pro Asp Gly Phe Gln Ala
 35 40 45

59

Ile	Ala	Ser	Phe	His	Ala	Leu	Pro	Pro	Leu	Cys	Pro	Ser	Pro	Ser	Ala
50						55					60				
Ala	His	Arg	Tyr	Ala	Cys	Cys	Val	His	Gly	Met	Ala	Thr	Phe	Pro	Gln
65					70					75					80
Trp	His	Arg	Leu	Tyr	Thr	Val	Gln	Phe	Gln	Asp	Ala	Leu	Arg	Arg	His
				85					90					95	
Gly	Ala	Thr	Val	Gly	Val	Pro	Tyr	Trp	Asp	Trp	Leu	Arg	Pro	Gln	Ser
			100					105					110		
His	Leu	Pro	Glu	Leu	Val	Thr	Met	Glu	Thr	Tyr	His	Asp	Ile	Trp	Ser
		115					120					125			
Asn	Arg	Asp	Phe	Pro	Asn	Pro	Phe	Tyr	Gln	Ala	Asn	Ile	Glu	Phe	Glu
	130					135					140				
Gly	Glu	Asn	Ile	Thr	Thr	Glu	Arg	Glu	Val	Ile	Ala	Asp	Lys	Leu	Phe
145					150					155					160
Val	Lys	Gly	Gly	His	Val	Phe	Asp	Lys	Leu	Val	Leu	Gln	Thr	Ser	His
				165					170					175	
Pro	Ser	Ala	Glu	Gln	Glu	Asn	Tyr	Cys	Asp	Phe	Glu	Ile	Gln	Phe	Glu
			180					185					190		
Ile	Leu	His	Asn	Gly	Val	His	Thr	Trp	Val	Gly	Gly	Ser	Arg	Thr	Tyr
		195					200					205			
Ser	Ile	Gly	His	Leu	His	Tyr	Ala	Phe	Tyr	Asp	Pro	Leu	Phe	Tyr	Leu
	210					215					220				
His	His	Phe	Gln	Thr	Asp	Arg	Ile	Trp	Ala	Ile	Trp	Gln	Glu	Leu	Gln
225					230					235					240
Glu	Gln	Arg	Gly	Leu	Ser	Gly	Asp	Glu	Ala	His	Cys	Ala	Leu	Glu	Gln
				245					250					255	
Met	Arg	Glu	Pro	Leu	Lys	Pro	Phe	Ser	Phe	Gly	Ala	Pro	Tyr	Asn	Trp
			260					265					270		
Asn	Gln	Leu	Thr	Gln	Asp	Phe	Ser	Arg	Pro	Glu	Asp	Thr	Phe	Asp	Tyr
		275					280					285			
Arg	Lys	Phe	Gly	Tyr	Glu	Tyr	Asp	Asn	Leu	Glu	Phe	Leu	Gly	Met	Ser
	290					295					300				
Val	Ala	Glu	Leu	Asp	Gln	Tyr	Ile	Ile	Glu	His	Gln	Glu	Asn	Asp	Arg
305					310					315					320
Val	Phe	Ala	Gly	Phe	Leu	Leu	Ser	Gly	Phe	Gly	Gly	Ser	Ala	Ser	Val
				325					330					335	
Asn	Phe	Gln	Val	Cys	Arg	Ala	Asp	Ser	Thr	Cys	Gln	Asp	Ala	Gly	Tyr
			340					345					350		

60

Phe Thr Val Leu Gly Gly Ser Ala Glu Met Ala Trp Ala Phe Asp Arg
355 360 365

Leu Tyr Lys Tyr Asp Ile Thr Glu Thr Leu Glu Lys Met His Leu Arg
370 375 380

Tyr Asp Asp Asp Phe Thr Ile Ser Val Ser Leu Thr Ala Asn Asn Gly
385 390 395 400

Thr Val Leu Ser Ser Ser Leu Ile Pro Thr Pro Ser Val Ile Phe Gln
405 410 415

Arg Gly His

<210> 69

<211> 378

<212> PRT

<213> Megathura crenulata

<400> 69

Arg Tyr Gln Ala Thr Ala Glu Tyr His Gly Leu Pro Ala Arg Cys Pro
1 5 10 15

Arg Pro Asp Ala Lys Asp Arg Tyr Ala Cys Cys Val His Gly Met Pro
20 25 30

Ile Phe Pro His Trp His Arg Leu Phe Val Thr Gln Val Glu Asp Ala
35 40 45

Leu Val Gly Arg Gly Ala Thr Ile Gly Ile Pro Tyr Trp Asp Trp Thr
50 55 60

Glu Pro Met Thr His Ile Pro Gly Leu Ala Gly Asn Lys Thr Tyr Val
65 70 75 80

Asp Ser His Gly Ala Ser His Thr Asn Pro Phe His Ser Ser Val Ile
85 90 95

Ala Phe Glu Glu Asn Ala Pro His Thr Lys Arg Gln Ile Asp Gln Arg
100 105 110

Leu Phe Lys Pro Ala Thr Phe Gly His His Thr Asp Leu Phe Asn Gln
115 120 125

Ile Leu Tyr Ala Phe Glu Gln Glu Asp Tyr Cys Asp Phe Glu Val Gln
130 135 140

Phe Glu Ile Thr His Asn Thr Ile His Ala Trp Thr Gly Gly Ser Glu
145 150 155 160

His Phe Ser Met Ser Ser Leu His Tyr Thr Ala Phe Asp Pro Leu Phe
165 170 175

Tyr Phe His His Ser Asn Val Asp Arg Leu Trp Ala Val Trp Gln Ala
180 185 190

61

Leu Gln Met Arg Arg His Lys Pro Tyr Arg Ala His Cys Ala Ile Ser
195 200 205

Leu Glu His Met His Leu Lys Pro Phe Ala Phe Ser Ser Pro Leu Asn
210 215 220

Asn Asn Glu Lys Thr His Ala Asn Ala Met Pro Asn Lys Ile Tyr Asp
225 230 235 240

Tyr Glu Asn Val Leu His Tyr Thr Tyr Glu Asp Leu Thr Phe Gly Gly
245 250 255

Ile Ser Leu Glu Asn Ile Glu Lys Met Ile His Glu Asn Gln Gln Glu
260 265 270

Asp Arg Ile Tyr Ala Gly Phe Leu Leu Ala Gly Ile Arg Thr Ser Ala
275 280 285

Asn Val Asp Ile Phe Ile Lys Thr Thr Asp Ser Val Gln His Lys Ala
290 295 300

Gly Thr Phe Ala Val Leu Gly Gly Ser Lys Glu Met Lys Trp Gly Phe
305 310 315 320

Asp Arg Val Phe Lys Phe Asp Ile Thr His Val Leu Lys Asp Leu Asp
325 330 335

Leu Thr Ala Asp Gly Asp Phe Glu Val Thr Val Asp Ile Thr Glu Val
340 345 350

Asp Gly Thr Lys Leu Ala Ser Ser Leu Ile Pro His Ala Ser Val Ile
355 360 365

Arg Glu His Ala Arg Gly Lys Leu Asn Arg
370 375

<210> 70
<211> 419
<212> PRT
<213> Megathura crenulata

<400> 70
Asp Ser Ala His Thr Asp Asp Gly His Thr Glu Pro Val Met Ile Arg
1 5 10 15

Lys Asp Ile Thr Gln Leu Asp Lys Arg Gln Gln Leu Ser Leu Val Lys
20 25 30

Ala Leu Glu Ser Met Lys Ala Asp His Ser Ser Asp Gly Phe Gln Ala
35 40 45

Ile Ala Ser Phe His Ala Leu Pro Pro Leu Cys Pro Ser Pro Ala Ala
50 55 60

62

Ser	Lys	Arg	Phe	Ala	Cys	Cys	Val	His	Gly	Met	Ala	Thr	Phe	Pro	Gln	65	70	75	80
Trp	His	Arg	Leu	Tyr	Thr	Val	Gln	Phe	Gln	Asp	Ser	Leu	Arg	Lys	His	85	90	95	
Gly	Ala	Val	Val	Gly	Leu	Pro	Tyr	Trp	Asp	Trp	Thr	Leu	Pro	Arg	Ser	100	105	110	
Glu	Leu	Pro	Glu	Leu	Leu	Thr	Val	Ser	Thr	Ile	His	Asp	Pro	Glu	Thr	115	120	125	
Gly	Arg	Asp	Ile	Pro	Asn	Pro	Phe	Ile	Gly	Ser	Lys	Ile	Glu	Phe	Glu	130	135	140	
Gly	Glu	Asn	Val	His	Thr	Lys	Arg	Asp	Ile	Asn	Arg	Asp	Arg	Leu	Phe	145	150	155	160
Gln	Gly	Ser	Thr	Lys	Thr	His	His	Asn	Trp	Phe	Ile	Glu	Gln	Ala	Leu	165	170	175	
Leu	Ala	Leu	Glu	Gln	Thr	Asn	Tyr	Cys	Asp	Phe	Glu	Val	Gln	Phe	Glu	180	185	190	
Ile	Met	His	Asn	Gly	Val	His	Thr	Trp	Val	Gly	Gly	Lys	Glu	Pro	Tyr	195	200	205	
Gly	Ile	Gly	His	Leu	His	Tyr	Ala	Ser	Tyr	Asp	Pro	Leu	Phe	Tyr	Ile	210	215	220	
His	His	Ser	Gln	Thr	Asp	Arg	Ile	Trp	Ala	Ile	Trp	Gln	Ser	Leu	Gln	225	230	235	240
Arg	Phe	Arg	Gly	Leu	Ser	Gly	Ser	Glu	Ala	Asn	Cys	Ala	Val	Asn	Leu	245	250	255	
Met	Lys	Thr	Pro	Leu	Lys	Pro	Phe	Ser	Phe	Gly	Ala	Pro	Tyr	Asn	Leu	260	265	270	
Asn	Asp	His	Thr	His	Asp	Phe	Ser	Lys	Pro	Glu	Asp	Thr	Phe	Asp	Tyr	275	280	285	
Gln	Lys	Phe	Gly	Tyr	Ile	Tyr	Asp	Thr	Leu	Glu	Phe	Ala	Gly	Trp	Ser	290	295	300	
Ile	Arg	Gly	Ile	Asp	His	Ile	Val	Arg	Asn	Arg	Gln	Glu	His	Ser	Arg	305	310	315	320
Val	Phe	Ala	Gly	Phe	Leu	Leu	Glu	Gly	Phe	Gly	Thr	Ser	Ala	Thr	Val	325	330	335	
Asp	Phe	Gln	Val	Cys	Arg	Thr	Ala	Gly	Asp	Cys	Glu	Asp	Ala	Gly	Tyr	340	345	350	
Phe	Thr	Val	Leu	Gly	Gly	Glu	Lys	Glu	Met	Pro	Trp	Ala	Phe	Asp	Arg	355	360	365	

63

<400> 74																
Gly 1	Leu	Pro	Tyr	Trp 5	Asp	Trp	Thr	Met	Pro 10	Met	Ser	His	Leu	Pro 15	Glu	
Leu	Ala	Thr	Ser 20	Glu	Thr	Tyr	Leu	Asp 25	Pro	Val	Thr	Gly	Glu 30	Thr	Lys	
Asn	Asn	Pro 35	Phe	His	His	Ala	Gln 40	Val	Ala	Phe	Glu	Asn 45	Gly	Val	Thr	
Ser	Arg 50	Asn	Pro	Asp	Ala	Lys 55	Leu	Phe	Met	Lys	Pro 60	Thr	Tyr	Gly	Asp	
His 65	Thr	Tyr	Leu	Phe	Asp 70	Ser	Met	Ile	Tyr	Ala 75	Phe	Glu	Gln	Glu 80	Asp	
Phe	Cys	Asp	Phe	Glu 85	Val	Gln	Tyr	Glu	Leu 90	Thr	His	Asn	Ala	Ile 95	His	
Ala	Trp	Val	Gly 100	Gly	Ser	Glu	Lys	Tyr	Ser	Met	Ser	Ser	Leu 110	His	Tyr	
Thr	Ala	Phe 115	Asp	Pro	Ile	Phe	Tyr	Leu	His	His	Ser	Asn 125	Val	Asp	Arg	
Leu	Trp 130	Ala	Ile	Trp	Gln	Ala 135	Leu	Gln	Ile	Arg	Arg	Gly	Lys	Ser	Tyr	
Lys 145	Ala	His	Cys	Ala	Ser 150	Ser	Gln	Glu	Arg	Glu 155	Pro	Leu	Lys	Pro	Phe 160	
Ala	Phe	Ser	Ser	Pro 165	Leu	Asn	Asn	Asn	Glu 170	Lys	Thr	Tyr	His	Asn 175	Ser	
Val	Pro	Thr	Asn 180	Val	Tyr	Asp	Tyr	Val	Gly	Val	Leu	His	Tyr 190	Arg	Tyr	

67

Asp Asp Leu Gln Phe Gly Gly Met Thr Met Ser Glu Leu Glu Glu Tyr
195 200 205

Ile His Lys Gln Thr Gln His Asp Arg Thr Phe Ala Gly Phe Phe Leu
210 215 220

Ser Tyr Ile Gly Thr Ser Ala Ser Val Asp Ile Phe Ile Asn Arg Glu
225 230 235 240

Gly His Asp Lys Tyr Lys Val Gly Ser Phe Val Val Leu Gly Gly Ser
245 250 255

Lys Glu Met Lys Trp Gly Phe Asp Arg Met Tyr Lys Tyr Glu Ile Thr
260 265 270

Glu Ala Leu Lys Thr Leu Asn Val Ala Val Asp Asp Gly Phe Ser Ile
275 280 285

Thr Val Glu Ile Thr Asp Val Asp Gly Ser Pro Pro Ser Ala Asp Leu
290 295 300

Ile Pro Pro Pro Ala Ile Ile Phe Glu Arg
305 310

<210> 75

<211> 416

<212> PRT

<213> Megathura crenulata

<400> 75

Ala Asp Ala Lys Asp Phe Gly His Ser Arg Lys Ile Arg Lys Ala Val
1 5 10 15

Asp Ser Leu Thr Val Glu Glu Gln Thr Ser Leu Arg Arg Ala Met Ala
20 25 30

Asp Leu Gln Asp Asp Lys Thr Ser Gly Gly Phe Gln Gln Ile Ala Ala
35 40 45

Phe His Gly Glu Pro Lys Trp Cys Pro Ser Pro Glu Ala Glu Lys Lys
50 55 60

Phe Ala Cys Cys Val His Gly Met Ala Val Phe Pro His Trp His Arg
65 70 75 80

Leu Leu Thr Val Gln Gly Glu Asn Ala Leu Arg Lys His Gly Phe Thr
85 90 95

Gly Gly Leu Pro Tyr Trp Asp Trp Thr Arg Ser Met Ser Ala Leu Pro
100 105 110

His Phe Val Ala Asp Pro Thr Tyr Asn Asp Ala Ile Ser Ser Gln Glu
115 120 125

Glu Asp Asn Pro Trp His His Gly His Ile Asp Ser Val Gly His Asp
130 135 140

<213> Megathura crenulata

<400> 76

Gly	Ser	His	Gln	Ala	Asp	Glu	Tyr	Arg	Glu	Ala	Val	Thr	Ser	Ala	Ser	1	5	10	15
His	Ile	Arg	Lys	Asn	Ile	Arg	Asp	Leu	Ser	Glu	Gly	Glu	Ile	Glu	Ser	20	25	30	
Ile	Arg	Ser	Ala	Phe	Leu	Gln	Ile	Gln	Lys	Glu	Gly	Ile	Tyr	Glu	Asn	35	40	45	
Ile	Ala	Lys	Phe	His	Gly	Lys	Pro	Gly	Leu	Cys	Glu	His	Asp	Gly	His	50	55	60	
Pro	Val	Ala	Cys	Cys	Val	His	Gly	Met	Pro	Thr	Phe	Pro	His	Trp	His	65	70	75	80
Arg	Leu	Tyr	Val	Leu	Gln	Val	Glu	Asn	Ala	Leu	Leu	Glu	Arg	Gly	Ser	85	90	95	
Ala	Val	Ala	Val	Pro	Tyr	Trp	Asp	Trp	Thr	Glu	Lys	Ala	Asp	Ser	Leu	100	105	110	
Pro	Ser	Leu	Ile	Asn	Asp	Ala	Thr	Tyr	Phe	Asn	Ser	Arg	Ser	Gln	Thr	115	120	125	
Phe	Asp	Pro	Asn	Pro	Phe	Phe	Arg	Gly	His	Ile	Ala	Phe	Glu	Asn	Ala	130	135	140	
Val	Thr	Ser	Arg	Asp	Pro	Gln	Pro	Glu	Leu	Trp	Asp	Asn	Lys	Asp	Phe	145	150	155	160
Tyr	Glu	Asn	Val	Met	Leu	Ala	Leu	Glu	Gln	Asp	Asn	Phe	Cys	Asp	Phe	165	170	175	
Glu	Ile	Gln	Leu	Glu	Leu	Ile	His	Asn	Ala	Leu	His	Ser	Arg	Leu	Gly	180	185	190	
Gly	Arg	Ala	Lys	Tyr	Ser	Leu	Ser	Ser	Leu	Asp	Tyr	Thr	Ala	Phe	Asp	195	200	205	
Pro	Val	Phe	Phe	Leu	His	His	Ala	Asn	Val	Asp	Arg	Ile	Trp	Ala	Ile	210	215	220	
Trp	Gln	Asp	Leu	Gln	Arg	Tyr	Arg	Lys	Lys	Pro	Tyr	Asn	Glu	Ala	Asp	225	230	235	240
Cys	Ala	Val	Asn	Glu	Met	Arg	Lys	Pro	Leu	Gln	Pro	Phe	Asn	Asn	Pro	245	250	255	
Glu	Leu	Asn	Ser	Asp	Ser	Met	Thr	Leu	Lys	His	Asn	Leu	Pro	Gln	Asp	260	265	270	
Ser	Phe	Asp	Tyr	Gln	Asn	Arg	Phe	Arg	Tyr	Gln	Tyr	Asp	Asn	Leu	Gln	275	280	285	

70


```
<210> 78
<211> 417
<212> PRT
<213> Megathura crenulata
```

<400> 78

His Gly Ile Asn Val Arg His Val Gly Arg Asn Arg Ile Arg Met Glu
1 5 10 15

Leu Ser Glu Leu Thr Glu Arg Asp Leu Ala Ser Leu Lys Ser Ala Met
20 25 30

Arg Ser Leu Gln Ala Asp Asp Gly Val Asn Gly Tyr Gln Ala Ile Ala
35 40 45

Ser Phe His Gly Leu Pro Ala Ser Cys His Asp Asp Glu Gly His Glu
50 55 60

Ile Ala Cys Cys Ile His Gly Met Pro Val Phe Pro His Trp His Arg
65 70 75 80

Leu Tyr Thr Leu Gln Met Asp Met Ala Leu Leu Ser His Gly Ser Ala
85 90 95

Val	Ala	Ile	Pro	Tyr	Trp	Asp	Trp	Thr	Lys	Pro	Ile	Ser	Lys	Leu	Pro
			100					105					110		

Asp Leu Phe Thr Ser Pro Glu Tyr Tyr Asp Pro Trp Arg Asp Ala Val
115 120 125

Val Asn Asn Pro Phe Ala Lys Gly Tyr Ile Lys Ser Glu Asp Ala Tyr
130 135 140

Thr Val Arg Asp Pro Gln Asp Ile Leu Tyr His Leu Gln Asp Glu Thr
145 150 155 160

Gly Thr Ser Val Leu Leu Asp Gln Thr Leu Leu Ala Leu Glu Gln Thr
165 170 175

Asp Phe Cys Asp Phe Glu Val Gln Phe Glu Val Val His Asn Ala Ile
180 185 190

His Tyr Leu Val Gly Gly Arg Gln Val Tyr Ala Leu Ser Ser Gln His
195 200 205

Tyr Ala Ser Tyr Asp Pro Ala Phe Phe Ile His His Ser Phe Val Asp
210 215 220

Lys Ile Trp Ala Val Trp Gln Ala Leu Gln Lys Lys Arg Lys Arg Pro
225 230 235 240

Tyr His Lys Ala Asp Cys Ala Leu Asn Met Met Thr Lys Pro Met Arg
245 250 255

Pro Phe Ala His Asp Phe Asn His Asn Gly Phe Thr Lys Met His Ala
260 265 270

Asp	His	Ile	Ala	Gly	Ser	Gly	Val	Arg	Lys	Asp	Val	Thr	Ser	Leu	Thr
1				5					10					15	
Ala	Ser	Glu	Ile	Glu	Asn	Leu	Arg	His	Ala	Leu	Gln	Ser	Val	Met	Asp
			20					25					30		
Asp	Asp	Gly	Pro	Asn	Gly	Phe	Gln	Ala	Ile	Ala	Ala	Tyr	His	Gly	Ser
		35					40					45			
Pro	Pro	Met	Cys	His	Met	Xaa	Asp	Gly	Arg	Asp	Val	Ala	Cys	Cys	Thr
	50					55					60				
His	Gly	Met	Ala	Ser	Phe	Pro	His	Trp	His	Arg	Leu	Phe	Val	Lys	Gln
65					70					75					80
Met	Glu	Asp	Ala	Leu	Ala	Ala	His	Gly	Ala	His	Ile	Gly	Ile	Pro	Tyr
				85					90					95	
Trp	Asp	Trp	Thr	Ser	Ala	Phe	Ser	His	Leu	Pro	Ala	Leu	Val	Thr	Asp
			100					105					110		

<210> 80
 <211> 1266
 <212> DNA
 <213> *Haliotis tuberculata*

<400> 80
 cttgttcagt ttctactcgt cgcccttgtg gtgggggctg gagcagacaa cgtcgtcaga 60
 aaggacgtga gtcacctcac ggatgacgag gtgcaagctc tccacggcgc cctccatgac 120
 gtcactgcat ctacagggcc tctgagtttc gaagacataa catcttacca tgccgcacca 180
 gcgctcgtgtg actacaaggg acggaagatc gcctgctgtg tccacgggtat gccagtttc 240
 cccttctggc acagggcata tgtcgtccaa gccgagcggg cactgttgtc caaacggaag 300
 actgtcggaa tgcccttactg ggactggacg caaacgctga ctacttacc atctcttgtg 360
 actgaaccca totacattga cagtaaagggt ggaaaggctc aaaccaacta ctggtaccgc 420
 ggcgagatag cgttcatcaa taagaagact gcgcgagctg tagatgatcg cctattcgag 480
 aagggtggagc ctggtcacta cacacatctt atggagactg tctcgcacgc tctcgaacag 540
 gacgaattct gtaaatttga aatccagttc gagttggctc ataatgctat ccattacttg 600
 gttggcggtg aatttgaata ttcaatgtca aacttggaa acacctccta cgaccccatc 660
 ttcttctctc accactccaa cgttgaccgc ctcttcgcca tctggcagcg tcttcaggaa 720
 ctgcgaggaa agaatcccaa tgcaatggac tgtgcacatg aactcgctca ccagcaactc 780
 caacccttca acagggacag caatccagtc cagctcacia aggaccactc gacacctgct 840
 gacctctttg attacaaaca acttgatgac agctacgaca gcttaaacct gaatggaatg 900
 acgccagaac agctgaaaac agaactagac gaacgccact ccaaagaacg tgcgtttgca 960
 agcttccgac tcagtggctt tgggggttct gccaacgttg ttgtctatgc atgtgtccct 1020
 gatgatgac cagcagtgta tgactactgc gagaaagcag gcgacttctt cattcttggg 1080
 ggtcaaagcg aaatgccgtg gagattctac agacccttct tctatgatgt aactgaagcg 1140
 gtacatcacc ttggagtccc gctaagtggc cactactatg tgaaaacaga actcttcagc 1200
 gtgaatggca cagcactttc acctgatctt ctctctcaac caactgttgc ctaccgacct 1260
 gggaaa 1266

<210> 81
 <211> 1257
 <212> DNA
 <213> *Haliotis tuberculata*

<400> 81
 ggtcaccttg acccacctgt gcatcatcgc cacgatgacg atcttattgt tcgaaaaaat 60
 atagatcatt tgactcgtga agaggaatac gagctaagga tggctctgga gagattccag 120
 gccgacacat ccgttgatgg gtaccaggct acagtagagt accatggcct tctgtcgt 180
 tgccacgac cagatgcaaa agtcaggctt gcctgttgta tgcattggat gccatccttc 240
 cctcactggc accggctggt cggtaccag gtggaagatg ctcttgtagc gcgtggatcg 300
 cctatcggtg ttcttatttg ggactggaca aaacctatga ctacacctcc agacttggca 360
 tcaaatgaga cgtacgtaga cccgtatgga catacacatc ataattcatt ctcaatgca 420
 aatatactt ttgaggaggg acaccatcac acgagcagga tgatagattc gaaactgttt 480
 gccccagtcg cttttgggga gcattcccat ctgtttgatg gaatcctgta cgcatttgag 540
 cagggaagatt tctgcgactt tgagattcag tttgagttag tccataattc tattcatgag 600
 tggataggcg gttccgaaga ttactccatg gccaccctgc attacacagc ctttgacccc 660
 attttctacc ttcatcttca caatgtcgat cgtctatggg caatctggca agctcttcaa 720
 atcaggagac acaagccata tcaagcccac tgtgcacagt ctgtggaaca gttgccaatg 780
 aagccatttg ctttcccatc acctcttaac aacaacgaga agacacatag tcattcagtc 840
 ccgactgaca tttatgacta cgagggaagt ctgcactaca gctacgatga tctaactgtt 900
 ggtgggatga accttgaaga aatagaagaa gctatacatc tcagacaaca gcatgaacga 960
 gtcttcgagg gatttctcct tgcgtggaata ggaacatctg cacttggtga cattttcata 1020
 aataaaccgg ggaaccaacc actcaaagct ggagatattg ccattcttgg tgggtgccaag 1080
 gaaatgcctt gggcgtttga ccgcttgat aaggtcgaaa taactgactc attgaagaca 1140
 ctttctctcg atgtcgatgg agattatgaa gtcactttta aaattcatga tatgcacgga 1200
 aacgctcttg atacggacct gattccacac gcagcagttg tttctgagcc agctcac 1257

<210> 82
<211> 1242
<212> DNA
<213> *Haliotis tuberculata*

<400> 82
cctacctttg aggatgaaaa gcacagctta cgaatcagaa aaaatgtcga cagcttgact 60
cctgaagaaa caaatgaact gcgtaaagcc ctggagcttc ttgaaaatga tcatactgca 120
ggtaggattca atcagcttgg cgccctccat ggagagccta aatgggtgcc taatcctgaa 180
gcggagcaca aggttgcatt ctgtgttcat ggcatggctg ttttccctca ttggcacagg 240
cttcttgctc tccaggcgga gaatgctctt agaaagcatg ggtacagtgg tgctctacca 300
tactgggatt ggactcgccc cctttcccaa ctccctgac tggttagtca tgagcagtat 360
acagatcctt ccgaccatca cgtgaagcat aaccctgtgt tcaatggcca catcgatata 420
gtaaatcagg ataccaccag aagcgtacgg gaggatcttt atcaacaacc tgaatttgga 480
catttcacgg atattgtctc acaagtcctc ttagcattag aacaagatga cttctgttcg 540
tttgaagtgc agtatgagat ttcccataat tttatccatg cacttgtagg aggaaccgac 600
gcttatggca tggcatcgct gagatataca gcatacgatc caatcttttt cttgcatcat 660
tcaaacaccg acaggatctg ggctatattg caatccctgc aaaaatacag aggcaaaccg 720
tacaacactg ccaactgcgc catagaatct atgagaaggc ccctgcaacc atttggacta 780
agcagtgcc aataacctga cagaatcacc agagagcatg ctatcccgtt tgatgtcttc 840
aactatagag ataaccttca ttacgtatat gataccctgg aatttaattg tttgtcgatt 900
tcacaacttg atagagagct ggaaaaaatc aagagtcacg aaagagtatt tgcctggattc 960
ttgctgtcgg ggattaaaaa atctgctctt gtgaaattcg aagtttgtag tccacctgat 1020
aattgtcata aagcagggga gttttatcta ctcggggacg aaaacgagat ggcttgggac 1080
tatgaccgac ttttcaagta tgatattact caggttcttg aagcaaacca tctacacttc 1140
tatgatcacc tcttcattcg ctacgaagtc tttgatctta aaggagttag tttgggaact 1200
gacctgttcc acactgcaaa tgtggtacat gattccggca ca 1242

<210> 83
<211> 1239
<212> DNA
<213> *Haliotis tuberculata*

<400> 83
ggcaccctgt atcgtgataa ctacgttgaa gaagttactg gggccagtca tatcaggaag 60
aatttgaacg acctcaatac cggagaaatg gaaagcctta gagctgcttt cctgcatatt 120
caggacgacg gaacatatga atctattgcc cagtaccatg gcaaaccagg caaatgtcaa 180
ttgaatgatc ataataattgc gtgttgtgtc catggtatgc ctaccttccc ccagtggcac 240
agactgtatg tggttcaggt ggagaatgct ctccataaca ggggatctgg tgtggctggt 300
ccttactggg agtggactgc tcccatagac catctacctc atttcattga tgatgcaaca 360
tacttcaatt cccgacaaca gcggtacgac cctaaccctt tcttcagggg aaaggttact 420
tttgaaaacg cagtcacaac aagggaccca caagccgggc tcttcaactc agattatatg 480
tatgagaatg ttttacttgc actggagcag gaaaattatt gtgactttga aattcagttt 540
gagcttgctc ataacgcact tcattccatg ctgggaggta aagggcagta ctccatgtcc 600
tccctggact attctgcgtt tgatcccgtt ttcttccctc atcatgcca cacggacaga 660
ctgtgggcaa tctggcagga actacaaaga ttccgagaac tgcttatga agaagcgaac 720
tgtgcaatca acctcatgca tcaaccactg aagcctgtca gtgatccaca tgagaatcac 780
gacaatgtca ctttgaata ctcaaaacca caggacggat tcgactacca gaaccacttc 840
ggatacaagt atgacaacct tgagttccat cacttatcta tcccaagtct tgatgctacc 900
ctgaagcaaa ggagaaatca cgacagagtg tttgcgggct tecttcttca taacatagga 960
acttctgctg acataactat ctacatatgt ctgcctgacg gacggcgtgg caatgactgc 1020
agtcatgagg cgggaacatt ctatatcttc ggaggcgaaa cagagatgcc ttttatcttt 1080
gaccgtttgt ataaatttga aatcaccaaa ccactgcaac agttaggagt caagctgcat 1140
ggtaggagtt tcgaactgga gcttgagatc aaggcataca acggttccca tctggatccc 1200
catacctttg atccaactat catctttgaa cctggaaca 1239

<210> 86
 <211> 1209
 <212> DNA
 <213> *Haliotis tuberculata*

<400> 86
 gatcaccatg acgaccatca gtcgggaagc atagcaggat ccgggggtccg caaggacgtg 60
 aacaccttga ctaaggctga gaccgacaac ctgagggagg cgctgtgggg tgtcatggca 120
 gaccacggtc ccaatggctt tcaagctatt gctgctttcc atggaaaacc agcttttgtgt 180
 cccatgcctg atggccacaa ctactcatgt tgtactcacg gcatgggtac cttcccacac 240
 tggcatcgcc tctacaccaa gcagatggag gatgcaatga gggcgcatgg gtctcatgtc 300
 ggctgacct actgggactg gactgctgcc ttcaccacac tgccaacact ggtcacccgac 360
 acggacaaca accccttcca acatggacac attgattatc tcaatgtcag cacaactcga 420
 tctccccgag acatgctggt caacgacccc gagcatggat cagagtcggt cttctacaga 480
 caagtcctct tagctctgga acaaactgat ttctgcaaat tcgaagtcca gtttgagata 540
 acccacaatg ccatccattc ctggacagggt ggccacagcc cctacggaat gtccactctc 600
 gacttcactg cctacgatcc tctcttctgg ctccaccact ccaacaccga cagaatctgg 660
 gctgtctggc aagcttttga agaatacaga ggacttccat acaaccatgc caattgtgag 720
 atccaggcaa tgaaaacgcc cctgaggcct ttcagtgcag atatcaacca caaccagtc 780
 acaaaggcta acgcgaagcc attagatgtg ttcgagtata atcggttgag ctccagtagc 840
 gacaacctca tcttccatgg atacagtatt ccggaacttg atcgctgct tgaagaaaga 900
 aaggaggagg acagaatatt tgctgccttc cttctcagtg gaatcaagcg tagtgctgat 960
 gtagtgttcg acatatgcca gccagaacac gaatgtgtgt tcgcaggggac ttttgcgatt 1020
 ttgggagggg agctagaaat gccctgggcc ttcgacagac tgttccgcta tgatatcacc 1080
 aaggtgatga agcagctaca cctgaggcat gactctgact ttaccttcag ggtgaagatt 1140
 gtcggcaccg acgaccacga gcttccttca gacagtgtca aagcaccaac tattgaattt 1200
 gaaccgggc 1209

<210> 87
 <211> 1536
 <212> DNA
 <213> *Haliotis tuberculata*

<400> 87
 gtgcacagag gcggaaacca cgaagatgaa caccatgatg acagactcgc agatgtcctg 60
 atcaggaaag aagttgactt cctctccctg caagaggcca acgcaattaa ggatgcactg 120
 tacaagctcc agaatgacga cagtaaaggg ggctttgagg ccatagctgg ctatcacggg 180
 tatectaata tgtgtccaga aagaggatcc gacaagtatc cctgctgtgt ccacggaatg 240
 cccgtgttcc cccactggca ccgcctgcat accattcaga tggagagagc tctgaaaaac 300
 catggctctc caatgggcat tcttacttgg gattggacaa agaagatgtc gactcttcca 360
 tctttctttg gagattccag caacaacaac ccttctaca aatattacat ccggggcggtg 420
 cagcacgaaa caaccaggga cattaatcag agactcttta atcaaaccaa gtttggtgaa 480
 tttgattacc tatattacct aactctgcaa gtccctggagg aaaactcgta ctgtgacttt 540
 gaagttcagt atgagatcct ccataacgcc gtccactcct ggcttggagg aactggaaag 600
 tattccatgt ctaccctgga gcattcggcc tttgacctg tcttcatgat tcaccactcg 660
 agtttgagata gaattctgat cctttggcag aagttgcaaa agataagaat gaagccttac 720
 tacgcatttg attgtgctgg cgacagactt atgaaagacc ccttgcaccc cttcaactac 780
 gaaaccgtta atgaagatga attcaccgcg atcaactctt tcccaagcat actgtttgac 840
 cactacaggt tcaactatga atacgataac atgagaatca ggggtcagga catacatgaa 900
 cttgaagagg taattcagga attaagaac aaagatcgca tatttgctgg ttttgttttg 960
 tcgggcttac ggatatcagc tacagtgaag gtattcattc attcgaaaaa cgatacaagt 1020
 cacgaagaat atgcaggaga atttgcagtt ttgggagggt agaaggagat gccgtgggca 1080
 tatgaaagaa tgctgaaatt ggacatctcc gatgctgtac acaagcttca cgtgaaagat 1140
 gaagacatcc gtttttagagt ggttggttact gcctacaacg gtgacgttgt taccaccagg 1200
 ctgtctcagc cattcatcgt ccaccgtcca gccatgtgg ctacacgacat cttggtaatc 1260
 ccagtaggtg cgggccatga ccttccgcct aaagtgcgtg taaagagcgg caccaaagtc 1320
 gagtttacac caatagattc gtcggtgaac aaagcaatgg tggagctggg cagctatact 1380

79

gctatggcta aatgcacgtg tccccctttc tttaccacg gctttgaact ggacaaagtc 1440
tacagcgctg atcacggaga ctactacatt gctgcaggta cccacgcgtt gtgtgagcag 1500
aacctcaggc tccacatcca cgtggaacac gagtag 1536

<210> 88

<211> 591

<212> DNA

<213> *Haliotis tuberculata*

<400> 88

ggtcttccgt actgggactg gacgcagcat ctgactcaac tcccagatct ggtgtcagac 60
cccttgtttg tgcacccgga aggaggaaag gcccatgaca acgcatggta tctgggaaac 120
atcaagtttg agaataagaa gactgcaaga gctggtgacg atcgctttt cgagaagggt 180
ggaccaggag agaatacccg actcttttgaa ggaattctcg atgctcttga acaggatgaa 240
ttctgcaact tgcagatcca gtttgagttg gtcacaacg ctatccacta cctgggtggc 300
ggcgcgcaca cgtactccat gtctcatctc gactacacct cctacgacct cctcttcttc 360
ctccatcact ccaacccgga cgcactcttc gccatctggg aacgtcttca ggtactcaga 420
ggaaaggacc ccaacacgcg cgactgcgca cacaacctca tccatgagcc catggaaccg 480
ttccgctggc atgagcccat ggaaccgttc cgtcgggact cgaacctct tgacctcacc 540
agggaaaact ccaaaccaat tgacagcttt gattatgccc accttggtta c 591

<210> 89

<211> 1245

<212> DNA

<213> *Haliotis tuberculata*

<400> 89

gttacagagg cccagctcc ctccctcgat gctcacctcg ccgtcaggaa ggatatcaac 60
catctgacac gcgaggaggt gtacgagctg cgcagagcta tggagagatt ccaggccgac 120
acatccgttg atgggtacca ggctacggtt gagtatcacg gcttacctgc tgcagtcca 180
ttccccgagg ccacaaatag gtccgctgt tgcacccacg gcatggcgac attccctcat 240
tggcacagac tgttcgtcac ccagggtgaa gatgctctga tcaggcgagg atcgctata 300
gggggtccct actgggactg gactcagcct atggcgcatc tcccaggact tgcagacaac 360
gccacctata gagatcccat cagcggggac agcagacaca accccttcca cgatgttgaa 420
gttgcccttg aaaatggacg tacagaacgt caccagata gtagattgtt tgaacaacct 480
ttatttgga aacatacgcg tctcttcgac agtatagtct atgcttttga gcaggaggac 540
ttctgcgatt ttgaagttca atttgagatg acccataata atattcacgc ctggattggt 600
ggcggcgaga agtattccat gtcttctcta cactacacag ccttcgacct tatcttctac 660
cttcgtcact ccaacactga ccggctcttg gcaatttggc aagcgttgca gatacgaaga 720
aacaggcctt acaaggctca ttgtgcttg tctgaggaac gccagcctct caaaccttct 780
gccttcagtt cccactgaa caacaacgaa aaaactcagc aaaactcggg gccaccaaac 840
gtttacgact ccgaaggagt ccttggttat acttatgatg acctcaactt cgggggcatg 900
gacctgggtc agcttgagga atacatccag aggcagagac agagagacag gacctttgct 960
ggtttctttc tgtcacatat tgggtacatc gcgaatgttg aaatcattat agaccatggg 1020
actcttcata cctccgtggg cacgtttgct gttcttggcg gagagaagga gatgaaatgg 1080
ggatttgacc gtttgtacaa atatgagatt acagatgaac tgaggcaact taatctccgt 1140
gctgatgatg ttttcagcat ctctgttaaa gtaactgatg ttgatggcag tgagctgtcc 1200
tctgaactca tcccatctgc tgctatcatc ttccaacgaa gccat 1245

<210> 90

<211> 1251

<212> DNA

<213> *Haliotis assimilis*

<400> 90

attgaccatc aggacccgca tcatgacaca atcattagga aaaatgttga taatcttaca 60
cccaggagaaa ttaattctct gaggcgggca atggcagacc ttcaatcaga caaaaccgcc 120

80

```

ggtggattcc agcaaattgc tgcttttccac ggggaaccca aatgggtgcc aagtccegat 180
gctgagaaga agttctcctg ctgtgtccat ggaatggctg tcttccctca ctggcacaga 240
ctcctgaccg tgcaaggcga gaatgccctg agaaagcatg gatgtctcgg agctctcccc 300
tactgggact ggactcggcc cctgtctcac ctacctgatt tggttttggg aagtagcaga 360
actacaccga tgccatattc caccgtggaa gcccgaacc cctggtacag cggccatatt 420
gatacagttg gtgttgacac aacaagaagc gtccgtcaag aactgtatga agctcctgga 480
tttggccatt ataactgggg atgtaagcaa gtgcttctgg ctttggagca ggatgacttc 540
tgtgattttg aagtccagtt tgagatagct cacaatttca ttcacgctct tgcggcgga 600
agcgagccat atggtatggc gtcactccgt tacactactt atgatccaat tttctacctc 660
catcattcta aactgacag actctgggct atatggcagg ctctacaaaa gtacaggggc 720
aaaccttaca attccgcca ctgcgccatt gcttctatga gaaaaccctt acaacccttt 780
ggtctgactg atgagatcaa cccggatgat gagacaagac agcatgctgt tcttttcagt 840
gtctttgatt acaagaacaa cttcaattat gaatatgaca ccttgactt caacggacta 900
tcaatctccc agctggaccg tgaactgtca cggagaaagt ctcacgacag agtatttgcc 960
ggatttttgc tgcattggtat tcagcagctc gcaactagta aattctttgt ctgcaaatca 1020
gatgatgact gtgaccacta tgctgggtgaa ttctacatcc ttggtgatga agctgaaatg 1080
ccatggggct atgatcgtct ttacaaatat gagatcactg agcagctcaa tgccttgat 1140
ctacacatcg gagatagatt cttcatcaga tacgaagcgt ttgatcttca tgggtacaagt 1200
cttggaagca acatcttccc caaaccttct gtcatacatg acgaaggggc a 1251

```

<210> 91

<211> 1242

<212> DNA

<213> *Haliotis tuberculata*

<400> 91

```

ggtcaccatc aggctgacga gtaacgacga gttgtaactg ctgcaagcca catcagaaag 60
aattttaaag atctgtcaaa gggagaagta gagagcctaa ggtctgcctt cctgcaactt 120
cagaacgacg gagtctatga gaattattgcc aagttccacg gcaagcctgg gttgtgtgat 180
gataacggtc gcaagggttg ctgttggtgc catggaatgc ccaccttccc ccagtggcac 240
aggctctatg tctctcaggt ggagaatgct ttgctggaga gaggatctgc cgtctctgtg 300
ccatactggg actggactga aacattttaca gagctgccat ctttgattgc tgaggctacc 360
tatttcaatt cccgtcaaca aacgtttgac cctaatectt tcttcagagg taaaatcagt 420
tttgagaatg ctgtttacaac acgtgatccc cagcctgagc tgtacgttaa caggactact 480
taccaaaacg tcatgttggt ttttgaacag gacaactact gcgacttcca gatacagttt 540
gagatgggtc acaatgttct ccatgcttgg cttggtggaa gagctactta ttctatttct 600
tctcttgatt attctgcatt cgaccctgtg tttttccttc accatgcgaa cacagataga 660
ttgtgggcca tctggcagga gctgcagagg tacaggaaga agccatacaa tgaagcggat 720
tgtgccatta acctaatgcg caaacctcta catccttccg acaacagtga tctcaatcat 780
gatcctgtaa cctttaaata ctcaaaaccc actgatggct ttgactacca gaacaacttt 840
ggatacaagt atgacaacct tgagttcaat catttcagta ttcccaggct tgaagaaatc 900
attcgtatta gacaacgtca agatcgtgtg tttgcaggat tctccttcca caacattggg 960
acatccgcaa ctgttgagat attcgtctgt gtcctacca ccagcgggtg gcaaaaactgt 1020
gaaaacaaaag ccggaacatt tgccgtactc ggaggagaaa cagagatggc gtttcatttt 1080
gacagactct acaggtttga catcagtgaa aactgaggg acctcggcat acagctggac 1140
agccatgact ttgacctcag catcaagatt caaggagtaa atggatccta ccttgatcca 1200
cacatcctgc cagagccatc cttgattttt gtgcctgggt ca 1242

```

<210> 92

<211> 1257

<212> DNA

<213> *Haliotis tuberculata*

<400> 92

```

agttctttcc tgcgtcctga tgggcattca gatgacatcc ttgtgagaaa agaagtgaac 60
agcctgacaa ccaggagagac tgcattctctg atccatgctc tgaaaagtat gcaggaagac 120
cattcacctg acgggttcca agccattgcc tctttccatg ctctgccacc actctgcctc 180

```

81

tcaccatctg	cagctcaccg	ttatgcttgc	tgtgtccacg	gcattggctac	atttccccag	240
tggcacagat	tgtacactgt	acagttccag	gatgcactga	ggagacatgg	agctacggta	300
ggtgtaccgt	attgggattg	gctgcgaccg	cagtctcacc	taccagagct	tgtcaccatg	360
gagacatacc	atgatatttg	gagtaacaga	gatttcccca	atcctttcta	ccaagccaat	420
attgagtttg	aaggagaaaa	cattacaaca	gagagagaag	tcattgcaga	caaacttttt	480
gtcaaagggt	gacacgtttt	tgataaactg	gttcttcaaa	caagccatcc	tagcgctgag	540
caggaaaact	actgtgactt	tgagattcag	tttgaaattc	ttcacaacgg	cgttcacacg	600
tgggtcggag	gcagtcgtac	ctactctatc	ggacatcttc	attacgcatt	ctacgaccct	660
cttttctacc	ttcaccattt	ccagacagac	cgtatttggg	caatctggca	agaactccag	720
gaacagagag	ggctctcggg	tgatgaggct	cactgtgctc	tcgagcaaat	gagagaacca	780
ttgaagcctt	tcagcttcgg	cgctccttat	aactggaatc	agctcacaca	ggatttctcc	840
cgacccgagg	acaccttcga	ctacaggaag	tttgggttat	aatatgacaa	tttagaattc	900
ctgggaatgt	cagttgctga	actggatcaa	tacattattg	aacatcaaga	aatgataga	960
gtattcgctg	ggttcctggt	gagtggattc	ggagggttccg	catcagttaa	tttccagggt	1020
tgtagagctg	attccacatg	tcaggatgct	gggtacttca	ccgttcttgg	tggcagtgct	1080
gagatggcgt	gggcatttga	caggtcttac	aaatatgaca	ttactgaaac	tctggagaaa	1140
atgcaccttc	gatatgatga	tgacttcaca	atctctgtca	gtctgaccgc	caacaacgga	1200
actgtcctga	gcagcagctt	aatcccaaca	ccgagtgtca	tattccagcg	gggacat	1257

<210> 93

<211> 1248

<212> DNA

<213> *Haliotis tuberculata*

<400> 93

cgtgacataa	ataccaggag	catgtcaccg	aaccgtgttc	gccgtgagct	gagcgatctg	60
tctgcgaggg	acctgtctag	tctcaagtct	gctctgcgag	acctacagga	ggatgatggc	120
cccaacggat	accaggtctt	tgcagccttc	catgggctac	cagcaggctg	ccatgatagc	180
cggggaaatg	agatcgcatt	ttgcattcac	gggatgccga	ccttcccca	gtggcacaga	240
ctgtacaccc	tgcagttgga	gatggctctg	aggagacatg	gatcatctgt	cgccatcccc	300
tactgggact	ggacaaagcc	tatctccgaa	ctccccctgc	tcttcaccag	ccctgagtat	360
tatgacccat	ggcatgatgc	tgtggtaaac	aaccattctt	ccaaagggtt	tgtcaaattt	420
gcaaatacct	acacagtaag	agacccacag	gagatgctgt	tccagctttg	tgaacatgga	480
gagtcaatcc	tctatgagca	aactcttctt	gctcttgagc	aaaccgacta	ctgtgatttt	540
gagggtacagt	ttgaggctct	ccataacgtg	atccactacc	ttgttggtgg	acgtcagacc	600
tacgcattgt	cttctctgca	ttatgctctc	tacgacccat	tcttctttat	acaccattcc	660
tttgtggata	agatgtgggt	agtatggcaa	gctcttcaaa	agaggaggaa	acttccatac	720
aagcgagctg	actgtgctgt	caacctaatg	actaaaccaa	tgaggccatt	tgactccgat	780
atgaatcaga	accatttcac	aaagatgcac	gcagttccca	acacactcta	tgactacgag	840
acactgtact	acagctacga	taatctcgaa	ataggtggca	ggaatctcga	ccagcttcag	900
gctgaaattg	acagaagcag	aagccacgat	cgcgtttttg	ctggattctt	gcttcgtgga	960
atcggaactt	ctgctgatgt	caggtttttg	atttgtagaa	atgaaaatga	ctgccacagg	1020
ggtggaataa	ttttcatctt	aggtggagcc	aaggaaatgc	catgggtcatt	tgacagaaac	1080
ttcaagtttg	atatcaccca	tgtactcgag	aatgctggca	ttagcccaga	ggacgtgttt	1140
gatgctgagg	agccatttta	tatcaagggt	gagatccatg	ctgttaacaa	gaccatgata	1200
ccgtcgtctg	tgatcccagc	cccaactatc	atctattctc	ctgggggaa		1248

<210> 94

<211> 1206

<212> DNA

<213> *Haliotis tuberculata*

<400> 94

ggctcgcgctg	ctgacagtgc	gcactctgcc	aacattgctg	gctctgggggt	gaggaaggac	60
gtcacgaccc	tactgtgtgc	tgagaccgag	aacctaaagac	aggctcttca	aggtgtcatc	120
gatgatactg	gtcccaatgg	ttaccaagca	atagcatcct	tccacggaag	tcctccaatg	180
tgcgagatga	acggccgcaa	ggttgccctgt	tgtgctcagc	gtatggcctc	cttcccacac	240

82

tggcacagac	tgtatgtgaa	gcagatggaa	gatgccctgg	ctgaccacgg	gtcacatatc	300
ggcatccctt	actgggactg	gacaactgcc	ttcacagagt	tacccgccct	tgtcacagac	360
tccgagaaca	atcccttcca	tgaggggcgc	attgatcatc	tccgtgtaac	cacgtcacgt	420
tccccagag	acatgctggt	taacgaccca	gagcaaggat	cagagtcggt	cttctataga	480
caagtccctc	tggtcttggg	gcagactgac	tactgccagt	tccaagtcca	gtttgagctg	540
accacacaacg	ccattcactc	ctggacaggt	ggacgtagcc	cttacggaat	gtcgaccttc	600
gagttcacag	cctacgatcc	tctcttctgg	cttcaccact	ccaacaccga	cagaatctgg	660
gctgtctggc	aagcactgca	gaaataccga	ggactcccat	acaacgaagc	acactgtgaa	720
atccagggttc	tgaaacagcc	cttgaggcca	ttcaacgatg	acatcaacca	caatccaatc	780
accaagacta	atgccaggcc	tatcgattca	tttgattatg	agaggtttaa	ctatcagtat	840
gacaccctta	gcttccatgg	taagagcatc	cctgaactga	atgacctgct	cgaggaaaga	900
aaaagagaag	agagaacatt	tgctgccttc	cttcttcgtg	gaatcggttg	cagtgtgat	960
gtcgtctttg	acatctgccg	gccaatggt	gactgtgtct	ttgcaggaaac	ctttgtctgtg	1020
ctgggagggg	agctagaaat	gccttggtcc	ttcgacagac	tgttccgcta	tgacatcacc	1080
agagtcatga	atcagctcca	tctccagtat	gattcagatt	tcagtttcag	ggtgaagctt	1140
gttgccacca	atggcactga	gctttcatca	gaccttctca	agtcaccaac	aattgaacat	1200
gaactt						1206

<210> 95

<211> 1548

<212> DNA

<213> *Haliotis tuberculata*

<400> 95

ggagcccaca	gaggaccagt	tgaagaaaca	gaagtcactc	gccaacatac	tgacggcaat	60
gcacactttc	atcgtaagga	agttgattcg	ctgtccctgg	atgaagcaaa	caacttgaag	120
aatgcccttt	acaagctaca	gaacgaccac	agtctaacgg	gatacgaagc	aatctctggg	180
taccatggat	accccaatct	gtgtccggaa	gaaggcgatg	acaaaatacc	cctgctgcgt	240
ccccggatgg	gcatctttcc	ttactggcac	agactcttga	ccattcaact	ggaaagagct	300
cttgagcaca	atgggtgcact	gcttggtggt	ccttactggg	actggaacaa	ggacctgtcg	360
tcactgccgg	cgttcttctc	cgactccagc	aacaacaatc	cctacttcaa	gtaccacatc	420
gccggtgttg	gtcacgacac	cgtcagagag	ccaactagtc	ttatatataa	ccagccccaa	480
atccatgggt	atgatttatct	ctattaccta	gcattgacca	cgcttgaaga	aaacaattac	540
tgggactttg	aggttcagta	tgagatcctc	cacaacgccg	tccaactcctg	gcttggagga	600
tcccagaagt	attccatgtc	taccctggag	tattcggcct	ttgacctgt	ctttatgata	660
cttcactcgg	gtctagacag	actttggatc	atctggcaag	aacttcagaa	gatcaggaga	720
aagccctaca	acttcgctaa	atgtgcttat	catatgatgg	aagagccact	ggcgcccttc	780
agctatccat	ctatcaacca	ggacgagttc	acccgtgcc	actccaagcc	ttctacagtt	840
tttgacagcc	ataagttcgg	ctaccattac	gataacctga	atggttagagg	tcacagcatc	900
caagaactca	acacaatcat	caatgacttg	agaaacacag	acagaatcta	cgcaggattt	960
gttttgtcag	gcacgggtac	gtctgctagt	gtcaagatct	atctccgaac	agatgacaat	1020
gacgaagaag	ttggaacttt	cactgtcctg	ggaggagaga	gggaaatgcc	atgggcctac	1080
gagcgagttt	tcaagtatga	catcacagag	gttgacagata	gacttaaaat	taagttatgg	1140
ggacaccctt	taacttcggg	aactggagat	cacatcctta	cgaatggaat	cgggtggtaaa	1200
caagagccta	cccaaactct	ttcatcatct	acagacctgc	caatcatgac	tacgatgttc	1260
ttgttatccc	agtanggaag	aaaccttcac	atccctccca	aagttgtcgt	caagaaaggc	1320
acccgcacgc	agttccaccc	agtcgatgat	tcagttacga	gaccagttgt	tgatcttgga	1380
agctacactg	cactcttcaa	ctgtgtggta	ccaccgttca	cataccacgg	attcgaactg	1440
aaccacgtct	attctgtcaa	gcctgggtgac	tactatgtta	ctggaccac	gagagacctt	1500
tgccagaatg	cagatgtcag	gattcatatc	catgttgagg	atgagtaa		1548

<210> 96

<211> 966

<212> DNA

<213> *Megathura crenulata*

<400> 96

83

```

ggcctaccgt actgggactg gactgaaccc atgacacaca ttccgggtct ggcaggaaac 60
aaaacttatg tggattctca tgggtgcatcc cacacaaatc cttttcatag ttcagtgatt 120
gcatttgaag aaaatgctcc ccacaccaaa agacaaatag atcaaagact ctttaaacc 180
gctacctttg gacaccacac agacctgttc aaccagattt tgtatgcctt tgaacaagaa 240
gattactgtg actttgaagt ccaatttgag attaccata acacgattca cgcttggaca 300
ggaggaagcg aacattttctc aatgtcgtcc ctacattaca cagctttcga tcctttgttt 360
tactttcacc attctaactg tgategtctt tgggcgttt ggcaagcctt acagatgaga 420
cggcataaac cctacagggc ccactgcgcc atatctctgg aacatatgca tctgaaacca 480
ttcgcctttt catctccctt taacaataac gaaaagactc atgccaatgc catgccaaac 540
aagatctacg actatgaaaa tgcctccat tacacatacg aagatttaac atttggaggc 600
atctctctgg aaaacataga aaagatgac cagcaaaacc agcaagaaga cagaatatat 660
gccggttttc tcctggctgg catacgtact tcagcaaattg ttgatatctt cattaanaact 720
accgattccg tgcaacataa ggctggaaca tttgcagtgc tcgggtggaag caaggaaatg 780
aagtggggat ttgatcgctg tttcaagttt gacatcacgc acgttttgaa agatctcgat 840
ctcactgctg atggcgattt cgaagttact gttgacatca ctgaagtcga tggaaactaaa 900
cttgcaccca gtcttatctc acatgcttct gtcattcgtg agcatgcacg tggtaagctg 960
aataga

```

<210> 97
 <211> 1242
 <212> DNA
 <213> Megathura crenulata

```

<400> 97
gttaaatttg acaaagtgcc aaggagtcgt cttattcgaa aaaatgtaga ccgtttgagc 60
cccgaggaga tgaatgaact tcgtaaagcc cttagccttac tgaaagagga caaaagtgcc 120
gggtggatttc agcagcttgg tgcattccat ggggagccaa aatgggtgtc tagtcccga 180
gcatctaaaa aatttgctg ctgtgttcac ggcattgtctg tgttccctca ctggcatcga 240
ctgttgacgg ttcagagtga aaatgctttg agacgacatg gctacgatgg agctttgccg 300
tactgggatt ggacctctcc tcttaatcac cttcccgaac tggcagatca tgagaagtac 360
gtcgaccctg aagatggggg agagaagcat aacccttggg tcgatgggtca tatagataca 420
gtcgacaaaa caacaacaag aagtgttcag aataaactct tcgaacagcc tgagtttgg 480
cattatacaa gcattgccaa acaagtactg cttagcgttgg aacaggacaa tttctgtgac 540
tttgaaatcc aatatgagat tgcccataac tacatccatg cacttgtagg aggcgtcag 600
ccttatggta tggcatcgct tcgctacact gcttttgatc cactattcta cttgcatcac 660
tctaatacag atcgtatatg ggcaatatgg caggctttac agaagtacag aggaaaaccg 720
tacaacgttg ctaactgtgc tgttacatcg atgagagaac ctttgcaacc atttggcctc 780
tctgccaata tcaacacaga ccatgtaacc aaggagcatt cagtgccatt caacgttttt 840
gattacaaga ccaatttcaa ttatgaatat gacactttgg aatttaacgg tctctcaatc 900
tctcagttga ataaaaagct cgaagcgata aagagccaag acaggttctt tgcaggcttc 960
ctgttatctg gtttcaagaa atcatctctt ctgggtgatg aaaacgagat gccatgggca 1020
aactgtcacc ccgctggaga gttttacett ctgggtgatg aaaacgagat gccatgggca 1080
tacgatagag tcttcaaata tgacataacc gaaaaactcc acgatctaaa gctgcatgca 1140
gaagaccact tctacattga ctatgaagta tttgacctta aaccagcaag cctgggaaaa 1200
gatttggtca agcagccttc agtcattcat gaaccaagaa ta 1242

```

<210> 98
 <211> 1236
 <212> DNA
 <213> Megathura crenulata

```

<400> 98
ggtcaccatg aaggcgaagt atatcaagct gaagtaactt ctgccaaaccg tattcgaaaa 60
aacattgaaa atctgagcct tgggtgaactc gaaagtctga gagctgcctt cctggaaatt 120
gaaaacgatg gaacttacga atcaatagct aaattccatg gtagccctgg tttgtgccag 180
ttaaatggta accccatctc ttgttgtgtc catggcatgc caactttccc tctctggcac 240
agactgtacg tgggtgtcgt tgagaatgcc ctctgaaaa aaggatcctc tgtagctgtt 300

```

cctattggg	actggacaaa	acgaatcgaa	catttacctc	acctgatttc	agacgccact	360
tactacaatt	ccaggcaaca	tcactatgag	acaaacccat	tccatcatgg	caaaatcaca	420
cacgagaatg	aaatcactac	tagggatccc	aaggacagcc	tcttccattc	agactacttt	480
tacgagcagg	tcttttacgc	cttggagcag	gataacttct	gtgatttcga	gattcagttg	540
gagatattac	acaatgcatt	gcattcttta	cttgggtggca	aaggtaaata	ttccatgtca	600
aaccttgatt	acgctgcttt	tgatcctgtg	ttcttccttc	atcacgcaac	gactgacaga	660
atctgggcaa	tctggcaaga	ccttcagagg	ttccgaaaac	ggccataccg	agaagcgaat	720
tgcgctatcc	aattgatgca	cacgccactc	cagccgtttg	ataagagcga	caacaatgac	780
gaggcaacga	aaacgcatgc	cactccacat	gatggttttg	aatatcaaaa	cagctttggg	840
tatgcttacg	ataatctgga	actgaatcac	tactcgattc	ctcagcttga	tcacatgctg	900
caagaaagaa	aaaggcatga	cagagtattc	gctggcttcc	tccttcacaa	tattggaaca	960
tctgccgatg	gccatgtatt	tgtatgtctc	ccaactgggg	aacacacgaa	ggactgcagt	1020
catgaggtcg	gtatgttctc	catcttaggc	ggctcaaacg	agatgtcctt	tgtatttgac	1080
agactttaca	aacttgacat	aactaaagcc	ttgaaaaaga	acggtgtgca	cctgcaaggg	1140
gatttcgata	tggaaattga	gattacggct	gtgaatggat	ctcatctaga	cagtcatgtc	1200
atccactctc	ccactatact	gtttgaggcc	ggaaca			1236

<210> 99

<211> 1257

<212> DNA

<213> Megathura crenulata

<400> 99

gattctgccc	acacagatga	tggacacact	gaaccagtga	tgattcgcaa	agatatcaca	60
caattggaca	agcgtcaaca	actgtcactg	gtgaaagccc	tcgagtcgat	gaaagccgac	120
cattcatctg	atgggttcca	ggcaatcgct	tccttccatg	ctcttccctc	tctttgtcca	180
tcaccagctg	cttcaaagag	gtttgcgtgc	tgcgtccatg	gcatggcaac	gttcccacaa	240
tggcaccgct	tgtacacagt	ccaattccaa	gattctctca	gaaaacatgg	tgcatcggtt	300
ggacttccgt	actgggactg	gaccctacct	cgttctgaat	taccagagct	cctgaccgtc	360
tcaactattc	atgacccgga	gacaggcaga	gatataccaa	atccatttat	tggttctaaa	420
atagagtttg	aaggagaaaa	cgtacatact	aaaagagata	tcaataggga	tcgtctcttc	480
cagggatcaa	caaaaacaca	tcataactgg	tttatgtagc	aagcactgct	tgctcttgaa	540
caaaccaact	actgcgactt	cgaggttcag	tttgaaatta	tgcataatgg	tgttcatacc	600
tgggttggag	gcaaggagcc	ctatggaatt	ggccatctgc	attatgcttc	ctatgatcca	660
cttttctaca	tccatcactc	ccaaactgat	cgtatttggg	ctatatggca	atcgttgcag	720
cgtttcagag	gactttctgg	atctgaggct	aactgtgctg	taaatctcat	gaaaactcct	780
ctgaagcctt	tcagcttttg	agcaccatat	aatcttaatg	atcacacgca	tgattttctca	840
aagcctgaag	atacattcga	ctaccaaaag	tttggataca	tatatgacac	tctggaattt	900
gcagggtggt	caattcgtgg	cattgaccat	attgtccgta	acaggcagga	acattcaagg	960
gtctttgccc	gattcttgct	tgaaggattt	ggcacctctg	ccactgtcga	tttccagggtc	1020
tgtcgcacag	cgggagactg	tgaagatgca	gggtacttca	ccgtgttggg	aggtgaaaaa	1080
gaaatgcctt	gggccttttg	tcggctttac	aagtaacgca	taacagtaaac	cttagacaag	1140
atgaaccttc	gacatgacga	aatcttccag	attgaagtaa	ccattacatc	ctacgatgga	1200
actgtactcg	atagtggcct	tattcccaca	ccgtcaatca	tctatgatcc	tgctcat	1257

 $\langle 210 \rangle$ 100 $\langle 211 \rangle$ 1254

<212> DNA

<213> Megathura crenulata

<400> 100

catgatatta	gttcgcacca	cctgtcgtct	aacaagggttc	gtcatgatct	gagtacactg	60
agtgagcgag	atattggaag	ccttaaatat	gctttgagca	gcttgcaggc	agatacctca	120
gcagatggtt	ttgctgccat	tgcattcctt	catggctctg	ctgccaaatg	taatgacagc	180
cacataaacg	agggtggcat	ctgtatccat	ggaatgccta	cattccccc	ctggcacaga	240
ctctacaacc	tccaatttga	gcaagctcta	agaagacatg	gctctagtgt	agcagtagcc	300
tactgggaact	qqacaaaqcc	aatacataat	attccacatc	tgttcacaga	caaaqaatac	360

85

tacgatgtct	ggagaaataa	agtaatgcca	aatccatttg	cccgagggtg	tgtccctca	420
cacgatacat	acacggtaag	agacgtccaa	gaaggcctgt	tccacctgac	atcaacgggt	480
gaacactcag	cgcttctgaa	tcaagctctt	ttggcgctgg	aacagcacga	ctactgcgat	540
tttgagtc	agtttgaagt	catgcacaac	acaatccatt	acctagtggg	aggacctcaa	600
gtctattctt	tgtcatccct	tcattatgct	tcatatgac	cgatcttctt	catacaccac	660
tcctttgtag	acaaggtttg	ggctgtctgg	caggctcttc	aagaaaagag	aggccttcca	720
tcagaccgtg	ctgactgcgc	tgttagtctg	atgactcaga	acatgaggcc	tttccattac	780
gaaattaacc	ataaccagtt	caccaagaaa	catgcagttc	caaatgatgt	tttcaagtac	840
gaactcctgg	gttacagata	cgacaatctg	gaaatcggtg	gcatgaattt	gcatgaaatt	900
gaaaaggaaa	tcaaagacaa	acagcaccat	gtgagagtgt	ttgcagggtt	cctccttcac	960
ggaattagaa	cctcagctga	tgtccaattc	cagatttgta	aaacatcaga	agattgtcac	1020
catggaggcc	aaatcttcgt	tcttgggggg	actaaagaga	tggcctgggc	ttataaccgt	1080
ttattcaagt	acgatattac	ccatgctctt	catgacgcac	acatcactcc	agaagacgta	1140
ttccatccct	ctgaaccatt	cttcatcaag	gtgtcagtga	cagccgtcaa	cggaacagtt	1200
cttcoggtct	caatcctgca	tgcaccaacc	attatctatg	aacctggtct	cggt	1254

<210> 101

<211> 510

<212> DNA

<213> Megathura crenulata

<400> 101

gaccatcacg	aagatcatca	ttcttcttct	atggctggac	atggtgtcag	aaaggaaatc	60
aacacactta	ccactgcaga	ggtggacaat	ctcaaagatg	ccatgagagc	cgatcatggca	120
gaccacggtc	caaattggata	ccaggctata	gcagcgttcc	atggaaaccc	accaatgtgc	180
cctatgccag	atggaaagaa	ttactcgtgt	tgtacacatg	gcatggctac	tttccccac	240
tggcacagac	tgtacacaaa	acagatggaa	gatgccttga	ccgcccattg	tgccagagtc	300
ggccttcctt	actgggacgg	gacaactgcc	tttacagctt	tggcaacttt	tgtcacagat	360
gaagaggaca	atcctttcca	tcattggtcac	atagactatt	tgggagtggg	tacaactcgg	420
tcgccccgag	acaagttgtt	caatgatcca	gagcgaggat	cagaatcgtt	cttctacagg	480
caggttctct	tggctttgga	gcagacagat				510

<210> 102

<211> 942

<212> DNA

<213> Megathura crenulata

<400> 102

ggcctgcctt	actgggattg	gaccatgcca	atgagtcatt	tgccagaact	ggctacaagt	60
gagacctacc	tcgatccagt	tactggggaa	actaaaaaca	accctttcca	tcacgcccac	120
gtggcgtttg	aaaatggtgt	aacaagcagg	aatcctgatg	ccaaactttt	tatgaaacca	180
acttacggag	accacactta	cctcttcgac	agcatgatct	acgcatttga	gcaggaagac	240
ttctgcgact	ttgaagtcca	atatgagctc	acgcataatg	caatacatgc	atgggttggg	300
ggcagtga	agtattcaat	gtcttctctt	cactacactg	cttttgatcc	tatatattac	360
ctccatcact	caaattgttg	tcgtctctgg	gccatttggc	aagctcttca	aatcaggaga	420
ggcaagtctt	acaaggccca	ctgcgcctcg	tctcaagaaa	gagaaccatt	aaagcctttt	480
gcattcagtt	ccccactgaa	caacaacgag	aaaacgtacc	acaactctgt	ccccactaac	540
gtttatgact	atgtgggagt	tttgcaactat	cgatatgatg	accttcagtt	tggcggtatg	600
accatgtcag	aacttgagga	atatattcac	aagcagacac	aacatgatag	aacctttgca	660
ggattcttcc	tttcatatat	tggaaacatca	gcaagcgtag	atatcttcat	caatcgagaa	720
ggtcatgata	aatacaaagt	gggaagtgtt	gtagtacttg	gtggatccaa	agaaatgaaa	780
tggggctttg	atagaatgta	caagtatgag	atcactgagg	ctctgaagac	gctgaatgtt	840
gcagtggatg	atgggttcag	cattactgtt	gagatcaccg	atgttgatgg	atctccccca	900
tctgcagatc	tcattccacc	tcctgctata	atctttgaac	gt		942

<210> 103
<211> 1248
<212> DNA
<213> Megathura crenulata

<400> 103
gctgatgcc aagacttttg ccatagcaga aaaatcagga aagccgttga ttctctgaca 60
gtcgaagaac aaacttcggt gaggcgagct atggcagatc tacaggacga caaaacatca 120
gggggtttcc agcagattgc agcattccac ggagaaccaa aatgggtgtcc aagccccgaa 180
gaggagaaaa aatttgcatt ctgtgttcat ggaatggctg ttttccctca ctggcacaga 240
ttgctgacag ttcaaggaga aaatgctctg aggaaacatg gctttactgg tggactgcc 300
tactgggact ggactcgatc aatgagcgcc ctccacatt ttgttgctga tctacttac 360
aatgatgcta tttccagcca ggaagaagat aacccatggc atcatggtea catagactct 420
gttgggcatg atactacaag agatgtgcgt gatgatcttt atcaatctcc tggtttcggg 480
cactacacag atattgcaaa acaagtcctt ctggcctttg agcaggacga tttctgtgat 540
tttgaggtag aatttgaaat tgcccataat ttcatacatg ctctggttgg tggtaacgaa 600
ccatacagta tgatcatctt gaggtatact acatacagtc caatcttctt cttgcaccgc 660
tccaatacag accgactttg ggccattttg caagcttttg aaaaataacc ggggaaacca 720
tacaacactg caaactgtgc cattgcatcc atgagaaaac cacttcagcc atttgggtct 780
gatagtgtca taaatccaga tgacgaaact cgtgaacatt cggttccttt ccgagtcttc 840
gactacaaga acaacttcga ctatgagtag gagagcctgg catttaattg tctgtctatt 900
gcccactgg accgagagtt gcagagaaga aagtcacatg acagagtctt tgcaggattc 960
cttcttcatg aaatttgaca gtctgcactc gtgaaattct acgtttgcaa acacaatgta 1020
tctgactgtg accattatgc tggagaattc tacatttttg gagatgaagc tgagatgcct 1080
tgagggtatg accgtgtgta caagtacgag ataacacagc agctgcacga tttagatcta 1140
catgttgagg ataatttctt ccttaaatat gaagcctttg atctgaatgg cggaagtctt 1200
ggtggaagta tcttttctca gccttcgggtg attttcgagc cagctgca 1248

<210> 104
<211> 1257
<212> DNA
<213> Megathura crenulata

<400> 104
ggttcacacc aggtctgatg atatcgtgag gcagtaacaa gcgctagcca cataagaaaa 60
aatatccggg acctctcaga gggagaaatt gagagcatca gatctgcttt cctccaaatt 120
caaaaagagg gtatatatga aaacattgca aagttccatg gaaaaccagg actttgtgaa 180
catgatggac atctgtttgc ttgttggtgc catggcatgc ccacttttcc cactggcac 240
agactgtacg ttcttcaggt ggagaatgcg ctcttagaac gagggctctg agttgctgtt 300
ccttactggg actggaccga gaaagctgac tctctgccat cattaatcaa tgatgcaact 360
tatttcaatt cagcatccca gacctttgat cctaatectt tcttcagggg acatattgcc 420
ttcgagaatg ctgtgacgtc cagagatcct cagccagAAC tatgggacaa taaggacttc 480
tacgagaatg tcatgctggc tcttgagcaa gacaacttct gtgactttga gattcagctt 540
gagctgatac acaacgccct tcattctaga cttggaggaa gggctaaata ctccctttcg 600
tctcttgatt ataccgcatt tgatcctgta tttttccttc accatgcaaa cgttgacaga 660
atctgggcca tctggcagga cttgcagaga tatagaaaga aaccatacaa tgaggctgac 720
tgcgagtcga acgagatgcg taaacctctt caaccattta ataaccaga acttaacagt 780
gattccatga cgcttaaaca caacctccca caagacagtt ttgattatca aaaccgcttc 840
aggtaccaat atgataacct tcaatttaac cacttcagca tacaaaagct agaccaaact 900
attcaggcta gaaaacaaca cgacagagtt tttgctggct ttattcttca caacattggg 960
acatctgctg ttgtagatat ttatatttgc gttgaacaag gaggagaaca aaactgcaag 1020
acaaaggcgg gtctcttcac gattctgggg ggagaaacag aaatgccatt ccactttgac 1080
cgcttgtaga aatttgacat aacgtctgct ctgcataaac ttggtgttcc cttggacgga 1140
catggattcg acatcaaagt tgacgtcaga gctgtcaatg gatcgcatct tgatcaacac 1200
atcctcaacg aaccgagctc gctttttgtt cctgggtgaac gtaagaatat atattat 1257

<400>	106						
catgggatca	atgtacgtca	cgttggtcgt	aatcggattc	gtatggaact	atctgaactc	60	
accgagagag	atctcgccag	cctgaaatct	gcaatgaggt	ctctacaagc	tgacgatggg	120	
gtgaacgggt	atcaagccat	tgcattcattc	cacggtctcc	cggcttcttg	tcatgatgat	180	
gagggacatg	agattgcctg	ttgtatccac	ggaatgccag	tattcccaca	ctggcacagg	240	
ctttacacc	tgcaaattgga	catggctctg	ttatctcacg	gatctgctgt	tgctattcca	300	
tactgggact	ggaccaaacc	tatcagcaaa	ctgcctgatc	tcttcaccag	ccctgaatat	360	
tacgatacct	ggaggggatgc	agttgtcaat	aatccatttg	ctaaaggcta	cattaaatcc	420	
gaggacgctt	acacgggttag	ggatcctcag	gacattttgt	accacttgca	ggacgaaacg	480	
ggaacatctg	ttttgttaga	tcaaactctt	ttagccttag	agcagacaga	tttctgtgat	540	
tttgagggtc	aatttgaggt	cgtccataat	gctattcact	acttggtggg	tggtcgacaa	600	
gtttatgctc	tttcttctca	acactatgct	tcatatgacc	cagccttctt	tattcatcac	660	
tcctttgttg	acaaaatatg	ggcagtctgg	caagctctgc	aaaagaagag	aaagcgtccc	720	
tatcataaa	cggattgtgc	tcttaacatg	atgaccaaac	caatgcgacc	atttgcacac	780	
gattttcaatc	acaatggatt	cacaaaaatg	cacgcagtc	ccaacactct	atttgacttt	840	
caggaccttt	tctacacgta	tgacaactta	gaaattgctg	gcataaatgt	taatcagttg	900	
gaagcggaaa	tcaaccggcg	aaaaagccaa	acaagagtct	ttgccgggtt	ccttctacat	960	
ggcattggaa	gatcagctga	tgtacgattt	tggatttgca	agacagctga	cgactgccac	1020	
gaactctggca	tgatctttat	cttaggaggt	tctaaagaga	tgcactgggc	ctatgacagg	1080	
aacctttaaat	acgacatcac	ccaagctttg	aaggctcagt	ccatacaccc	tgaagatgtg	1140	
tttgacactg	atgctccttt	cttcattaaa	gtggagggtc	atgggtgtaa	caagactgct	1200	
ctcccatctt	caqctatccc	agcacctact	ataatctact	cagctggtga	a	1251	


<210> 107
 <211> 1185
 <212> DNA
 <213> Megathura crenulata

<400> 107
 gatcatattg ctggcagtg agtcaggaaa gacgtgaagt ctcttaccgc atctgagata 60
 gagaacctga ggcatgctct gcaaagcgtg atggatgatg atggacccaa tggattccag 120
 gcaattgctg cttatcacgg aagtcctccc atgtgtcaca tgcntgatgg tagagacgtt 180
 gcatgttgta ctcattggaat ggcatctttc cctcactggc acagactggt tgtgaaacag 240
 atggaggatg cactggctgc gcatggagct cacattggca taccatactg ggattggaca 300
 agtgcgttta gtcattctgcc tgccttagtg actgaccacg agcacaatcc cttccaccac 360
 ggacatattg ctcattcgga tgtggataca tctcgatctc cgagagacat gctgttcaat 420
 gaccccgaac acgggtcaga atcattcttc tatagacagg ttctcttggc tctagaacag 480
 acagacttct gccaatattga agttcagttt gaaataaacac acaatgcaat ccactcttgg 540
 actggaggac atactccata tggaaatgtca tcaactggaat atacagcata tgatccactc 600
 ttttatctcc accattccaa cactgatcgt atctgggcca tctggcaggc actccagaaa 660
 tacagagggt ttcaatacaa cgcagctcat tgcgatatcc aggttctgaa acaacctctt 720
 aaaccattca gcgagtcag gaatccaaac ccagtcacca gagccaattc tagggcagtc 780
 gattcatttg attatgagag actcaattat caatatgaca cacttacctt ccacggacat 840
 tctatctcag aacttgatgc catgcttcaa gagagaaaga aggaagagag aacatttgca 900
 gccttcctgt tgcacggatt tggcgccagt gctgatgttt cgtttgatgt ctgcacacct 960
 gatggtcatt gtgcctttgc tggaaacctc gcggtacttg gtggggagct tgagatgccc 1020
 tgggtccttg aaagattggt ccggttacgat atcacaaagg ttctcaagca gatgaatctt 1080
 cactatgatt ctgagttcca ctttgagttg aagattgttg gcacagatgg aacagaactg 1140
 ccatcggtac gtatcaagag ccctaccatt gaacaccatg gagga 1185

<210> 108
 <211> 309
 <212> DNA
 <213> Megathura crenulata

<400> 108
 ggtcacgac acagtgaacg tcacgatgga tttttcagga aggaagtcgg ttccctgtcc 60
 ctggatgaag ccaatgacct taaaaatgca ctgtacaagc tgcagaatga tcaggggtccc 120
 aatggatatg aatcaatagc cgggttaccat ggctatccat tctctgccc tgaacatggt 180
 gaagaccagt acgcatgctg tgtccacgga atgcctgtat ttccacattg gcacagactt 240
 catacaatcc agtttgagag agctctcaaa gaacatggtt ctcatttggg tctgccatac 300
 tgggactgg 309

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not
present
for scanning. (Document title)

Scanned copy is best available. some drawings dark